



**The Murine Local Lymph Node Assay:**  
*A Test Method for Assessing the Allergic Contact Dermatitis  
Potential of Chemicals/Compounds*

**The Results of an Independent Peer Review Evaluation  
Coordinated by the Interagency Coordinating Committee on  
the Validation of Alternative Methods (ICCVAM)  
and the  
National Toxicology Program Center for the Evaluation of  
Alternative Toxicological Methods (NICEATM)**

**National Toxicology Program  
P.O. Box 12233  
Research Triangle Park, NC 27709**

**February 1999  
NIH Publication No. 99-4494**

**National Institute of Environmental Health Sciences  
National Institutes of Health  
U.S. Public Health Service  
Department of Health and Human Services**



## Table of Contents

List of Tables.....	iv
List of Abbreviations .....	v
Peer Review Panel Members.....	vi
Acknowledgements.....	vii
Preface.....	x
Executive Summary.....	1
1. Test Method Description .....	5
2. Test Method Data Quality .....	11
3. Test Method Performance .....	13
4. Test Method Reliability (Repeatability/Reproducibility).....	21
5. Other Scientific Reviews.....	25
6. Other Considerations.....	27
7. Related Issues .....	31
8. Overall Summary Conclusions .....	35
References .....	41
Appendices	
A. LLNA Submission List of Chemicals .....	A-1
B. Results of LLNA Literature Search.....	B-1
C. LLNA Test Method Submission .....	C-1
D. LLNA Test Method Submission: Sample Protocol.....	D-1
E. Evaluation Guidance to the Peer Review Panel.....	E-1
F. ICCVAM Validation and Regulatory Acceptance Criteria .....	F-1
G. Federal Register Notice (July 10, 1998).....	G-1

H. LLNA Peer Review Meeting Agenda .....	H-1
I. LLNA Peer Review Meeting Summary Minutes.....	I-1
J. Proposed LLNA Protocol prepared by IWG .....	J-1
K. NICEATM Assessment of Intra/Inter-Laboratory Variability in the LLNA .....	K-1
L. NICEATM Assessment of the Performance of Irritants in the LLNA.....	L-1
M. NICEATM Assessment of Cost and Time Differences Between the LLNA and the Guinea Pig Maximization Test (GPMT).....	M-1
N. NICEATM Assessment of the Effect of Different Stimulation Index (SI) Levels on Performance of the LLNA.....	N-1
O. NICEATM Assessment of LLNA vs. GPMT/BA Discordant Compounds .....	O-1
P. NICEATM Comparison of the LLNA versus the GPMT and the Human Maximization Test (HMT) by Chemical and Product Class.....	P-1
Q. NICEATM Quality Assurance Audit Summary .....	Q-1

## List of Tables

1. Comparison of Original and Revised Concordance Between the LLNA and Guinea Pig Tests.....	13
2. Comparative Evaluation of the PRP's Revised LLNA Database.....	16
3. Comparative Evaluation of the PRP's LLNA Database Limited to Compounds with LLNA, Guinea Pig, and Human Data.....	17
4. Influence of the Threshold SI on Sensitivity and Specificity.....	18
5. Analysis of Intralaboratory Variability .....	22
6. Analysis of Interlaboratory Variability .....	22
7. Alternative Endpoints for the LLNA .....	31

## List of Abbreviations

ACD	Allergic Contact Dermatitis
AOO	Acetone-Olive Oil
BA	Beuhler Assay
CAS	Chemical Abstracts Service
cRT-PCR	Competitive Reverse Transcriptase-Polymerase Chain Reaction
CV	Coefficient of Variation
DMF	<i>N, N</i> -Dimethyl formamide
DMSO	Dimethyl sulfoxide
DNCB	2, 4 –Dinitrochlorobenzene
DPM	Disintegrations Per Minute
DTH	Delayed-Type Hypersensitivity
ELISA	Enzyme-Linked Immunosorbent Assay
FCM	Flow Cytometric (Flow Cytometry)
FDA	Food and Drug Administration
GLP	Good Laboratory Practice Regulations
GPMT	Guinea Pig Maximization Test
GPT	Guinea Pig Tests (Nonstandard)
HCA	Hexylcinnamic aldehyde
HMT	Human Maximization Test
HPTA	Human Patch Test Allergen
ICCVAM	Interagency Coordinating Committee on the Validation of Alternative Methods
IgE	Immunoglobulin Class E
IL-2	Interleukin Type 2
IL-6	Interleukin Type 6
i.v.	Intravenous
LLNA	Murine Local Lymph Node Assay
LNC	Lymph Node Cells
MEK	Methyl ethyl ketone
NICEATM	NTP Interagency Center for the Evaluation of Alternative Toxicological Methods
NTP	National Toxicology Program
PCNA	Proliferating Cell Nuclear Antigen
PG	Propylene glycol
PRP	ICCVAM Peer Review Panel Evaluating the LLNA
SD	Standard Deviation
SI	Stimulation Index
SLS	Sodium lauryl sulfate
SOP	Standard Operating Procedures
Th1	T-Helper Cell Type 1
Th2	T-Helper Cell Type 2

## Peer Review Panel Members

*The following individuals served on the Peer Review Panel that evaluated the LLNA on September, 17, 1998.*

**Jack Dean, Ph.D., Chairperson**

Sanofi Pharmaceuticals, Inc.  
Malvern, PA

**Lorraine E. Twerdok, Ph.D., Executive Secretary**

American Petroleum Institute  
Washington, DC

**Klaus E. Andersen, M.D., Ph.D.**

Odense University Hospital  
Odense, Denmark

**Paul Bailey, Ph.D.**

Mobil Oil Corporation  
Paulsboro, NJ

**Robert G. Hamilton, Ph.D.**

Johns Hopkins University  
Baltimore, MD

**Joseph Haseman, Ph.D.**

National Institute of Environmental Health Sciences  
Research Triangle Park, NC

**Masato Hatao, Ph.D.**

Shiseido Research Center  
Yokohama, Japan

**Martinus Løvik, M.D., Ph.D.**

Norway National Institute of Public Health  
Oslo, Norway

**Howard Maibach, M.D.**

University of California San Francisco  
San Francisco, CA

**B. Jean Meade, D.V.M., Ph.D.**

National Institute of Occupational Safety and Health  
Morgantown, WV

**Jean Regal, Ph.D.**

University of Minnesota  
Duluth, MN

**Ralph Smialowicz, Ph.D.**

U.S. Environmental Protection Agency  
Research Triangle Park, NC

**Peter Thorne, Ph.D.**

University of Iowa  
Iowa City, IA

**Stephen E. Ullrich, Ph.D.**

MD Anderson Cancer Center  
Houston, TX

## Acknowledgements

*The following individuals are acknowledged for their contributions to the peer review process.*

### ICCVAM Immunotoxicology Working Group (IWG)

- Denise Sailstad, M.S.P.H. (Co-chairperson)**, U.S. Environmental Protection Agency
- John Langone, Ph.D.**, Food and Drug Administration, Center for Devices and Radiological Health
- David G. Hattan, Ph.D. (Co-chairperson)**, Food and Drug Administration
- Marilyn M. Lightfoote, M.D., Ph.D.**, Food and Drug Administration, Center for Devices and Radiological Health
- Susan Aitken, Ph.D.**, U.S. Consumer Product Safety Commission
- Dennis M. Hinton, Ph.D.**, Food and Drug Administration, Center for Food and Safety and Applied Nutrition
- Ronald E. Ward, Ph.D.**, U.S. Environmental Protection Agency
- Mary Ann Principato, Ph.D.**, Food and Drug Administration, Center for Food Safety and Applied Nutrition
- Richard Hill, M.D., Ph.D.**, U.S. Environmental Protection Agency
- Kenneth Hastings, Dr.P.H.**, Food and Drug Administration, Center for Drug Evaluation and Research
- Anita Chang, Ph.D.**, Food and Drug Administration, Center for Food Safety and Applied Nutrition
- Josie Yang, Ph.D.**, Food and Drug Administration, Center for Drug Evaluation and Research
- Dori Germolec, Ph.D.**, National Institute of Environmental Health Sciences
- Lynnda Reid, Ph.D.**, Food and Drug Administration, Center for Drug Evaluation and Research
- William S. Stokes, D.V.M.**, National Institute of Environmental Health Sciences
- Susan D. Wilson, Ph.D.**, Food and Drug Administration, Center for Drug Evaluation and Research
- Kenneth Weber, Ph.D.**, National Institute for Occupational Safety and Health
- Anne M. Pilaro, Ph.D.**, Food and Drug Administration, Center for Biologics Evaluation and Research

### National Toxicology Program (NTP) Center for the Evaluation of Alternative Toxicological Methods (NICEATM)

- William Stokes, D.V.M.**, National Institute of Environmental Health Sciences
- Loretta Brammell**, National Institute of Environmental Health Sciences
- Raymond Tice, Ph.D.**, ILS, Inc.
- Heather Vahdat**, ILS, Inc.
- Thomas Goldsworthy, Ph.D.**, ILS, Inc.
- Patrick Herron**, ILS, Inc.
- Barry Margolin, Ph.D.**, ILS, Inc.
- Kathy Miner**, ILS, Inc.
- Bonnie Carson, M.S.**, ILS, Inc.
- Debbie McCarley**, National Institute of Environmental Health Sciences
- Karen Haneke, M.S.**, ILS, Inc.



**Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)****Agency for Toxic Substances and Disease Registry**

William Cibulas, Ph.D.

**Consumer Product Safety Commission**

Marilyn Wind, Ph.D.

Kailash Gupta, Ph.D.

Susan Aitken, Ph.D.

**Department of Defense**

Harrold Salem, Ph.D., U.S. Army Edgewood Research, Development and Engineering Center

Robert Finch, Ph.D., U.S. Army Center for Environmental Health Development Laboratory, Fort Detrick Army Base

John M. Frazier, Ph.D., DOD Tri-Service Toxicology Laboratory, Wright-Patterson Air Force Base

**Department of Energy**

Marvin Frazier, Ph.D.

**Department of the Interior**

Barnett A. Rattner, Ph.D.

**Department of Transportation**

James K. O'Steen

George Cushmac, Ph.D.

**Environmental Protection Agency**

Richard Hill, M.D., Ph.D. (Co-Chairperson)  
Office of Prevention, Pesticides, and Toxic Substances (OPPTS)

Angela Auletta, Ph.D., Office of Prevention, Pesticides, and Toxic Substances (OPPTS)

Karen Hamernik, Ph.D., Office of Prevention, Pesticides, and Toxic Substances (OPPTS)

Hugh Tilson, Ph.D., National Health and Environmental Effects Research/Office of Research and Development (NHEERL/ORD)

**Food and Drug Administration**

Neil L. Wilcox, D.V.M., M.P.H., Office of Science

Anita O'Connor, Ph.D., Office of Science

William T. Allaben, Ph.D., National Center for Toxicological Research

**Food and Drug Administration (Continued)**

Leonard M. Schechtman, Ph.D., Center for Drug Evaluation and Research

Anne M. Pilaro, Ph.D., Center for Biologics Evaluation and Research Raju Kammula, Ph.D., Center for Devices and Radiological Health

Melvin Stratmeyer, Ph.D., Center for Devices and Radiological Health

David G. Hattan, Ph.D., Center for Food Safety and Applied Nutrition

Neil Sass, Ph.D., Center for Food Safety and Applied Nutrition

Joseph F. Contrera, Ph.D., Center for Drug Evaluation and Research

Joseph DeGeorge, Ph.D., Center for Drug Evaluation and Research

Larry D'Hoostelaere, Ph.D., Office of Regulatory Affairs

**National Cancer Institute**

David Longfellow, Ph.D.

Victor A. Fung, Ph.D.

**National Institute of Environmental Health Sciences**

William S. Stokes, D.V.M. (Co-Chairperson)

John Bucher, Ph.D.

Errol Zeiger, Ph.D.

Rajendra Chhabra, Ph.D.

**National Institutes of Health, Office of the Director**

Louis Sibal, Ph.D.

Christina Blakeslee

**National Institute of Occupational Safety and Health**

Douglas Sharpnack, D.V.M.

Kenneth Weber, Ph.D.

**National Library of Medicine**

Vera Hudson

**Occupational Safety and Health Administration**

Surender Ahir, Ph.D.

## Preface

The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) with support from the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) recently sponsored the independent scientific peer review of the validation status of the Murine Local Lymph Node Assay (LLNA), a new test method proposed for assessing the allergic contact dermatitis potential of chemicals. The review was one of the critical components in the ICCVAM process that culminates in achieving regulatory acceptance and implementation of scientifically validated toxicological testing methods. These methods are generally more predictive of adverse human health effects than current methods, and they may be alternative methods that provide for improved animal well-being and that reduce or eliminate the need for animals. These activities were conducted in accordance with public health directives of Public Law 103-43, which directed the National Institute of Environmental Health Sciences to develop and validate improved alternative toxicological testing methods, and to develop criteria and processes for the validation and regulatory acceptance of such methods (NIEHS, 1997).

ICCVAM was established as a collaborative effort by NIEHS and 13 other Federal regulatory and research agencies and programs. The purpose of ICCVAM is to coordinate issues within the Federal government that relate to the development, validation, acceptance, and national/international harmonization of toxicological test methods. The Committee's functions include the coordination of interagency scientific reviews of toxicological test methods and communication with outside stakeholders throughout the process of test

method development and validation. The following Federal regulatory and research agencies and organizations participate in this effort:

Consumer Product Safety Commission  
Department of Defense  
Department of Energy  
Department of Health and Human Services  
    Agency for Toxic Substances and  
    Disease Registry  
    Food and Drug Administration  
    National Institute for Occupational  
    Safety and Health/CDC  
    National Institutes of Health, Office of  
    the Director  
    National Cancer Institute  
    National Institute of Environmental  
    Health Sciences  
    National Library of Medicine  
Department of the Interior  
Department of Labor  
    Occupational Safety and Health  
    Administration  
Department of Transportation  
    Research and Special Programs  
    Administration  
Environmental Protection Agency

The LLNA was proposed to ICCVAM in 1997 as a method that could be used as a stand alone alternative to the Guinea Pig Maximization Test (GPMT) and the Buehler Assay (BA), methods which are currently accepted by regulatory authorities for assessing the allergic contact dermatitis potential of chemicals. The LLNA was proposed by Dr. Frank Gerberick from Procter and Gamble, Dr. Ian Kimber from Zeneca (UK) and Dr. David Basketeer from Unilever (UK).

Through interactions with the sponsors, an ICCVAM Immunotoxicity Working Group

(IWG) composed of Federal employees assembled information for an independent scientific peer review of the method. The IWG reviewed and appropriately augmented the *ICCVAM Test Method Submission Guidelines* (ICCVAM, 1998) to provide useful guidance to the test method sponsors on the information needed for the review. The initial submission from the sponsors was reviewed by the IWG and additional information requested. Suggested experts for the peer review panel (PRP) were solicited from Federal agencies and national and international professional societies and organizations. The IWG recommended a PRP composition that would represent a broad range of experience and expertise, including immunotoxicology, clinical immunology, molecular biology, and biostatistics. PRP members were from industry, academia, and government, and included scientists from the US, Denmark, Japan, and Norway.

The PRP was charged with developing a scientific consensus on the usefulness and limitations of the new test method for assessing allergic contact dermatitis. In reaching this determination, the PRP was requested to evaluate all available information and data on the LLNA, and to assess the extent to which each of the ICCVAM criteria for validation and regulatory acceptance of toxicological test methods were addressed. The criteria used for the evaluation are described in the document *Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the Ad Hoc Interagency Coordinating Committee on the Validation of Alternative Methods*, NIH publication 97-3981 (ICCVAM, 1997). The PRP was provided with guidance for their evaluation (Appendix E), which included questions from the IWG to ensure that the assessment provided adequate information to facilitate ICCVAM and agency decisions on the method.

Test method submission materials were made available to the public and a request for public comments was made via a *Federal Register* Notice (Appendix G) and other announcements. Information was sought regarding the usefulness of the LLNA, including information about completed, ongoing, or planned studies, and other data or information about the LLNA. All comments and information submitted in response to the request were provided to the PRP in advance of the review meeting.

The PRP met in public session on September 17, 1998, at the Gaithersburg Hilton, 620 Perry Parkway, Gaithersburg, Maryland, and opportunity for public comment was provided during the meeting. PRP members presented their evaluations and proposed conclusions and recommendations on each of the major sections and the PRP subsequently reached a consensus for each section. Following the meeting, the written evaluations, conclusions, and recommendations were consolidated as this PRP Report.

Following the peer review meeting, the IWG prepared a proposed test method protocol (Appendix J) that incorporated the recommendations of the PRP into the original test method protocol submitted by the test sponsors (Appendix D). This protocol may be helpful to regulatory authorities that find the method acceptable for their purposes. Additional data analyses prepared by NICEATM for the PRP are also included as appendices in this document, as is the original test method submission.

This entire report has been reviewed and endorsed by IWG and ICCVAM. This report along with ICCVAM recommendations on the usefulness of the method will be forwarded by ICCVAM to Federal agencies for their consideration. Federal agencies will

determine the regulatory acceptability and applicability of this method according to their statutory mandates, and as deemed appropriate, issue guidelines, guidance documents, or proposed changes in regulations.

The work of the PRP was truly a team effort, and their thoughtful and unselfish contributions are gratefully acknowledged. While all members contributed to this evaluation, the exceptional efforts of Dr. Jack Dean, who served as the PRP chair, and Dr. Lorraine Twerdok, who served as executive secretary for the PRP, deserve special

recognition. The efforts of the IWG, and especially the IWG Co-Chairs Ms. Denise Sailstad and Dr. David Hattan, were instrumental in assuring a meaningful and comprehensive review that would address regulatory needs. Finally, the efforts of the NICEATM staff to ensure accurate analyses and timely distribution of information for the review, particularly Dr. Raymond Tice and Ms. Karen Haneke, are acknowledged. On behalf of ICCVAM, we thank all of the many individuals who contributed to this report.

*William S. Stokes, Co-Chair, ICCVAM*  
*Richard N. Hill, Co-Chair, ICCVAM*

## Executive Summary

For decades, guinea pig assays have been the standard used to assess the allergic contact dermatitis (ACD) potential of chemicals and products. These assays, in highly experienced hands, have considerable credibility, but are subject to false positive and false negative results. Interpretation of the results requires experience and expertise; follow-up testing in humans is sometimes required.

In January 1998, the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) received the Local Lymph Node Assay (LLNA) Submission (Submission) from Drs. G. Frank Gerberick (Procter & Gamble, US), Ian Kimber (Zeneca, UK), and David A. Basketter (Unilever, UK) (Sponsors) for peer review. Following the receipt of this Submission, ICCVAM assembled an independent peer review panel (PRP) to evaluate the usefulness of the LLNA for hazard identification of potential human contact sensitizers. The ultimate aim of new ACD assays, such as the LLNA, is to minimize the frequency and severity of sensitization in human populations.

Evaluation of the LLNA Submission was separated into seven sections, with three to five PRP members assigned to conduct an in-depth analysis of each section. This report is organized by these sections, as follows: (1) Test Method Description; (2) Test Method Data Quality; (3) Test Method Performance; (4) Test Method Reliability (Repeatability/Reproducibility); (5) Other Scientific Reviews; (6) Other Considerations; and (7) Related Issues. The evaluations from the seven sections are then summarized in Overall Summary Conclusions. This report focuses on the performance of the LLNA, and some of the critical assumptions (i.e., the potency of the standard allergens) have only been evaluated minimally.

A public meeting of the PRP took place on September 17, 1998, in Gaithersburg, MD, to reach conclusions and make recommendations regarding the usefulness of the LLNA for hazard identification. In addition to reaching final conclusions on the analysis by section,

the PRP also addressed the following two major questions:

1. *Has the LLNA been evaluated sufficiently and is its performance satisfactory to support its adoption as a stand-alone alternative to the Guinea Pig Maximization Test (GPMT)/Beuhler Assay (BA)?*
2. *Does the LLNA offer advantages with respect to animal welfare considerations (refinement<sup>1</sup>, reduction<sup>2</sup>, and replacement<sup>3</sup> alternatives)?*

In response to the first question, the consensus of the PRP was that the LLNA results, as submitted and supplemented by the Sponsors, demonstrated that the assay performed at least as well as currently accepted guinea pig methods (GPMT/BA) for the hazard identification of strong to moderate chemical sensitizing agents. The data submitted indicate that the LLNA does not accurately predict all weak sensitizers (false negative) and some strong irritants (false positive). The term weak sensitizer is somewhat arbitrary, since the terms weak, moderate, and strong apply to the percentage of animals reacting in the GPMT/BA as described in the published literature or papers submitted by the Sponsors. When comparing the LLNA with currently accepted methods (i.e., guinea pig methods), the LLNA appears to provide an equivalent prediction of the risk for human ACD. The review involved the evaluation of data on 209 chemicals, of which both LLNA and guinea pig data were available for 126 chemicals and both LLNA and human (HMT and HPTA) data were provided for 74 chemicals. An in-depth review of all the chemicals that have been defined in the published literature as human

---

<sup>1</sup> Refinement alternative: A new or revised test method that refines procedures to lessen or eliminate pain or distress to animals, or that enhances animal well-being.

<sup>2</sup> Reduction alternative: A new or revised test method that reduces the number of animals required.

<sup>3</sup> Replacement alternative: A new or revised test method that replaces animals with non-animal systems or one animal species with a phylogenetically lower one.

allergens was not conducted for this evaluation. From the analysis generated during the review process, the accuracy<sup>1</sup> of the LLNA vs. GPMT/BA was 89% (N=97), LLNA vs. all guinea pig tests (GPT) was 86% (N=126), the LLNA vs. human data was 72% (N=74), GPMT/BA vs. human was 72% (N=57), and all guinea pig tests (GPT) vs. human was 73% (N=62). In terms of accuracy, sensitivity<sup>2</sup>, specificity<sup>3</sup>, and positive<sup>4</sup> and negative<sup>5</sup> predictivity, the PRP found the performance of the LLNA to be similar to that of the GPMT/BA. Equally important, the performance of the LLNA and the GPMT/BA was similar when each were compared to human data (HMT/HPTA). Performance calculations may be found in Tables 2 and 3 of this report.

The PRP also agreed that the LLNA has several advantages over guinea pig methods for the following reasons:

- (1) provides quantitative data;
- (2) provides dose response assessment;
- (3) reduces animal distress;
- (4) potentially reduces animal numbers;
- (5) potentially more cost effective;
- (6) requires much less time;
- (7) involves the induction phase of sensitization; and
- (8) will allow for future assay improvement and mechanistic studies.

<sup>1</sup> Accuracy: (a) The closeness of agreement between a test result and an accepted reference value. (b) The proportion of correct outcomes of a method. Often used interchangeably with concordance.

<sup>2</sup> Sensitivity: The proportion of all positive chemicals that are correctly classified as positive in a test. A measure of test performance.

<sup>3</sup> Specificity: The proportion of all negative chemicals that are correctly classified as negative in a test. A measure of test performance.

<sup>4</sup> Positive predictivity: The proportion of correct positive responses among materials testing positive. A measure of test performance. The positive predictivity is a function of the sensitivity of the test and the prevalence of positives among the chemicals tested.

<sup>5</sup> Negative predictivity: The proportion of correct negative responses among materials testing negative. A measure of test performance. The negative predictivity is a function of the sensitivity of the test and the prevalence of negatives among the chemicals tested.

Possible assay weaknesses (e.g., false negative results with some weak sensitizing agents and metals, false positive results with some strong irritants) were identified. It was recommended that these should be evaluated in future workshops. Also, data to support the testing in the LLNA of mixtures was not provided and the evaluation of pharmaceuticals was limited.

In response to the second question, the PRP concluded that the LLNA offers several advantages with respect to animal use refinement compared to conventional guinea pig methods in that it involves less pain and distress. The method evaluates the induction phase and not the elicitation phase of the response, which significantly reduces the distress suffered by mice used in the LLNA when compared to guinea pig procedures (GPMT/BA). Furthermore, Freund's adjuvant is not used, and there is a substantial reduction in time required to perform the assay. Animal usage may also be reduced (protocol-dependent).

In summary, the PRP unanimously recommended<sup>6</sup> the LLNA as a stand-alone alternative for contact sensitization hazard assessment, provided that the following protocol modifications were made:

- (1) Until a systematic comparison of data between (a) mouse strains, and (b) male and female mice are conducted, the protocol should specify the use of female CBA mice only;
- (2) Animals should be individually identified;
- (3) Body weight data should be collected at the start and end of the assay;
- (4) Lymphocyte proliferation data should be collected at the level of the individual animal;
- (5) Statistical analysis should be performed;
- (6) A single dose of a sensitizer inducing a moderate response should be included as a concurrent positive control in each study;
- (7) <sup>3</sup>H-methyl thymidine or <sup>125</sup>I-iododeoxyuridine may be used in the LLNA;

<sup>6</sup> After the peer review meeting, one abstention was changed to approval.

- (8) The decision process to identify a positive response should include a  $SI \geq 3$ , statistical significance, and dose response information;
- (9) An illustration should be added to the protocol, indicating the nodes draining the exposure site that are to be harvested.

Additionally, the PRP recommended that retrospective data audits be conducted on at least three of the intra- and inter-laboratory LLNA validation studies conducted by the Sponsors. The panel commented that as additional experience is gained with the LLNA, there will be an opportunity to refine these interpretations.

Further, the PRP concluded unanimously that the LLNA is a definite improvement with respect to animal welfare (i.e., refinement and reduction) over the currently accepted GPMT.

The LLNA test as proposed measures lymphocyte proliferation using incorporation of  $^3\text{H}$ -methyl thymidine in draining lymph nodes of animals topically exposed to the test article. The measured lymphocyte proliferation response is an essential biological element in the induction phase of sensitization. In contrast, currently used guinea pig assays measure skin reactivity to a secondary challenge with the substance under investigation. It may even be argued that for hazard identification, sensitization (the primary immune response) is more relevant than the secondary response (eczematous reaction) of challenged skin. Sensitization is a prerequisite for ACD, and it is sensitization that constitutes the hazard. In a sensitized person, be it a respiratory or contact allergy, an allergic

disease manifestation will not always develop upon challenge: there are individual-dependent factors, dose and mode of exposure factors, and adjuvant effects (including irritant potential and substances that increase skin penetration). All of these factors can be considered part of the risk assessment process rather than hazard identification. In the guinea pig models, hazard is combined with a set of defined risk conditions (secondary challenge conditions) and disease-analogous skin responses are measured. Thus, because of its pivotal role and obligatory presence in the process of allergic sensitization, cellular proliferative activity in the lymph node(s) draining the area of skin exposed to the substance under investigation must be considered an important and biologically relevant parameter in relation to contact allergy.

In the proposed LLNA, increased levels of radioactive thymidine or uridine incorporation, measured from lymph nodes draining the application site, results from increased proliferation of cells in the lymph node at the time of chemical exposure and of cells that migrate to the lymph node because of the chemical exposure. Thus, there are two mechanisms behind an increased stimulation index with the current protocol: a net influx of lymphoid cells/increase in cell numbers, and an increased proliferative rate. A stimulation index ( $SI$ )  $\geq 3$  may predominately reflect an increase in cell numbers and/or an increased proliferative activity (per cell) of cells residing in the lymph node. This dual response probably increases the sensitivity of the test, because it measures the additive effect of two biological phenomena.





## 1. Test Method Description

### 1.1. Sufficiency of test method and protocol description

The Submission contains a thorough protocol. The scientific basis for the test is described as the measurement of the incorporation of <sup>3</sup>H-methyl thymidine into lymphocytes in draining lymph nodes of animals topically exposed to the test article, as a measurement of sensitization. The endpoint of interest is stated clearly ( $SI \geq 3$ ). The proposed protocol provides sufficient detail such that appropriately trained personnel should be able to properly conduct independent studies. Dosing procedures, including the preparation and disposal of dosing solutions, are clear. The protocol specifies that the test article be applied to the dorsal aspect of the ear. Dosing only the dorsal aspect of the ear as opposed to splitting the dose between the dorsal and ventral aspect increases the concentration of chemical exposure per surface area. Information is provided on the appropriate choice of vehicles and the selection of doses, including the need to assess for a dose-response relationship. Problems associated with choice of vehicles and concentrations to be tested are discussed in Section III.

The range of applications of the method are described in the Submission. It is implied but not directly stated that the method is to be used for low molecular weight organic chemicals and that the assay has not been validated for all metals or larger molecular weight compounds, such as proteins. The majority of the supporting data represents the testing of simple chemicals. One publication was included in the Submission on the testing of pharmaceuticals (Kimber et. al., 1998), although the number of pharmaceuticals tested was limited. The use of the LLNA to assess the skin sensitizing potential of mixtures and extracts was also not addressed in the Submission or by the PRP.

Safety issues relating to the handling of chemicals and radioisotopes were well presented. Appropriate forms for record keeping were included as an appendix to the Submission. Acceptable variations in the

protocol (e.g., the choice of animal strains, the number of mice per dose group, and the choice of vehicles) are described and prioritized. Although the use of different vehicles is described, the majority of the data presented in the Submission resulted from test articles applied in acetone-olive oil (AOO). The majority of the data was analyzed from pooled animals per group. However, the PRP strongly supports the analysis of data from individual animals.

An aspect of the protocol that could cause differences in procedure between laboratories is the description of the lymph nodes to be assayed. These nodes, referred to as the auricular lymph nodes, are a designation for nodes draining the ear. Given that this is not standard anatomical nomenclature, it is possible that different laboratories could be removing different nodes for evaluation. To the best of the reviewers' knowledge, there is no specific nomenclature for this set of lymph nodes. The anatomical location (e.g., diagram or photograph) of the auricular lymph nodes would be a beneficial addition to the protocol. Furthermore, it should be noted that locating the proper lymph nodes might be difficult when there is no induction by the test material. It is suggested that inexperienced personnel practice with a known sensitizer until competence is obtained.

#### 1.1.1. Adequacy of agreement between the protocol used to generate Submission data and the proposed protocol

Much of the data presented in support of the Submission were collected by following the proposed protocol. In some cases, slight modifications were made. Variations from the protocol included the use of four days of consecutive dosing instead of three; and the use of <sup>125</sup>I-iododeoxyuridine as compared to <sup>3</sup>H-methyl thymidine. In cases where variations occurred between laboratories in inter-laboratory validation studies, similar results were obtained from modified protocols (Kimber et. al., 1995; Loveless et. al., 1996). Information on variations in the protocol used

for each of the chemicals included in the provided LLNA database would have been useful in understanding the total experience with the current “standard” protocol. In most instances, there is no clear rationale for the choice of one modification over another. Having a two-day rest period prior to injecting with  $^3\text{H}$ -methyl thymidine instead of one day is more convenient in a setting where people are working five-day weeks. There has been much more experience with the use of  $^3\text{H}$ -methyl thymidine as compared to  $^{125}\text{I}$ -iododeoxyuridine in the LLNA. Following discussion, the PRP recommended allowing the use either of  $^3\text{H}$ -methyl thymidine or  $^{125}\text{I}$ -iododeoxyuridine.  $^{125}\text{I}$ -iododeoxyuridine has a shorter half-life which results in less cost associated with radioactive waste disposal.

### 1.1.2. Appropriateness of dose selection procedure

The dose selection process as defined by the protocol is based on previous experience in guinea pig tests, structure analysis, and solubility factors. If the LLNA is to be used as a 'stand-alone' assay on new substances, reference to guinea pig tests is inappropriate. Where no information is available, concentrations to be tested should be based on toxicity, solubility, and irritancy. The standard protocol states that three to five concentrations are selected among ten possible dose levels ranging from 0.1% to 100%. The published LLNA tests are usually performed by testing the substance of interest using a minimum of three concentrations. It is crucial to test high concentrations to avoid false negatives. An example of this potential problem is with ethylenediamine (free base) in Table 3 of Assessment of the Skin Sensitization Potential of Topical Medicaments using the Local Lymph Node Assay: An Interlaboratory Evaluation (Kimber et al., 1998). Ethylenediamine would have been classified as nonsensitizing if concentrations of 0.1 to 1.0% had been selected. Strong sensitization responses were observed at concentrations of 5.0 and 10% in AOO. Some other well known allergens require high concentrations to yield a  $\text{SI} \geq 3$  (i.e., eugenol, hexyl cinnamic aldehyde, and penicillin G) (Montelius et al., 1998). For much of the data presented in the Submission, compounds were not tested at the

highest possible concentrations and solubility data were not provided. The PRP recommends that a rationale for the selection of vehicle as well as for concentrations tested be included for each test article. Discussion of this issue is included in Section III.

No information was provided regarding the need for determination of dermal irritation or acute toxicity data prior to conducting the actual test. If one assumes that irritation is not a confounding issue in the LLNA as it is in the guinea pig assays where the end point is a measurement of erythema and edema, then there are benefits to being able to test higher concentrations of compounds. If one was limited to testing non-irritating concentrations of highly irritating compounds, it is possible that high enough concentrations to reach a sensitizing dose may not be tested, resulting in false negative responses. Although several reports have presented data where exposure to highly irritating concentrations of chemicals resulted in an  $\text{SI} \geq 3$ , the Sponsors have addressed the issue of irritation and suggest that proliferation induced by irritation may be non-dose responsive and rarely exceeds the required three-fold increase in SI over control to predict sensitization potential. The Sponsors have stated that local or systemic toxicity may result in a suppression of the response at high doses. It is possible that, in the absence of preliminary toxicity testing, using toxic concentrations of chemicals may result in the need for repeat studies.

The protocol does not specify that animals be weighed at the beginning and end of the study. Having weight gain data available would allow for an evaluation of toxicity that may be useful in assessing data in which a decline in the dose-response relationship is seen at high doses and is recommended. To collect animal weight data, identification of individual animals is required. Individual animal identification is also a requirement for studies performed in compliance with Good Laboratory Practice (GLP) regulations.

Additional comments relating to irritation were made by PRP members. The PRP members questioned whether a grading system for dermal irritation should be developed to quantify the degree of skin irritation at the

treatment sites. It is not clear as to what prevents the application of a severe irritant or a corrosive substance. Further, the PRP questions whether there is a need for a prestudy screen of the irritation potential of the test material. Although solubility and potential toxicity may influence the concentrations that will be used in a test, the protocol does not provide clear guidance on the selection of a concentration for the performance of the assay.

### **1.1.3. Appropriateness of the number of dose groups**

The protocol specifies that a vehicle group and three to five test groups be assayed. Assuming that the appropriate concentrations are chosen (see No. 2 above), this study design is appropriate for a toxicology study. However, in the absence of any data on toxicity or solubility, details regarding how test concentrations should be chosen is necessary.

## **1.2. Adequacy and completeness of the test method protocol**

### **1.2.1. Test method material and equipment, and animal usage**

The test method protocol is detailed and provides sufficient information on materials and equipment needed and technical procedures, such that trained personnel should be able to conduct the LLNA. The appendix of the Submission provides details on reagent preparation and sample sheets for record keeping. The LLNA is analyzed based on a comparison of the mean DPM from treated animals as compared to controls. This differs from the scoring of the guinea pig assays in which a test substance is scored as positive or negative based on the percentage of animals in a group which are responders (15% in a nonadjuvant assay and at least 8% in an adjuvant test) (Marzulli and Maibach, 1996). The guinea pigs used in these assays are outbred animals with a greater genetic variability than the inbred mice chosen for use in the murine LLNA. Test results have shown that, based on using a  $SI \geq 3$  as the sole criteria for determining a positive response in the LLNA, an N of four or five mice per test group provides comparable results to the guinea pig tests with 10 to 20 animals.

The specified age range of 8 to 12 weeks is appropriate for immunotoxicological studies. Mice become immune competent at approximately six to eight weeks of age (Shultz and Bailey, 1975; Tyan, 1981).

The strain chosen is a known Th1 (T-helper cell type 1) responder. However, the choice of strain has been made without a systematic comparison of alternatives. There is adequate documentation for the influence of genetic factors on contact allergy, although there is less documentation on how important a role this might have in testing. There is adequate documentation that inbred mouse strains differ in delayed-type hypersensitivity (DTH) reactions to antigens (Shultz and Bailey, 1975). Few studies have been conducted to compare the responsiveness of other inbred mouse strains to the CBA mouse in the LLNA. The documentation in the paper cited on this point (Kimber and Weisenberger, 1989) is preliminary, with only one (strong) sensitizer (2,4-dinitrochlorobenzene [DNCB]), and with a protocol different from the one submitted to ICCVAM. A range of sensitizers should be tested in parallel in a number of representative inbred strains of mice before another strain can be considered validated.

A better description of the responder properties of various mouse strains would be useful for evaluation of the robustness of the LLNA. Different lines of mice within a given strain (i.e., substrains) show genetic differences and will drift further apart genetically over time. Substrains may differ in their immune responses; one example is the DTH response to mycobacterial antigens in different substrains of C3H mice (Løvik et al., 1982). If different mouse strains are found to differ significantly in their LLNA response and genetic factors play a role, one obvious measure to help avoid false negatives would be to retest (suspicious) negative substances in a different strain of mice. Documentation provided (Kimber et al., 1998) suggests that for some CBA substrains, substrain differences have minimal effect on the LLNA response.

The Sponsor's protocol permits the use of both male and female mice, but only one sex in each experiment is proposed. Female CBA mice

have been shown to develop a stronger contact dermatitis response as compared to males (Ptek et al., 1988). Furthermore, males are considered to show larger variation because of a greater tendency to fight and to be involved in 'social ranking' processes if group housed. However, this clearly is mouse strain-dependent. In the future, the use of both genders of mice might offer economic advantages, both for institutions breeding their own mice, and for users who buy their mice from commercial breeders. The documentation supplied is with female mice only. If the protocol permits the use of male mice, systematic studies on sex differences in the response should be documented.

### **1.2.2. Test method data collection procedure**

The protocol adequately describes the measurement of the incorporation of  $^3\text{H}$ -methyl thymidine into proliferating lymphocytes in draining lymph nodes as a measure of sensitization. However, there appears to be two methods of performing the assay, one based on using lymph node samples pooled across mice within a treatment group (favored by the European collaborators) and another based on individual animal responses (favored by the American collaborators), which is evident in reviewing the publications from the inter-laboratory validation studies. It appears an assessment of DPM in lymph nodes from individual animals is advantageous to using lymph nodes pooled within a dose group to determine radioisotope incorporation. The pooled approach precludes statistical analysis of the data which should be used to aid in result interpretation. Thus, the draft protocol should be modified to recommend only the collection and analysis of individual animal data.

### **1.2.3. Data analysis, evaluation, and decision criteria**

The protocol allows for pooling of the draining lymph nodes from multiple mice within each test group or the analysis of pooled nodes from individual animals. The mean DPM for each test group is compared to the control group and

if the SI of a test group is  $\geq 3$  fold higher than the concurrent control, the test chemical is considered to be a sensitizer. The Sponsors state that the three-fold increase is an arbitrary number chosen based on the performance of the assay with a group of known sensitizers. Extensive analysis performed by NICEATM with the assay supported the three-fold increase as an adequate indicator of the sensitizing ability of chemicals. The Sponsors state that the three-fold factor takes into consideration the variability within and between groups and allow for the assumption that irritation may elicit a low level of lymphocyte proliferation.

The PRP had significant concerns about the lack of emphasis on statistical analysis in the Submission. Pooling lymph nodes from animals by dose group for radioisotope incorporation versus an evaluation of lymph nodes from individual animals to estimate the SI does not represent replicate testing and precludes any statistical analysis of the data. Statistical analysis would definitely benefit the LLNA protocol. It would confirm whether or not an apparently high SI ( $\geq 3$ ) is due to chance variation (e.g., see Table 4, Kimber et al., 1995), thereby reducing possible false positives. It may detect whether an apparently low SI ( $< 3$ ) for a particular compound are statistically higher than can be explained by chance variation, and may thereby reduce the number of potential false negative responses. In both of these situations, the statistical results would at least call into question the decision based solely on SI, and thus suggest a retest. Additionally, the evaluation of individual animal data provides for trend analysis to confirm dose responsiveness. However, not all statistical differences are biologically meaningful or relevant for regulatory decision making. It is a practical question whether the qualitative statement from a statistical test is sufficient, or whether a quantitative element/magnitude of the difference also has to be considered. The SI represents one such quantitative parameter. Similar combinations of statistical and practical decision rules are used in genetic toxicology tests.

Although the statistical significance of an observed response is very important, no rigid

statistical decision rule should be the sole factor in determining the biological significance of a skin sensitization response. Other factors that should be considered include the magnitude of the effect ( $SI \geq 3$ ), the strength of the dose-response relationship, chemical toxicity and solubility, and the consistency of the (positive and negative) control response with other contemporary studies.

It is the recommendation of the PRP that data be generated by analyzing lymph nodes from individual animals. This view was supported by individuals at the Public Meeting representing regulatory agencies. This would allow for the use of a  $SI \geq 3$  for identifying positive responses and dose-response relationship, evaluation of incidence, and statistical analysis may be used as an aid in evaluating test results. Use of individual animal data allows for a formal statistical analysis of whether or not an elevated SI is significant relative to controls. These results can be used in conjunction with the three-fold SI rule to determine the skin sensitization potential of the test chemical. The following guidelines should be considered.

The calculated measure of response (SI) will generally be simply the ratio of the mean DPM responses in the dosed and control groups. However, the investigator should be alert to possible "outlier" responses for individual animals within a group that may necessitate the use of an alternative measure of response (e.g., median rather than mean) or elimination of the outlier.

Each SI should include a measure of variability that takes into account the inter-animal variability in both the dosed and control groups. For example, dividing each dosed group animal response by the mean control response and calculating the SD of these ratios does not take into account the variability inherent in the control group. The SI is a ratio of two random variables, and the formula for the SD of this ratio is available in many standard statistical textbooks.

The statistical analysis should include an assessment of the dose-response relationship as well as pairwise dosed group vs. control comparisons. In choosing an appropriate

method of statistical analysis, the investigator should maintain an awareness of possible inequality of variances and other related problems that may necessitate a data transformation or a nonparametric statistical analysis.

### **1.3. Positive, negative, and irritation control chemicals**

The protocol does not adequately address the use of controls. The protocol specifies the inclusion of a vehicle control but not a positive or irritation control. The inclusion of a single concentration of a moderate grade sensitizer as a concurrent positive control would provide validity to the assay indicating that all procedures involved in the assay were conducted properly. In addition, a positive control will provide a standard to compare between studies and laboratories. Regulatory agency representatives present at the public meeting supported the need for a concurrent positive control with each assay. The PRP recommends the use of a positive control in the form of a sensitizer inducing a moderate response. Based on the criteria set for the evaluation of the LLNA, there is no need for an irritation control.

### **1.4. Dose response interpretation**

The dose-response relationship is an advantage of this method and becomes important in the evaluation of equivocal results. The ability to evaluate multiple concentrations of the chemicals is an advantage of the LLNA because it provides added confidence that compounds that are skin sensitizers will be detected. The Sponsors have designated a  $SI \geq 3$  as the limit for classifying a chemical as a sensitizer. In equivocal cases where the SI does not reach three-fold, but there is a positive dose response, repeating the study to assess reproducibility may be appropriate. Also, the dose response relationship allows for the evaluation of potential systemic toxicity. In cases where a suppressed response is seen at high doses, the dose response may allow for recognition of a toxic response.

### 1.5. Strengths and/or limitations

The strengths of the LLNA are its quantitative nature, the inclusion of a dose response relationship, the ability to test colored substances, improved animal welfare, and the reduction in the time required to conduct a study. The usefulness of the method for testing mixtures and extracts was not addressed in the proposal. Some strong irritants and sensitizing metals appear to be problematic for the LLNA. A failing of the LLNA, as described, is its inability to identify some metal salts as contact allergens. Ikarashi et al. (1992a; 1992b; 1993) suggest that the use of DMSO as a vehicle results in a positive LLNA test when metal salts, including nickel and copper salts, are applied to the skin. To better evaluate interlaboratory comparisons, the PRP would like to have seen more data generated from blinded studies.

### 1.6. Editorial/technical corrections

The PRP found the protocol to be well written and easy to follow.

### 1.7. Conclusions

The PRP found the recommended protocol to be thorough. The strengths of the assay were seen as its mechanistic basis, quantitative endpoint, and the inclusion of a dose response relationship. Weakness were seen as the assay resulting in false negatives (e.g., some metals and some clinically relevant allergens) and false positives (e.g., some irritants). Furthermore, there is limited experience with pharmaceuticals and mixtures/extracts. The value of adding a concurrent positive control was seen as providing validity to the assay and giving a standard by which to compare

between studies and laboratories. It is crucial to test high concentrations of test materials to avoid false negatives. The choice of the highest concentrations tested should be based on solubility and toxicity. The choice of suitable vehicles are described and prioritized. However, the majority of the data presented in the Submission resulted from exposure to test articles applied in AOO.

### 1.8. Recommendations

The following changes to the protocol were recommended:

- (1) Until a systematic comparison of data between (a) mouse strains, and (b) male and female mice are conducted, the protocol should specify the use of female CBA mice only;
- (2) Animals should be individually identified;
- (3) Body weight data should be collected at the start and end of the assay;
- (4) Lymphocyte proliferation data should be collected at the level of the individual animal;
- (5) Statistical analysis should be performed;
- (6) A single dose of a moderate sensitizer should be included as a concurrent positive control in each study;
- (7)  $^3\text{H}$ -methyl thymidine or  $^{125}\text{I}$ -iododeoxyuridine may be used in the LLNA;
- (8) The decision process to identify a positive response should include a  $\text{SI} \geq 3$ , statistical significance, and dose response information;
- (9) An illustration should be added to the protocol, indicating the nodes draining the exposure site that are to be harvested.

## 2. Test Method Data Quality

Validation studies appear to have been conducted in the “spirit” of Good Laboratory Practice (GLP) (or Good Research Practice) as determined by standard operating procedures (SOP) at the individual institutions. Formal audited reports were not prepared because the data were primarily intended for publication. By definition, without an audited final report, a study does not conform to GLP. Data record forms in the sample protocol (Appendix D) and supplemental individual animal data supplied solely for PRP review indicated that record-keeping and data collection were adequate.

### 2.1. Protocol consistency during validation

Assurance was not provided to indicate adherence to a standard protocol during the validation studies. Early validation studies were conducted before a standard protocol was available; thus, slight procedural variations occurred as described in the next section. Two protocol modifications were intentionally introduced during the later validation studies.

### 2.2. Protocol variations and modification during validation

Several variations/modifications of the standard protocol are described in the validation studies. These variations and modifications included:

- (1) exposure of mice for four rather than three consecutive days;
- (2) differences in the number of mice per treatment group;
- (3) removal of nodes four days rather than five days after initiation of the study;
- (4) use of different mouse strains;
- (5) use of pooled nodes vs nodes from individual mice for each treatment group; and
- (6) use of  $^{125}\text{I}$ -iododeoxyuridine rather than  $^3\text{H}$ -methyl thymidine.

However, data based on using a four-day treatment protocol were not included in the

database and this modification is currently not considered acceptable. Procedural variations nos. 2 to 4 are difficult to identify as true changes or modifications of the standard protocol, since they appeared to have more to do with how a particular laboratory performed the LLNA, rather than being an intentional modification for assay optimization. With the available documentation, in most cases it was not possible to distinguish which studies used which of these modifications. Consequently, a rigorous evaluation of the effects of these four protocol variations on test results was not possible. Modification nos. 5 and 6 were intentional modifications and are clearly described in Kimber et al. (1998). The justification for these two modifications was to evaluate the effects of slight modification on the predictive value of the test. This justification is adequate and, overall, these variations and modifications did not significantly alter test results, indicating that the LLNA is relatively insensitive to minor variations in procedure.

### 2.3. Data audits

In the absence of formal audited reports and GLP compliance statements, it is not possible to determine if data audits were conducted by Quality Assurance Units. The Sponsors state that much of the data presented in support of the Submission were derived from audited GLP compliant studies (Appendix C), inferring that data audits were conducted. Additionally, the Sponsors state that, with retrospective audits, GLP compliance statements could be issued for the great majority of substances tested. The integrity of the validation data is also supported by the fact that all interlaboratory validation data were made available to, and scrutinized by, all participants.

### 2.4. Recommendation

Due to lack of representative quality assurance and GLP documentation in the Submission, it is recommended that data quality and

adherence to protocol (in individual studies) be confirmed by retrospective auditing of at least three individual LLNA studies. The studies should be selected by NICEATM from those

conducted in the later phase of the interlaboratory validation, and should include laboratories from both the US and UK.



### 3. Test Method Performance

#### 3.1. Data presentation

The Sponsors' Submission applies a three-fold SI for evaluating the sensitization potential of a chemical using the LLNA. The Sponsor's initial Submission, which included only a table of "+" and "-" data, did not provide sufficient detail for the comprehensive evaluation of the LLNA. However, subsequent literature evaluation (Basketter and Scholes, 1992; Basketter et al., 1994; Basketter et al., 1996a; Basketter et al., 1998; Gerberick et al., 1992; Kimber et al., 1990; Loveless et al., 1996) carried out by NICEATM and PRP members provided more detailed information on SI for a majority of the chemicals evaluated. This compilation permitted a more definitive evaluation of LLNA performance, in particular, the application of the  $SI \geq 3.0$  rule and the determination of sensitivity and specificity of the assay in comparison to the GPMT/BA and human sensitization data.

There were minor data inconsistencies, including double reporting under chemical synonyms for one chemical, inaccurate reporting of whether or not a standard guinea pig test method was used, and minor omissions in the Submission. Most of these inconsistencies were resolved during the review process and in discussions and teleconferences with the Sponsors. Comparison to literature citations confirmed the accuracy of almost all of the LLNA classifications provided by the Sponsors. However, the PRP could not confirm positive results (but did confirm negative results)

reported for aniline, 4-chloroaniline, streptomycin sulfate, or  $\alpha$ -trimethylammonium 4-tolyoxy-4-benzenesulfonate, nor the equivocal result reported for neomycin sulfate. These chemicals were considered negative in the analysis of LLNA assay data, although it is recognized that unpublished data may exist that would support a positive call. Hydroquinone and quinol had the same CAS number and were changed to a single listing. Benzoic acid and glycerol were tested using a non-standard LLNA protocol and, in agreement with the Sponsors and consistent with other similar data, excluded from further consideration. Benzocaine yielded equivocal LLNA results among six separate studies and was excluded from subsequent performance evaluations. The revised data are compared to the Submission in Table 1.

The LLNA was validated for hazard identification of chemicals, as defined by the National Research Council (NRC, 1983) with a proclivity to produce ACD.

The LLNA assesses the induction process and does not assess the elicitation process. ACD refers to an immunologically mediated process in man or animal that is characterized by redness and swelling of the skin and is a cell mediated (type IV) process (Kawabata et al., 1996). For the purposes of this report, the LLNA assesses type IV hypersensitivity and no attempt has been made to validate this assay for immediate hypersensitivity and contact urticaria syndrome.

**Table 1. Comparison of Original and Revised Concordance Between the LLNA and Guinea Pig Tests**

LLNA	GPT	Original	Revised
+	+	86	81
+	-	6	6
-	+	10	12
-	-	28	27
Total		130	126
Concordance		88% (114/130)	86% (108/126)

### 3.2. Adequacy of the test method performance evaluation

There is a century of experience on the identification of chemicals that produce ACD in man. The definition of ACD in man is operational in nature in that several components are required for verification: this includes history, physical examination, diagnostic patch testing with appropriate controls, and natural history after removal of the contact allergen.

For this review, the PRP compared the LLNA against guinea pig data and compared both the LLNA and guinea pig test data against human data, where available. This PRP did not conduct an in-depth review of all the chemicals that have been defined in the published literature as human allergens.

The PRP, with the assistance of NICEATM, compared the LLNA to the guinea pig assays in terms of specificity, sensitivity, positive and negative predictivity, and accuracy. The purpose of this evaluation was to determine if the LLNA, as a test for hazard identification, is equivalent to or superior to the guinea pig assays. To accurately make that comparison, the guinea pig assay would have to undergo the same rigorous evaluation as the LLNA. The PRP is not aware of any such evaluation.

Although much effort was expended to compare the LLNA to the GPMT/BA, the goal of LLNA testing is for hazard identification and to prevent human sensitization. Thus, the PRP attempted to compare the performance of the LLNA to available sources of human data that were viewed as the "gold standard." Of the 209 chemicals tested in the LLNA, 97 were also tested in the GPMT/BA, an additional 29 were tested using non-standard guinea pig tests, and 39 were tested using the human maximization test (HMT). Inclusion of compounds that are included in human patch test allergen (HPTA) panels expanded the comparative human data set to 74 compounds. These human data were not further validated as that would have required an exhaustive study of the literature to determine their potency. Thus, these data should be considered with the caveat that a few of the HPTA compounds may cause human sensitization only infrequently.

Several deficiencies in the Submission materials were noted by the PRP. Since the choice of vehicle may be problematic in the LLNA, analysis of vehicle effects should have been more thoroughly evaluated. Acetone or AOO appeared to be the preferred vehicle in most studies, followed by *N,N*-dimethyl formamide (DMF), methyl ethyl ketone (MEK), propylene glycol (PG), dimethyl sulfoxide (DMSO), and saline or 50% acetone/saline. There are very few data available on vehicles other than AOO, DMF, and DMSO. It is desirable that predictive animal tests be performed with vehicles relevant for human exposure where possible. The choice of vehicle may be decisive for the determination of the SI. For instance, olive oil may pose problems in the LLNA since it is reported as an allergen giving an SI=16 to 23 when tested at 100%, and 2.9 to 3.6 when tested as AOO (4:1) (Montelius et al., 1996).

The choice of test concentrations is also crucial to the proper performance of the LLNA. It is given in the standard protocol that "three to five concentrations are selected among ten possibilities ranging from 0.1% – 100%." The preponderance of data is based on tests performed using three concentrations. It appears that some well known allergens require high concentrations to yield a SI  $\geq 3$  (e.g., eugenol, hexylcinnamic aldehyde, ethylenediamine, and penicillin G). For some non-sensitizing irritants (e.g., nonanoic acid and methyl salicylate), it appears that high concentrations yield a SI  $\geq 3$  (Montelius et al., 1998). It was not stated clearly enough in the Submission that the range of concentrations tested may be decisive for the result.

### 3.3. Adequacy of the numbers of chemicals/products evaluated

There have been a substantial number of chemicals and classes of chemicals tested using the LLNA to evaluate its performance. Few other toxicological assays have had this type of rigorous evaluation prior to use. However, the PRP noted that several classes of compounds for which the LLNA has been used were under-represented in the Submission. These include some weak sensitizers, irritants, organometals, and petroleum additives. The PRP noted that preferential testing of potent

and moderate sensitizers over weak sensitizers would tend to yield better performance data for the LLNA than would be expected in general use for hazard assessment. The PRP disagrees with the statement in the Submission (Appendix C, page C-22) that a LLNA false negative for nickel sulfate is “. . . as unsurprising as it is unimportant” since “. . . new metals are not being invented.” The PRP recognizes the importance of LLNA testing of new organometals, particularly in the petroleum additives industry. Data derived from the testing of coded samples in blinded studies would have allowed for a better comparison of LLNA performance to guinea pig and human data. The PRP is aware that such data exist but that it was considered proprietary and was not available for analysis.

### **3.4. Adequacy of test method performance data**

There is consensus among the PRP that with the inclusion of the additional material requested of the Sponsors, plus that drawn from published sources, sufficient information was available to evaluate the LLNA. As stated above, additional data for weak sensitizers, some irritants and certain metals, plus data from blinded studies, would have added further rigor to the review.

### **3.5. Sensitivity, specificity, concordance, false positive rate, and false negative rates**

The revised database described above and included in Appendix A was analyzed to determine sensitivity, specificity, false positive and false negative rates, and accuracy of the methods compared to guinea pig and human data. The results of these analyses are tabulated below in Tables 2 and 3. Table 2 is based on analysis of all available data for each comparison; Table 3 is limited to compounds

for which there are LLNA, guinea pig and human sensitization data for the same compound.

#### **3.5.1. Prediction of non-sensitizers**

According to a Chi square evaluation, there is a significant association between the LLNA and guinea pig test (GPMT/BA plus GPT) classification of positive and negative sensitizers (p value < 0.001). Based on 126 compounds (93 guinea pig positive and 33 guinea pig negative), the LLNA exhibited a sensitivity of 87%, specificity of 82%, and accuracy of 86%. The predictive value of a positive test was 93% and the predictive value of a negative test was 69%. The latter value suggests that the LLNA is more likely than guinea pig tests to identify compounds as non-sensitizers. However, the predictive value of a negative test when compared against the GPMT/BA only was 80%. From a regulatory standpoint, false negatives are of greater concern than false positives.

In comparison to the human data, the LLNA exhibited a sensitivity of 72%, specificity of 67%, and accuracy of 72%. The predictive value of a positive test was 96% and the predictive value of a negative test was 17%. GPT gave a similar value for negative predictivity. It should be recognized that this latter value was based on only four human non-sensitizers.

These analyses were also performed applying different SI values to establish a LLNA result as positive. As shown in Table 4, no overall improvement in accuracy was demonstrated if a SI of 2.0, 2.5, 3.5 or 4.0 was chosen instead of 3.0. A higher threshold improves the specificity but reduces the sensitivity. A SI  $\geq 3$  provided better concordance with guinea pig tests than the other thresholds tested.

**Table 2. Comparative Evaluation of the PRP's Revised LLNA Database<sup>1</sup>**

Comparison	Number of Comparisons	Sensitivity <sup>2</sup>		Specificity <sup>3</sup>		Positive Predictivity <sup>4</sup>		Negative Predictivity <sup>5</sup>		Accuracy <sup>6</sup>	
		%	Number	%	Number	%	Number	%	Number	%	Number
LLNA vs GPMT/BA	97	91%	(62/68)	83%	(24/29)	93%	(62/67)	80%	(24/30)	89%	(86/97)
LLNA vs GPT	126	87%	(81/93)	82%	(27/33)	93%	(81/87)	69%	(27/39)	86%	(108/126)
LLNA vs HUMAN	74	72%	(49/68)	67%	(4/6)	96%	(49/51)	17%	(4/23) <sup>7</sup>	72%	(53/74)
GPMT/BA vs HUMAN	57	70%	(38/54)	100%	(3/3)	100%	(38/38)	16%	(3/19) <sup>7</sup>	72%	(41/57)
GPT vs HUMAN	62	71%	(42/59)	100%	(3/3)	100%	(42/42)	16%	(3/20) <sup>7</sup>	73%	(45/62)

**Abbreviations:** LLNA = Local Lymph Node Assay; GPMT = Guinea Pig Maximization Test; BA = Buehler Assay; GPT includes nonstandard Guinea pig tests; HUMAN = Human Maximization Test (HMT) plus Human Patch Test Allergen (HPTA)

**Number of comparisons refers to the number of substances tested in both systems. Numbers in parentheses indicate actual number of comparisons for each analysis.**

<sup>1</sup> This analysis was conducted by NICEATM based on the LLNA Submission List of Chemicals provided in Appendix A of this report.

<sup>2</sup> Sensitivity: The proportion of all positive chemicals that are correctly classified as positive in a test. A measure of test performance.

<sup>3</sup> Specificity: The proportion of all negative chemicals that are correctly classified as negative in a test. A measure of test performance.

<sup>4</sup> Positive predictivity: The proportion of correct positive responses among materials testing positive. A measure of test performance. The positive predictivity is a function of the sensitivity of the test and the prevalence of positives among the chemicals tested.

<sup>5</sup> Negative predictivity: The proportion of correct negative responses among materials testing negative. A measure of test performance. The negative predictivity is a function of the sensitivity of the test method and the prevalence of negatives among the chemicals tested.

<sup>6</sup> Accuracy: (a) The closeness of agreement between a test result and an accepted reference value. (b) The proportion of correct outcomes of a method. Often used interchangeably with concordance.

<sup>7</sup> The poor but equal negative predictivity for the LLNA, GPMT/BA, and GPT test results versus human may be due to the nature of the human database used, which was biased towards substances used as HPTAs (approx. 57% when N=74; 61% when N=57; and 60% when N=62).

**Table 3. Comparative Evaluation of the PRP's LLNA Database Limited to Compounds with LLNA, Guinea Pig, and Human Data<sup>1</sup>**

Comparison	Number of Comparisons	Sensitivity <sup>2</sup>		Specificity <sup>3</sup>		Positive Predictivity <sup>4</sup>		Negative Predictivity <sup>5</sup>		Accuracy <sup>6</sup>	
		%	Number	%	Number	%	Number	%	Number	%	Number
LLNA vs HUMAN	57	72%	(39/54)	67%	(2/3)	98%	(39/40)	12%	(2/17) <sup>7</sup>	72%	(41/57)
GPMT/BA vs HUMAN	57	70%	(38/54)	100%	(3/3)	100%	(38/38)	17%	(3/19) <sup>7</sup>	72%	(41/57)
LLNA <sup>8</sup> vs HUMAN	62	73%	(43/59)	67%	(2/3)	98%	(43/44)	11%	(2/18) <sup>7</sup>	73%	(45/62)
GPT vs HUMAN	62	71%	(42/59)	100%	(3/3)	100%	(42/42)	15%	(3/20) <sup>7</sup>	73%	(45/62)

Abbreviations: LLNA = Local Lymph Node Assay; GPMT = Guinea Pig Maximization Test; BA = Buehler Assay; GPT includes nonstandard guinea pig tests; HUMAN = Human Maximization Test (HMT) plus Human Patch Test Allergen (HPTA)

Numbers in parenthesis indicate actual number of comparisons for each analysis.

<sup>1</sup> This analysis was conducted by NICEATM based on the LLNA Submission List of Chemicals provided in Appendix A of this report.

<sup>2</sup> Sensitivity: The proportion of all positive chemicals that are correctly classified as positive in a test. A measure of test performance.

<sup>3</sup> Specificity: The proportion of all negative chemicals that are correctly classified as negative in a test. A measure of test performance.

<sup>4</sup> Positive predictivity: The proportion of correct positive responses among materials testing positive. A measure of test performance. The positive predictivity is a function of the sensitivity of the test and the prevalence of positives among the chemicals tested.

<sup>5</sup> Negative predictivity: The proportion of correct negative responses among materials testing negative. A measure of test performance. The negative predictivity is a function of the sensitivity of the test method and the prevalence of negatives among the chemicals tested.

<sup>6</sup> Accuracy: (a) The closeness of agreement between a test result and an accepted reference value. (b) The proportion of correct outcomes of a method. Often used interchangeably with concordance.

<sup>7</sup> The poor but equal negative predictivity for the LLNA, GPMT/BA, and GPT test results versus human may be due to the nature of the human database used, which was biased towards substances used as HPTAs (approx. 61% when N=57 and 60% when N=62).

<sup>8</sup> This analysis includes compounds tested in nonstandard guinea pig tests. Number of comparisons refers to the number of substances tested in both systems.

**Table 4. Influence of the Threshold SI on Sensitivity and Specificity**

Comparison	Number of Comparisons	SI Threshold	Sensitivity %	Specificity %	Accuracy %
LLNA vs. GPT	105	2.0	85% (66/78)	59% (16/27)	78% (82/105)
		2.5	82% (64/78)	74% (20/27)	80% (84/105)
		3.0	81% (63/78)	89% (24/27)	83% (87/105)
		3.5	79% (62/78)	89% (24/27)	82% (86/105)
		4.0	78% (61/78)	93% (25/27)	82% (86/105)
LLNA vs. Human	60	2.0	72% (39/54)	33% (2/6)	68% (41/60)
		2.5	72% (39/54)	50% (3/6)	70% (42/60)
		3.0	65% (35/54)	67% (4/6)	65% (39/60)
		3.5	65% (35/54)	67% (4/6)	65% (39/60)
		4.0	61% (33/54)	83% (5/6)	63% (38/60)

Using human response data as the “gold standard”, three compounds (aniline, nickel sulfate, neomycin sulfate) were false negatives in the LLNA and one (sodium lauryl sulfate [SLS]/sodium dodecyl sulfate) was a false positive in the LLNA. The GPMT/BA registered four false negatives (musk ambrette,

### 3.5.2. Prediction of positive sensitizers

The LLNA shows a high concordance with human data and guinea pig test data for strong and moderate sensitizers. The Sponsors reported a 93% positive predictivity in comparison with the guinea pig assays. Improvements in the LLNA should be targeted toward enhancing the detection of weak sensitizers. It is the opinion of some of the PRP members that improved detection of weak sensitizers may be accomplished using the LLNA if the number of exposures (or dose groups) and the number of animals were increased. However, from some false negative cases, the data demonstrate that compounds negative in the LLNA are strongly so and increasing the numbers of test animals would not be likely to have any effect on the test outcome.

As stated in the previous section, three compounds yielded false negatives in the

ammonium thioglycolate, ethylene glycol dimethacrylate, neomycin sulfate) and no false positives. While these data show one more false positive for the LLNA than the GPMT/BA, the rates of mis-classification for both are low and not significantly different.

LLNA in comparison to human response data. The GPMT/BA also registered three false negatives. The analyses of sensitivity and specificity indicated the predictive value of a positive LLNA test was 93% and the predictive value of a negative test was 80% compared to GPMT/BA. When compared to human data the predictive value of a positive LLNA test was 96% and the predictive value of a negative LLNA test was 17%. Similar positive and negative predictivity values (100% and 16%, respectively) were found when the GPMT test was compared to human data.

### 3.6. Acceptability of sensitivity, specificity, concordance, and false positive and negative rates

Analysis of concordance between the LLNA and guinea pig data and the LLNA and human data give confidence that the LLNA can reasonably predict human responses to sensitizers when compared to currently accepted methods for regulatory decisionmaking. Potential problems in the

LLNA test with certain non-sensitizing irritants mis-classified as positive for sensitization and false negatives (compared to human data) represented by compounds from several different classes.

### **3.7. Scientific validity of conclusions on assay usefulness**

#### **3.7.1. Clinical relevance and human predictivity**

The results of the LLNA are clinically relevant and the test is predictive except for some weak human contact allergens. The functioning of the immune systems of mice and humans are very similar as they relate to ACD. Human ACD generally arises through dermal exposure to non-abraded skin. It is a two-step process requiring first induction of specific immunity, followed by an elicitation response several weeks later. The LLNA utilizes topical application of the test compound to non-

abraded skin and quantifies the induction phase (proliferation of T-lymphocytes in the draining auricular lymph nodes) as the indication of the potential of a compound to produce sensitization. One concern is that some non-sensitizing, irritant compounds may produce sufficiently profound lymphocyte proliferation to yield a false positive result. Also, some compounds that are recognized as human sensitizers do not produce a sufficiently strong proliferative response in the LLNA and are mis-classified as negative. This is also true for the guinea pig tests.

#### **3.7.2. Regulatory utility of the method**

The utility of the method for regulatory use in hazard assessment of chemicals as potential human contact sensitizers has been clearly established, subject to the limitations discussed above.





## 4. Test Method Reliability (Repeatability/Reproducibility)

In general, the initial LLNA Submission presented qualitative data, which demonstrate adequate intra- and inter-laboratory repeatability and reproducibility. The Submission was deficient, however, in the presentation of quantitative data supporting the reliability of the test method.

The reproducibility of the test method results across laboratories was adequate for a biological assay. In all but one interlaboratory comparison study, all of the test chemicals were identified prior to testing. In the only blinded study, 20 of 25 test chemicals were coded and of these, six chemicals were not reproducibly identified among the four laboratories. More confidence in the intra- and inter-laboratory repeatability and reproducibility of the test method would have been achieved had more quantitative blinded studies been performed. Also, while in most cases the sensitizers and non-sensitizers were correctly identified, it is likely to be more difficult to yield repeatable data with non-sensitizing irritant compounds or weak sensitizers.

### 4.1. Adequacy of intralaboratory repeatability and reproducibility evaluations

The data evaluated for intralaboratory repeatability and reproducibility were limited, in that only six chemicals were evaluated. These data (i.e., Basketter et al., 1996a; Kimber et al., 1998; Loveless et al., 1996) are presented in a summarized form in Tables 1 and 2 (Appendix C, pages C-12 and C-13, respectively) of the Submission. These data, while limited, indicate sufficient agreement; however, there are some discrepancies between the tables. For example, Table 1 of the Submission indicates that three tests were carried out on DNCB and all were positive. However, Table 2 of the Submission indicates that only two tests were carried out for this chemical, not three.

Table 1 of the Submission presents qualitative intralaboratory repeatability data from one laboratory for six compounds including one

potent sensitizer assayed three times, three moderate sensitizers assayed four to six times, and two non-sensitizers assayed four or six times. The data indicate that the LLNA correctly identified four known sensitizers, which occurred in three to six repeated tests on each chemical. In this same laboratory, methyl salicylate was correctly identified as a non-sensitizer in each of four tests, while benzocaine was identified as a non-sensitizer in five of six tests.

Table 2 of the Submission presents quantitative intralaboratory data (i.e., EC3 values, defined as the estimated concentration needed to produce an SI of three) from five laboratories that performed two tests each on the potent sensitizer DNCB and two laboratories that performed six tests each on the moderate sensitizer HCA. An assessment (Appendix K) of the DNCB data presented in Table 2 of the Submission indicate a lack of significant intralaboratory variability.

The data in Table 2 of the Submission also allows for a calculation of coefficient of variation (CV) for intralaboratory variability, which is presented in Table 5.

Recognizing the limitations of such a calculation (i.e., five of the CVs were based on only two tests), overall the CVs are reasonable. In all cases, the sensitizers and non-sensitizers were correctly identified. However, it is likely to be more difficult to yield repeatable data with non-sensitizing irritant compounds or weak sensitizers.

The information provided is sufficient to show that the LLNA can be reproducibly performed in a qualitative manner. However, it would be useful if future evaluations included further statistical analysis of the data to more accurately establish responses by chemical class. Also, it would be useful if future studies include an analysis of the intralaboratory repeatability of this method with an emphasis on compounds with a maximum SI clustered around three.

**Table 5: Analysis of Intralaboratory Variability**

Laboratory	N	Mean	SD	CV (%)
DNCB Laboratory 1	2	0.040	0.01414	35.4
DNCB Laboratory 2	2	0.055	0.00707	12.9
DNCB Laboratory 3	2	0.050	0.01414	28.3
DNCB Laboratory 4	2	0.075	0.02121	28.3
DNCB Laboratory 5	2	0.045	0.02121	47.1
Isoeugenol	5	0.420	0.10955	26.1
HCA Laboratory 1	6	7.7167	2.0605	26.7
HCA Laboratory 2	6	9.1667	1.7166	18.7
Eugenol	5	9.62	1.7693	18.4

#### 4.2. Adequacy of interlaboratory reproducibility evaluations

The NICEATM assessment (Appendix K) of the interlaboratory reproducibility of the LLNA data presented in Table 2 of the Submission (Appendix C, page C-13) indicated a lack of significant between-laboratory variability. Interlaboratory CVs of 25.5% and 12.1% were obtained for DNCB and HCA, respectively. These CVs are adequate for a biological assay.

However, these values were derived from the mean of two tests in five laboratories and six tests taken at each of two laboratories for DNCB and HCA, respectively, and thus may not be truly representative of a more general single test result at one or more laboratories. Based on EC3 values contained in Kimber et al. (1995) and Loveless et al. (1996), some calculations of inter-laboratory CVs can be made, as presented in Table 6.

**Table 6: Analysis of Interlaboratory Variability**

Compound	Quantitative Interlaboratory Data						Reference
	Lab 1	Lab 2	Lab 3	Lab 4	Lab 5	CV (%)	
DNCB	0.3	0.5	0.6	0.9	0.6	37.4	Kimber et al. (1995)*
	0.5	0.6	0.4	0.6	0.3	27.2	Loveless et al. (1996)*
HCA	7.9	7.6	8.4	7.0	8.1	6.8	Loveless et al. (1996)
Isoeugenol	1.3	3.3	1.8	3.1	1.6	41.2	
Eugenol	5.8	14.5	8.9	13.8	6.0	42.5	
SLS	13.4	4.4	1.5	17.1	4.0	83.7	

\*These data are also provided in Table 2 of the Submission.

With the exception of SLS, which is a false positive irritant, these data indicate acceptable interlaboratory variability.

There were several earlier open study design interlaboratory studies performed in the UK that showed adequate concordance (72% to 100%) among methods/laboratories; however, these studies remain limited for drawing conclusions about quantitative EC3 variation. In the first study (Kimber et al., 1991), four laboratories evaluated eight chemicals using the same protocol vehicles and test concentrations. All the laboratories appropriately identified the eight chemicals (100% concordance). In a second study, the same four laboratories tested 25 chemicals (Basketter et al., 1991). Eighteen of 25 equivalent predictions of sensitizing potential (72% concordance) were achieved. In this study, 20 of 25 test chemicals were coded and of these, six chemicals were not reproducibly identified among the four laboratories. However, in the single blinded study, there was low concordance. In a third study, four laboratories evaluated nine chemicals with a protocol deviation from the proposed protocol (i.e., the LLNA was performed on day five instead of day four after three consecutive days of topical application [Scholes et al., 1992a]). Chemicals were evaluated at three concentrations that were pre-selected and differed among the participating laboratories. Eight of nine equivalent predictions of sensitizing potential (89% concordance) were obtained, with 4-chloroaniline being the exception. In a fourth study, five laboratories (i.e., two in the UK and three in the US), in collaboration with the FDA (Kimber et al., 1998), showed five of six equivalent predictions of sensitization potential (83%), with streptomycin being the exception.

#### **4.2.1. Inter- and intra-laboratory vehicle control data**

There is a considerable range of values for vehicle control data; however, it is difficult to determine if the differences actually affect data quality because the endpoint (SI) in the LLNA is based on the ratio of DPM in the test lymph nodes to that in the vehicle controls. For example, the data presented in Kimber et al. (1998) indicate that the DPM for vehicle

controls in the test for benzoyl peroxide ranged from a low of 262 to a high of 463, and for hydroquinone from 257 to 781. However, the SIs for these two chemicals tested at the same concentrations were comparable. Therefore, it is not apparent that the vehicle control results significantly affected data quality.

#### **4.3. Reproducibility of reference chemicals or products**

The studies appear to have included both clinically relevant sensitizing and non-sensitizing chemicals that represent the types of substances for which the test is proposed for use. The reproducibility of the LLNA was evaluated on a total 49 chemicals/ products (Tables 1 and 2 of the Submission, Appendix C; Kimber et al., 1991; Basketter et al., 1991; Scholes et al., 1992a; Kimber et al., 1995; Loveless et al., 1996; Kimber et al., 1998), with a concordance of 82% among laboratories for identifying the sensitization potential of these chemicals/products.

#### **4.4. Repeatability and reproducibility of results**

The results obtained with the LLNA appear to be sufficiently repeatable and reproducible. As indicated above (A and B) for the small data set presented in Tables 1 and 2 of the Submission, which were analyzed by NICEATM (Appendix K), sufficient intra- and inter-laboratory repeatability and reproducibility were indicated for the LLNA. However, it is not known how other LLNA data would fare in such an analysis. More confidence in the repeatability and reproducibility of the results would have been gained had an additional blinded study been performed.

#### **4.5. Reproducibility and reliability of LLNA versus standard guinea pig assays**

A study that directly compares the reproducibility and reliability of the LLNA with the guinea pig assay has not been performed. To the best of the reviewers' knowledge, the guinea pig data have not been evaluated for intra- and inter-laboratory reproducibility and reliability.

**4.6. Conclusion:**

The Submission presents qualitative data, which demonstrate adequate intra- and inter-laboratory repeatability and reproducibility.

**4.7. Recommendation:**

Further testing of the assay should include an additional blinded interlaboratory study with moderate and weak sensitizers.

## 5. Other Scientific Reviews

### 5.1. Literature Reviewed

A literature search was conducted on August 17, 1998 (Medline data base, 1966 to present) using "Local Lymph Node Assay" as the key phrase. A total of 69 articles were retrieved (Appendix B). Of the 69, 42 were published by one or more of the Sponsors involved in the ICCVAM Test Method Submission, or their colleagues, and 27 papers were published by others working in the field.

The PRP concentrated on papers published by investigators not directly involved with the ICCVAM Test Method Submission. Thirteen of these papers reported that the LLNA showed concordance with the GPMT or human results. Three suggested non-concordance (not including the issue of the inability of the LLNA to identify metal salts as contact allergens). The PRP did not independently verify these results. Four papers dealt with other endpoints for the LLNA, two using cytokine production *in vitro*, one using flow cytometry (FCM) to measure proliferation, and one using immunohistochemistry to measure cytokine production *in vivo*. Six publications covered the issue of false negatives when metal salts were used. Finally, five different papers dealt with generating LLNA data in different species (rats-four; hamsters-one).

Perhaps the most interesting were the publications suggesting that modifications in the LLNA procedure may serve to make the assay more sensitive when irritants were tested and thereby reduce the false positive rate. When common irritants are used in the LLNA, they give a false positive result, inasmuch as these irritants are not contact allergens when applied to human skin. This issue has been described in the literature by others and it is possible that a modification of the LLNA, a pre-exposure to the irritant by use of an occluded patch (Boussiquet-Leroux et al., 1995), or by intradermal injection (in Freund's complete Adjuvant) of the irritant followed by cutaneous application (Ikarashi et al., 1993), resolves this issue and renders the irritants

non-sensitizers in the LLNA. As yet, these findings have not been independently verified.

A major failing of the LLNA, as described, is its inability to identify metal salts as contact allergens. This issue has also been addressed by others in the literature. In three papers, Ikarashi et al. (1992a; 1992b; 1993) suggested that the use of DMSO as a vehicle results in a positive LLNA test when metal salts, including nickel and copper salts, are applied to the skin.

Another paper describing the effect the vehicle may have on the results was published by Montelius et al. (1996). Olive oil poses problems in the LLNA as it is reported as an allergen giving SI values of at least 16 when tested at 100% concentration and at least 2.9 when tested as AOO (4: 1).

### 5.2. Conclusions

A review of the other scientific literature supports the use of the LLNA as an alternative assay to identify contact allergens. The LLNA is deficient in detecting sensitization by some weak contact sensitizers, some metals, and organometal compounds.

### 5.3. Recommendations for future workshops

- 1) Evaluation of whether the LLNA procedure should be modified to contain a second test, including a pre-exposure, as described by Boussiquet-Leroux et al. (1995) and/or Ikarashi et al. (1993), when positive test results are obtained in the first test, such as occurred for irritants, xylene, and pyridine. The purpose of such a modification is to avoid the number of false positive test results.
- 2) Consideration of whether DMSO should be required as the vehicle in order to increase the sensitivity of the assay (i.e., allow the assay to detect metal salts as contact allergens).
- 3) Consideration of whether the use of the differentiation index should be employed,

as described by Homey et al. (1998), to differentiate between irritant and contact allergic reactions.

- 4) Evaluation of the design, performance, and execution of assays for the prediction of

allergic contact sensitivity. Since 1943, various agencies have attempted to minimize the frequency of ACD in man. This workshop would review the half century of experience in the hopes of refining our techniques and interpretation.

## **6. Other Considerations**

### **6.1. Test method transferability**

In general, the test method can be readily transferred among properly equipped and staffed laboratories. The method is tolerant of minor protocol changes, the techniques are commonly used, personnel can readily be trained, and the necessary equipment and supplies can be readily obtained. Whether the method is sensitive to more substantial changes in protocol such as varying the strain of mouse or varying the gender of the mouse is not clear. Some concern was raised regarding the availability of the CBA/Ca or CBA/J mouse worldwide. In addition, the differences in SI obtained by the Montelius group raises concern about the transfer of the method between laboratories. With the inclusion of a concurrent positive control in the protocol, the concern regarding transfer of the technique is reduced. Interlaboratory variability can be more easily determined in the future (see section III).

#### **6.1.1. Sensitivity to minor protocol changes**

The LLNA appears to be insensitive to minor changes in protocol. In addition, the use of radioiodinated uridine rather than tritiated thymidine is said to produce the same assay results and conclusions.

Changing the mouse strain or gender cannot be defined as minor changes in protocol until more substantive data and comparisons are provided. No systematic comparisons of alternative mouse strains or effect of gender have been presented. Documentation provided (Kimber et al., 1998) suggests that for some CBA substrains, substrain differences do not have much effect on the LLNA response. A clear concise presentation of the effect of gender and strain of the mouse would provide evidence that any such changes in the protocol would not make a difference in the conclusion.

### **6.1.2. Considerations regarding training and expertise**

The training and expertise in biology available to perform the LLNA is substantial. Tritiated thymidine incorporation as a measure of cellular proliferation is a technique which has been used in immunology laboratories for many years. Thus, expertise in this method is widespread. Individuals skilled in animal handling, including tail vein injection and lymph node harvesting, are required. The technical skills required are significant, but not prohibitive. The test endpoint is objective and requires minimal training in judgment. The use of radioactivity adds to the training requirements of personnel and the level of expertise required.

#### **6.1.3. Ease in obtaining necessary equipment and supplies**

The laboratory equipment and supplies required are standard and readily obtainable. The assay can be readily conducted in research laboratories with radioisotope facilities.

### **6.2. Cost-effectiveness**

A direct comparison of the actual cost required to conduct the LLNA vs the GPMT was not provided in the Submission. It is expected that the cost of the LLNA will not exceed the current guinea pig tests and will decrease as the use of the assay is increased. The following data were obtained by NICEATM.

Animal costs: Assume that 16 to 30 mice (LLNA) or 24 to 32 guinea pigs (GPMT) are required for the testing of one chemical. Then, 16 to 30 six-week old CBA/J mice cost from \$160.80 to \$301.50. This is compared to the cost of 32 to 43 guinea pigs (400 to 450 g) from Charles River Laboratories at \$1832 to \$2462. In addition, care costs for mice are less than that for guinea pigs because of their smaller size and space requirements and shorter experimental duration.

Cost for testing of chemicals: Two US contract laboratories were contacted regarding testing using the LLNA. These labs quoted prices per chemical in the range of \$4,950 (if two chemicals were tested) to \$6,900 (if one chemical was tested). The only laboratory contacted regarding the cost of testing using the GPMT quoted a price of \$6000 to \$7000 per chemical. These estimates suggest that the dollars saved in the purchase of animals for the LLNA would be required for the technical time and expertise required to tail vein inject and harvest and process lymph nodes from the mice. However, an exact analysis of this issue is not provided in the Submission. Certainly animal costs would be reduced even if the cost for running the whole test would not necessarily be reduced. One advantage cited for the LLNA was that the amount of test chemical required is much less than for the guinea pig tests, resulting in additional cost reduction and overall safety. The actual cost of the assay will depend on how many concentrations of chemicals are tested. The cost of radio-labeled thymidine (\$20 to 30/test chemical) as well as the cost of radioactive facilities and disposal of radioisotope contaminated waste must also be considered in the final analysis.

### **6.3. Considerations regarding the time needed to conduct the test**

The time needed to conduct the test is reasonable. The time from the beginning treatment of animals to a final result is maximally seven days. This is a substantial improvement over the time frame required in the GPMT to obtain a result (i.e., at least 25 days).

### **6.4. Refinement, reduction, and replacement considerations**

The LLNA procedure is a definite refinement in terms of reducing or eliminating distress in animals compared to the GPMT. The LLNA does not replace the use of animals for assessing the potential of compounds to cause ACD. Whether the LLNA will result in a reduction in the number of animals used will depend on the actual number of concentrations required for testing the particular compound.

#### **6.4.1. Refinement**

In the LLNA the induction phase of sensitization is being evaluated. Thus, discomfort to animals associated with the elicitation phase is eliminated. The ACD reaction itself is not being measured so redness and erythema are not induced unless the substance causes irritation over the three-day period of treatment of the mouse ear. Very importantly, the LLNA reduces the distress associated with administering adjuvants such as Freund's adjuvant. The animals are involved in the experiment for a considerably shorter period of time than in the GPMT (i.e., seven days compared to  $\geq 25$  days). The only manipulation of the animal is the application of the test solution to the ears on three consecutive days, and one intravenous (i.v.) injection, before the termination of the experiment. This level of manipulation is contrasted to shaving, injection into the skin, and occlusive bandaging in the guinea pig models.

#### **6.4.2. Reduction**

As required in the protocol, lymph nodes from individual animals are processed, five animals are used per group, and a positive control is included in each assay. Thus, for testing one chemical alone, 25 to 35 animals are required for testing three to five concentrations of a compound. Whether three or five concentrations are tested, the number of mice required will be less than or equal to the number of guinea pigs, with dose response information being obtained as well. Testing of multiple compounds in one assay will further reduce the number of animals required since the vehicle and positive controls will not need to be duplicated. In the opinion of some reviewers, testing three concentrations of each test chemical is sufficient. In this case, adoption of the LLNA would definitely result in a reduction in the number of animals used.

### **6.5. Conclusions**

The test method can be readily transferred among properly equipped and staffed laboratories. The method is cost effective and the time required to conduct the assay is considerably less than the current guinea pig



assays. The LLNA procedure is a refinement in terms of reducing or eliminating distress in animals compared to the GPMT.

#### **6.6. Recommendation**

Future submissions to ICCVAM should include quantitative cost data for determination of cost-effectiveness. This cost data should be specific with regard to the number and species/strain of animals (purchase, housing); required reagents and other equipment; and amount of labor (other than animal husbandry) reported in man-hours.



## 7. Related Issues

### 7.1. Alternative endpoints for the LLNA or test method modifications to be considered

proliferative response of lymphocytes to allergens at the induction phase of contact dermatitis. Endpoint assays assessing cell proliferation other than  $^3\text{H}$ -methyl thymidine incorporation may be applicable to the LLNA.

#### 7.1.1. Alternative Endpoints for the LLNA

Published results using alternative endpoints in the LLNA assays are summarized in Table 7. The concept of LLNA is based on the

One approach was published using  $^{125}\text{I}$ -iododeoxyuridine, which has a shorter half-life and reportedly saves on the expense for radiolabeled waste (Ladics et. al., 1995).

**Table 7. Alternative Endpoints for the LLNA**

Assay Type	Targeted Biological Reactions	Assay Endpoint	Application Period*	Animal Strain	Test chemicals <sup>b</sup>	Reference
<b>Original</b>	LNC proliferation	$^3\text{H}$ -methyl thymidine uptake	Day -3 to -1	CBA/Ca	-	-
	LNC proliferation	$^{125}\text{I}$ -iododeoxyuridine uptake	Day -5 to -3	CBA/JHsd	P:4, N:1	Ladics et al. (1995)
	LNC proliferation (Tissue)	Microscopic observation (BrdU)	Day -5 to -3	Rat	P:1, N:1	Arts et al. (1997)
<i>in vivo</i>	LNC proliferation (Tissue)	Microscopic observation (BrdU)	**	CD1	P:4, N:2	Boussiquet-Leroux et al. (1995)
	LNC proliferation (PCNA)	FCM	Day -4 to -1	BALB/c, C57/BL6	P:3, N:2	Kuhn et al. (1995)
	Cellularity & LNC phenotype	FCM	Day -4 to -2	BALB/c, CBA/J	P:5, N:6	Sikorski et al. (1996)
	Cellularity, proliferation, & phenotype	FCM	Day -5 to -3	BALB/c	P:1, N:1	De Silva et al. (1993)
	LNC proliferation & cytokine profile	cRT-PCR, ELISA	Day -3 to -1	BALB/c	P:1, N:0	Ulrich et al. (1998)
<i>ex vivo</i>	Cytokine production (IL-2)	ELISA	Day -3 to -1	BALB/c	P:8, N:2	Hatao et al. (1995)
	Cytokine production (IL-2)	ELISA, FCM	Day -3 to -1	BALB/c	P:10, N:4	Hariya et al. (1999)
	Cytokine production (IL-6)	ELISA	Day -3 to -1	BALB/c	P:9, N:2	Dearman et al. (1994)

Abbreviations: BrdU = bromodeoxyuridine; cRT-PCR = competitive reverse transcriptase-polymerase chain reaction; FCM = flow cytometry; ELISA = enzyme-linked immunosorbent assay; IL-2 = interleukin type 2; IL-6 = interleukin type 6; LNC = lymph node cell; N = negative; P = positive; PCNA = proliferating cell nuclear antigen

\* Day 0=lymph node excision

\*\* Pre-exposure with occluded patch plus three-day application

However, radioisotopes are still used. A proliferative response of lymph node cells (LNC) in rats (Arts et al., 1997) and mice (Boussiquet-Leroux et al., 1995) was assessed by a non-radioisotope method using bromodeoxyuridine (BrdU). However, these methods may not be as accurate as the original LLNA since they necessitate cell counting under microscopic observation. If the non-radioisotope method can produce a reproducible SI similar to that obtained with the standard LLNA, it may be an acceptable alternative. The proliferation of LNC was also determined by the FCM analysis of proliferating cell nuclear antigen (PCNA) (Kuhn et al., 1995). This method could possibly be a promising alternative to the radioisotope-dependent assay but needs to be validated with a wider range of allergenic chemicals.

Other than the proliferative response, several functional approaches were reported, including phenotypic analysis of LNC subpopulations B220 positive cells which increase in number in response to allergenic chemicals (Sikorski et al., 1996). This method does not require the use of radioisotopes and was reportedly effective in differentiating allergens from irritants. Another non-radioisotope LLNA was based on the use of FCM (De Silva et al., 1993). The strong sensitizer DNCB induced a significant increase in CD3 positive and CD25 positive cells compared with vehicle control and SLS. This method reportedly distinguished contact allergens from irritants as well, but is unvalidated.

Cytokine production in LNC was assessed using competitive reverse transcriptase-polymerase chain reaction (cRT-PCR) or enzyme-linked immunosorbent assay (ELISA). As Th1 lymphocytes are considered to play an important role in contact allergy, several efforts were attempted to detect Th1-cytokine production induced by contact allergens. Analysis of cytokine gene transcription *ex vivo* and cytokine release revealed that Th1 type cytokines as well as Th2 (T-helper cell type 2) type cytokines were produced during the induction phase of contact dermatitis (Ulrich et al., 1998). Production of IL-2 (interleukin type 2), one of the important Th1-cytokines, was investigated as well (Hatao et al., 1995).

The amount of IL-2 was increased by strong allergens but was not always increased by moderate allergens. However, the inclusion of IL-2 production with lymph node weight and CD4 positive subset ratio in LNC improved the sensitivity (Hariya et al., 1999).

The CD IV positive subset ratio reportedly detected the difference between allergens and SLS although the difference is small. In addition to Th1 cytokines, the production of IL-6 (interleukin type 6), an inflammatory cytokine with a co-stimulatory effect on T cell proliferation, was measured in *ex vivo* LLNA (Dearman et al., 1994). IL-6 production was increased by strong allergens; however, the sensitivity of this method was reportedly not sufficient for routine identification of skin allergens.

Proliferation of LNC possibly includes both antigen-specific expansion by contact sensitizers and non-specific proliferation by irritants (Homey et al., 1998). Therefore, a functional analysis may have the potential to differentiate allergens from irritants in addition to the measurement of proliferative response. These approaches have not been fully validated and should be further studied using a wider range of chemicals.

### 7.1.2. Test method modifications

In addition to the *in vivo* LLNA, there have been several reports dealing with *ex vivo* LLNA. One of the major disadvantages of *in vivo* LLNA is the radioisotope-contaminated carcasses. To eliminate this disadvantage, a change from *in vivo* LLNA to *ex vivo* LLNA may be a possible alternative.

The extra work needed for *ex vivo* LLNA would be cell-counting and short-time cell culture. Nevertheless, there would be gains as follows;

- (1) No need for i.v. injection;
- (2) The amount of radiolabeled thymidine is reduced;
- (3) Only simple precautions are necessary; and
- (4) Slightly better in terms of animal welfare.

*Ex vivo* LLNA with *in vitro* thymidine uptake would offer advantages in handling but may reduce the sensitivity of the assay.

Several reports are published for the purpose of improving the sensitivity of LLNA. Vitamin A acetate enriched diet for three weeks increased the sensitivity of *ex vivo* LLNA (Sailstad et al., 1995). As a result, the allergenicity of 15% formalin and 3% glutaraldehyde (sensitizers) was detected. Also, the use of an adjuvant improved the sensitivity of the *ex vivo* LLNA (Ikarashi et al., 1993). Mice were treated with intradermal injections of test chemical in Freund's complete adjuvant emulsion prior to sensitization. Then, the test chemicals were applied on the ears of mice for *ex vivo* LLNA. The LNC proliferation induced by allergenic chemicals was increased in this modification; however, the one by irritants was not. Another example is pre-exposure with an occluded patch, which reportedly enhanced the sensitivity of a modified LLNA (Boussiquet-Leroux et al., 1995).

## 7.2. Potential workshops and validation efforts

### 7.2.1. General

A workshop on the evaluation process of ICCVAM would be helpful for individuals planning on making Submissions as well as for individuals who may be involved in the evaluation process.

### 7.2.2. Optimization of test conditions in LLNA

There have been several reports regarding modifications of LLNA, which are intended to improve sensitivity, specificity, or handling, and which could be considered for future research needs. The reports include the following modifications;

- a. Pre-exposure of test chemicals: When a positive LLNA result is obtained, should the procedure be refined to include a second test including a pre-exposure, as described by Boussiquet-Leroux, et al. (1995) and/or Ikarashi et al. (1993) to avoid false positives such as is seen when

the irritants, xylene and pyridine, are applied?

- b. Solvent used for topical application: Should DMSO be considered as the vehicle to use to increase the sensitivity of the assay for metal salts?
- c. The administration route of [<sup>3</sup>H]thymidine: i.v. using the tail vein or peritoneal?
- d. Use of abrasion for water-soluble chemicals: Should the ear skin be abraded to increase the sensitivity to water-soluble chemicals?

In addition to these future optimizations, LLNA endpoints other than <sup>3</sup>H-thymidine uptake and the modified LLNA procedures cited in the section VII.A.1. of this report may be a target of research or a validation study.

### 7.2.3. Photosensitization

A photosensitization test composed of UVA irradiation and the LLNA may be a methodological target once the LLNA protocol is accepted for regulatory purposes. One methodological paper used <sup>3</sup>H-thymidine uptake as an endpoint combined with UVA irradiation, which is reportedly able to detect moderate photoallergenic potential (Scholes et al., 1991). An additional two papers are evaluated on the reactions in draining lymph node such as cytokine expression pattern (Ulrich et al., 1998), lymph node weight, LNC count, or used FCM (Vohr et al., 1994). These methods reportedly are able to differentiate photoallergenic compounds from phototoxic compounds; however, they should be further studied using a wider range of chemicals.

### 7.2.4. Immediate-type hypersensitivity

It is recommended that ICCVAM consider a workshop to identify the most predictive methods for detecting immediate-type hypersensitivity following exposure to chemicals and drugs. This is problematic in preclinical drug development as there are no robust models which have been properly evaluated or validated to predict drugs that will

produce immediate-type hypersensitivity following oral exposure in humans. This continues to be a major reason for failure of new pharmaceuticals upon their introduction in clinical trials or the market.

The methods being developed use elevations in total serum immunoglobulins as well as an increase in specific IgE+ (immunoglobulin class E+) lymphocyte populations as a measurement of a chemical's ability to elicit an IgE response. However, investigators have recently started to evaluate the cytokine profiles of lymphocytes following chemical exposures and examining lymphocyte phenotypes as an indication of a chemical's ability to induce irritation or type I or type IV hypersensitivity responses.

Therefore, an immediate-type hypersensitivity test utilizing LLNA could be a topic of a future workshop or validation work.

### **7.3. Summary of Related Issues**

#### **7.3.1 Future assay improvements should be investigated**

- a. Improvement for detection of weak sensitizers, strong irritants, and metals;
- b. *Ex vivo* LLNA with <sup>3</sup>H-methyl thymidine incorporation;
- c. Cytokine production (ELISA or cRT-PCR); and
- d. Cellularity and LNC phenotype analysis.

#### **7.3.2 Future potential workshops**

- a. Explanation of the ICCVAM process for Sponsors and the scientific community.
- b. Potential modification and research needs of LLNA.
- c. Use of LLNA to assess photosensitization.
- d. Models to predict immediate-type hypersensitivity

## 8. Overall Summary Conclusions

### 8.1. Compared with current methods (e.g., the GPMT), could this method be used to provide equivalent or better prediction of human ACD?

The stated objective of the ICCVAM PRP was to determine if the mouse LLNA as a test for hazard identification was equivalent to the guinea pig assays (GPMT/BA). This review involved the evaluation of data on 209 chemicals of which data on 126 chemicals were provided for both LLNA and the guinea pig, and 74 chemicals with both LLNA and human data (human maximization test and Human Patch Test Allergens). The accuracy of the LLNA vs. GPMT/BA was 89% (N = 97), LLNA vs. all guinea pig tests (GPT) was 86% (N = 126), the LLNA vs. the human data was 72% (N = 74), GPMT/BA vs. human data was 72% (N = 57), and GPT vs. human data was 73% (N = 62). The PRP found the concordance between the LLNA and the GPMT/BA to be acceptable, as was the concordance between the LLNA vs. human response, in terms of accuracy, sensitivity, specificity, and positive or negative predictive value compared to that for GPT results. Thus, the consensus of the PRP was that the LLNA results, as submitted and supplemented by the Sponsors, demonstrated that the assay performed well and gave equivalent results to guinea pig methods (GPMT/BA) for the hazard identification of strong to moderate chemical sensitizing agents. An in-depth review of all the chemicals that have been defined in the published literature as human allergens was not conducted as part of this evaluation.

The data demonstrate that the LLNA was less sensitive compared to the GPMT with certain types of agents since results were negative or equivocal in the LLNA with nickel salts, benzocaine (equivocal), 4-chloroaniline, streptomycin sulfate, and sulfanilic acid. All were positive in the GPMT. In cases where there were equivocal data, the LLNA provided more information for evaluation, often including a dose-response curve. Also, the quantitative DPM endpoint removed the

subjectivity of evaluating equivocal responses as with the guinea pig assays.

The PRP determined that dose-response evaluation, individual animal data, and statistical analysis would allow one to evaluate response trends and could suggest the need to retest at higher or lower concentrations. Decision rules for the consistency of interpretation and future use of the method were recommended by the PRP, as discussed in Section I.

In evaluating the LLNA as a stand-alone method for hazard assessment, the PRP further explored discordance of chemicals between the LLNA and GPMT/BA relative to available human data. Only six chemicals were identified to be discordant after discussion between the PRP and Sponsors. For three of these chemicals, the LLNA results were discordant with human data, while the remaining three chemicals were discordant between GPMT/BA and human data.

The data submitted indicate that the LLNA does not accurately predict all weak sensitizers (false negative) and some strong irritants (false positive). The term weak sensitizer is somewhat arbitrary, since the terms weak, moderate, and strong apply to the percentage of animals reacting in the GPMT/BA as described in the published literature or papers submitted by the Sponsors. When comparing the LLNA with the current guideline guinea pig methods, the LLNA appears to provide an equivalent prediction of the risk for human ACD.

The PRP found that the test method protocol was detailed and provided sufficient information on materials and equipment needed and technical procedures such that trained personnel should have no problem in reproducing the assay. The PRP recommended a retrospective audit of at least three of the intra- and interlaboratory validation studies since these were performed in the "spirit" of GLP, but without audit.

As part of the review, the PRP also reviewed papers published by investigators not directly involved with the ICCVAM Test Method Submission. Thirteen of these papers reported that the LLNA showed concordance with the GPMT or human results while three suggested non-concordance (not including the issue of the inability of the LLNA to identify some metal salts as contact allergens). The conclusion of the PRP was that the LLNA was equivalent to the current guinea pig methods as a stand-alone method and offered several advantages including opportunities for future assay improvement and mechanistic studies.

**8.2. Does the LLNA adequately identify the lack of potential of chemicals to induce human ACD? If applicable, specify those circumstances (e.g., specific chemicals/chemical classes) where the LLNA, or test results from the LLNA, would be considered either (i) inadequate or (ii) equal to or better than current methods for concluding that the test article is not a contact sensitizer.**

Some chemicals expected to give negative results based on guinea pig data tested positive or equivocal in the LLNA. This issue was discussed in a telephone conference including PRP members and the Sponsors, and many of these discordant results were resolved to the satisfaction of the PRP.

The PRP was also concerned that some strong irritants may give false positive results in the LLNA assay although the Sponsors have evaluated these issues. In Basketter et al. (1998), a comparison of the HMT and LLNA for identifying irritants is presented. Of the eight chemical irritants tested in the HMT, the LLNA produced false positive results for SLS and false negative results for benzalkonium chloride, lactic acid and octanoic acid. This indicates that there is only a 50% chance of identifying chemicals that are irritants in humans, although irritation has also been a confounding problem with guinea pig assays. The Sponsors have

suggested methods for evaluating the data that may help to distinguish the proliferative effects of irritation in the LLNA. Such improvement may be required to correctly classify irritants in the LLNA.

On a proportional basis, the LLNA appears to be better at identifying the potential of chemicals that induce contact dermatitis than in identifying a non-sensitizing chemical. Relative to GPMT/BA data, the LLNA misidentified aniline, 4-chloroaniline, nickel chloride, nickel sulfate, streptomycin sulfate, and sulfanilic acid as non-sensitizers, and ammonium thioglycolate, copper chloride, ethylene glycol dimethacrylate, musk ambrette, and SLS as sensitizers.

The predictive value of the LLNA vs. GPMT/BA to give a positive test was 93% and the predictive value of a negative test was 80%, giving an accuracy of 89%. The negative test value suggests that the LLNA produced a slightly higher frequency of false negatives than the guinea pig methods. However, it is important to note that in some cases where there was discordance between the assays, the LLNA was a better predictor of the human response.

**8.3. Does the LLNA adequately identify the potential of chemicals to induce human ACD? If applicable, specify those circumstances (e.g., specific chemicals/chemical classes) where the LLNA, or test results from the LLNA, would be considered either (i) inadequate or (ii) equal to or better than current methods for concluding that the test article is a contact sensitizer.**

The LLNA produced negative results for 12 chemicals that tested positive in guinea pig tests, including nonstandard tests. Of the 57 chemicals tested in both the LLNA and GPMT/BA, and for which there are human data (HMT and/or HPTA), the LLNA misidentified 16 chemicals. Similarly, the GPT misidentified 16 chemicals. It was the opinion of the PRP that detection of weak sensitizers was not a significant issue and



some improvement may be accomplished if the number of treatments and the number of animals was increased. Likewise, the use of a three-fold SI to call a chemical a sensitizer along with statistical analysis should improve the decision process.

Another weakness of the LLNA, as described, was the inability to identify some metal salts as contact allergens. This issue has been addressed by others in the literature. In three different papers, Ikarashi et al. (1992a; 1992b; 1993) suggest that the use of DMSO as a vehicle results in a positive LLNA test when metal salts, including nickel and copper salts, are applied to the skin.

Circumstances where the LLNA may give discordant results would include cases where weak sensitizers require extensive exposure time or where dermal penetration does not occur or is delayed through intact skin.

As mentioned earlier, when some common irritants were used in the LLNA, they give false positive results, in as much as they were not contact allergens when applied to human skin. This issue has been described in the literature by others and it has been demonstrated that a modification of the LLNA, involving pre-exposure to the irritant by use of an occluded patch (Boussiquet-Leroux et al., 1995), or by intradermal injection (in Freund's complete adjuvant) of the irritant followed by cutaneous application (Ikarashi et al., 1993) renders the irritants non-reactive in the LLNA.

#### **8.4. Discuss conditions/limitations/restrictions that may affect the intended use of the LLNA, and that are justified based upon the presence or lack of scientific evidence.**

Two limitations of the LLNA have been mentioned and discussed previously. Firstly, in the material provided by the Sponsor, the LLNA failed to detect certain metal salts which are sensitizers in both guinea pigs and humans. Publications by Ikarashi et al. (1992a; 1992b; 1993) may have resolved this weakness through the use of DMSO as the vehicle. Secondly, some common irritants

have given false positive results in the assay. Modifications described by Boussiquet-Leroux et al. (1995) involving pre-exposure of the animal to the irritant by the occluded patch method or by Ikarashi et al. (1993) with intradermal injection (Freund's) of the irritant dissolved in Freund's adjuvant followed by cutaneous exposure improved the ability of the LLNA to discriminate irritant responses.

The protocol does not adequately address the use of a concurrent positive control. A concurrent positive control would provide validity to the assay by indicating that all procedures involved in the assay were conducted properly. In addition, a positive control will provide an internal standard to compare between studies. Guinea pig sensitization studies (e.g., BA and GMPT) usually require a reliability check every six months with substances that are known to have mild-to-moderate skin sensitization properties. The PRP recommended the inclusion of a moderate sensitizer (single dose) as a positive control in all assays.

The mouse strain chosen was a known Th1 responder although a choice based on a systematic comparison of alternative strains was not provided. The literature contains sufficient documentation for the influence of genetic factors on contact allergy, although there is less documentation on how important a role this plays in practice. Likewise, there is evidence that inbred mouse strains differ in DTH reactions to various antigens. The PRP was concerned that little had been done to compare other inbred mouse strains to the CBA mouse in the LLNA. The documentation in the paper cited on this point (Kimber and Weisenberger, 1989), is very preliminary, and with only one strong sensitizer (DNCB) evaluated, and with a protocol different from the one proposed. The PRP recommended that additional research with other strains is required before strains other than CBA are considered validated.

The majority of the data documented in the Submission was generated using female mice. Therefore, it was the opinion of the PRP that the protocol should be limited to the

use of female mice until a systematic comparison of the data from male mice is made available.

The anatomical location (e.g., photograph or diagram) of the auricular lymph nodes was a highly recommended addition to the protocol.

The ability to determine and consider the dose-response relationship (three to five doses) represents an important advantage of the LLNA compared to guinea pig tests. Dose-response analysis becomes very important in the evaluation of equivocal results because the presence of a dose response provides added confidence that skin sensitizing compounds were correctly identified. The dose response also allows for the evaluation of potential toxicity.

Safety issues relating to the handling of radioisotopes were discussed and the PRP recommended that a future improvement might be a non-radioactive endpoint. The PRP saw significant advantages to the use of *ex vivo-in vitro* pulsing to assess thymidine incorporation if sensitivity was not sacrificed, and identified this method as a research need for the future.

#### **8.5. Discuss advantages of the proposed LLNA, as compared to the standard guinea pig methods.**

The LLNA appears to offer several advantages as compared to the standard guinea pig methods. The LLNA:

- (1) evaluates the induction phase of the contact dermatitis response;
- (2) has an objective and quantitative endpoint which can be analyzed to evaluate dose-response;
- (3) is a relatively robust assay as indicated by test method transferability between laboratories;
- (4) requires significantly shorter time to conduct;
- (5) is not confounded by colored compounds; and
- (6) has potential to be less costly than the guinea pig assays.

#### **8.5.1. Mechanistic basis of the assay**

The LLNA is based on auricular lymph node proliferation (as assessed by incorporation of radiolabeled thymidine or uridine) following topical administration of test material to the mouse ear. The results are expressed as DPM from treated animals as compared to control. This differs from the scoring of the guinea pig assays in which a test substance is scored as positive based on the percentage of animals in a group that are responders (15% in a nonadjuvant assay and at least 8% in an adjuvant test) (Marzulli and Maibach, 1996). Increased understanding of the underlying mechanisms of the induction of contact sensitization will provide many areas for future improvement of the LLNA, such as assessment of non-radioactive endpoints including cytokine production or local lymph node cell phenotyping.

#### **8.5.2. Endpoint is objective and quantitative**

The LLNA uses the measurement of the incorporation of <sup>3</sup>H-methyl thymidine into proliferating lymphocytes in draining lymph nodes as a measurement of sensitization. Proliferation is directly measured by DPM count, which is an objective endpoint that requires no training in judgement. This is a distinct advantage over the subjective visual scoring of the intensity of erythema and occurrence of palpable edema used in the guinea pig tests.

#### **8.5.3. Time required to conduct assay**

The time from beginning the treatment of animals to a final result in is within seven days. This is a substantial improvement over the minimum 25-day time frame required to conduct the standard guinea pig tests.

#### **8.5.4 Insensitivity to minor variations in protocol**

The LLNA appears to be fairly insensitive to minor changes in protocol. The use of radioiodinated uridine rather than tritiated

thymidine is said to produce the same assay results and conclusions.

#### **8.5.5. Evaluation is not confounded by colored compounds**

Colored compounds can confound visual scoring systems for erythema and edema as used in the guinea pig sensitization tests. Measurement of incorporation of radiolabeled thymidine (or uridine) in the LLNA eliminates this confounder, making the assay more suited for testing of colored compounds.

#### **8.5.6. Cost-effectiveness**

A direct comparison of the actual cost required to conduct the LLNA vs the GPMT was not provided in the Submission. It is expected that the cost of the LLNA will not exceed the current guinea pig tests and decrease as experience with the assay is obtained.

#### **8.6. Has there been adequate consideration and appropriate incorporation of animal use refinement, reduction, and replacement alternatives? Will the LLNA reduce the number of animals required or refine the procedure to eliminate distress compared with the reference tests?**

The LLNA procedure is a definite refinement in terms of reducing or eliminating distress in animals compared to the GPMT. The LLNA does not replace the use of animals for assessing the potential of compounds to cause ACD. Whether the LLNA will result in a reduction in the number of animals will depend on the actual number of concentrations required for testing a particular compound.

##### **8.6.1. Refinement**

In the LLNA, the induction phase of sensitization is being evaluated. Thus, discomfort to animals associated with the elicitation phase is eliminated. The ACD reaction itself is not being measured so

redness and erythema are not induced unless the substance causes irritation over the three-day period of treatment of the mouse ear. Very importantly, the LLNA reduces the distress associated with administering adjuvants such as Freund's adjuvant. The animals are involved in the experiment for a considerably shorter period of time than in the GPMT (i.e., seven days compared to  $\geq 32$  days) The only manipulation of the animal is the application of the test solution to the ears on three consecutive days, and one intravenous (i.v.) injection, before the termination of the experiment. This level of manipulation is contrasted to shaving, injection into the skin, and occlusive bandaging in the guinea pig models.

##### **8.6.2. Reduction**

As required in the protocol, lymph nodes from individual animals are processed, five animals are used per group, and a positive control is included in each assay. Thus, for testing one chemical alone, 25 to 35 animals are required for testing three to five concentrations of a compound. Whether three or five concentrations are tested, the number of mice required will be less than or equal to the number of guinea pigs, with dose response information being obtained as well. Testing of multiple compounds in one assay will further reduce the number of animals required since the vehicle and positive controls may not need to be duplicated. In the opinion of some PRP members, testing three concentrations of each test chemical is sufficient. In this case, adoption of the LLNA would definitely result in a reduction in the number of animals used.

##### **8.7. Recommendations for Future ICCVAM Workshops and Research**

A workshop on the ICCVAM evaluation process would be helpful for individuals planning on making future assay Submissions as well as for individuals which may be involved in the evaluation process.

A workshop on the use of the LLNA for detecting photosensitization in conjunction with UV irradiation would be useful.

A workshop to optimize test conditions of the LLNA was recommended by the PRP.

immediate type hypersensitivity to chemicals/pharmaceuticals was also recommended.

A workshop to discuss and describe research needs for preclinical models to predict

## References

- Arts, J. H. E., C. M. Droge, S. Spanhaak, N. Bloksma, A. H. Penninks, and C. F. Kuper. 1997. Local lymph node activation and IgE responses in Brown Norway and Wistar rats after dermal application of sensitizing and non-sensitizing chemicals. *Toxicology* 117:229-237.
- Ashby, J., D. A. Basketter, D. Paton, and I. Kimber. 1995. Structure-activity relationships in skin sensitization using the murine local lymph node assay. *Toxicology* 103:177-194.
- Basketter, D. A., and E. W. Scholes. 1992. Comparison of the local lymph node assay with the guinea pig maximization test for the detection of a range of contact allergens. *Food Chem. Toxicol.* 30:65-69.
- Basketter, D.A., E. W. Scholes, I. Kimber, P. A. Botham, J. Hilton, K. Miller, M. C. Robbins, P. T. C. Harrison, and S. J. Waite. 1991. Interlaboratory evaluation of the local lymph node assay with 25 chemicals and comparison with guinea pig test data. *Toxicol. Methods* 1:30-43.
- Basketter, D. A., D. W. Roberts, M. Cronin, and E. W. Scholes. 1992. The value of the local lymph node assay in quantitative structure activity investigations. *Contact Derm.* 27:137-142.
- Basketter, D. A., D. W. Roberts, M. T. D. Cronin, and E. W. Scholes. 1993. The value of the local lymph node assay in the development of QSARs for skin sensitization potential. In: C. G. Wermuth (Ed.), *Trends in QSAR and Molecular Modeling 1992*. ESCOM. pp. 580-583.
- Basketter, D. A., E. W. Scholes, and I. Kimber. 1994. The performance of the local lymph node assay with chemicals identified as contact allergens in the human maximization test. *Food Chem. Toxicol.* 32:543-547.
- Basketter, D. A., G. F. Gerberick, I. Kimber, and S. E. Loveless. 1996a. The local lymph node assay: A viable alternative to currently accepted skin sensitization tests. *Food Chem. Toxicol.* 34:985-997.
- Basketter, D. A., E. W. Scholes, I. Fielding, R. J. Dearman, J. Hilton, and I. Kimber. 1996b. Dichloronitrobenzene: A reappraisal of its skin sensitization potential. *Contact Derm.* 34:55-58.
- Basketter, D. A., R. J. Dearman, J. Hilton, and I. Kimber. 1997. Dinitrohalobenzenes: Evaluation of relative skin sensitization potential using the local lymph node assay. *Contact Derm.* 36:97-100.
- Basketter, D. A., G. F. Gerberick, and I. Kimber. 1998. Strategies for identifying false positive responses in predictive skin sensitization tests. *Food Chem. Toxicol.* 36:327-333.
- Bertrand, F., D. A. Basketter, D. W. Roberts, and J.-P. Lepoittevin. 1997. Skin sensitization to eugenol and isoeugenol in mice: Possible metabolic pathways involving ortho-quinone and quinone methide intermediates. *Chem. Res. Toxicol.* 10:335-343.
- Botham, P. A., J. Hilton, C. D. Evans, D. Lees, and T. J. Hall. 1991. Assessment of the relative skin sensitizing potency of 3 biocides using the murine local lymph node assay. *Contact Dermatitis* 25:172-177.
- Boussiquet-Leroux, C., G. Durand-Cavagna, K. Herlin, and D. Holder. 1995. Evaluation of lymphocyte proliferation by immunohistochemistry in the local lymph node assay. *J. Appl. Toxicol.* 15:465-475.

Budavari, S. (Ed.). 1996. The Merck Index, 12<sup>th</sup> ed. Merck Research Laboratories, Merck and Co., Inc., Whitehouse Station, NJ.

Chemfinder. [database online]. 1997. CambridgeSoft Corporation (formerly Cambridge Scientific Computing), Cambridge, JA. Available from the internet, <http://chemfinder.camsoft.com>.

Dearman, R. J., E. W. Scholes, L. S. P. Ramdin, D. A. Basketter, and I. Kimber. 1994. The local lymph node assay: An interlaboratory evaluation of interleukin 6 (IL-6) production by draining lymph node cells. *J. Appl. Toxicol.* 14:287-291.

De Silva, O., M. J. Perez, N. Pineau, A. Rougier, and K. G. Dossou. 1993. Local lymph node assay: Study of the *in vitro* proliferation and control of the specificity of the response by FACScan analysis. *Toxicol. In Vitro* 7:299-303.

Gerberick, G. F., R. V. House, E. R. Fletcher, and C. A. Ryan. 1992. Examination of the local lymph node assay for use in contact sensitization risk assessment. *Fundam. Appl. Toxicol.* 19:438-445.

Hariya, T., M. Hatao, and H. Ichikawa. 1999. Development of a non-radioactive endpoint in a modified lymph node assay. *Food Chem. Toxicol.* 37:87-93.

Hatao, M., T. Hariya, Y. Katsumura, and S. Kato. 1995. A modification of local lymph node assay for contact allergenicity screening: Measurement of interleukin-2 as an alternative to radioisotope dependent proliferation assay. *Toxicology* 98:15-22.

Hausen, B. M., and W. Beyer. 1992. The sensitizing capacity of the antioxidants propyl, octyl, and dodecyl gallate and some related gallic acid esters. *Contact Derm.* 26:253-258.

Hausen, B. M., A. Krueger, J. Mohnert, H. Hahn, and W. A. Konig. 1989. Contact allergy due to colophony. (III). Sensitizing potency of resin acids and some related products. *Contact Dermatitis* 20:41-50.

Homey, B., C. Von Schilling, J. Blumel, H.-C. Schuppe, T. Ruzicka, H. J. Ahr, P. Lehmann, and H.-W. Vohr. 1998. An integrated model for the differentiation of chemical-induced allergic and irritant skin reactions. *Toxicol. Appl. Pharmacol.* 153:83-94.

ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods). 1997. Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the *ad hoc* Interagency Coordinating Committee on the Validation of Alternative Methods. NIH Publication 97-3981. National Institute of Environmental Health Sciences, Research Triangle Park, NC. Available on the internet, <http://ntp-server.niehs.nih.gov/htdocs/ICCVAM/iccvam.html>.

ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods) [website online]. 1998. Evaluation of the validation status of toxicological methods: General guidelines for submissions to ICCVAM (Rev. May 22, 1998). NICEATM, Research Triangle Park, NC. Available on the internet, <http://iccvam.niehs.nih.gov/doc1.htm>.

Ikarashi, Y., T. Tsuchiya, and A. Nakamura. 1992a. Detection of contact sensitivity of metal salts using the murine local lymph node assay. *Toxicol. Lett.* 62:53-61.

- Ikarashi, Y., K. Ohno, T. Tsuchiya, and A. Nakamura. 1992b. Differences of draining node cell proliferation among mice, rats, and guinea pigs following exposure to metal allergens. *Toxicology* 76:283-292.
- Ikarashi, Y., T. Tsuchiya, and A. Nakamura. 1993. A sensitive mouse lymph node assay with two application phases for detection of contact allergens. *Arch. Toxicol.* 67:629-636.
- Kawabata, T. T., L. S. Babcock, and P. A. Horn. 1996. Specific IgE and IgG1 responses to subtilisin carlsberg (alcalase) in mice: Development of an intratracheal exposure model. *Fundam. Appl. Toxicol.* 29:238-243.
- Kimber, I., and D. A. Basketter. 1997. Contact sensitization: A new approach to risk assessment. *Hum. Ecol. Risk Assess.* 3:385-395.
- Kimber, I., and R. J. Dearman. 1991. Investigation of lymph node cell proliferation as a possible immunological correlate of contact sensitizing potential. *Food Chem. Toxicol.* 29:125-129.
- Kimber, I., and C. Weisenberger. 1989. A murine local lymph node assay for the identification of contact allergens. Assay development and results of an initial validation. *Arch. Toxicol.* 63:274-282.
- Kimber, I., J. Hilton, and C. Weisenberger. 1989. The murine local lymph node assay for identification of contact allergens: A preliminary evaluation of in situ measurement of lymphocyte proliferation. *Contact Derm.* 21:215-220.
- Kimber I., J. Hilton, and P. A. Botham. 1990. Identification of contact allergens using the murine local lymph node assay: Comparisons with the Buehler occluded patch test in guinea pigs. *J. Appl. Toxicol.* 10:173-80.
- Kimber, I., J. Hilton, P. A. Botham, D. A. Basketter, E. W. Scholes, K. Miller, M. C. Robbins, P. T. C. Harrison, T. J. B. Gray, and S. J. Waite. 1991. The murine local lymph node assay: Results of an inter-laboratory trial. *Toxicol. Lett.* 55:203-213.
- Kimber, I., J. Hilton, R. J. Dearman, G. F. Gerberick, C. A. Ryan, D. A. Basketter, E. W. Scholes, G. S. Ladics, S. E. Loveless, R. V. House, and A. Guy. 1995. An international evaluation of the murine local lymph node assay and comparison of modified procedures. *Toxicology* 103:63-73.
- Kimber, I., J. Hilton, R. J. Dearman, G. F. Gerberick, C. A. Ryan, D. A. Basketter, L. Lea, R. V. House, G. S. Ladics, S. E. Loveless, and K. L. Hastings. 1998. Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: An inter-laboratory evaluation. *J. Toxicol. Environ. Health* 53:563-579.
- Kligman, A. M. 1990. The spectrum of contact urticaria. Wheals, erythema, and pruritis. *Dermatol. Clin.* 8:57-60.
- Krasteva, M., J. Pequet-Navarro, P. Courtellemont, G. Redziniak, and D. Schmitt. 1996. In vitro primary sensitization of hapten-specific T cells by cultured human epidermal Langerhans cells—A screening predictive assay for contact sensitizers. *Clin. Exp. Allergy* 26:563-570.
- Kuhn, U., U. Lempertz, J. Knop, and D. Becker. 1995. A new method for phenotyping proliferating cell nuclear antigen positive cells using flow cytometry: Implications for analysis of the immune response *in vivo*. *J. Immunol. Meth.* 179:215-222.

- Ladics, G. S., C. Smith, K. L. Heaps, and S. E. Loveless. 1995. Comparison of 125-iododeoxyuridine (125 IUdR) and [3H]thymidine ([3H]TdR) for assessing cell proliferation in the murine local lymph node assay. *Toxicol. Methods* 5:143-152.
- Loveless, S. E., G. S. Lacks, G. F. Gerberick, C. A. Ryan, D. A. Basketter, E. W. Scholes, R. V. House, J. Hilton, R. J. Dearman, and I. Kimber. 1996. Further evaluation of the local lymph node assay in the final phase of an international collaborative trial. *Toxicology* 108:141-152.
- Lovik, M., F. M. Collins, and O. Closs. 1982. Inbred C3H mouse substrain differences demonstrated in experimental murine leprosy. *Immunogenetics* 16:607-611.
- Marzulli, F. N., and H. I. Maibach (Eds.). 1996. *Dermatotoxicology*, 5<sup>th</sup> ed. Taylor & Francis, Washington, D.C.
- Maurer, T., and I. Kimber. 1991. Draining lymph node activation in guinea pigs: Comparisons with the murine local lymph node assay. *Toxicology* 69:209-218.
- Moller, H. 1984. Attempts to induce contact allergy to nickel in the mouse. *Contact Derm.* 10:65-68.
- Montelius J., A. Boman, H. Wahlkvist, and J. E. Wahlberg. 1996. The murine local lymph node assay: Search for an alternative, more adequate, vehicle than acetone/olive oil (4:1). *Contact Dermatitis* 34:428-30.
- Montelius J., H. Wahlkvist, A. Boman, and J. E. Wahlberg. 1998. Murine local lymph node assay for predictive testing of allergenicity: Two irritants caused significant proliferation. *Acta Derm. Venereol.* 78:433-437.
- NRC (National Research Council). 1983. *Risk assessment in the federal government: Managing the process*. National Academy Press, Washington, D.C.
- Prystowsky, S. D., A. M. Allen, R. W. Smith, J. H. Nonomura, R. B. Odom, and W. A. Akers. 1979. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine. Relationships between age, sex, history of exposure, and reactivity to standard patch tests and use tests in a general population. *Arch. Dermatol.* 115:959-962.
- Ptak, W., Z. Dobrowloski, J. Marcinkiewicz, and A. Gryglewski. 1988. Sex differences in regulation of contact sensitivity reaction in mice. 1. Influence of sex on the generation of contrasuppressor and afferent suppressor cells. *Clin. Immunol. Immunopathol.* 47:289-295.
- Sailstad, D. M., S. D. Krishnan, J. S. Tepper, D. L. Doerfler, and M. K. Selgrade. 1995. Dietary vitamin A enhances sensitivity of the local lymph node assay. *Toxicology* 96:157-163.
- Scholes, E. W., D. A. Basketter, W. W. Lovell, A. E. Sarll, and R. U. Pendlington. 1991. The identification of photoallergic potential in the local lymph node assay. *Photodermatol. Photoimmunol. Photomed.* 8:249-254.
- Scholes, E. W., D. A. Basketter, A. E. Sarll, I. Kimber, C. D. Evans, K. Miller, M. C. Robbins, P. T. C. Harrison, and S. J. Waite. 1992a. The local lymph node assay: Results of a final inter-laboratory validation under field conditions. *J. Toxicol. Appl. Pharmacol.* 12:217-222.
- Scholes, E. W., D. A. Basketter, W. W. Lovell, A. E. Sarll, and R. U. Pendlington. 1992b. The identification of photoallergic potential in the local lymph node assay. *Photodermatol.*



Photoimmunol. Photomed. 8:249-254. Scholes, E. W., R. U. Pendlington, R. K. Sharma, and D. A. Basketter. 1994. Skin metabolism of contact allergens. *Toxicol. In Vitro* 8:551-553.

Shultz, L. D., and D. W. Bailey. 1975. Genetic control of contact sensitivity in mice: Effect of H-2 and non H-2 loci. *Immunogenetics* 1:570-583.

Sikorski, E. E., G. F. Gerberick, C. A. Ryan, C. M. Miller, and G. M. Ridder. 1996. Phenotypic analysis of lymphocyte subpopulations in lymph nodes draining the ear following exposure to contact allergens and irritants. *Fund. Appl. Toxicol.* 34:25-35.

Tarayre, J. P., M. Aliaga, G. Villanova, M. Barbara, V. Caillol, M. Bru, and H. Laouressergues. 1984. Pharmacological comparison of the immune and non-immune inflammations induced by picryl chloride and oxazolone in mice. *Arch. Int. Pharmacodyn. Ther.* 269:153-166.

Truett, T. [website online]. 1998. Contact Dermatitis Home Page. Vanderbilt University Medical Center. Available on the internet, [http:// www.mc.vanderbilt.edu.vumcdept/derm/contact/AM003.html](http://www.mc.vanderbilt.edu.vumcdept/derm/contact/AM003.html).

Ulrich, P., B. Homey, and H. Vohr. 1998. A modified murine local lymph node assay for the differentiation of contact photoallergy from phototoxicity by analysis of cytokine expression in skin-draining lymph node cells. *Toxicology* 125:149-168.

Vohr, H. W., B. Homey, H. C. Schuppe, and P. Kind. 1994. Detection of photoreactivity demonstrated in a modified local lymph node assay in mice. *Photodermatol. Photoimmunol. Photomed.* 10:57-64.

## LLNA Submission List of Chemicals

The following list of chemicals includes information from Appendix B, Table 1 of the original submission (Appendix C), unpublished data from a laboratory participating in the validation studies, and supplemental sources.

Participating laboratories in the validation studies have provided statements indicating that the studies were conducted under Good Laboratory Practice (GLP) guidelines or within the spirit of GLP. The laboratory that submitted unpublished data also provided a representative sample of raw data for review. NICEATM concluded that the data provided

supported the results given in the original submission (Appendix C).

NICEATM has included human patch test allergen information from the Contact Dermatitis web site (Truett, 1998); chemical class assignments (some of which are based on categories used by Ashby et al., 1995); product class information from *The Merck Index*, 12<sup>th</sup> edition (Budavari, 1996), and other sources; dermal irritancy potential; sensitization incidence in a cohort of patch tested dermatitis patients (from Marzulli and Maibach, 1996) [*Dermatotoxicology*]; and other comments.

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Abietic acid// Sylvic acid	514-10-3	rosin isomer// terpene derivative// decahydrophenanthrene carboxylic acid// pot. epoxide	cosmetics// manuf. of esters for use in lacquers and varnishes and of metal resins for sizing// metalworking fluids	+	+		+	10% pet. *	Basketter and Scholes (1992); Ashby et al. (1995); Hausen et al. (1989)	Weak sensitizer in a modified FCA method.
2-Acetamidofluorene// 2-AAF// 2-Acetylaminofluorene	53-96-3	amide// PAH		-					Ashby et al. (1995)	
2-(N-Acetoxyacetamido)fluorene// 2-AAAF		amide// PAH// ?acetylated N-oxide// potential epoxide		+					Ashby et al. (1995)	
4-Acetylphenyl benzoate	1523-18-8	aromatic ester// benzoate		-					Ashby et al. (1995)	
3-Acetylphenyl benzoate		aromatic ester// benzoate// acylating agent// benzoylating agent		+	+				Ashby et al. (1995)	
C16-1,3-Alkene sultone		alkene sultone (sulfur analog of a lactone)		+	+ nonstd				Unpublished Unilever data	
4-Allylanisole// Estragole	140-67-0	aryl alkyl ether	fragrance// flavoring in foods and liqueurs	+	+				Unpublished Unilever data	
4-Aminobenzoic acid// p-Aminobenzoic acid// PABA	150-13-0	arylamine// benzoic acid derivative	UV B sunscreen (cosmetics)// manuf. esters, folic acid, and azo dyes// formerly, antirickettsial	-	-	-	+	10% pet. *	Ashby et al. (1995); Loveless et al. (1996); Basketter et al. (1996a); Truett (1998)	Constituent of photoallergen patch test kit.
3-Aminophenol// m-Aminophenol// 3-Hydroxyaniline	591-275	phenolic// arylamine	dye intermediate// manuf. of p-aminosalicylic acid// potential epoxide	+	+ nonstd		+		Basketter and Scholes (1992)	
2-Aminophenol// o-Aminophenol// 2-Hydroxyaniline	95-55-6	phenolic// arylamine// potential epoxide	manuf. azo and sulfur dyes// dyeing furs and hair	+	+ nonstd				Ashby et al. (1995)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Ammonium tetrachloroplatinate// Ammonium platinous chloride	13820-41-2	heavy metal salt// heavy metal coordination compound	photographic chemical	+	+		+	0.25% pet. *	Basketter and Scholes (1992)	
Ammonium thioglycolate// Ammonium mercaptoacetate	5421-46-5	carboxylic acid salt	hairdressing (reducing agent in permanent hair waving solutions)	+	-		+	1% pet. *	Unpublished Unilever data	
Aniline// Benzenamine	62-53-3	arylamine	manuf. dyes, medicinals, varnishes, etc.// vulcanizing rubber// as solvent	-	+	+			Basketter and Scholes (1992); Basketter et al. (1994); Basketter et al. (1996a)	
Benzalkonium chloride	8001-54-5	quaternary ammonium halide	antimicrobial// cationic surfactant// Pharmaceutic aid (preservative)	-	-		+	0.1% water *	Basketter et al. (1996a); Basketter et al. (1998)	High human skin irritancy potential (52% of panel responded [83% to positive control]).
3-(Benzenesulfonyloxymethyl)-5,5-dimethyldihydro-2(3H)-furanone		benzenesulfonate// lactone// butyrolactone derivative		-					Ashby et al. (1995)	
Benzene-1,3,4-tricarboxylic anhydride// Trimellitic anhydride	552-30-7	aromatic carboxylic acid anhydride// benzoylating agent// acylating agent	preparation of resins, adhesives, polymers, dyes, printing inks	+	+				Ashby et al. (1995); Basketter and Scholes (1992)	
1,2-Benzisothiazolin-3-one	2634-33-5	aromatic amide// heterocyclic	antimicrobial, preservative (sodium salt)	+	+		+	0.1% pet. * (Na salt)	Botham et al. (1991); Ashby et al. (1995)	
Benzocaine	9/7/94	p-aminobenzoic acid	local anesthetic	+/-	+	+/-			Basketter and Scholes (1992); Ashby et al. (1995); Basketter et al. (1994); Kimber and Weisenberger (1989); Kimber et al. (1989); Kimber et al. (1991); Gerberick et al. (1992)	Classified as a moderate sensitizer in the GPMT.
Benzo[a]pyrene	50-32-8	PAH// potential epoxide after metabolism?	none	+					Ashby et al. (1995)	
Benzoquinone// p-Quinone// 1,4-Cyclohexadienedione	106-51-4	quinone// potential Michael-reactive agent	oxidizing agent// manuf. hydroquinone, dyes// tanning hides, etc.	+	+				Basketter and Scholes (1992); Ashby et al. (1995);	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Benzoyl chloride	98-88-4	aroyl halide// acylating agent// benzoylating agent	acylating agent in synthesis// manufacture of benzoyl peroxide and dyes	+	+				Ashby et al. (1995); Budavari (1996)	Skin and mucous membrane irritant.
Benzoyloxy-3,5-benzenedicarboxylic acid// 5-Benzoyloxyisophthalic acid		benzoate// benzoic acid derivative// isophthalic acid deriv.// acylating agent// benzoylating agent		-	+ nonstd				Unpublished Unilever data	
Benzoyl peroxide	94-36-0	aromatic peroxide	pharmaceuticals// food additive (bakery series patch tests)// metalworking fluids// plastics and glues	+	+		+	1% pet. ***	Kimber et al. (1998); Marzulli and Maibach (1996)	20 of 1115 dermatitis patients sensitized// 3 of 1115 showed skin irritation.
Benzyl bromide// .alpha.-Bromotoluene	100-39-0	alkyl halide	alkylating agent?	+					Unpublished Unilever data; Budavari (1996)	Strong skin irritant.
Beryllium sulfate	7787-56-6	alkaline earth metal salt		+	+	+			Basketter et al. (1994); Basketter et al. (1996a)	
C12-13-.beta. Branched primary alcohol sulfate		alkyl sulfate		+					Basketter et al. (1998)	Moderate skin irritant in 4-hour human patch test (84% of panel responded// 90% in positive control).
1-Bromobutane	109-65-9	alkyl halide	alkylating agent	-					Basketter et al. (1992); Ashby et al. (1995)	
1-Bromododecane// Lauryl bromide	143-15-7	alkyl halide		+	+ nonstd				Basketter et al. (1992) Ashby et al. (1995)	
12-Bromododecanoic acid// 12-Bromolauric acid	73367-80-3	bromoalkanoic acid// alkyl halide// aliphatic carboxylic acid		+					Unpublished Unilever data	
12-Bromo-1-dodecanol// 12-Bromolauryl alcohol	3344-77-2	alkanol// bromoalkanol// alkyl halide		+					Unpublished Unilever data	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
1-Bromoheptadecane				+					Basketter et al. (1992)	
1-Bromohexadecane// n-Hexadecyl bromide// Palmityl bromide// Cetyl bromide	112-82-3	alkyl halide		+	+				Basketter et al. (1992) Ashby et al. (1995); Basketter et al. (1996a)	
1-Bromohexane// n-Hexyl bromide	111-25-1	alkyl halide		+	+ nonstd				Basketter et al. (1992); Ashby et al. (1995)	
3-Bromomethyl-3-dimethylidihydrofuranone		lactone// butyrolactone derivative// alkyl halide		+	+				Unpublished Unilever data	
1-Bromononane				-					Basketter et al. (1992)	
1-Bromooctadecane				+					Basketter et al. (1992)	
1-Bromopentadecane// n-Pentadecyl bromide	629-72-1	alkyl halide		+					Basketter et al. (1992); Ashby et al. (1995)	
7-Bromotetradecane// 7-Tetradecyl bromide// 7-Myristyl bromide		alkyl halide		+						
1-Bromotetradecane				+					Basketter et al. (1992)	
2-Bromotetradecanoic acid// 2-Bromomyristic acid	10520-81-7	aliphatic carboxylic acid// alkyl halide		+					Unpublished Unilever data	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
1-Bromotridecane				+					Basketter et al. (1992)	
1-Bromoundecane				+					Basketter et al. (1992)	
2,3-Butanedione// Erythritol anhydride// Butadiene diepoxide	431-03-8	epoxide	crosslinking agent (polymers, textile fibers)	+					Unpublished Unilever data	Reasonably anticipated to be a human carcinogen
Butyl glycidyl ether	2426-08-6	epoxide// dialkyl ether		+	+	+			Basketter et al. (1996a)	
Camphorquinone// Camphoroquinone	465-29-2	quinone	dental material (visible light curing of acrylic composites)	+			+	1% pet. **	Unpublished Unilever data	
Chloramine T	10599-90-3	toluenesulfonamide derivative// sulfonamide//N-chloroamide	antibacterial [antimicrobial] (pharmaceutical, veterinary topical antiseptic)	+	+		+		Basketter and Scholes (1992)	
4-Chloroaniline	106-47-8	arylamine// aryl halide// aniline derivative		-	+				Basketter and Scholes (1992); Ashby et al. (1995); Basketter et al. (1996a)	
Chlorobenzene	108-90-7	aryl halide	synthetic organic intermediate// manufacture of phenol, aniline, DDT// paint solvent// heat transfer	-	-				Ashby et al. (1995); Basketter et al. (1998)	Presumed to have low irritancy potential.
3-(Chlorobenzenesulfonyloxymethyl)-5,5-dimethylidihydro-2(3H)-furanone		lactone// butyrolactone derivative// benzenesulfonate		-					Ashby et al. (1995)	
2-Chloroethanol// Ethylene chlorohydrin// Glycol chlorohydrin	107-07-3	aliphatic alcohol// alkyl halide	solvent// insecticide manufacture	-					Ashby et al. (1995); Budavari (1996)	Skin and mucous membrane irritant.

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
2-Chloromethylfluorene		alkyl halide// PAH		+					Ashby et al. (1995)	
5-Chloro-2-methyl-4-isothiazolin-3-one [no locants & different CASRN in list]	26172-55-4	potential Michael-reactive agent// active aryl halide	cosmetics, biocidal, antimicrobial. Major active ingredient of Kathon CG (200 ppm).	+	+		+	1.34% aq. **	Botham et al. (1991); Ashby et al. (1995)	Kathon CG or MCI/MI is used in paints, hair shampoos, skin care products, and cleaning agents, typically at 35 ppm.
1-Chloromethylpyrene	1086-00-6	alkyl halide// PAH		+					Ashby et al. (1995)	
1-Chlorononane// n-Nonyl chloride	2473-01-0	alkyl halide		+					Basketter et al. (1993)	
1-Chlorooctadecane// Stearyl chloride	3386-33-2	alkyl halide		+					Basketter et al. (1993)	
1-Chlorotetradecane// Myristyl chloride	2425-54-9	alkyl halide		+					Basketter et al. (1993)	
Chlorpromazine	69-09-0	phenothiazine// tertiary amine	pharmaceutical (antiemetic// antipsychotic// veterinary tranquilizer)	+	+ nonstd	+			Basketter et al. (1994); Basketter et al. (1996a)	
Cinnamic aldehyde// cinnamaldehyde	104-55-2	potential Michael-reactive agent	fragrance// food additive (bakery series kit)	+	+	+	+	1 pet. ***	Basketter and Scholes (1992); Ashby et al. (1995); Basketter et al. (1994); Kligman (1990); Marzulli and Maibach (1996)	Urticariogen. Irritant (60/1048) & sensitizer (62/1048) in dermatitis patients.
Citral// 3,7-Dimethyl-2,6-octadienal// Geranial-Neral mixture	5392-40-5	terpene alcohol// potential Michael-reactive agent	fragrance// flavoring// synthesis of vitamin A, ionone, and methylionone	+	+	+			Basketter et al. (1994); Basketter and Scholes (1992); Ashby et al. (1995)	
Clotrimazole	23593-75-1	aryl halide//imidazole derivative	pharmaceutical (topical antifungal [antimicrobial])	+			+	5% pet. *	Scholes et al. (1994)	



Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Concn.	References	Comment
Cobalt chloride	7646-79-9	heavy metal salt	fertilizer and feed additive// paints for glass and porcelain// vitamin B12 manufacture, etc.	+	+	+	+	1% pet. **	Basketter and Scholes (1992); Basketter et al. (1994); Basketter et al. (1996a)	Used in dental patch test series
Cocoamidopropyl betaine//CAPB	61789-40-0	quaternary ammonium compound// alkylaminobetaine	cosmetics// surfactant in shampoos, detergents, and cleaning agents	+	+		+	1% aq. ***	Ashby et al. (1995); Basketter et al. (1996a)	
Copper chloride// Cuprous chloride	7758-89-6	heavy metal salt	catalyst// condensing agent for soaps, fats, and oils// denitration of cellulose	+	-				Basketter and Scholes (1992); Basketter et al. (1996a)	Cupric chloride is a skin irritant. Articles refer to copper chloride. CASRN for cupric chloride is 7447-39-4.
Dextran	9004-54-0	polysaccharide (.alpha.-D-glucopyranosyl units)	foods (soft center confections, partial substitute for barley malt)// pharmaceutical (plasma volume expander)	-	-				Basketter and Scholes (1992); Basketter et al. (1996a)	
1,2-Dibromo-2,4-dicyanobutane	35691-65-7	alkyl halide// aliphatic nitrile	antimicrobial, preservative in paints, adhesives, metalworking fluids, etc.//cosmetic and personal care products	+	+		+	0.1% pet. *	Unpublished Unilever data	Component of Euxyl K-400 (1:4 mixture with phenoxyethanol). Trade name for use in paints is Tektamer 38
2,4-Dichloronitrobenzene	611-06-3	nitroaromatic// aryl halide		-	-				Basketter et al. (1997); Basketter et al. (1996b); Basketter et al. (1996a); Gerberick et al. (1992)	
Diethylenetriamine	111-40-0		hardener for epoxy resins// drilling muds// carbonless copy paper	+	+	+	+		Basketter et al. (1994); Basketter et al. (1996a)	
Diethyl sulfate	64-67-5	alkyl sulfate	alkylating agent// accelerator in ethylene sulfation// used in some sulfonations	+					Ashby et al. (1995)	Reasonably anticipated to be a human carcinogen
Di-2-furanylethanedione// .alpha.-Furil// 2,2'-Furil	492-94-4	potential Michael-reactive agent		-						
3,4-Dihydrocoumarin// Hydroxydihydrocinnamic acid lactone	119-84-6	lactone	fragrance	+					Ashby et al. (1995)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Dihydroeugenol// 2-Methoxy-4-propylphenol// 4-Propylguaicol	2785-87-7	phenolic// alkyl aromatic ether	fragrance	+	+				Unpublished Unilever data	
3-Dimethylaminopropylamine//N,N-Dimethyl-1,3-propanediamine// DMAPA	109-55-7	alkylenediamine// tertiary amine// primary amine	chemical intermediate	+	+				Basketter et al. (1996a)	Corrosive and severely irritating to skin, eyes, and respiratory tract.
7,12-Dimethylbenz[a]anthracene// DMBA// 9,10-Dimethyl-1,2-benzanthracene	57-97-6	PAH// potential epoxide		+					Ashby et al. (1995)	
Dimethyl isophthalate	1459-93-4	isophthalate// aromatic carboxylic acid ester	intermediate in polyester synthesis	-	-				Basketter and Scholes (1992)	
5,5-Dimethyl-3-(mesyloxymethyl)dihydro-2(3H)-furanone		lactone// butyrolactone derivative		-	+ nonstd				Ashby et al. (1995)	
5,5-Dimethyl-3-(methoxybenzenesulfonyloxymethyl)dihydro-2(3H)-furanone		lactone// butyrolactone derivative		-	+ nonstd				Unpublished Unilever data	
5,5-Dimethyl-3-methylenedihydro-2(3H)-furanone		lactone// butyrolactone derivative// potential Michael-reactive agent		+	- nonstd				Ashby et al. (1995)	
5,5-Dimethyl-3-(nitrobenzenesulfonyloxymethyl)dihydro-2(3H)-furanone		lactone// butyrolactone derivative		-	+ nonstd				Ashby et al. (1995)	
Dimethyl sulfate	77-78-1	alkyl sulfate	alkylating agent// methylating agent in organic chemical manufacture	+					Ashby et al. (1995)	Mucous membrane irritant. Reasonably anticipated to be a human carcinogen.
5,5-Dimethyl-3-(thiocyanatomethyl)dihydro-2(3H)-furanone		lactone// butyrolactone derivative// thiocyanate		+	+ nonstd				Ashby et al. (1995)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
5,5-Dimethyl-3-(tosyloxymethyl)dihydro-2(3H)-furanone		toluenesulfonate// lactone// butyrolactone derivative		-	- nonstd				Ashby et al. (1995)	
2,4-Dinitrochlorobenzene// DNCB	97-00-7	active aryl halide// nitroaromatic		+	+				Basketter et al. (1996a); Kimber et al. (1995) Loveless et al. (1996); Kimber and Dearman (1991) Basketter and Scholes (1992); Budavari (1996)	Used as positive control. May cause dermatitis of both primary and allergic types.
Dinitrofluorobenzene//DNFB				+					Kimber and Weisenberger (1989); Montelius et al. (1994); Maurer and Kimber (1991)	
2,4-Dinitrothiocyanobenzene// 2,4-Dinitrophenyl thiocyanate// Nirit	1594-56-5	aryl thiocyanate// nitroaromatic		+	+				Basketter et al. (1996a); Kimber and Dearman (1991); Kimber and Weisenberger (1989)	
Diphenylmethane-4,4'-diisocyanate// Methylenediphenyl diisocyanate// MDI	101-68-8	aryl isocyanate	monomer for polyurethane synthesis// plastics and glues	+	+		+	0.1% pet. *	Basketter et al. (1996a)	
Disodium benzoyloxy-3,5-benzenedicarboxylate		benzoate (ester)// isophthalate (salt)		-	-				Ashby et al. (1995)	
Disodium 1,2-diheptanoyloxy-3,5-benzenedisulfonate		aliphatic carboxylic acid ester// benzenesulfonate salt		+	+ nonstd				Ashby et al. (1995)	
Ditallowdihydroxypropenetrime thylammonium		quaternary ammonium compound		-	-				Unpublished Unilever data	
Dodecyl methanesulfonate// Lauryl methanesulfonate	51323-71-8	alkanesulfonate (ester)		+	+ nonstd				Ashby et al. (1995)	
Dodecyl thiosulfonate// Lauryl thiosulfonate				+	+				Ashby et al. (1995)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Ellipticine	519-23-3		antineoplastic activity	+					Unpublished Unilever data	
Ethylenediamine	107-15-3	alkylamine// alkylenediamine	solvent, stabilizer, inhibitor, textile lubricant, pharmaceutical, cosmetics, epoxy patch test kit	+	+		+	1% as 2HCl pet. **	Gerberick et al. (1992); Kimber et al. (1998); Marzulli and Maibach (1996); Prystowsky et al. (1979)	Dihydrochloride 66/1120 dermatitis patients// 0/1120 irritation// 5/1158 volunteers.
Ethylene glycol dimethacrylate// EGDMA	97-90-5	acrylate	dental materials (monomer)// plastics and glues	+	-		+	2% pet. *	Basketter et al. (1991)	Coded chemical results reported in this publication.
Ethyl methanesulfonate	62-50-0	alkanesulfonate (ester)	experimental mutagen, teratogen, carcinogen	-					Ashby et al. (1995)	Known human carcinogen
1-Ethyl-3-nitro-1- nitrosoguanidine// ENNG		nitrosoguanide// alkylating agent		+					Ashby et al. (1995)	
N-Ethyl-N-nitrosourea// ENU	759-73-9	nitrosamide		+					Ashby et al. (1995)	Reasonably anticipated to be a human carcinogen
Eugenol// Allylguaiacol// 4- Allyl-2-methoxyphenol	97-53-0	phenolic// potential epoxide after metabolism	fragrances// vanillin manufacture// dental analgesic// bakery series kit	+	+		+	2% pet. **	Kimber et al. (1991); Gerberick et al. (1992); Loveless et al. (1996); Basketter and Scholes (1992); Kimber and Basketter (1997); Ashby et al. (1995); Marzulli and Maibach (1996)	Irritating to 5 of 1016 at 4% in petrolatum// 14/1016 showed sensitization in patch test.
Fluorescein isothiocyanate	25168-13- 2	miscellaneous electrophile (Ashby et al., 1995)// isothiocyanate	biological stain or dye	+					Ashby et al. (1995); Krasteva et al. (1996)	Fluorescein is a skin irritant. Strong sensitizer. Product class assumption based on that of fluorescein.
Formaldehyde	50-0-0	aliphatic aldehyde	antimicrobial, disinfectant, monomer, manuf. wood products and shoes, fertilizers, plastics, textile finish	+	+	+	+	1% aq. **	Kimber and Weisenberger (1989); Kimber et al. (1991); Basketter and Scholes (1992); Basketter et al. (1994); Basketter et al. (1996a); Maurer and Kimber (1991); Marzulli and Maibach (1996)	Irritant to 13 of 1144 in human patch test// 70 of 1144 subjects tested were sensitized.
Geraniol	106-24-1	terpene alcohol	fragrance	-	-	-	+	2% pet. *	Basketter et al. (1994); Basketter et al. (1996a)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Concn.	References	Comment
Glyoxal// Oxaldehyde// Ethanedial// Biformyl	107-22-2	aldehyde	biocides, antimicrobial// in textiles, organic synthesis, glues	+	+	+			Basketter et al. (1994); Basketter et al. (1996a); Budavari (1996)	Moderately irritating to skin and mucous membranes.
Gold chloride	16903-35-8	heavy metal salt	photography, gold-plating, gilding glass and porcelain, ruby glass manufacture, reagent for alkaloids	+		+			Basketter et al. (1996a); Budavari (1996)	Caustic action (vesicant) on the skin.
Hexadecanoyl chloride// Palmitoyl chloride	112-67-4	alkanoyl chloride// acylating agent	acylating agent	+					Ashby et al. (1995)	Lacrimator
Hexane	110-54-3	alkane	solvent	-		-			Basketter et al. (1996a); Basketter et al. (1998)	Presumed low irritancy potential.
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	101-86-0	potential Michael-reactive agent	fragrance	+	+				Kimber and Basketter (1997) Loveless et al. (1996)	
Hydrocortisone// Cortisol	50-23-7	steroid	pharmaceutical (anti-inflammatory)	-		-	+	0.1% pet. as 17-butyrate	Basketter et al. (1996a)	
Hydroquinone// Quinol [separate entry in submission]	123-31-9	quinone// potential Michael reactive agent	cosmetics// photographic developer// plastics and glues// polymn. inhibitor// antioxidant// depigmenting skin	+	+		+	1% pet. ***	Kimber et al. (1998); Basketter and Scholes (1992); Ashby et al. (1995)	
4-Hydroxybenzoic acid	99-96-7	phenolic// benzoic acid derivative	chemical intermediate for dyes and fungicides	-	-				Basketter and Scholes (1992); Ashby et al. (1995)	
Hydroxycitronellal	107-75-5	terpene aldehyde// potential Michael-reactive agent// potential epoxide	fragrance// food flavoring// antiseptics [antimicrobial]// insecticides	+	+	+	+	2% pet. *	Basketter and Scholes (1992); Ashby et al. (1995); Basketter et al. (1994); Basketter et al. (1996a); Krasteva et al. (1996)	Weak human sensitizer. Two of 1049 showed irritation in human patch test at 4% in petrolatum// 16 were sensitized.
2-Hydroxyethyl acrylate// HEA	818-61-1	potential Michael-reactive agent// acrylate ester	acrylate monomer// cosmetics (artificial nails)// adhesives, lacquers, UV-curable inks and coatings	+	+		+		Ashby et al. (1995); Basketter and Scholes (1992)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Concn.	References	Comment
2-Hydroxypropyl methacrylate// 2-HPMA	923-26-2	acrylate ester// potential Michael-reactive agent	monomer used in UV-curable inks and coatings, dental composites, printing plates, sealants	-	-		+	0.1% pet.	Basketter and Scholes (1992); Ashby et al. (1995); Bjorkner (1984)	Reported to be a weak sensitizer in the GPMT.
Imidazolidinyl urea// Germall 115	39236-46-9		antimicrobial, preservative// in cosmetics	+	+		+	2% pet. * or aq. **	Basketter and Scholes (1992); Marzulli and Maibach (1996)	Two of 1134 showed irritation in the human patch test// 17/1134 were sensitized.
1-Iodoheptadecane// Palmityl iodide// Hexadecyl iodide	544-77-4	alkyl halide		+					Basketter et al. (1993)	
1-Iodoheptane				-					Basketter et al. (1992)	
1-Iodononane// n-Nonyl iodide	4282-42-2	alkyl halide		+					Basketter et al. (1993)	
1-Iodooctadecane				-					Basketter et al. (1992)	
1-Iodotetradecane// Myristyl iodide// n-Tetradecyl iodide	192-94-1	alkyl halide		+					Ashby et al. (1995)	
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiacol	97-54-1	phenolic// alkyl aryl ether// potential epoxide	fragrance (cosmetics)// food flavor	+	+		+	2% pet. ***	Kimber et al. (1991); Loveless et al. (1996); Basketter and Scholes (1992); Kimber and Basketter (1997)	Isoeugenol is a mixture of cis and trans isomers. Int. Fragrance Res. Assoc. recommends up to 1%
Isononyloxybenzenesulfonate		benzenesulfonate (ester)// aliphatic carboxylic acid ester		+	+				Basketter et al. (1996a)	
Isophorone diisocyanate// IPDI	4098-71-9	isocyanate	monomer for polyurethane plastics// biomedical polyurethane-based hydrogel	+	+		+		Basketter et al. (1996a)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Isopropanol// Isopropyl alcohol// 2-Propanol	67-63-0	alkanol// aliphatic secondary alcohol	solvent// cosmetics// body rubs// pharmaceutical aid (solvent)// manufacture of acetone, glycerol, isopropyl acetate	-	-				Basketter et al. (1996a); Basketter et al. (1998)	Low irritancy potential in human patch test.
Isopropylisoeugenol	29653-00-7	potential Michael-reactive agent	fragrance?	+	+				Unpublished Unilever data	
Kanamycin	25389-94-0	glucose (glucopyranose) derivative// primary alkylamine	pharmaceutical (antibacterial [topical antimicrobial])	-	- nonstd	+	+	10% pet. (as sulfate)	Basketter et al. (1996a); Budavari (1996)	CASRN given in submission is for kanamycin A sulfate// that for kanamycin is 8063-07-8.
Lactic acid// 2-Hydroxypropanoic acid	598-82-3	.alpha.-hydroxy carboxylic acid// alkanolic acid	food additive, mordant, solvent, treating hides, pharmaceutical, catalyst for casting phenolaldehyde resins (polymers).	-	-				Basketter et al. (1998)	CASRN is for racemic lactic acid. Highly irritant in 4-hour human patch test (81% of panel responded// 60% to pos. control).
Lanolin// Wool alcohols// Wool fat// Wool wax// Adeps lanae	8006-54-0	esters of alcohols (steroid, aliphatic, triterpenoid) and fatty acids	cosmetics// pharmaceuticals// insecticides (cancelled, e.g., flea and tick treatments for dogs and cats)	-	-		+		Basketter et al. (1996a); Truett (1998); Marzulli and Maibach (1996)	Lanolin allergy is most common among leg ulcer patients. In human patch test, 14/1135 were sensitized// one showed
Lead acetate	15347-57-6	heavy metal carboxylate salt	drier in paints, varnishes, and pigment inks// hair dye// manufacture of lead salts, etc.	-					Unpublished Unilever data.	Reasonably anticipated to be a human carcinogen.
2-Mercaptobenzothiazole	149-30-4	thiazole// heterocyclic	a thiazole rubber accelerator (one of the most common classes)	+	+	+	+	2% pet. **	Basketter and Scholes (1992); Ashby et al. (1995); Basketter et al. (1994); Basketter et al. (1996a); Truett (1998); Marzulli and Maibach (1996)	Most commonly identified allergen in allergic contact dermatitis due to shoes. In human patch test 33/1141 were sensitized.
Mercuric chloride// Corrosive sublimate	7487-94-7	heavy metal salt	pharmaceutical ([formerly] topical antiseptic, disinfectant [antimicrobial])// preservative// numerous industrial uses	+	+	+	+		Basketter et al. (1994); Basketter et al. (1996a); Truett (1998)	Strong sensitizer. May produce a nonspecific, pustular or irritant patch test response.
2-Methoxy-4-methylphenol	5635-98-3	phenolic// alkyl aryl ether		+	+					

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
3-Methoxyphenyl benzoate	5554-24-5	benzoate// alkyl aryl ether// acylating agent// benzoylating agent		+					Ashby et al. (1995)	
4-Methylaminophenol sulfate// Metol// p-Hydroxymethylaniline sulfate	55-55-0	phenolic// secondary amine// potential epoxide	photographic developer// dyeing furs	+	+		+	1% pet.	Basketter and Scholes (1992); Ashby et al. (1995)	
4-Methylcatechol	452-86-8	phenolic		+	+				Unpublished Unilever data	
3-Methylcatechol// 3-Methyl-1,2-benzenediol// 2,3-Dihydroxytoluene	488-17-5	phenolic		+						
3-Methylcholanthrene// 1,2-Dihydro-3-methylbenz[j]aceanthrylene	56-49-5	PAH	experimental use in cancer research	+					Unpublished Unilever data	
6-Methylcoumarin// 6-MC	92-48-8	lactone// potential Michael-reactive agent	fragrance (synthetic)// cosmetics, soaps, toiletries	-	-	-	+		Scholes et al. (1992);, Ashby et al. (1995);, Basketter et al. (1996a)	
N'-(4-Methylcyclohexyl)-N-(2-chloroethyl)-N-nitrosourea// MeCCNU	13909-09-6	nitrosourea// nitrosamide// alkylating agent// alkyl halide	pharmaceutical (antineoplastic agent)	-					Ashby et al. (1995)	
Methyl dodecanesulfonate				+	+				Basketter and Scholes (1992); Ashby et al. (1995)	
3-Methyleugenol		phenolic		+					Bertrand et al. (1997)	
5-Methyleugenol		phenolic		+					Bertrand et al. (1997)	



Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
6-Methyleugenol		phenolic		+					Bertrand et al. (1997)	
Methyl hexadecenesulfonate		alkenesulfonate (ester)		+	+ nonstd				Ashby et al. (1995)	
Methylisoeugenol		phenolic	fragrance	+	+ nonstd				Bertrand et al. (1997)	Submission listed as 3-methyl isoeugenol.
Methyl methanesulfonate	66-27-3	alkanesulfonate		+					Ashby et al. (1995)	
1-Methyl-3-nitronitrosoguanidine// MNNG	70-25-7	nitrosoguanide		+					Ashby et al. (1995)	Reasonably anticipated to be a human carcinogen.
N-Methyl-N-nitrosourea// MNU	684-93-5	nitrosourea		+					Ashby et al. (1995)	Reasonably anticipated to be a human carcinogen.
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	119-36-8	benzoate (ester)// phenolic	fragrance// flavoring// pharmaceutical (counterirritant)	-	-	-			Basketter et al. (1994); Basketter et al. (1996a); Gerberick et al. (1992); Basketter et al. (1998)	Used as a negative control. Presumed to have moderate human irritancy potential.
Methyl(2-sulfomethyl) octadecanoate		aliphatic carboxylic acid ester// alkanesulfonate?		+					Ashby et al. (1995)	
2-Methyl-4,5-trimethylene-4-isothiazolin-3-one		amide// heterocyclic		+	+				Ashby et al. (1995)	Does not attribute sensitization by this substance to any structural moiety.
Musk ambrette	83-66-9	synthetic nitro musk// lactone// potential epoxide	fragrance and fixative	+	-		+	1% or 5% pet. ***	Scholes et al. (1992); Ashby et al. (1995); Basketter et al. (1996a); Truett (1998)	Causes photoallergy.

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
.alpha.-Naphthoflavone	604-59-1	potential Michael-reactive agent		+					Unpublished Unilever data	
.beta.-Naphthoflavone	6051-87-2	potential Michael-reactive agent		+					Unpublished Unilever data	
Neomycin sulfate	1405-10-3	glucose (glucopyranose & glucofuranose) derivative// primary alkylamine	pharmaceutical (antibiotic in skin creams and ointments and eye and ear drops [antimicrobial])	-	-		+		Basketter et al. (1994); Basketter et al. (1996a); Gerberick et al. (1992); Truett (1998); Marzulli and Maibach (1996); Prystowsky et al. (1979)	Unusual reactions: Contact urticaria. 75/1131 allergy patients were sensitized, but only 13/1158 volunteers.
Nickel chloride	7718-54-9	heavy metal salt	metal coatings (nickel electroplating cast zinc)	-	+				Basketter and Scholes (1992); Gerberick et al. (1992); Moller (1984)	May be difficult to sensitize mice to nickel salts.
Nickel sulfate	10101-98-1	heavy metal salt	metal coatings (nickel electroplating, blackening zinc and brass)// mordant in dyeing and printing fabrics	-	+	+	+	5% pet. **	Basketter and Scholes (1992); Basketter et al. (1994); Basketter et al. (1996a); Marzulli and Maibach (1996)	Used in dental and shoe series patch tests. 2.5% pet. in human patch test: 109/1123 sensitized// 8 showed
4-Nitrobenzyl bromide// 1-(Bromomethyl)-4-nitrobenzene	100-11-8	nitroaromatic// alkyl halide		+	+ nonstd				Unpublished Unilever data	
4-Nitrobenzyl chloride// 1-(Chloromethyl)-4-nitrobenzene	100-14-1	nitroaromatic// alkyl halide// potential epoxide		+	+ nonstd				Ashby et al. (1995)	
2-Nitrofluorene// 2-Nitro-9H-fluorene	607-57-8	nitroaromatic// PAH		-					Ashby et al. (1995)	
4-Nitroso-N,N-dimethylaniline// N,N-Dimethyl-4-nitrosobenzenamine	138-89-6	arylamine// nitrosoaromatic// tertiary amine	synthetic organic intermediate// accelerator in vulcanizing rubber// printing fabrics	+	+				Ashby et al. (1995)	
Nonanoyl chloride// Pelargonoyl chloride	764-85-2	alkanoyl halide// carboxylic acid halide// acylating agent		+					Ashby et al. (1995)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Octadecanoyl chloride// Stearoyl chloride	112-76-5	alkanoyl halide// carboxylic acid halide// acylating agent		+					Ashby et al. (1995)	Lacrimator
Octadecyl methanesulfonate// Stearyl methanesulfonate	31081-59-1	alkanesulfonate (ester)		-	+ nonstd				Ashby et al. (1995)	
Octyl gallate// Octyl 3,4,5-trihydroxybenzoic acid	1034-01-1	phenolic// benzoic acid derivative	antioxidant in pharmaceuticals, cosmetics, and food (e.g., in margarine and peanut butter)	+			+	0.25% pet. *	Ashby et al. (1995); Truett (1998); Hausen and Beyer (1992)	Has caused dermatitis from airborne contact. Moderate to strong sensitizer in the guinea pig.
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	15646-46-5	potential Michael-reactive agent		+	+				Loveless et al. (1996); Gerberick et al. (1992); Tarayre et al. (1984)	Designated oxazolone as a weak primary irritant in the mouse.
Penicillin G	61-33-6	lactam	pharmaceutical (antibacterial [antimicrobial], antibiotic)	+	+	+			Kimber et al. (1998); Basketter and Scholes (1992); Ashby et al. (1995); Basketter et al. (1994); Basketter et al. (1996a)	
Pentachlorophenol// Penta// PCP	87-86-5	phenolic// aryl halide	pesticide (wood preservative, termite control [cancelled])// pre-harvest defoliant// general herbicide)	+		+			Basketter et al. (1996a)	
Phenol// Carboic acid	108-95-2	phenolic	pharmaceutical (topical anesthetic, antiseptic, and antipruritic)	-		-			Basketter et al. (1996a); Basketter et al. (1998)	Skin and mucous membrane irritant// burns skin
Phenyl benzoate	93-99-2	benzoate (ester)		+	+				Ashby et al. (1995)	
3-Phenylenediamine// m-Phenylenediamine	108-45-2	arylamine// potential epoxide	dye manufacture// rubber curing// resins and polymers// corrosion inhibitor// photography, etc.	+	+ nonstd		+	1% pet.	Ashby et al. (1995); Marzulli and Maibach (1996)	Human patch test: 79/1138 showed sensitization, 2/1138 showed irritation.
4-Phenylenediamine// p-PDA// p-Phenylenediamine	106-50-3	arylamine// potential epoxide	hairdressing (permanent hair dyes)// fur & leather dyes// photography// vulcanization accelerant, etc.	+	+	+	+	1% pet.	Kimber et al. (1991); Basketter and Scholes (1992); Ashby et al. (1995); Basketter et al. (1994); Basketter et al. (1996a); Truett (1998)	Causes contact urticaria// photoallergen.

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Phthalic acid diethyl ester// Diethyl phthalate	84-66-2	phthalate (ester)	cellulose ester plastics used in eyeglasses and hearing aids// fragrances (perfume fixative)	-			+		Unpublished Unilever data	
Phthalic anhydride	85-44-9	aromatic carboxylic acid anhydride// acylating agent	chemical intermediate (manuf. of phthaleins, phthalates, benzoic acid, synthetic indigo, artificial resins (glyptal))	+	+				Basketter and Scholes (1992); Ashby et al. (1995)	
Picryl chloride// Trinitrochlorobenzene// TNCB	88-88-0	nitroaromatic// aryl halide// strong electrophile		+	+				Kimber and Weisenberger (1989); Tarayre et al. (1984)	Skin and mucous membrane irritant. Designated as a primary irritant in the mouse as well as giving delayed hypersensitivity
Polyhexamethylene biguanide				+	+	+			Unpublished Unilever data	
Potassium dichromate	7778-50-9	heavy metal salt// strong oxidizer	leather tanning// oxidizer in organic synthesis// pigments, etc.	+	+	+	+	0.5% pet. ***	Kimber et al. (1991); Kimber et al. (1995); Basketter and Scholes (1992); Basketter et al. (1994); Basketter et al. (1996a); Marzulli and Maibach (1996)	Cr compds. are the most common cause of occup. dermatitis. Ulcerates skin, destroys mucous membranes. Patch test: 59/1138 cons // 34 irr
.beta.-Propiolactone	57-57-8	lactone	intermediate in organic synthesis// disinfectant [antimicrobial]	+					Ashby et al. (1995); Budavari (1996)	Skin exposure causes irritation, blistering, and burns. Reasonably anticipated to be a human carcinogen
Propylene glycol// 1,2-Dihydroxypropane// 1,2-Propanediol	57-55-6	glycol// dihydric alcohol	cosmetics and pharmaceutical vehicle// metalworking fluids// keratolytic// foods (solvent & emulsifier)// antifreeze	-	-		+	5% pet. ***	Basketter et al. (1998)	Contact urticaria, systemic contact dermatitis, keratolytic. Low irritancy in 4-hour human patch test (6% of panel).
Propyl gallate// Tenox PG// 3,4,5-Trihydroxybenzoic acid propyl ester	121-79-9	benzoate (ester)// phenolic	antioxidant in food (0.05 to 0.2%), cosmetics, & pharmaceuticals	+	+		+	1% pet. **	Basketter and Scholes (1992); Ashby et al. (1995); Hausen and Beyer (1992)	Moderate sensitizer in the guinea pig.
1-Propyl-3-nitro-1-nitrosoguanidine// PNNG		nitrosoguanide		+					Ashby et al. (1995)	
Propylparaben// Propyl 4-hydroxybenzoate	94-13-3	benzoate (ester)// phenolic	Parabens are the most widely used preservatives in cosmetics, foods, & topical pharmaceuticals.	-	-	+/-	+	3% unsp. vehicle **	Basketter and Scholes (1992); Basketter et al. (1994); Ashby et al. (1995); Basketter et al. (1996a)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Pyridine	110-86-1	aromatic heterocycle	intermediate in organic synthesis// solvent for anhydrous mineral salts	+		+			Basketter et al. (1996a); Budavari (1996)	Eye irritant, may cause dermatitis.
Resorcinol// 1,3-Dihydroxybenzene	108-46-3	phenolic	pharmaceutical (acne treatment, antipruritic, antiseptic, eye drops)// cosmetics// hair dyes// tanning// resins	-	-	-	+		Basketter et al. (1996a); Basketter et al. (1994); Basketter et al. (1998)	Keratolytic agent. Skin and mucous membrane irritant. Presumed to have low irritancy potential.
Salicylic acid// 2-Hydroxybenzoic acid	69-72-7	benzoic acid derivative// phenolic	pharmaceutical (keratolytic)// food preservative// manuf. of aspirin, methyl salicylate, & other salicylates	-	-	-			\$GEB97-97, Basketter et al. (1996a); Basketter et al. (1994); Basketter et al. (1998); Budavari (1996)	Keratolytic. May cause skin rashes in sensitive individuals (from ingestion). Presumed mod. human skin irr.
Sodium benzyloxybenzenesulfonate		benzenesulfonate (salt)// benzoate (ester)		+	+				Unpublished Unilever data	
Sodium benzyloxy-2-methoxy-5-benzenesulfonate		benzenesulfonate (salt)// benzoate (ester)		+	+ nonstd				Ashby et al. (1995)	
Sodium 4-(2-ethylhexyloxy)benzenesulfonate		benzenesulfonate (salt)// benzoate (ester)		+	+ nonstd				Ashby et al. (1995)	
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	151-21-3	alkyl sulfate (half ester salt)	surfactant (detergent, wetting agent, esp. textile industry)// toothpaste ingredient	+	-	-			Loveless et al. (1996); Basketter et al. (1996a); Basketter et al. (1998)	Moderate irritant in 4-hour human patch test (70% of panel [380/544] responded).
Sodium norbornanecetoxy-4-benzenesulfonate		benzenesulfonate (salt)// aliphatic carboxylic acid ester// alkanoate ester		+	+ nonstd				Ashby et al. (1995)	
Sodium 4-sulfophenyl acetate		benzenesulfonate (salt?)// alkanoate (ester?)// aliphatic carboxylic acid ester?//acetylating agent?		+	+ nonstd				Ashby et al. (1995)	
Streptomycin sulfate	57-92-1	glucose (glucofuranose & glucopyranose) derivative// guanidine derivative	pharmaceutical (antibacterial [antimicrobial], tuberculostatic)	-	+				Kimber et al. (1998)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Streptozotocin	18883-66-4	nitrosourea derivative// nitrosamide// glucose (glucopyranose) derivative	pharmaceutical (antineoplastic)// production of exptl. diabetes in lab. animals	-					Ashby et al. (1995)	Reasonably anticipated to be a human carcinogen.
Sulfanilamide// 4-Aminobenzenesulfonamide// p-Anilinesulfonamide// p-Sulfamidoaniline	63-74-1	benzenesulfonamide// arylamine	pharmaceutical (antibacterial [antimicrobial])	-	-	+	+	5% pet. *	Basketter et al. (1994); Basketter et al. (1996a); Truett (1998)	May cause photoallergic contact sensitivity after topical application.
Sulfanilic acid// p-Aminobenzenesulfonic acid// p-Anilinesulfonic acid	121-57-3		pharmaceutical (antibacterial [antimicrobial])// intermediate in manuf. of dyes, other org. chem.// anal. chem. reagent	-	+				Basketter and Scholes (1992); Ashby et al. (1995)	
Tartaric acid// [R-(R*,R*)]-2,3-Dihydroxybutanedioic acid// d-Tartaric acid// L-Tartaric acid	87-69-4	aliphatic carboxylic acid// glycol	food (acidulant)// photography// tanning// ceramics	-	- nonstd				Unpublished Unilever data	Skin irritant
Tetrachlorosalicylanilide// 3,5-Dichloro-N-(3,4-dichlorophenyl)-2-hydroxybenzamide// TCS	1154-59-2	phenolic// benzoic acid derivative// benzamide// aryl halide	bacteriostat [antimicrobial] in surgical & laundry soaps, polishes, shampoos, deodorants// preservative in cutting oils	+	+	+	+	0.1% pet. *	Scholes et al. (1992); Ashby et al. (1995); Basketter et al. (1994); Basketter et al. (1996a); Budavari (1996)	Photoallergen. Banned in USA from use in cosmetics.
Tetradecyl iodide// Iodotetradecane// Myristyl iodide	19318-94-1	alkyl halide		+					Unpublished Unilever data	
Tetramethyl thiuram disulfide// Thiram// Bis(dimethylthiocarbamoyl) disulfide	137-26-8	thiourea derivative// disulfide	bacteriostat [antimicrobial] in soap, fungicide// rubber accelerator & vulcanizer// pharmaceutical	+	+ nonstd	+	+	1% pet.	Basketter et al. (1996a); Budavari (1996)	Potent skin sensitizer. Overexposure may cause dermatitis and irritation of mucous membranes.
1-Thioglycerol// 3-Mercapto-1,2-propanediol	96-27-5	glycol	pharmaceutical (vulnerary [promotes wound healing])	+	+	+			Basketter et al. (1996a); Basketter et al. (1994)	Irritates eyes, respiratory system, and skin.
Tixocortol pivalate// 11.beta.-11,17-Dihydroxy-21-mercaptopregn-4-ene-3,20-dione	55560-96-8	steroid	pharmaceutical (anti-inflammatory)	-			+		Unpublished Unilever data	
Toluenediamine bismaleimide		imide// potential Michael-reactive agent	hair dressing (free base)	+	+		+	1% pet. free base	Basketter and Scholes (1992)	

Chemical Name	CASRN	Chemical Class	Product Class	LLNA	GPMT/BT	HMT	HPTA	Patch Conc.	References	Comment
Toluenesulfonamide-formaldehyde resin	25035-71-6	benzenesulfonamide, 4-methyl polymer with formaldehyde	cosmetics (acrylics/ nail polish & hardeners)// plastics and glues	-	-		+	10% pet. ***	Unpublished Unilever data	
2,4,5-Trichlorophenol	95-95-4	phenolic// aryl halide	fungicide [pesticide]// bactericide [antibacterial, antimicrobial]	+					Ashby et al. (1995)	
2,4,6-Trichloro-1,3,5-triazine// Cyanuric chloride	108-77-1	active aryl halide	pharmaceutical (topical anti-infective [antimicrobial])// chlorinating agent, disinfectant	+					Ashby et al. (1995)	Submission gave CASRN 87-90-1 [trichloroisocyanuric acid].
Trimethylammonium-3-tolyl-epsilon.-caprolactimide chloride		quaternary ammonium compound	antimicrobial?	-					Ashby et al. (1995)	
.alpha.-Trimethylammonium 4-tolyloxy-4-benzenesulfonate		benzenesulfonate// benzoylating agent// acylating agent// quaternary ammonium compound	antimicrobial?	-	+ nonstd				Ashby et al. (1995)	Recorded as nonsensitizing.
3,5,5-Trimethylhexanoyl chloride	36727-29-4	acylating agent		+	+				Ashby et al. (1995)	
Tween 80// Polysorbate 80// Polyoxyethylenesorbitan oleate	9005-65-6	polyoxyethylene sorbitan ester	polyol surfactant & emulsifier in cosmetics, foods, and pharmaceuticals	-	-		+	5% pet. *	Basketter et al. (1996a)	No dose-response data in reference, only the call. Stated to be previously unpublished.
Vinylpyridine				+					Ashby et al. (1995); Kimber et al. (1989); Kimber and Weisenberger (1989)	CASRN of 1337-81-1 given in submission is for the 2-vinyl isomer. The references present results for 4-vinylpyridine.
Xylene// Dimethylbenzene (mixture of o-, m-, & p-isomers)	1330-20-7	aromatic hydrocarbon	solvent// intermediate in production of benzoic acid, phthalates, etc.	+			-		Basketter et al. (1996a); Budavari (1996)	Causes skin irritation and dermatitis due to defatting action. Eye irritation and corneal burns.
Zinc sulfate	7733-02-0	heavy metal salt	pharmaceutical [ophthalmic astringent, zinc supplement]// zinc refining & electroplating// manuf. zinc compds.// mordant	+					Unpublished Unilever data	

## Results of LLNA Literature Search

(August 17, 1998)

A literature search was done on August 17, 1998 (Medline data base, 1966 to present) using "Local Lymph Node Assay" as the key phrase. Following are the 69 articles retrieved.

Arts, J. H., S. C. Droge, N. Bloksma, and C. F. Kuper. 1996. Local lymph node activation in rats after dermal application of the sensitizers 2,4-dinitrochlorobenzene and trimellitic anhydride. *Food Chem. Toxicol.* 34:55-62.

Arts, J. H., S. C. Droge, S. Spanhaak, N. Bloksma, A. H. Penninks, and C. F. Kuper. 1997. Local lymph node activation and IgE responses in brown Norway and Wistar rats after dermal application of sensitizing and non-sensitizing chemicals. *Toxicology* 117:229-234.

Ashby, J., J. Hilton, R. J. Dearman, R. D. Callander, and I. Kimber. 1993. Mechanistic relationship among mutagenicity, skin sensitization, and skin carcinogenicity. *Environ. Health Persp.* 101:62-67.

Ashby, J., J. Hilton, R. J. Dearman, I. Kimber. 1995. Streptozotocin: Inherent but not expressed skin sensitizing activity. *Contact Derm.* 33:165-167.

Ashby, J., D. A. Basketter, D. Paton, and I. Kimber. 1995. Structure activity relationships in skin sensitization using the murine local lymph node assay. *Toxicology* 103:177-194.

Ashby, J., H. Tinwell, R. D. Callander, I. Kimber, P. Clay, S. M. Galloway, R. B. Hill, S. K. Greenwood, M. E. Gaulden, M. J. Ferguson, E. Vogel, M. Nivard, J. M. Parry, and J. Williamson. 1997. Thalidomide: Lack of mutagenic activity across phyla and genetic endpoints. *Mutat. Res.* 396:45-64.

Basketter, D. A., and I. Kimber. 1996. Olive oil: Suitability for use as a vehicle in the local lymph node assay. *Contact Derm.* 35:190-191.

Basketter, D. A., and E. W. Scholes. 1992. Comparison of the local lymph node assay with the guinea-pig maximization test for the detection of a range of contact allergens. *Food Chem. Toxicol.* 30:65-69.

Basketter, D. A., E. W. Scholes, M. Cumberbatch, C. D. Evans, and I. Kimber. 1992. Sulphanilic acid: Divergent results in the guinea pig maximization test and the local lymph node assay. *Contact Derm.* 27:209-213.

Basketter, D. A., D. W. Roberts, M. Cronin, and E. W. Scholes. 1992. The value of the local lymph node assay in quantitative structure-activity investigations. *Contact Derm.* 27:137-142.

Basketter, D. A., E. Selbie, E. W. Scholes, D. Lees, I. Kimber, and P. A. Botham. 1993. Results with OECD recommended positive control sensitizers in the maximization, Buehler and local lymph node assays. *Food Chem. Toxicol.* 31:63-67.



- Basketter, D. A., J. N. Bremmer, M. E. Kammuller, T. Kawabata, I. Kimber, S. E. Loveless, S. Magda, T. H. Pal, D. A. Stringer, and H. W. Vohr. 1994. The identification of chemicals with sensitizing or immunosuppressive properties in routine toxicology. *Food Chem. Toxicol.* 32:289-296.
- Basketter, D. A., E. W. Scholes, and I. Kimber. 1994. The performance of the local lymph node assay with chemicals identified as contact allergens in the human maximization test. *Food Chem. Toxicol.* 32:543-547.
- Basketter, D. A., E. W. Scholes, H. Wahlkvist, and J. Montelius. 1995. An evaluation of the suitability of benzocaine as a positive control skin sensitizer. *Contact Derm.* 33:28-32.
- Basketter, D. A., E. W. Scholes, M. Chamberlain, and M. D. Barratt. 1995. An alternative strategy to the use of guinea pigs for the identification of skin sensitization hazard. *Food Chem. Toxicol.* 33:1051-1056.
- Basketter, D. A., G. F. Gerberick, I. Kimber, and S. E. Loveless. 1996. The local lymph node assay: A viable alternative to currently accepted skin sensitization tests. *Food Chem. Toxicol.* 34:985-97.
- Basketter, D. A., E. W. Scholes, I. Fielding, R. J. Dearman, J. Hilton, and I. Kimber. 1996. Dichloronitrobenzene: A reappraisal of its skin sensitization potential. *Contact Derm.* 34:55-58.
- Basketter, D. A., R. J. Dearman, J. Hilton, and I. Kimber. 1997. Dinitrohalobenzenes: Evaluation of relative skin sensitization potential using the local lymph node assay. *Contact Derm.* 36:97-100.
- Bertrand, F., D. A. Basketter, D. W. Roberts, and J. P. Lepoittevin. 1997. Skin sensitization to eugenol and isoeugenol in mice: Possible metabolic pathways involving ortho-quinone and quinone methide intermediates. *Chem. Res. Toxicol.* 10:335-343.
- Bezard, M., A. T. Karlberg, J. Montelius, and J. P. Lepoittevin. 1997. Skin sensitization to linalyl hydroperoxide: Support for radical intermediates. *Chem. Res. Toxicol.* 10:987-993.
- Botham, P. A. 1992. Classification of chemicals as sensitizers based on new test methods. *Toxicol. Lett.* 64-65: 165-171.
- Botham, P. A., D. A. Basketter, T. Maurer, D. Mueller, M. Potokar, and W. J. Bontinck. 1991. Skin sensitization—A critical review of predictive test methods in animals and man. *Food Chem. Toxicol.* 29:275-286.
- Botham, P. A., J. Hilton, C. D. Evans, D. Lees, and T. J. Hall. 1991. Assessment of the relative skin sensitizing potency of 3 biocides using the murine local lymph node assay. *Contact Derm.* 25:172-177.

- Boussiquet-Leroux, C., G. Durand-Cavagna, K. Herlin, and D. Holder. 1995. Evaluation of lymphocyte proliferation by immunohistochemistry in the local lymph node assay. *J. Appl. Toxicol.* 15:465-75.
- Chamberlain, M., and D. A. Basketter. 1996. The local lymph node assay: Status of validation. *Food Chem. Toxicol.* 34:999-1002.
- Clottens, F. L., A. Breysens, H. De Raeve, M. Demedts, and B. Nemery. 1996. Assessment of the ear swelling test and the local lymph node assay in hamsters. *J. Pharmacol. Toxicol. Meth.* 35:167-72.
- Dearman, R. J., E. W. Scholes, L. S. Ramdin, D. A. Basketter, and I. Kimber. 1994. The local lymph node assay: An interlaboratory evaluation of interleukin 6 (IL-6): Production by draining lymph node cells. *J. Appl. Toxicol.* 14:287-291.
- Edwards, D. A., T. M. Soranno, M. A. Amoruso, R. V. House, A. C. Tummey, G. W. Trinuner, P. T. Thomas, and P. L. Ribeiro. 1994. Screening petrochemicals for contact hypersensitivity potential: A comparison of the murine local lymph node assay with guinea pig and human test data. *Fundam. Appl. Toxicol.* 23:179-187.
- Gad, S. C. 1994. The mouse ear swelling test (MEST) in the 1990s. *Toxicology* 93:33-46.
- Gerberick, G. F., R. V. House, E. R. Fletcher, and C. A. Ryan. 1992. Examination of the local lymph node assay for use in contact sensitization risk assessment. *Fundam. Appl. Toxicol.* 19:438-445.
- Hatao, M., T. Hariya, Y. Katsumura, and S. Kato. 1995. A modification of the local lymph node assay for contact allergenicity screening: Measurement of interleukin-2 as an alternative to radioisotope-dependent proliferation assay. *Toxicology* 98:15-22.
- Hilton, J., and I. Kimber. 1995. The murine local lymph node assay. *Meth. Mol. Biol.* 43:227-235.
- Hilton, I., R. J. Dearman, I. Fielding, D. A. Basketter, and I. Kimber. 1996. Evaluation of the sensitizing potential of eugenol and isoeugenol in mice and guinea pigs. *J. Appl. Toxicol.* 16:459-464.
- Hilton, J., R. J. Dearman, D. A. Basketter, E. W. Scholes, I. Kimber. 1996. Experimental assessment of the sensitizing properties of formaldehyde. *Food Chem. Toxicol.* 34:571-578.
- Hilton, J., R. J. Dearman, P. Harvey, P. Evans, D. A. Basketter, and I. Kimber. 1998. Estimation of relative skin sensitizing potency using the local lymph node assay: A comparison of formaldehyde with glutaraldehyde. *Am. J. Contact Derm.* 9:29-33.

Homey, B., H. C. Schuppe, T. Assmann, H. W. Vohr, A. L. Lauerma, T. Ruzicka, and P. Lehmann. 1997. A local lymph node assay to analyse immunosuppressive effects of topically applied drugs. *Eur. J. Pharmacol.* 325:199-207.

Hostynek, J. J., A. I. Lauerma, P. S. Magee, E. Bloom, and H. I. Maibach. 1995. A local lymph-node assay validation study of a structure-activity relationship model for contact allergens. *Arch. Dermatol. Res.* 287:567-571.

Ikarashi, Y., T. TsucWya, and A. Nakamura. 1992. Detection of contact sensitivity of metal salts using the murine local lymph node assay. *Toxicol. Lett.* 62:53-61.

Ikarashi, Y., K. Ohno, T. Tsuchiya, and A. Nakamura. 1992. Differences of draining lymph node cell proliferation among mice, rats and guinea pigs following exposure to metal allergens. *Toxicology* 76:283-292.

Ikarashi, Y., T. Tsuchiya, and A. Nakamura. 1993. A sensitive mouse lymph node assay with two application phases for detection of contact allergens. *Arch. Toxicol.* 67:629-636.

Ikarashi, Y., Y. Tsukamoto, T. Tsuchiya, and A. Nakamura. 1993. Influence of irritants on lymph node cell proliferation and the detection of contact sensitivity to metal salts in the murine local lymph node assay. *Contact Derm.* 29:128-132.

Ikarashi, Y., T. Tsuchiya, and A. Nakamura. 1993. Evaluation of contact sensitivity of rubber chemicals using the murine local lymph node assay. *Contact Derm.* 28:77-80.

Ikarashi, Y., T. Tsuchiya, and A. Nakamura. 1994. Contact sensitivity to Tinuvin P in mice. *Contact Derm.* 30:226-230.

Ikarashi, Y., K. Ohno, J. Momma, T. Tsuchiya, and A. Nakamura. 1994. Assessment of contact sensitivity of four thiourea rubber accelerators: Comparison of two mouse lymph node assays with the guinea pig maximization test. *Food Chem. Toxicol.* 32:1067-1072.

Kimber, I., and D. A. Basketter. 1992. The murine local lymph node assay: A commentary on collaborative studies and new directions. *Food Chem. Toxicol.* 30:165-169.

Kimber, I. and R. J. Dearman. 1993. Approaches to the identification and classification of chemical allergens in mice. *J. Pharmacol. Toxicol. Meth.* 29:11-16.

Kimber, I. and C. Weisenberger. 1989. A murine local lymph node assay for the identification of contact allergens. Assay development and results of an initial validation study. *Arch. Toxicol.* 63:274-282.

Kimber, I., and C. Weisenberger. 1991. Anamnestic responses to contact allergens: Application in the murine local lymph node assay. *J. Appl. Toxicol.* 11:129-133.

- Kimber, I., J. Hilton, and C. Weisenberger. 1989. The murine local lymph node assay for identification of contact allergens: A preliminary evaluation of in situ measurement of lymphocyte proliferation. *Contact Derm.* 21:215-220.
- Kimber, I. J. Hilton, and P. A. Botham. 1990. Identification of contact allergens using the murine local lymph node assay: comparisons with the Buehler occluded patch test in guinea pigs. *J. Appl. Toxicol.* 10:173-180.
- Kimber, I., J. Hilton, P. A. Botham, D. A. Basketter, E. W. Scholes, K. Miller, M. C. Robbins, P. T. Harrison, T. J. Gray, and S. J. Waite. 1991. The murine local lymph node assay: Results of an inter-laboratory trial. *Toxicol. Lett.* 55:203-213.
- Kimber, I., R. J. Dearman, E. W. Scholes, and D. A. Basketter. 1994. The local lymph node assay: Developments and applications. *Toxicology* 93:13-31.
- Kimber, I., J. Hilton, R. J. Dearman, G. F. Gerberick, C. A. Ryan, D. A. Basketter, E. W. Scholes, G. S. Ladics, S. E. Loveless, and R. V. House. 1995. An international evaluation of the murine local lymph node assay and comparison of modified procedures. *Toxicol.* 103:63-73.
- Kimber, I., J. Hilton, R. J. Dearman, G. F. Gerberick, C. A. Ryan, D. A. Basketter, L. Lea, R. V. House, G. S. Ladics, S. E. Loveless, and K. L. Hastings. 1998. Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: An interlaboratory evaluation. *J. Toxicol. Environ. Health* 53:563-579.
- Kuhn, U., U. Lempertz, J. Knop, and D. Becker. 1995. A new method for phenotyping proliferating cell nuclear antigen positive cells using flow cytometry: Implications for analysis of the immune response *in vivo*. *J. Immunol. Meth.* 179:215-222.
- Lauerma, A. L., B. Homey, H. W. Vohr, C. H. Lee, E. Bloom, and H. I. Maibach. 1996. Effect of topical *cis*-urocanic acid on local lymph node activation during contact sensitization in mouse, rat and guinea-pig. *Brit. J. Dermatol.* 134:904-909.
- Loveless, S. E., G. S. Ladics, G. F. Gerberick, C. A. Ryan, D. A. Basketter, E. W. Scholes, R. V. House, J. Hilton, R. J. Dearman, and I. Kimber. 1996. Further evaluation of the local lymph node assay in the final phase of an international collaborative trial. *Toxicology* 108:141-152.
- Mandervelt, C., F. L. Clottens, M. Demedts, and B. Nemery. 1997. Assessment of the sensitization potential of five metal salts in the murine local lymph node assay [see comments]. *Toxicology.* 120:65-73.
- Maurer, T., and I. Kimber. 1991. Draining lymph node cell activation in guinea pigs: Comparisons with the murine local lymph node assay. *Toxicology* 69:209-218.
- Montelius, J., H. Wahlkvist, A. Boman, P. Fernstrom, L. Grabergs, and J. E. Wahlberg. 1994. Experience with the murine local lymph node assay: inability to discriminate between allergens and irritants. *Acta Derm.-Venereol.* 74:22-27.

Montelius, J., A. Boman, H. Wahlkvist, and J. E. Wahlberg. 1996. The murine local lymph node assay: Search for an alternative, more adequate, vehicle than acetone/olive oil (4: 1). *Contact Derm.* 34:428-430.

Robinson, M. K., C. A. Cruze. 1996. Preclinical skin sensitization testing of antihistamines: Guinea pig and local lymph node assay responses. *Food Chem. Toxicol.* 34:495-506.

Sailstad, D. M., J. S. Tepper, D. L. Doerfler, M. Qasim, and M. K. Selgrade. 1994. Evaluation of an azo and two anthraquinone dyes for allergic potential. *Fundam. Appl. Toxicol.* 23:569-577.

Sailstad, D. M., S. D. Krishnan, J. S. Tepper, D. L. Doerfler, and M. K. Selgrade. 1995. Dietary vitamin A enhances sensitivity of the local lymph node assay. *Toxicol.* 96:157-63.

Scholes, E. W., D. A. Basketter, V. W. Lovell, A. E. Sarll, and R. U. Pendlington. 1991. The identification of photoallergic potential in the local lymph node assay. *Photodermatol. Photoimmunol. Photomed.* 8:249-254.

Scholes, E. W., D. A. Basketter, A. E. Sarll, I. Kimber, C. D. Evans, K. Miller, M. C. Robbins, P. T. Harrison, and S. J. Waite. 1992. The local lymph node assay: Results of a final inter-laboratory validation under field conditions. *J. Appl. Toxicol.* 12:217-222.

Sikorski, E. E., G. F. Gerberick, C. A. Ryan, C. M. Miller, and G. M. Ridder. 1996. Phenotypic analysis of lymphocyte subpopulations in lymph nodes draining the ear following exposure to contact allergens and irritants. *Fundam. Appl. Toxicol.* 34:25-35.

Ulrich, P., B. Homey, and H. W. Vohr. 1998. A modified murine local lymph node assay for the differentiation of contact photoallergy from phototoxicity by analysis of cytokine expression in skin-draining lymph node cells. *Toxicology* 125:149-168.

Vohr H. W., B. Homey, H. C. Schuppe, and P. Kind. 1994. Detection of photoreactivity demonstrated in a modified local lymph node assay in mice. *Photodermatol. Photoimmunol. Photomed.* 10:57-64.

# Procter & Gamble

The Procter & Gamble Company  
Miami Valley Laboratories

3 April, 1998

Dr. William S. Stokes  
Environmental Toxicology Program  
National Institute of Environmental Health Sciences  
P.O. Box 12233  
Research Triangle Park, NC 27709

Dear Dr. Stokes:

As promised, we have revised our ICCVAM Test Method Submission for the Local Lymph Node Assay (LLNA) based on the comments we received from Ms. Sailstad (Letter dated March 16, 1998). Specifically, we revised Appendix B by giving more detailed information on areas of discordance in the LLNA data. In addition, we have provided disintegration per minute data and stimulation indices for these compounds. The submission was prepared by David Basketter, Ian Kimber and me.

As you know, the LLNA is currently accepted as a screening test in the OECD 406 guidelines as well as in the EU guidelines. In our submission, extensive data are reviewed supporting the use of the LLNA as a stand-alone method for the identification of contact allergens. Comparative studies have confirmed that the local lymph node assay is of equal predictivity to guinea pig methods used currently for the identification of skin sensitizing chemicals. Furthermore, it is clear that the local lymph node assay offers a number of important advantages, including significant animal welfare advantages.

Since the initial publication on the LLNA in 1986 by Kimber and his associates, there have been numerous publications addressing the immunological mechanisms underlying the assay as well as its use in regulatory toxicology - 61 references are listed in the submission. A list of approximately 200 chemicals which have been tested in the LLNA are listed also in the submission. Of the 130 chemicals tested in one of the reference guinea pig tests, approximately 83% gave the same result in the LLNA and the guinea pig tests.

In light of advancing knowledge and experience, and given animal welfare considerations, it is our opinion that the LLNA is now fully validated as a methodology for the identification of significant skin sensitizers and, therefore, should be adopted formally as an alternative skin sensitization test and incorporated fully into regulatory guideline documents addressing skin sensitization testing. Please note that the proposal relates to the standard LLNA. Consequently, data from modified versions of the LLNA have not been included in the submission.

Please feel free to contact us if you have any questions regarding the submission.

Sincerely yours,

/s/

G. Frank Gerberick, Ph.D.  
Procter & Gamble Principal Scientist

cc: Dr. I. Kimber; Dr. D. Basketter

**The Local Lymph Node Assay**  
**ICCVAM Test Method Submission**

**Prepared by G. Frank Gerberick, Ian Kimber and David A. Basketter**

**G. Frank Gerberick**  
**Procter & Gamble**  
**Miami Valley Laboratory**  
**P.O. Box 538707**  
**Cincinnati, OH 45253-8707**  
**Tel: 513-627-2909**  
**Fax: 513-627-0400**  
**email: gerberick.gf@pg.com**

**Ian Kimber**  
**Zeneca**  
**Central Toxicology Laboratory**  
**Alderley Park Macclesfield**  
**Cheshire SK10 4TJ England**  
**Tel: 44-1625-515408**  
**Fax: 44-1625-590249**  
**email: Ian.Kimber@ctl.zeneca.com**

**David A. Basketter**  
**Unilever**  
**Environmental Safety Laboratory**  
**Colworth House Sharnbrook**  
**Bedford MK44 1LQ**  
**Tel: 44-1234-222236**  
**Fax: 44-1234-222122**  
**email: David.Basketter@unilever.co.uk**

**The Local Lymph Node Assay**

# ICCVAM Test Method Submission

## A. INTRODUCTION AND RATIONALE

Allergic contact dermatitis is a frequent occupational health problem and, in common with other forms of allergic disease, develops in two phases. The first or induction phase is initiated when a susceptible individual encounters on the skin sufficient amounts of an inducing allergen to stimulate a primary cutaneous immune response. This results in allergic sensitization. If the now sensitized individual is subsequently exposed, at the same or a different skin site, to the same allergen then an accelerated and more aggressive secondary immune response will be provoked at the site of contact. Allergen-responsive T lymphocytes are activated in the skin at the site of contact and release cytokines and other inflammatory mediators which cause the accumulation of mononuclear cells and the inflammatory reaction that is recognized clinically as allergic contact dermatitis.

For many years the species of choice for the identification of contact allergens was the guinea pig . A variety of guinea pig test methods has been described and while these vary in detail, the principles of the assays are in each case the same, sensitizing activity being measured as a function of challenge-induced erythematous and edematous reactions in previously sensitized animals. There is no doubt that some at least of these guinea pig methods have served toxicologists well. Nevertheless, it is clear that such assays are subject to some important limitations, including the fact that the endpoint is subjective and may be difficult to measure and interpret if colored or irritant chemicals are evaluated. Moreover, some of the more sensitive guinea pig methods demand the use of adjuvant. These limitations encouraged consideration of alternative approaches.

Some ten years ago the local lymph node assay was described (Kimber *et al*, 1986; Kimber *et al*, 1989; Kimber and Basketter, 1992; Kimber *et al*, 1994; Kimber, 1996). This method was founded on the belief that an increasingly sophisticated appreciation of the immune system would facilitate the design of alternative methods for the identification of chemical allergens that cause adverse effects through the stimulation of specific immune responses. The local lymph node assay employs mice, the experimental species where there is the most detailed information available about the induction and regulation of immunological responses. In contrast to guinea pig test methods, the local lymph node assay identifies potential skin sensitizing chemicals as a function of events associated with the induction, rather than elicitation, phase of skin sensitization.



The induction phase of skin sensitization is characterized by the stimulation of an allergen-specific immune response in lymph nodes draining the site of exposure. Epidermal Langerhans cells (LC) recognize, internalize and process the chemical hapten associated with protein. LC are induced to migrate to draining lymph nodes. While in transit they develop into immunostimulatory dendritic cells which in the lymph nodes are able to interact with, and present antigen to, responsive T lymphocytes (Kimber and Cumberbatch, 1992; Kimber and Dearman, 1996). Immune activation in draining lymph nodes is characterized by T lymphocyte division and differentiation, the production by activated cells of cytokines and other mediators and an increase in the size, weight and cellularity of the lymph nodes. The division of activated T cells results in an increase in the number of allergen-reactive lymphocytes; this clonal expansion being the cellular basis of immunological memory and allergic sensitization. The importance of clonal expansion is reflected by the fact that the vigor of proliferative responses induced by chemicals in draining lymph nodes correlates closely with the extent to which sensitization develops (Kimber and Dearman, 1991; Kimber and Dearman, 1996).

In initial investigations several parameters of draining lymph node activation were measured following topical exposure of mice to contact allergens and to non-sensitizing chemicals. These comprised changes in lymph node weight and cellularity and lymphocyte proliferation measured as a function of radiolabelled thymidine incorporation during culture of lymph node cells (Kimber *et al*, 1986; Kimber and Weisenberger, 1989a; Kimber, 1989). The marker that proved to be the most sensitive and selective correlate of skin sensitizing activity was the induction of lymph node cell proliferation and subsequent investigations focused upon this. Another change introduced following these preliminary experiments was to measure the proliferative activity *in situ*, by intravenous injection of tritiated thymidine, rather than following culture of isolated lymph node cells ( Kimber and Weisenberger 1989b; Kimber *et al*, 1989). It is this version of the method that has been evaluated extensively in the context of national and international collaborative trials and which has been the subject of detailed comparisons with guinea pig tests and with human data. The results of these evaluations and comparisons will be discussed later.

A criterion of positivity was required to facilitate decisions regarding the sensitizing potential of chemicals based on activity in the local lymph node assay. The decision was made, based on extensive experience gained with the method, that a chemical should be classified as a skin sensitizer if, at one or more test concentrations, proliferative

activity three-fold or greater than that measured in concurrent vehicle treated controls was induced. The validity of the use of a stimulation index of 3 for the identification of contact allergens is discussed later in this submission.

In summary, the local lymph node assay provides a novel approach to the identification of skin allergens where immunobiological events stimulated during the induction phase of skin sensitization are measured. Decisions are based upon assessment of draining lymph node cell proliferative responses - responses that are known to be essential for, and to correlate with, the induction of skin sensitization.

For practical purposes the following recommendations are made for use of the local lymph node assay:

- A chemical which, at one or more test concentrations, elicits a three-fold or greater increase in proliferative activity compared with concurrent vehicle treated controls should be classified as being a contact allergen and handled and labeled accordingly.
- Chemicals that fail at all test concentrations to elicit a positive response in the local lymph node should be classified as lacking significant skin sensitizing potential and should be handled and labeled accordingly. No further confirmation of negative results is required.

There is currently some interest in comparing and contrasting the nature of immune responses induced in mice by different types of chemical allergens. It is very important to emphasize here, however, that the proposal is that the local lymph node assay can be used to identify those chemicals that are able to cause skin sensitization. A case is not being made here for use of the local lymph node assay in the identification of any other classes of chemical allergen. Moreover, this submission is focused on the standard LLNA. Consequently, papers describing modified versions of the assay are not reviewed in this document.

The proposal is that the local lymph node assay provides an alternative method for use in the identification of skin sensitizing chemicals and for confirming that chemicals lack a significant potential to cause skin sensitization. This does not necessarily imply that in all instances the local lymph node assay should be used in place of guinea pig tests, but rather that the assay is of equal merit and may be employed as a full alternative in which positive and negative results require no further confirmation.

The local lymph node assay is not an *in vitro* method and as a consequence will not eliminate the use of animals in the assessment of contact sensitizing activity. It will, however, permit a **reduction** in the number of animals required for this purpose. It has been estimated that, in practice, on average half the number of animals required for a standard guinea pig test is needed for conduct of a local lymph node assay. Moreover, the local lymph node assay does offer a substantial **refinement** of the way in which animals are used for contact sensitization testing. One important point is that, unlike some of the guinea pig methods, such as the guinea pig maximization test, the local lymph node assay does not require the use of adjuvant. Furthermore, the local lymph node assay is based upon consideration of immunobiological events stimulated by chemicals during the induction phase of sensitization. Unlike guinea pig tests the local lymph node assay does not require that challenged-induced dermal hypersensitivity reactions are elicited.

Due to the fact that the local lymph node assay requires far fewer animals than needed for standard guinea pig tests, it can be conducted for approximately half the cost. The time taken for conduct of a local lymph node assay is some eight times less than that needed for a standard guinea pig method.

It is estimated currently that in excess of 25 separate laboratories world-wide are conducting the local lymph node assay.

## **B. TEST METHOD PROTOCOL**

The contact allergenic potential of a test substance, under the conditions of this protocol, is evaluated by its ability to cause proliferation of draining lymph node cells in mice treated topically compared to appropriate concurrent vehicle treated controls. Direct epicutaneous application of a test substance to the ears is an appropriate route of administration for assessing the contact allergic potential of a test substance. Incorporation of <sup>3</sup>H-thymidine into DNA of lymphocytes results from the stimulation of S-phase prior to proliferation of the cells after receipt of antigenic stimulation. Measurement of <sup>3</sup>H-thymidine uptake by the cells is an objective and quantifiable correlate of immune activation.

Protocol The standard protocol described previously (Kimber and Basketter, 1992) utilizes young adult (6-16 week old) female CBA/Ca stain mice. In strain comparisons, CBA/Ca mice were found to exhibit a more marked

response to contact allergens than did the other strains examined (Kimber and Weisenberger, 1989a). However, female CBA/J and CBA/JHsd strain mice are also acceptable for use in the assay as, in several interlaboratory validation studies, they display responses comparable with those of CBA/Ca strain mice (Kimber *et al*, 1995; Loveless *et al*, 1996). Mice are housed under standard conditions, individually or by treatment group, in plastic shoe box type cages for the duration of the study. Food and tap water are provided *ad libitum*. Control of bias is addressed by randomization of mice prior to initiation of the study.

Groups of mice (n=4 or 5) are treated by topical application, on the dorsum of both ears, of 25 µl of one of several concentrations of test material, or with an equal volume of the relevant vehicle alone. Treatments are performed daily for three consecutive days and the mice are then rested for 2 days prior to analysis. On the sixth day (five days after initiation of treatment), the mice are injected intravenously via the tail vein with 250 µl of sterile phosphate buffered saline (PBS) containing 20 µCi of [<sup>3</sup>H] methyl thymidine (<sup>3</sup>H-TdR; specific activity between 2 and 7 Ci/mmol). Five hours later, the mice are killed and the draining auricular lymph nodes excised and pooled for each experimental group or for each individual animal. Single cell suspensions of lymph node cells (LNC) are prepared by gentle mechanical disaggregation through 200-mesh nylon or stainless steel gauze. LNC are washed twice with an excess of PBS and precipitated with 5% trichloroacetic acid (TCA) at 4°C. Twelve-18 hours later the samples, pelleted by centrifugation, are resuspended in 1 ml 5% TCA and transferred to 10 ml of scintillation cocktail. Incorporation of <sup>3</sup>H-TdR is measured by  $\beta$ -scintillation counting and expressed as disintegrations per minute (dpm). The use of <sup>125</sup>IUdR rather than <sup>3</sup>H-TdR as the isotope has been shown to be comparably robust in the LLNA (Kimber *et al*, 1995; Loveless *et al*, 1996).

A sample protocol is provided in Appendix D.

Dose selection No additional animals are used for dose range finding. The current practice is to select at least three consecutive concentrations from the following range: 100, 50, 25, 10, 5, 2.5, 1, 0.5, 0.25 and 0.1% (w/v). The selection is made to provide the highest possible test concentration, limited by compatibility with the vehicle chosen (and the suitability of the resultant preparation for unoccluded dermal application), while avoiding dermal trauma or

systemic toxicity. The test chemical is dissolved in an appropriate vehicle. Vehicle selection is important and a variety of organic solvents is suitable. The following are recommended, in order of preference: acetone-olive oil (4:1) (AOO), acetone, dimethylformamide, methyl ethyl ketone, propylene glycol and dimethylsulfoxide (Kimber and Basketter, 1992). While aqueous vehicles are not recommended, aqueous and aqueous-organic mixtures such as 3:1 acetone:water have been used successfully.

Control Materials The current OECD positive control sensitizers hexyl cinnamic aldehyde, 2-mercaptobenzothiazole and benzocaine have each been evaluated in the local lymph node assay. Results with these positive controls in the local lymph node assay met or exceeded the minimum acceptable standard set forth by the OECD (Basketter *et al*, 1993). The strong sensitizer 2,4-dinitrochlorobenzene (DNCB) may be used as a positive control as it has produced consistent responses in the LLNA, including when tested in two recent international interlaboratory trials (Kimber *et al*, 1995; Loveless *et al*, 1996). Currently, there are no recommended negative controls for the LLNA as is the case with the reference guinea pig methods. However, methyl salicylate, tested at 1, 2.5, 5, 10 and 20% (w/v) in acetone:olive oil (4:1) (Kimber *et al*, 1995; Kimber *et al*, 1998) and *para*-aminobenzoic acid tested at 0.5, 1, 2.5, 5 and 10% (w/v) in acetone:olive oil (Loveless *et al*, 1996) have been used successfully as negative control chemicals in interlaboratory validation studies. In common with other skin sensitization tests, a control substance for irritation has not been defined for the LLNA.

Data collection and analysis *In vivo* <sup>3</sup>H-thymidine incorporation into lymph node cell DNA associated with proliferation induced by application of a contact sensitizer (measured by liquid scintillation counting) is an objective and quantifiable response. Data are collected as disintegrations per minute (dpm).

The data are expressed as mean dpm for each experimental group and the stimulation indices (SI) for each experimental group are determined as the increase in <sup>3</sup>H-TdR incorporation relative to concurrent vehicle-treated controls (test/control ratio). A test material which at one or more concentrations causes a stimulation index of 3 or greater is considered to have skin sensitizing activity. Thus, whether the draining auricular lymph nodes are excised and pooled for each experimental group or for each individual animal, the three-fold or greater increase in

proliferative activity compared with concurrent vehicle treated control animals is the sole criterion for a classification of skin sensitizing activity.

In cases where individual mice are being used for determining the mean dpm value for an experimental group, statistical analysis may be performed. The value of statistical analyses, either alone or in conjunction with the three-fold stimulation index, has not yet been established and is still the subject of investigations. Where isotope incorporation is determined for individual mice, a mean dpm value  $\pm$  standard error of the mean (SEM) is calculated for each experimental group. A stimulation index is derived for each experimental group by dividing the mean dpm of that group by the mean dpm of the vehicle-control group.

One approach to the development of statistical methods that may prove of value in the local lymph node assay is as follows. For statistical analyses, the mean dpm values for each treatment group and the vehicle control group are initially normalized by obtaining their log value. Bartlett's test (Bartlett, 1937) is then used to examine the data for homogeneity of the within-chemical treatment variance. When analysis of variance reveals significant differences in parametric data, experimental groups are compared with vehicle-treated controls using Dunnett's *t* test (Dunnett, 1955). For non-parametric data, a Kurskal-Wallis test (Kruskal and Wallis, 1952) followed by Dunn's multiple comparison procedure (Dunn, 1964) is used. Groups differing from vehicle-treated controls at the level of  $P \leq 0.05$  are considered significantly different. Alternately, if Bartlett's test for homogeneity of variance is not significant, comparisons with the control group (and other specific, pairwise comparisons of groups) are based on the least significant difference criterion. If Bartlett's test is significant, these comparisons are based on Wilcoxon's rank sum test.

In addition, an estimate of the test material concentration required to produce a stimulation index of 3 ( $EC_3$ ) can be calculated using fitted quadratic regression analyses. An advantage of the  $EC_3$  calculation is that data from the entire dose response curve are used to produce a single value of intrinsic potency (Loveless *et al*, 1996). The  $EC_3$  value can then be used to rank order the skin sensitizing potential of chemicals. Stronger sensitizers such as DNCB and oxazolone have lower  $EC_3$  values than more moderate sensitizers such as hexyl cinnamic aldehyde and eugenol

(Loveless *et al*, 1996). Dose response analyses in the local lymph node assay, combined with the mathematical derivation of the lowest test concentration of a chemical required for a defined stimulation index, such as the EC<sub>3</sub>, provides a convenient, reliable and realistic approach to evaluation of relative potency (Kimber and Basketter, 1997).

An examination of the application of statistical analyses to the local lymph node assay is continuing. At present, it is not clear whether, or in what way, an evaluation of statistical significance would add value to the interpretation of the local lymph node assay. This, together with consideration of EC<sub>3</sub> values for measurement of relative potency are areas of investigation that may pay dividends in the future, but which are not currently part of the standard protocol.

Summary of control data The recommended positive control material, hexyl cinnamic aldehyde (HCA), was tested independently by five laboratories over a dose range of 2.5, 5.0, 10.0, 25.0, and 50% (w/v) in AOO (Loveless *et al*, 1996). All five correctly identified HCA as a contact allergen. Four of the five laboratories found the lowest concentration to produce an SI of 3 or greater was 10%. The fifth laboratory reported an SI of 2.5 for this concentration. Calculations of the EC<sub>3</sub> for HCA ranged from 7.0 to 8.4%. DNCB was tested in two separate trials by the same five laboratories at concentrations of 0.01, 0.025, 0.05, 0.1, and 0.25% (w/v) in AOO. EC<sub>3</sub> calculations for DNCB from both trials ranged from 0.03 to 0.09%.

Recently the stability with time of responses induced in the local lymph node assay by HCA has been evaluated in a single laboratory. Over a ten month period HCA elicited very similar EC<sub>3</sub> values in the local lymph node assay (Dearman *et al*, 1998). These issues are discussed further in Section D below.

### **C. CHARACTERIZATION OF MATERIALS TESTED**

Two of the interlaboratory evaluations of the LLNA were carried out under conditions where all details of the test materials and test conditions were not known to the participating laboratories. In the first of these studies, 20 substances were coded and supplied to each of 4 laboratories (Basketter *et al*, 1991). In a subsequent study, the chemical names were given, but no advice on dose/vehicle selection was provided (Scholes *et al*, 1992). The results from both of these investigations demonstrated a high degree of interlaboratory agreement. It is interesting to compare these results with those from unblinded interlaboratory studies of the GPMT and the Buehler test (Robinson

*et al*, 1990; Andersen *et al*, 1985). In these instances, relatively poor interlaboratory reproducibility was achieved, which is in sharp contrast to experience with LLNA.

**D. ASSESSMENT OF RELIABILITY (REPEATABILITY AND REPRODUCIBILITY)**

There are considerable data on intralaboratory reproducibility of the LLNA, some of which has been published (Basketter *et al*, 1996; Kimber *et al*, 1998) and some of which is based on unpublished individual laboratory experience. Table 1 summarizes the information on this topic.

Although it is not the aim within the current validation to examine assessment of relative skin sensitizing potency, it is possible to derive such information from the LLNA (Basketter *et al*, 1996; Kimber and Basketter, 1997). For this, the estimated concentration of the test chemical which is sufficient to cause a 3-fold stimulation (EC<sub>3</sub>) is determined by interpolation of the dose response data. What precise value this may have for risk assessment is currently the subject of various pieces of work (eg Basketter *et al*, 1996; Kimber and Basketter, 1997; Basketter, 1998). However, the approach taken also allows better comparison of individual LLNA results. Examples of this type of data are contained in Table 2.

**Table 1: Intralaboratory reproducibility of the LLNA**

Chemical	Test 1	Test 2	Test 3	Test 4	Test 5	Test 6
DNCB	+	+	+	ND	ND	ND
Hexyl cinnamic aldehyde	+	+	+	+	+	+
Isoeugenol	+	+	+	+	ND	ND
Eugenol	+	+	+	+	+	ND
Methyl salicylate	-	-	-	-	ND	ND
Benzocaine	-	-	+/-	-	-	-

ND = No data

The first collaborative LLNA validation trial involved four independent laboratories in the UK which evaluated the same batch of eight chemicals, using the same protocol, vehicles and test concentrations. Each laboratory identified 2,4-dinitrochlorobenzene (DNCB), formalin, eugenol, isoeugenol, paraphenylenediamine (p-PDA), and potassium



dichromate as positive with benzocaine and methyl salicylate as negatives. With the exception of isoeugenol, no significant differences between the laboratories were found with respect to the characteristics of dose-response curves (Kimber *et al*, 1991).

The same four laboratories participated in a more extensive evaluation involving 25 chemicals (Basketter *et al*, 1991). Of the 25 chemicals, equivalent predictions of sensitizing potential were made for 18 chemicals by all laboratories. An additional five chemicals were identified as potential sensitizers in the LLNA by two or three laboratories. Three of these subsequently gave a positive response in laboratories which initially failed to detect them when retested under identical or altered conditions (e.g. higher concentration, different vehicle). It should be noted that these investigations were conducted prior to publication of the definitive LLNA protocol.

**Table 2 Reproducibility of LLNA quantitative data**

Chemical	Test 1	Test 2	Test 3	Test 4	Test 5	Test 6
DNCB - Laboratory 1	0.05 <sup>1</sup>	0.03	ND <sup>2</sup>	ND	ND	ND
DNCB - Laboratory 2	0.06	0.05	ND	ND	ND	ND
DNCB - Laboratory 3	0.04	0.06	ND	ND	ND	ND
DNCB - Laboratory 4	0.06	0.09	ND	ND	ND	ND
DNCB - Laboratory 5	0.03	0.06	ND	ND	ND	ND
Isoeugenol	0.3	0.4	0.4	0.4	0.6	ND
Hexyl cinnamic aldehyde	7.9	6.9	9.6	8.7	4.0	9.2
Hexyl cinnamic aldehyde	7.6	7.2	8.8	9.5	10.0	11.9
Eugenol	5.1	6.1	10.5	11.9	14.5	ND
Methyl salicylate	NS <sup>3</sup>	NS	NS	NS	ND	ND
Benzocaine	NS	NS	? <sup>4</sup>	NS	NS	NS

<sup>1</sup>% concentration required to give a stimulation index of 3

<sup>2</sup>ND = Not done

<sup>3</sup>NS = Not a sensitizer

<sup>4</sup>Not possible to determine an EC3 value from the dose response data.

For the final phase of this national collaboration, nine chemicals were evaluated and each laboratory independently selected the test concentrations and vehicles (Scholes *et al*, 1992). One modification that all laboratories employed

was applying chemicals topically for three consecutive days and then terminating the experiment five days after the initiation of exposure, rather than four days. Chemicals were evaluated at three concentrations which were chosen independently by each laboratory with regard to potential toxicity. The choice of vehicle was based upon solubility and viscosity. For eight chemicals, equivalent predictions were made by all laboratories and by three of the four laboratories for the remaining chemical. Identical vehicles and concentrations were selected independently by all laboratories for two chemicals and by three laboratories for six chemicals. In those cases where different concentrations or vehicles were chosen, equivalent predictions (positive or negative LLNA results) were still made.

To determine what effect minor protocol modifications would have on the predictive value of the test, the LLNA was evaluated in an international study by five independent laboratories, two of which had participated in the UK national validation exercise. Modifications to the standard protocol included exposure of mice for four, rather than three, consecutive days, removal of auricular lymph nodes four rather than five days after study initiation, the use of an alternative isotope and analysis of lymph nodes from individual mice to allow for statistical evaluation proposed (reviewed in Gerberick *et al*, 1992; Ladics *et al*, 1995).

In the first phase of this international validation, two skin sensitizers, DNCB and potassium dichromate, and one non-sensitizer, methyl salicylate, were evaluated (Kimber *et al*, 1995). In the LLNA, the criteria for a positive result is a three-fold or greater stimulation of proliferative activity relative to vehicle controls. In the laboratories analyzing nodes from individual mice, a positive result was also defined, for the purpose of this investigation, as treatment groups differing from vehicle treated controls at a predetermined level of statistical significance ( $p < 0.05$  or  $p < 0.01$  depending upon the statistical method employed). By either criterion, and regardless of the protocol utilized, all five laboratories identified the two known sensitizers as being positive in the LLNA. Estimates of the test concentration required to yield a stimulation index of three ( $EC_3$ ) were very similar for all laboratories for both chemicals. Using the stimulation index criteria, all laboratories reported a negative finding for methyl salicylate at all concentrations tested. Two of the three laboratories evaluating nodes from individual mice did detect a statistically significant increase in radioisotope incorporation at the highest of the five concentrations tested (20%).

In the second phase of the international collaborative trial, the sensitivity and selectivity of the assay were examined further by analysis of six additional chemicals: hexylcinnamic aldehyde (HCA), oxazolone, isoeugenol, eugenol,

sodium lauryl sulphate (SLS), and para-aminobenzoic acid (pABA) (Loveless *et al*, 1996). The last two are considered to be non-sensitizing chemicals, while the remainder exhibit skin sensitizing potential to varying extents, with HCA being one of three chemicals recommended by the OECD for use as positive controls in skin sensitization studies (OECD, 1993). All laboratories retested DNCB under the conditions employed in phase I of the trial (Kimber *et al*, 1995) to provide information on the temporal stability of assay data. All five laboratories identified as positive the five moderate to strong sensitizers (DNCB, HCA, oxazolone, isoeugenol and eugenol). SLS, considered to be a non-sensitizing skin irritant, also induced a positive response in the assay. pABA, a non-sensitizing chemical, was negative in each laboratory.

Oxazolone was clearly the most potent sensitizer evaluated in Phase II, with predicted EC<sub>3</sub> values ranging from 0.0007 to 0.0026%. This chemical highlights the benefit of utilizing the entire dose response curve for predicting the concentration required for a SI of 3, since four of the five laboratories recorded stimulation indices of above three at the lowest concentration tested. It also demonstrates that determination of an EC<sub>3</sub> maybe useful in assessing the relative sensitizing potency of a class of chemicals. Results with HCA, eugenol, isoeugenol and pABA were similar to published LLNA results (Basketter *et al*, 1993; Basketter and Scholes, 1992; Basketter *et al*, 1994 ).

The results of Phase I and II provide strong support that the incorporation of minor procedural modifications did not affect the performance of the LLNA. In that regard applying a test chemical for either three or four consecutive days, with removal of lymph nodes five or four days, respectively, after the initiation of treatment, did not change the ability of the assay to detect skin allergens. Three consecutive daily exposures to a chemical is therefore considered sufficient for the purpose of the identification of potential skin sensitization hazard.

Concerning the choice of isotope utilized for detection of proliferation, there was no difference in the ability of <sup>3</sup>HTdR or <sup>125</sup>IUDR to identify correctly the chemicals evaluated in this study. Either isotope can be used in the LLNA (Ladics *et al*, 1995; Kimber *et al*, 1995; Loveless *et al*, 1996).

An important modification assessed during Phase I and II of this international validation study was the analysis of proliferation within lymph nodes of individual mice as opposed to lymph nodes pooled for each experimental group.

In the majority of cases, the lowest concentration yielding a positive response was identical by either method of analysis.

One objective of Phase II was to examine inter-experimental variability by evaluating DNCB twice. Three of the five laboratories obtained identical results to the first study (Kimber *et al*, 1995). Depending upon which of the criteria were used, the other two participating laboratories had either identical inter-experimental results or were within one adjacent concentration level. Therefore, the intralaboratory inter-experimental variability was very low.


The overall conclusion from this and the previous phase of the validation study (Kimber *et al*, 1995) is that five independent laboratories, despite the use of procedural modifications and different methods for data analysis, successfully and consistently employed the LLNA to reach identical conclusions on the sensitizing potential of nine chemicals.

The most recent interlaboratory validation study involved the same five laboratories working in collaboration with the US FDA. In this study (Kimber *et al*, 1998), a small series of chemicals used in topical drug products was examined. Again there was very close agreement between laboratories, with all five identifying correctly benzoyl peroxide, hydroquinone, penicillin G and methyl salicylate. Streptomycin sulfate induced equivocal responses, insofar as this material provoked a positive LLNA response in only one of the five laboratories, and then only at the highest concentration tested. Ethylenediamine dihydrochloride was uniformly negative. Collectively these data serve to confirm that the LLNA is sufficiently robust to yield equivalent results when performed independently in separate laboratories. The data indicate also that the LLNA is of value in assessing the skin sensitization potential of topical medicaments.

A total of 7 laboratories have been involved in interlaboratory validations of the LLNA. The results of the work have appeared in the several associated publications (Kimber *et al*, 1991; Basketter *et al*, 1991; Scholes *et al*, 1992; Kimber *et al*, 1995; Loveless *et al*, 1996; Kimber *et al*, 1998). This work has involved investigation of more than 40 different chemicals.

An overview of the time frame for the development and validation of the LLNA is displayed in Figure 1 (adapted from Chamberlain and Basketter, 1996). Information on consistency/performance over time has been given earlier in this section.

**Figure 1. LLNA Timeline**



**E. REFERENCE DATA**

A variety of guinea pig tests has been developed for evaluation of the skin sensitizing potential of chemicals. Among those most widely applied are the guinea pig maximization test (GPMT) (Magnusson and Kligman, 1969,1970) and the occluded patch test of Buehler (Buehler, 1965, 1985; Robinson et al, 1990). These two assays are the preferred guinea pig sensitization tests outlined in the OECD 406 guideline for skin sensitization.

Figure 1. LLNA Timeline

The GPMT used for comparisons with LLNA results is based on and similar to that described by Magnusson and Kligman (1970) which uses Freund’s adjuvant. Albino Dunkin-Hartley guinea pigs, weighing approximately 350g at the start of each study, are used. Preliminary irritation tests are carried out to determine the concentrations of the test substances suitable for induction of sensitization and for challenge. Guinea pigs are then treated by a series of six intradermal injections in the shoulder region to induce sensitization. After 6-8 days, sensitization is boosted by a 48 hr occluded patch placed over the injection site. Twelve to fourteen days later, the animals are challenged on one flank by a 24 hr occluded patch at the maximum non-irritant concentration. Challenge sites are scored for erythema

(scale 0-3) and edema 24 and 48 hr after removal of the patches. The EC guidelines state that a material is positive if the incidence is  $\geq 30\%$  (European Communities, 1993).

The standard Buehler test (BT) protocol uses an occluded topical patch technique for the induction and elicitation of contact sensitization (Buehler, 1965, 1985; Robinson *et al*, 1990). The procedure calls for 20 animals in the test (sensitized) group, 10 naive (control) animals for challenge, and 10 separate naive control animals for rechallenge. For induction, a single dorsal site is used for three 6 hour induction patches (applied occluded once per week to the same pre-shaven induction site on the dorsal surface of the test animals). Following a two week rest period, the test and non-induced control animals receive 6 hour challenge patches at a naive skin site for the primary challenge. The same test animals and additional new control animals can be rechallenged by this procedure 7-15 days after primary challenge at any remaining naive skin sites. Reactions are graded for erythema 24 and 48 hours after patch removal, according to a 5 point grading scale. The grades "1", "2" and "3" denote increasing severity of erythema with grades  $\geq 1$  considered positive. The EC guidelines state that a material is positive if the incidence is  $\geq 15\%$  (European Communities, 1993).

In addition to comparison of the LLNA with guinea pig sensitization test data, the LLNA has also been compared with human data (Basketter *et al*, 1994; Basketter *et al*, 1996). Specifically, the LLNA has been compared with the human maximization test (HMT) (Kligman, 1966a,b,c). This method was specifically designed to provide a rigorous assessment of the skin sensitization potential of chemicals in humans. In principle, a group of 25 subjects is subjected to 48 hour occlusive patch treatments with as high a concentration of test chemical as possible. This treatment is repeated five times over a two week period. If the substance is not sufficiently irritating, the irritancy is enhanced by prior treatment of the site for 24 hours with sodium lauryl sulfate prior to each 48 hour patch. The extent of sensitization in the panel is assessed by 48 hour treatments on a slightly irritated skin site using the maximum non-irritant concentration of the test substance. The challenge sites are scored at 48 hours and 96 hours post-application. In essence, this procedure can provide a stringent assessment of intrinsic sensitization hazard and its relative potency.

To define the role of the LLNA in predictive testing, results from the assay have been compared with predictions from guinea pig and human tests. In some instances, the LLNA results and the reference results (guinea pig or human) are presented together. In other cases, LLNA studies have been conducted with chemicals whose

sensitization potential, or lack thereof, are well known. Basketter and Scholes (1992) investigated the correlation between results in the LLNA and those derived from the GPMT for materials that covered a range of chemical types and levels of skin sensitization potency. Kimber *et al* (1990) reported comparative analyses in which 24 chemicals, of previously unknown contact sensitizing potential, were evaluated in both the local lymph node assay and the occluded patch test of Buehler. The data reported demonstrate that the local lymph node assay identified successfully those chemicals that were classified as moderate or strong skin sensitizers in the Buehler test. Basketter *et al* (1991) evaluated the performance of the LLNA with 25 chemicals for which guinea pig maximization test or Buehler occluded patch test data were available. The 25 chemicals included preservatives, perfume ingredients, surfactants, plastics/resin chemicals and oil additives. A high level of agreement between the results of local lymph node assays and guinea pig test data was found.

As stated above, an essential point of comparison for the LLNA is with human data. Basketter *et al* (1994 and 1996) compared human maximization tests results with those obtained with the LLNA for the same 38 chemicals. The former being a rigorous assessment of the sensitization potential of chemicals in humans. The authors reported that the LLNA identifies those chemicals that are significant human contact allergens and that the specificity of the assay is good. A comprehensive review of published and unpublished LLNA data is given in Appendix A.

#### **F. TEST METHOD RESULTS AND PERFORMANCE ASSESSMENT**

The predictive power of the LLNA in comparison to standard guinea pig methods is given in Appendix B. This type of information has been reviewed in detail in a recent paper (Basketter *et al*, 1996). While it is clear that the LLNA is not quite as sensitive as the GPMT, it is of similar or greater sensitivity than the Buehler test. It is important to note that this comparison is only true where the guinea pig tests have been conducted to the very highest standards. In terms of predictive identification of important skin sensitizers, the LLNA is at least as sensitive as, and much more reliable than, current guinea pig tests. Of the 130 chemicals tested in one of the reference guinea pig tests, approximately 88% gave the same result in the LLNA and the guinea pig tests. An overview of this information is contained in the 2 X 2 contingency table (Table 3).

**Table 3: Comparison of LLNA and guinea pig classifications**

		Guinea Pig Classification <sup>a</sup>			
		Guinea Pig Positive	Guinea Pig Negative	unclear	total
LLNA Classification	LLNA Positive	86	6	0	92
	LLNA Negative	10	28	0	38
	total	96	34	0	130

**table statistics for the shadowed 2 x 2 table**

<i>sensitivity:</i>	90%	<i>prevalence:</i>	2.82
<i>specificity:</i>	82%		
<i>positive predictivity:</i>	93%		
<i>negative predictivity:</i>	74%		
<b><i>accuracy:</i></b>	<b>88%</b>		
<b><i>x<sub>2</sub>:</i></b>	<b>59.38</b>	<b>(p&lt;0.001)</b>	

<sup>a</sup>Guinea pig classifications are based on GPMT or Buehler results - some of the results are derived from non-standard GPMT guinea pig tests.

The 2 x 2 contingency table is a means to compare the *in vivo* classifications of skin sensitization of the guinea pig test with the *in vivo* predictions obtained in the LLNA. This procedure is recommended as a standard way of assessing data from validation studies (Balls *et al*, 1990). However, it is critical to point out that not all the guinea pig results are based on data generated by a standard protocol. Moreover, the guinea pig classifications are derived from both GPMT and Buehler studies. With these limitations in mind, the accuracy of the prediction of the LLNA amounts to 88%, with a sensitivity of 90% and a specificity of 82%. The test is characterized by a high positive predictivity of 93% and by a negative predictivity of 74%. Obviously, the LLNA does an excellent job of correctly identifying chemicals that are classified as skin sensitizers in the guinea pig tests. The high  $X^2$  value confirms that the classification of test chemicals by the LLNA is significant ( $p<0.001$ ). Overall, the results given in Appendix B, Table 1, and Table 3 above, reveal a high level of concordance between the LLNA and guinea pig data in the determination of skin sensitization potential of a wide range of chemicals.

Appendix B-Table 2 lists those chemicals for which there is discord in results between the LLNA and guinea pig or human test methods. It is important to emphasize, however, that comparisons between LLNA data and the results



of guinea pig tests should be viewed with caution. Guinea pig test data cannot be regarded as representing the gold standard in skin sensitization testing. Thus, for instance, it should not be concluded that the failure of the LLNA to identify as a contact allergen a chemical that is known to elicit a positive response in a guinea pig test necessarily suggests a false negative in the former method. A case in point is sulfanilic acid, a chemical that is positive in the GPMT but which fails to provoke a response in the LLNA. There is compelling evidence that sulfanilic acid fails to induce allergic contact dermatitis in humans despite extensive occupational exposure (Basketter *et al*, 1992). In contrast to the case of sulphanic acid, ammonium thioglycolate, a well described, important, occupational contact allergen, notably among hairdressers, was positive in the LLNA, but was found not to give a significant response in the GPMT of Magnusson and Kligman. This particular chemical would be expected to test positive in a predictive assay. Thus, the LLNA result is the correct one. Ethylene glycol dimethacrylate (EGDMA) produced a positive LLNA response but was negative in guinea pig testing. Acrylate allergy is a complex subject, with many acrylate derivatives being suspected of giving rise to at least some degree of clinical disease. In the case of EGDMA, the LLNA result may be the more accurate reflection of the true importance of this substance as a potential human contact allergen, however, the clinical evidence is lacking.

Guinea pig or mouse data may not always mirror precisely and quantitatively the extent of the hazard to humans. Benzocaine, a substance selected as an OECD positive control for skin sensitization (OECD, 1993), has proven notoriously difficult to obtain reliable/reproducible positive results in either the LLNA or the GPMT (Basketter *et al*, 1993). Although it is well known as a skin sensitizer, one of its most common presentations arises from its use in puritis ani. In this situation, it is the repeated semi-occlusive exposure to inflamed mucosal tissue that renders a rather weak allergen positive. At the opposite end of the spectrum from ammonium thioglycollate, is the preservative propyl paraben. It is negative in both the LLNA and GPMT (Basketter and Scholes, 1992). This is not altogether surprising as except for behaving as a medicament allergen, notably in stasis ulcers, it is a very rare skin sensitizer, despite extensive skin exposure, e.g. from cosmetics. The consequence, is that it is unreasonable to expect a normal predictive skin sensitization test to identify this substance as an allergen. Neither nickel chloride nor nickel sulphate produced clear positive results in the standard LLNA. In contrast, and although nickel has been documented as a difficult allergen in predictive tests (Wahlberg, 1989), positive results can be obtained in the GPMT. While nickel is a common allergen, it is not a strong allergen, since it is the extensive and intimate

exposure (e.g. pierced ears) which results in the high incidence of allergy. Thus, the conclusion is that the failure of the LLNA to identify nickel salts as allergens is as unsurprising as it is unimportant.

Comparison of skin sensitization data from predictive tests such as the GPMT and the LLNA with human clinical information is far from simple. Clinical data are complicated by the varying nature and extent of exposure to which individuals may have been subjected together with their individual sensitivities. Thus, it is easy to confuse a strong allergen with a common one (e.g. nickel) or to expect that the parabens esters or lanolin should be positive in predictive tests because clinicians often refer to these as allergens. In this latter case, skin allergies do arise, but most commonly in a special group of patients (stasis eczema/medicament allergy) which cause dermatologists particular problems. However, it is evident from the large list of chemicals in Appendix B, Table 1, that the LLNA is quite capable of detecting essentially all of the major human contact allergens. It is worth repeating here what has been said elsewhere about metals - that the precise mechanisms of metal allergy are probably rather different than those for organic chemical; since it is known which metals are allergens and which are not, and given that new metals are not being invented, the ability of the LLNA, or indeed any other predictive sensitization assay to detect metal allergens is rather irrelevant to the main need - the identification of new organic chemical skin sensitizers.

The data for the discordant results are reported in Appendix B-Table 3. Specifically, the disintegrations per minute (dpm) and stimulation indices (SI) are given for each concentration of test material tested. For comparison, a positive control (hexyl cinnamic aldehyde) and negative control (para-aminobenzoic acid) are listed to illustrate typical results obtained in the LLNA. For the allergen, benzocaine, one can see that the SI increase with increasing concentrations tested, but the 3-fold level is not reached and the material is classified as negative in the LLNA. In contrast, the irritant, sodium lauryl sulphate, leads to SI above the 3-fold level leading to its positive classification in the LLNA.

In relation to the mouse ear swelling test (MEST) (Gad *et al*, 1986), the LLNA offers several important animal welfare advantages, not least that unlike the MEST it does not use adjuvant. In addition, the state of validation of the MEST is quite preliminary. The data which does exist suggests that results are not wholly reliable, but clearly a great deal more work would be required to establish in detail its merits as a full replacement for the current guinea pig methods.

It is not expected, from our current knowledge of the mechanism of skin sensitization to organic chemicals, and what is known of the immunology of guinea pigs, mice and man, that the LLNA will face special problems. Little is known of the impact of interspecies differences in skin metabolism of prohaptens and its importance in predictive testing. What limited information exists has suggested that there may be species differences (Bertrand *et al*, 1997) but examination of the concordance in the identification of skin sensitizers implies that these may not be of major practical importance.

One question commonly asked about skin sensitization tests concerns their ability to discriminate allergens from irritants. This question has been posed for the LLNA (Montelius *et al*, 1995), as it has for the guinea pig maximization test (Kligman and Basketter, 1995; Buehler, 1996). In practice, all guinea pig skin sensitization tests may have such difficulties and strategies for dealing with them are available (Kligman and Basketter, 1995; Frankild *et al*, 1996). The LLNA deals well with irritancy - it is not a confounding factor for dose selection and the majority of irritants are negative in the assay. Strategies for dealing with potential false positives in the LLNA and other predictive skin sensitization tests have been reviewed recently (Basketter *et al*, 1998).

If the LLNA is determined to be an acceptable alternative, then it will enhance further what is already happening, that this assay begins to be used ever more widely as the first choice method when it is necessary to assess skin sensitization potential of an unknown chemical. The limitations of the assay are minor compared with its advantages. They comprise the inability to evaluate the elicitation response and to test for cross challenge reactions. This latter item is of some use in research, but rarely forms part of testing for regulatory purposes, which is the reason for this assay validation.

## **G. DATA INTERPRETATION**

In the local lymph node assay skin sensitizing activity is measured as a function of proliferative activity induced in draining lymph nodes by repeated topical exposure of mice to a test chemical. For the purposes of developing a criterion for identification of contact allergens a stimulation index of 3, relative to background cell turnover measured in concurrent vehicle treated controls, was proposed as an empirical arbiter. This value was chosen on the basis of previous experience with the local lymph node assay and an apparent high level of discrimination between

contact allergens and non-sensitizing chemicals. Since that proposal was first adopted in 1990 a number of independent laboratories has gained considerably greater experience with the method and in excess of one hundred additional chemicals have been tested. The accumulated evidence reveals that the use of a stimulation index of 3 continues to provide an accurate and reliable criterion for the identification of skin sensitizing chemicals. However, as discussed in a review article published in 1992 (Kimber and Basketter, 1992), while the three-fold stimulation index provides a very useful criterion for judging sensitizing activity, in practice a dose-related increase in proliferative activity that approaches, but does not reach, a stimulation index of 3 might trigger a repeat analysis using higher concentrations and/or an alternative application vehicle (Robinson and Cruze, 1996). In this context the potential utility of a higher or lower stimulation index for the identification of sensitizing activity has been considered, but there is no evidence that this would enhance further the specificity or selectivity of the method.

Whether the draining auricular lymph nodes are excised and pooled for each experimental group or for each individual animal, a stimulation index of 3 is used as the sole criterion against which to judge skin sensitizing activity. The use of statistical analysis for classifying the skin sensitization potential of chemicals is still under investigation. This is also the case for using EC<sub>3</sub> values for determining the potency of a sensitizing chemical. Further research will be required to determine the usefulness of these approaches in LLNA testing. In the meantime, the approach is the use of the three-fold stimulation index.

In the standard local lymph node assay protocol test chemicals are evaluated using 3 application concentrations. In the vast majority of assays conventional dose responses are recorded with sensitizing chemicals such that increasing concentrations of the allergen provoke increasingly more vigorous proliferative responses. In some instances the dose response profile may be relatively flat which suggests either that saturation kinetics for absorption have been achieved or that maximal immune stimulation has been induced. In such instances where a repeat analysis is performed using lower concentrations of the test chemical then invariably a conventional dose response profile is achieved. Very rarely there may be some indication at the top concentration of an inversed dose response. In these cases the cause is either local or systemic toxicity. Again, repeat studies conducted with reduced application concentrations yield normal dose responses. The local lymph node assay is not associated normally, and certainly no more frequently than any other biological analytical system, with ambiguous dose responses.

In conclusion, the view is that the local lymph node assay should be employed as a 'stand alone' method for reaching decisions about the skin sensitizing potential of chemicals. There would be no added value in using instead a battery of methods that included, with the local lymph node assay for instance, analyses of skin penetration or identification of structural alerts using structure-activity relationships. The local lymph node assay provides a holistic mechanistically-based assessment of the ability of a test chemical to provoke the cutaneous immune response necessary for the induction of contact sensitization. If the chemical tested fails to gain access through the skin, or is unable to interact with protein to form an immunogenic hapten-macromolecular complex, then immune activation will not be initiated and sensitization will fail to develop. The current status of the LLNA and its application in regulatory toxicology has been reviewed in detail elsewhere (Basketter *et al*, 1996).

## **H. DATA QUALITY**

Much of the data used here to support this submission and much of the data contained within the publications cited in this document have been derived from audited Good Laboratory Practices (GLP) compliant studies. Where this is not the case all investigations have been conducted to the spirit of GLP or Good Research Practice in GLP compliant facilities. Data quality audits when conducted have been satisfactory.

It is worth emphasizing that in all collaborative studies, both national and international, all data from each of the participating units have been made available to, and have been scrutinized by, all laboratories.

There is now a long history of the local lymph node assay being used successfully in many independent laboratories for conduct of GLP compliant studies.

## **I. SUPPORTING MATERIALS**

The LLNA is already mentioned in detail in the main internationally accepted regulatory guideline describing test methods, namely, by the OECD (1993), where it is presented as a screening method. It is also similarly represented in EU guidelines (EC, 1996). If the result is positive, then the chemical can be defined as a contact allergen. On the basis of this OECD update to the skin sensitization test guideline, the European Commission adopted the LLNA as a screening method acceptable for the identification of skin sensitizers which in its view should be formally classified and labeled as such (European Communities, 1993). Chemicals classified would carry the R43 risk phase May

cause sensitization by skin contact . However, both the OECD and EC tests state that, when the result of the LLNA is negative, it is necessary to conduct a confirmatory guinea pig test according to the standard protocol. It is important to point out that these guidelines were crafted before most of the LLNA validation work had been completed. In fact, the references cited in the OECD 406 guidelines dated from 1989 and 1990.

Recently, Dr. Peter Evans (UK-Health and Safety Executive) stated that the LLNA has been extensively and rigorously validated against both animal and human data and that the assay should be adopted by the OECD and accepted by the EU as suitable method for classification purposes for skin sensitization (Evans, 1998). In light of advancing knowledge and experience, and given animal welfare considerations, it is our opinion that the LLNA is now fully validated as a methodology for the identification of significant skin sensitizers and, therefore, should be adopted formally as an alternative skin sensitization test and incorporated fully into OECD Guideline 406.

Since the initial publication on the LLNA in 1986 by Kimber and his associates, there have been numerous publications addressing the immunological mechanisms underlying the assay as well as its use in regulatory toxicology. In Appendix A, a bibliography of 61 relevant publications is provided. These papers are related directly to the development of the LLNA for its use in assessing the skin sensitization potential of chemicals. Copies of ten selected manuscripts are included in Appendix C to permit reference to specific information supporting the validation of this assay for regulatory toxicology.

## **ACKNOWLEDGMENTS**

The authors gratefully acknowledge Rebecca J. Dearman, Linda J. Lea and Cindy A. Ryan for their contributions to the preparation of this submission.

## Llnaguid REFERENCES

- Andersen K. E., Boman A., Volund A. and Wahlberg J. E. (1985) Induction of formaldehyde contact sensitivity and dose response relationship in the guinea pig maximisation test. *Acta Derm Venereol* **65**, 472-478.
- Bartlett, M.S. (1937) Sub-sampling for attributes. *J. R. Stat. Soc. Suppl.* **4**, 131.
- Balls M., Botham P., Cordier A., Fumaero S., Kayser D., Koeter H., Koundakijan P., Lindquist N.G., Meyer O., Pioda L., Reinhardt C., Rozemond H., Smyrniotis T., Spielmann H., von Looy H., van der Veene M.T. and Walum E. (1990) Report and recommendations of an international workshop on the promotion of the regulatory acceptance of validated non-animal toxicity test procedures. *ATLA* **18**, 339-344.
- Basketter D.A., Scholes E.W., Kimber I., Botham P.A., Hilton J., Miller K., Robbins M.C., Harrison P.T.C. and Waite S.J. (1991) Interlaboratory evaluation of the local lymph node assay with 25 chemicals and comparison with guinea pig test data. *Toxicol. Methods* **1**, 30-43.
- Basketter D.A. and Scholes E.W. (1992) Comparison of the Local Lymph Node Assay with the guinea-pig maximization test for the detection of a range of contact allergens. *Fd. Chem. Toxic.* **30**, 65-69.
- Basketter, D.A., Scholes, E.W., Cumberbatch, M., Evans, C.D. and Kimber, I. (1992) Sulphanilic acid: divergent results in the guinea pig maximization test and the local lymph node assay. *Contact Derm.* **26**, 1-5.
- Basketter D.A., Selbie E., Scholes E.W., Lees D., Kimber I. and Botham P.A. (1993) Results with OECD recommended positive control sensitizers in the maximization, Buehler and local lymph node assays. *Fd. Chem. Toxic.* **31**, 63-67.
- Basketter D.A., Scholes E.W. and Kimber I. (1994) The performance of the local lymph node assay with chemicals identified as contact allergens in the human maximization test. *Fd. Chem. Toxic.* **32**, 543-547.
- Basketter D.A., Gerberick G.F., Kimber I. and Loveless S.E. (1996) The local lymph node assay: a viable alternative to currently accepted skin sensitization tests. *Fd. Chem. Toxic.* **34**, 985-997.
- Basketter D.A. (1998) Current trends in the assessment of contact sensitising potential. *Toxicology*, Submitted.
- Bertrand F, Basketter DA, Roberts DW and Lepoittevin J-P (1997) Skin sensitization to eugenol and isoeugenol in mice: Evidence of different metabolic pathways involving orthoquinone and quinonemethide intermediates. *Chem. Res. Toxicol.* **10**, 335-343.
- Buehler E.V. (1965) Delayed contact hypersensitivity in the guinea pig. *Arch. Dermatol.* **91**, 171-175.
- Buehler E.V. (1985) A rationale for the selection of occlusion to induce and elicit delayed contact hypersensitivity in the guinea pig. A prospective test. *Current Prob. Dermatol.* **14**, 39-58.
- Buehler, E.V. (1996) Nonspecific hypersensitivity: false positive responses with the use of Freund's complete adjuvant. *Contact Derm.* **34**, 111-114.
- Chamberlain M. and Basketter D.A. (1996) The local lymph node assay: status of validation. *Fd. Chem. Toxic.* **34**, 999-1002.
- Dearman R.J., Hilton, J., Evans P., Harvey P., Basketter D.A. and Kimber, I. (1998) Temporal stability of local lymph nodes assay response to hexyl cinnamic aldehyde. (Submitted for Publication).
- Dunn, O.J. (1964) Multiple comparisons using rank sums. *Technometrics* **6**, 241-252.
- Dunnett, C.W. (1955) A multiple comparison procedure for comparing several treatments with a control. *J. Am. Stat. Assoc.* **50**, 1096-1121.



European Communities (1993) Annex IV to Commission Directive 93/21/EEC of 27 April 1993 adapting to technical progress for the 18<sup>th</sup> time Council Directive 67/548/EEC on the approximation of laws, regulations and administration provisions relating to the classification, packaging and labeling of dangerous substances. *Official Journal of the European Communities* **36**, 59.

European Communities (1996) Annex to Commission Directive 96/54/EC. *Official Journal of the European Communities* LL48, 1-230.

Evans P. (1998) Contact and respiratory allergy; a regulatory perspective. In: *Diversification in Toxicology - Man and Environment*. Eds: J P Seiler, J L Autrup and H Autrup, Springer-Verlag, Berlin pp275-284.

Frankild S., Basketter D.A., and Andersen K.E. (1996) The value and limitations of rechallenge in the guinea pig maximization test. *Contact Derm.* **35**, 135-140.

Gad S., Dunn B.J., Dobbs D.W., Reilly C. and Walsh R.D. (1986) Development and validation of an alternative dermal sensitization test: the mouse ear swelling test (MEST). *Toxic. Appl. Pharm.*, **84**, 93-114.

Gerberick G.F., House R.E., Fletcher R.E. and Ryan C.A. (1992) Examination of the local lymph node assay for use in contact sensitization risk assessment. *Fund. Appl. Toxicol.* **19**, 438-445.

Kimber I., Mitchell J.A. and Griffin A.C. (1986) Development of a murine local lymph node assay for the determination of sensitizing potential. *Fd. Chem. Toxic.* **24**, 585-586.

Kimber I., Hilton J. and Weisenberger C. (1989) The murine local lymph node assay for identification of contact allergens : a preliminary evaluation of in situ measurement of lymphocyte proliferation. *Contact Derm.* **21**, 215-220.

Kimber I. and Weisenberger C. (1989a) A murine local lymph node assay for the identification of contact allergens. Assay development and results of an initial validation study. *Arch. Toxicol.* **63**, 274-282.

Kimber I. and Weisenberger C. (1989b) A modified murine local lymph node assay for the identification of contact allergens. In: *Current Topics in Contact Dermatitis*. Eds. P J Frosch, A Dooms-Goossens, J M Lachapelle, R J G Rycroft and R J Scheper, Springer-Verlag, Heidelberg pp 592-595.

Kimber I. (1989) Aspects of the immune response to contact allergens: Opportunities for the development and modification of predictive test methods. *Fd. Chem. Toxic.* **27**, 755-762.

Kimber I., Hilton J. and Botham P.A. (1990) Identification of contact allergens using the murine local lymph node assay. Comparisons with the Buehler occluded patch test in guinea pigs. *J. Appl. Toxicol.* **10**, 173-180.

Kimber I. and Dearman R.J. (1991) Investigation of lymph node cell proliferation as a possible immunological correlate of contact sensitizing potential. *Fd. Chem. Toxic.* **29**, 125-129.

Kimber I., Hilton J., Botham P.A., Basketter D.A., Scholes E.W., Robbins M.L., Harrison P.T.C., Gray T.J.B. and Waite S.J. (1991) The murine local lymph node assay. Results of an inter-laboratory trial. *Toxicol. Lett.* **55**, 203-213.

Kimber I. and Basketter D.A. (1992) The murine local lymph node assay. A commentary on collaborative studies and new directions: *Fd. Chem. Toxic.* **30**, 165-169.

Kimber I. and Cumberbatch M. (1992) Dendritic cells and cutaneous immune responses to chemical allergens. *Toxicol. Appl. Pharmacol.* **117**, 137-146.

Kimber I., Dearman R.J., Scholes E.W. and Basketter D.A. (1994) The local lymph node assay: developments and applications. *Toxicology* **93**, 13-31.

Kimber I., Hilton J., Dearman R.J., Gerberick G.F., Ryan C.A., Basketter D.A., Scholes E.W., Ladics G.S., Loveless S.E., House R.V. and Guy A. (1995) An international evaluation of the murine local lymph node assay and comparison of modified procedures. *Toxicology* **103**, 63-73.

- Kimber I. (1996) The local lymph node assay. In: *Dermatotoxicology* 5th Ed. Eds: F N Marzulli and H I Maibach, Taylor and Francis, Washington DC, pp 469-475.
- Kimber I. and Dearman R.J. (1996) Contact hypersensitivity: immunological mechanisms. In: *Toxicology of Contact Hypersensitivity*, Eds: I Kimber and T. Maurer, Taylor and Francis, London, pp 4-25.
- Kimber I. and Basketter D.A. (1997) Contact sensitization: a new approach to risk assessment. *Human and Ecological Risk Assessment*, **3**, 385-395.
- Kimber I., Hilton J., Dearman R.J., Gerberick G.F., Ryan C.A., Basketter D.A., Lea L., House R.V., Ladics G.S., Loveless S.E. and Hastings K.L. (1998) Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: an inter-laboratory exercise. *J Toxicol. Environ. Health*. Accepted for publication.
- Kligman A.M. (1966a) The identification of contact allergens by human assay. I. *J. Invest. Dermatol.* **36**, 573-581.
- Kligman A.M. (1966b) The identification of contact allergens by human assay. II. *J. Invest. Dermatol.* **47**, 375-392.
- Kligman A.M. (1966c) The identification of contact allergens by human assay. III. *J. Invest. Dermatol.* **47**, 393-409.
- Kligman A.M. and Basketter D.A. (1995) A critical commentary and updating of the guinea pig maximization test. *Contact Derm.* **32**, 129-134.
- Kruskal W.H. and Wallis W.A. (1952) Use of ranks in one-criterion variance analysis. *J. Am. Stat. Assoc.* **47**, 583-621.
- Ladics G.S., Smith C., Heaps K. and Loveless S.E. (1995) Comparison of 125-Iododeoxyuridine (<sup>125</sup>IUdR) and [<sup>3</sup>H]thymidine ([<sup>3</sup>H]TdR) for assessing cell proliferation in the murine local lymph node assay. *Toxicol. Meth.* **5**, 143-152.
- Loveless S.E., Ladics G.S., Gerberick G.F., Ryan C.A., Basketter D.A., Scholes E.W., House R.V., Hilton J., Dearman R.J. and Kimber I. (1996) Further evaluation of the local lymph node assay in the final phase of an international collaborative trial. *Toxicology* **108**, 141-152.
- Magnusson, B. and Kligman, A.M. (1969) The identification of contact allergens by animal assay. The guinea pig maximization test. *J. Invest. Dermatol.* **52**, 268-276.
- Magnusson, B. and Kligman, A.M. (1970) *Allergic contact Dermatitis in the Guinea Pig. Identification of Contact Allergens*. Charles C. Thomas, Springfield.
- Montelius J., Wahlkvist H., Boman A., Fernstrom P., Grabergs L., and Wahlberg J.E. (1994) Experience with the murine local lymph node assay: inability to discriminate between allergens and irritants. *Acta Derm. Venereol. Stockholm* **74**, 22-27.
- OECD (1993) OECD guidelines for testing of chemicals, No 406, Skin Sensitization. OECD, Paris.
- Robinson M.K., Nusair T.L., Fletcher E.R., and Ritz H.L. (1990) A review of the Buehler guinea pig skin sensitization test and its use in a risk assessment process for human skin sensitization. *Toxicology* **61**, 91-107.
- Robinson M.K. and Cruse C.A. (1996) Preclinical skin sensitization testing of antihistamines: guinea pig and local lymph node assay responses. *Fd. Chem. Toxic.* **34**, 495-506.
- Scholes E.W., Basketter D.A., Sarll A.E., Kimber I, Evans C.D., Miller K., Robbins M.C., Harrison P.T.C. and Waite S.J. (1992) The local lymph node assay: Results of a final inter-laboratory validation under field conditions. *J. Appl. Toxicol.* **12**, 217-222.

Wahlberg J.E. (1989) Nickel: Animal sensitisation assays. In *Nickel and the Skin: Immunology and Toxicology*. Edited by H. I. Maibach and T. Menne. pp.59-106. Karger, Basel.

### Local Lymph Node Assay Bibliography

1. Ashby J., Basketter D.A., Paton D. and Kimber, I. (1995) Structure-activity relationships in skin sensitization using the murine local lymph node assay. *Toxicology* **103**, 177-194.
2. Basketter D.A., Scholes E.W., Kimber I., Botham P.A., Hilton J., Miller K., Robbins M.C., Harrison P.T.C. and Waite S.J. (1991) Interlaboratory evaluation of the local lymph node assay with 25 chemicals and comparison with guinea pig test data. *Toxicol. Methods* **1**, 30-43.
3. Basketter D.A. and Scholes E.W. (1992) Comparison of the Local Lymph Node Assay with the guinea-pig maximization test for the detection of a range of contact allergens. *Fd. Chem. Toxic.* **30**, 65-69.
4. Basketter D.A., Scholes E.W., Cumberbatch M., Evans C.D. and Kimber I. (1992) Sulphanilic acid: divergent results in the guinea pig maximization test and the local lymph node assay. *Contact Derm.* **27**, 209-213.
5. Basketter D.A., Roberts D.W., Cronin M. and Scholes E.W. (1992) The value of the local lymph node assay in quantitative structure activity investigations. *Contact Derm.* **27**, 137-142.
6. Basketter D.A., Selbie E., Scholes E.W., Lees D., Kimber I. and Botham P.A. (1993) Results with OECD recommended positive control sensitizers in the maximization, Buehler and local lymph node assays. *Fd. Chem. Toxic.* **31**, 63-67.
7. Basketter D.A., Roberts D.W., Cronin M.T.D. and Scholes E.W. (1993) The value of the local lymph node assay in the development of QSARs for skin sensitisation potential. In: *Trends in QSAR and Molecular Modelling 1992*. Eds. C. G. Wermuth, ESCOM, pp. 580-583.
8. Basketter D.A., Scholes E.W. and Kimber I. (1994) The performance of the local lymph node assay with chemicals identified as contact allergens in the human maximization test. *Fd. Chem. Toxic.* **32**, 543-547.
9. Basketter D.A., Scholes E.W., Wahlkvist H. and Montelius J. (1995) An evaluation of the suitability of benzocaine as a positive control skin sensitizer. *Contact Derm.* **33**, 28-32.
10. Basketter D.A. and Chamberlain M. (1995) The validation of skin sensitization assays. *Fd. Chem. Toxic.* **33**, 1057-1059.
11. Basketter D.A., Scholes E.W., Chamberlain M. and Barratt M.D. (1995) An alternative strategy to the use of guinea pigs for the identification of skin sensitisation hazard. *Fd. Chem. Toxic.* **33**, 1051-1056.
12. Basketter D.A., Scholes E.W., Chamberlain M. and Barratt M.D. (1996) Skin allergy-identifying the causative chemicals: A strategy to replace animal tests. In: *Alternatives to Animal Testing*. Eds. S. G. Lisansky, R. Macmillan and J. Dupuis, CPL Press, pp. 225-230.
13. Basketter D.A. and Kimber, I. (1996) Olive oil: suitability for use as a vehicle in the local lymph node assay. *Contact Derm.* **35**, 190-191.
14. Basketter D.A., Scholes E.W., Fielding I., Dearman R.J., Hilton J. and Kimber (1996) Dichloronitrobenzene: a reappraisal of its skin sensitization potential. *Contact Derm.* **34**, 55-58.
15. Basketter D.A., Gerberick G.F., Kimber I. and Loveless S.E. (1996) The local lymph node assay: a viable alternative to currently accepted skin sensitization tests. *Fd. Chem. Toxic.* **34**, 985-997.
16. Basketter D.A., Dearman R.J., Hilton J. and Kimber I. (1997) Dinitrohalobenzenes: evaluation of relative skin sensitization potential using the local lymph node assay. *Contact Derm.* **36**, 97-100.
17. Basketter D.A., Gerberick G.F. and Kimber I. (1998) Strategies for identifying false positive responses in predictive skin sensitization tests. *Fd. Chem. Toxic.* **36**(4): 327-333.

18. Basketter D.A. (1998) Current trends in the assessment of contact sensitising potential. *Toxicology* Submitted.
19. Chamberlain M. and Basketter D.A. (1996) The local Lymph node assay: status of validation. *Fd. Chem. Toxic.* **34**, 999-1002.
20. Cronin M.T.D. and Basketter D.A. (1993) A QSAR evaluation of existing contact allergy database. In: Trends in QSAR and Modecular Modelling 1992. Eds. C. G. Wermuth, ESCOM, pp. 297-298.
21. Dearman R.J., Hope J.C., Hopkins S.J., Debicki R.J. and Kimber (1993) Interleukin 6 (IL-6) production by lymph node cells : An alternative endpoint for the murine local lymph node assay. *Toxicol. Methods* **3**, 268-278.
22. Dearman R.J., Scholes E.W., Ramdin L.S.P., Basketter D.A. and Kimber I. (1994) The local lymph node assay: an interlaboratory evaluation of interleukin 6 (IL-6) production by draining lymph node cells. *J. Appl. Toxicol.* **14**, 287-291.
23. Dearman R.J., Hilton J., Evans P., Harvey P., Basketter D.A. and Kimber, I. (1998) Temporal stability of local lymph node assay response to hexyl cinnamic aldehyde. (Submitted for Publication).
24. Edwards, D.A., Soranno, T.M., Amoruso, M.A., House, R.V., Tummey, A.C., Trimmer, G.W., Thomas, P.T. and Ribeiro, P.L. (1994) Screening petrochemicals for contact hypersensitivity potential: a comparison of the murine local lymph node assay with guinea pig and human test data. *Fund. Appl. Toxicol.* **23**, 179-187.
25. Gerberick G.F., House R.V., Fletcher, R.E. and Ryan, C.A. (1992) Examination of the local lymph node assay for use in contact sensitization risk assessment. *Fund. Appl. Toxicol.* **19**, 438-445.
26. Gerberick, G.F., Cruse, L.W., Miller, C.M., Sikorski, E.E. and Ridder, G.M. (1997) Selective modulation of T cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment. *Toxicol. Appl. Pharm.* **146**, 1-10.
27. Hilton J. and Kimber I. (1995) The murine local lymph node assay. In: *Methods in Molecular Biology* Vol. 43 : In Vitro Toxicity Testing Protocols. Eds: S. O'Hare and CK Atterwill, Humana Press, Totowa, NJ, pp 227-235.
28. Hilton J., Dearman R.J., Basketter D.A., Scholes E.W. and Kimber, I. (1996) Experimental assessment of the sensitizing properties of formaldehyde. *Fd. Chem. Toxic.* **34**, 571-578.
29. Kimber I., Mitchell J.A. and Griffin A.C. (1986) Development of a murine local lymph node assay for the determination of sensitizing potential. *Fd. Chem. Toxic.* **24**, 585-586.
30. Kimber I., Hilton J. and Weisenberger C. (1989) The murine local lymph node assay for identification of contact allergens : a preliminary evaluation of in situ measurement of lymphocyte proliferation. *Contact Derm.* **21**, 215-220.
31. Kimber I. and Weisenberger C. (1989) A murine local lymph node assay for the identification of contact allergens. Assay development and results of an initial validation study. *Arch. Toxicol.* **63**, 274-282.
32. Kimber I. and Weisenberger C. (1989) A modified murine local lymph node assay for the identification of contact allergens. In: *Current Topics in Contact Dermatitis*. Eds. P J Frosch, A Dooms-Goossens, J M Lachapelle, R J G Rycroft and R J Scheper, Springer-Verlag, Heidelberg pp 592-595.
33. Kimber I. (1989) Aspects of the immune response to contact allergens: Opportunities for the development and modification of predictive test methods. *Fd. Chem. Toxic.* **27**, 755-762.
34. Kimber I., Hilton J. and Botham P.A. (1990) Identification of contact allergens using the murine local lymph node assay. Comparisons with the Buehler occluded patch test in guinea pigs. *J. Appl. Toxicol.* **10**, 173-180.

35. Kimber I., Hilton J., Botham P.A., Basketter D.A., Scholes E.W., Miller K., Robbins M.C., Harrison P.T.C., Gray T.J.B. and Waite S.J. (1991) The murine local lymph node assay. Results of an inter-laboratory trial. *Toxicol. Lett.* **55**, 203-213.
36. Kimber I. and Weisenberger C. (1991) Anamnestic responses to contact allergens: Applications in the murine local lymph node assay. *J. Appl. Toxicol.* **11**, 129-133.
37. Kimber I. and Dearman R.J. (1991) Investigation of lymph node cell proliferation as a possible immunological correlate of contact sensitizing potential. *Fd. Chem. Toxic.* **29**, 125-129.
38. Kimber I. and Basketter D.A. (1992) The murine local lymph node assay. A commentary on collaborative studies and new directions: *Fd. Chem. Toxic.* **30**, 165-169.
39. Kimber I. (1993) The murine local lymph node assay: Principles and practice. *Am. J. Contact Derm.* **4**, 42-44.
40. Kimber I. and Dearman R.J. (1993) Approaches to the identification and classification of chemical allergens in mice. *J. Pharmacol. Toxicol. Meth.* **29**, 11-16.
41. Kimber I., Dearman R.J., Scholes E.W. and Basketter D.A (1994) The local lymph node assay: developments and applications. *Toxicology* **93**, 13-31.
42. Kimber I. and Dearman R.J. (1994) Assessment of contact and respiratory sensitivity in mice. In: *Immunotoxicology and Immunopharmacology* 2nd Ed. Eds: J H Dean, M I Luster, A E Munson and I Kimber, Raven Press, New York, pp 721-732.
43. Kimber I., Hilton J., Dearman R.J., Gerberick G.F., Ryan C.A., Basketter D.A., Scholes E.W., Ladics G.S., Loveless S.E., House R.V. and Guy A. (1995) An international evaluation of the murine local lymph node assay and comparison of modified procedures. *Toxicology* **103**, 63-73.
44. Kimber I. (1995) The local lymph node assay. In: *Methods in Immunotoxicology*. Volume 2. Eds : G R Burlison, J H Dean and A E Munson, Wiley-Liss, New York, pp 279-290.
45. Kimber I. (1996) Mouse predictive tests. In: *Toxicology of Contact Hypersensitivity*. Eds: I Kimber and T Maurer, Taylor and Francis, London, pp 127-139.
46. Kimber I. (1996) The local lymph node assay. In: *Dermatotoxicology* 5th Ed. Eds: F N Marzulli and H I Maibach, Taylor and Francis, Washington DC, pp 469-475.
47. Kimber I. (1997) The local lymph node assay and other approaches to the evaluation of skin sensitizing potential. In: *Advances in Animal Alternatives for Safety and Efficacy Testing*. Eds.: H. Salem and S. A. Katz, Taylor and Francis, Washington DC, pp. 49-54.
48. Kimber I and Basketter D.A. (1997) Contact sensitization: a new approach to risk assessment. *Human and Ecological Risk Assessment* **3**, 385-395.
49. Kimber I., Hilton J., Dearman R.J., Gerberick G.F., Ryan C.A., Basketter D.A., Lea L., House R.V., Ladics G.S., Loveless S.E. and Hastings K.L. (1998) Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: an inter-laboratory exercise. *J Toxicol. Environ. Health.* **53(7)**: 563-579.
50. Kimber I. The local lymph node assay. Hazard and Risk Assessment. In: *Dermatotoxicology Methods*. Eds : F N Marzulli and H I Maibach. Accepted for publication.
51. Ladics G.S., Smith C. Heaps K. and Loveless S.E. (1995) Comparison of 125-Iododeoxyuridine (<sup>125</sup>IUdR) and [<sup>3</sup>H]thymidine ([<sup>3</sup>H]TdR) for assessing cell proliferation in the murine local lymph node assay. *Toxicol. Meth.* **5**, 143-152.

52. Loveless S.E., Ladics G.S., Gerberick G.F., Ryan C.A., Basketter D.A., Scholes E.W., House R.V., Hilton J., Dearman R.J. and Kimber I. (1996) Further evaluation of the local lymph node assay in the final phase of an international collaborative trial. *Toxicology* **108**, 141-152.
53. Maurer T. and Kimber I. (1991) Draining lymph node activation in guinea pigs: Comparisons with the murine local lymph node assay. *Toxicology* **69**, 209-218.
54. Montelius J., Wahlkvist H., Boman A., Fernstrom P., Grabergs L. and Wahlberg J.E. (1994) Experience with the murine local lymph node assay: inability to discriminate between allergens and irritants. *Acta Derm. Venerol. Stockholm* **74**, 22-27.
55. Potter, D.W. and Hazelton, G.A. (1995) Evaluation of auricular lymph node cell proliferation in isothiazolone-treated mice. *Fund. Appl. Toxicol.* **24**, 165-172.
56. Robinson M. K. and Sozeri T.J. (1990) Immunosuppressive effects of clonidine on the induction of contact sensitization in the Balb/c mouse. *J. Invest. Dermatol.* **95**, 587-591.
57. Robinson, M.K. and Cruze, C.A. (1996) Preclinical skin sensitization testing of antihistamines: guinea pig and local lymph node assay responses. *Fd. Chem. Toxic.* **34**, 495-506.
58. Sailstad, D.M., Krishnan, S.D., Tepper, J.S., Doerfler, D.L. and Selgrade, M.J. (1995) Dietary vitamin A enhances sensitivity of the local lymph node assay. *Toxicology* **96**, 157-163.
59. Scholes E.W., Basketter D.A., Lovell W.W., Sarll A.E. and Pendlington R.U. (1992) The identification of photoallergic potential in the local lymph node assay. *Photodermatol. Photoimmunol. Photomed.* **8**, 249-254.
60. Scholes E.W., Basketter D.A., Sarll A.E., Kimber I, Evans C.D., Miller K., Robbins M.C., Harrison P.T.C. and Waite S.J. (1992) The local lymph node assay: Results of a final inter-laboratory validation under field conditions. *J. Appl. Toxicol.* **12**, 217-222.
61. Sikorski, E.E., Gerberick, G.F., Ryan, C.A., Miller, C.M. and Ridder, G.M. (1996) Phenotypic analysis of lymphocyte subpopulations in lymph nodes draining the ear following exposure to contact allergens and irritants. *Fund. And Appl. Toxicol.* **34**, 25-35.

APPENDIX B (of Original Submission): Table 1. Chemicals Tested in Local Lymph Node Assay

Chemical	CAS number	LLNA	GPMT /BT <sup>#</sup>	HMT	MEST
Abietic acid	514-10-3	+	+		
2-(N-acetoxy-acetamido)fluorene		+			
3-Acetylphenylbenzoate		+	+		
4-Allylanisole	140-67-0	+	+		
2-Aminophenol	95-55-6	+	+*		
3-Aminophenol	591-275	+	+*		
Ammonium tetrachloroplatinate	13820-41-2	+	+		
Ammonium thioglycollate	5421-46-5	+	-		
Aniline	62-53-3	+	+	+	
Benzene-1,3,4-tricarboxylic anhydride		+	+		
1,2-Benzisothiazolin-3-one		+	+		
Benzo[a]pyrene	50-32-8	+			
Benzocaine	94-09-7	+/-**	+/-**	+	
Benzoquinone	106-51-4	+	+		
Benzoyl chloride	98-88-4	+	+		
Benzoyl peroxide	94-36-0	+	+		+
Benzyl bromide	100-39-0	+			
Beryllium sulphate	7787-56-6	+	+	+	
1-Bromododecane	143-15-7	+	+*		
12-Bromododecanoic acid	73367-80-3	+			
12-Bromo-1-dodecanol	3344-77-2	+			
1-Bromohexadecane	112-82-3	+	+		
1-Bromohexane	111-25-1	+	+*		
3-Bromomethyl-3-dimethyldihydrofuranone		+	+		
1-Bromopentadecane	629-72-1	+			
7-Bromotetradecane		+			
2-Bromotetradecanoic acid	10520-81-7	+			
2,3-Butanedione	431-03-8	+			
Butylglycidyl ether	2426-08-6	+	+	+	
C <sub>12-13</sub> -β branched primary alcohol sulphate		+			
C <sub>16</sub> -1,3-alkene sultone		+	+*		
Camphorquinone	465-29-2	+			
Chloramine T	10599-90-3	+	+		
4-Chloroaniline	106-47-8	+	+		
2-Chloromethylfluorene		+			
(Chloro)methylisothiazolinone	55965-84-9	+	+		
1-Chloromethylpyrene	1086-00-6	+			
1-Chlorononane	2473-01-0	+			
1-Chlorooctadecane	3386-33-2	+			
1-Chlorotetradecane	2425-54-9	+			
Chlorpromazine	69-09-0	+	+*	+	
Cinnamic aldehyde	104-55-2	+	+	+	+
Citral	5392-40-5	+	+	+	
Clotrimazole	23593-75-1	+			
Cobalt chloride	7646-79-9	+	+	+	
Cocoamidopropyl betaine	59141-98-9	+	+		



APPENDIX B (of Original Submission): Table 1. Chemicals Tested in Local Lymph Node Assay

Chemical	CAS number	LLNA	GPMT /BT <sup>#</sup>	HMT	MEST
Copper chloride	7758-89-6	+	-		
Dibromodicyanobutane		+	+		
Diethyl sulphate	64-67-5	+			
Diethylenetriamine	111-40-0	+	+	+	
3,4-Dihydrocoumarin	119-84-6	+			
Dihydroeugenol	2785-87-7	+	+		
3-Dimethylaminopropylamine	109-55-7	+	+		
7,12-Dimethylbenz[a]anthracene	57-97-6	+			
5,5-Dimethyl-3-methylenedihydro-2(3H)-furanone		+	-*		
5,5-Dimethyl-3-(thiocyanatomethyl)dihydro-2(3H)-furanone		+	+*		
Dimethyl sulphate	77-78-1	+			
2,4-Dinitrochlorobenzene	97-00-7	+	+		+
2,4-Dinitrothiocyanobenzene	1594-56-5	+	+		
Diphenylmethane-4-4' diisocyanate	101-68-8	+	+		
Disodium 1,2-diheptanoyloxy-3,5-benzenedisulphonate		+	+*		
Dodecylmethanesulphonate	51323-71-8	+	+*		
Dodecylthiosulphonate		+	+		
Ellipticine	519-23-3	+			
Ethylene diamine	107-15-3	+	+		+
Ethylene glycol dimethacrylate	97-90-5	+	-		
1-Ethyl-3-nitro-1-nitrosoguanidine		+			
Eugenol	97-53-0	+	+		+
Fluorescein isothiocyanate	25168-13-2	+			
Formaldehyde	50-0-0	+	+	+	+
Glyoxal	107-22-2	+	+	+	
Gold chloride	16903-35-8	+		+	
Hexadecanoyl chloride	112-67-4	+			
Hexyl cinnamic aldehyde	101-86-0	+	+		
Hydroquinone	123-31-9	+	+		
Hydroxycitronellal	107-75-5	+	+	+	
2-Hydroxyethyl acrylate	818-61-1	+	+		
Imidazolidinyl urea	39236-46-9	+	+		
1-Iodohexadecane	544-77-4	+			
1-Iodononane	4282-42-2	+			
1-Iodotetradecane	192-94-1	+			
Isoeugenol	97-54-1	+	+		
Isopropylisoeugenol	29653-00-7	+	+		
Isononanoyloxybenzene sulphonate		+	+		
Isophorone diisocyanate	4098-71-9	+	+		
2-Mercaptobenzothiazole	149-30-4	+	+	+	
Mercuric chloride	7487-94-7	+	+	+	
2-Methoxy-4-methyl phenol	5635-98-3	+	+		
3-Methoxyphenylbenzoate	5554-24-5	+			
4-Methylaminophenol sulphate	55-55-0	+	+		
3-Methylcatechol	488-17-5	+			
4-Methylcatechol	452-86-8	+	+		

APPENDIX B (of Original Submission): Table 1. Chemicals Tested in Local Lymph Node Assay

Chemical	CAS number	LLNA	GPMT /BT <sup>#</sup>	HMT	MEST
3-Methylcholanthrene	56-49-5	+			
Methyl dodecane sulphonate		+	+		
3-Methyleugenol		+			
5-Methyleugenol		+			
6-Methyleugenol		+			
Methyl hexadecane sulphonate		+	+*		
3-Methyl isoeugenol		+	+*		
Methyl methane sulphonate	66-27-3	+			
1-Methyl-3-nitro-1-nitrosoguanidine	70-25-7	+			
Methyl(2-sulphomethyl)octadecanoate		+			
2-Methyl-4,5-trimethylene-4-isothiazolin-3-one		+	+		
Musk ambrette	83-66-9	+	-		
N-Ethyl-N-nitrosourea		+			
N-Methyl-N-nitrosourea	684-93-5	+			
α-Naphthoflavone	604-59-1	+			
β-Naphthoflavone	6051-87-2	+			
Neomycin sulphate	1405-10-3	+/-	+		
4-Nitrobenzyl bromide	100-11-8	+	+*		
4-Nitrobenzyl chloride	100-14-1	+	+*		
4-Nitroso-N,N-dimethylaniline	138-89-6	+	+		
Nonanoyl chloride	764-85-2	+			
Octadecanoyl chloride	112-76-5	+			
Octyl gallate	1034-01-1	+			
Oxazolone	15646-46-5	+	+		+
Penicillin G	61-33-6	+	+	+	
Pentachlorophenol	87-86-5	+		+	
Phenyl benzoate	93-99-2	+	+		
3-Phenylenediamine	108-45-2	+	+*		
4-Phenylenediamine	106-50-3	+	+	+	+
Phthalic anhydride	85-44-9	+	+		-
Picryl chloride	88-88-0	+	+		-
Polyhexamethylene biguanide		+	+	+	-
Potassium dichromate	7778-50-9	+	+	+	-
β-Propiolactone	57-57-8	+			
Propylgallate	121-79-9	+	+		
1-Propyl-3-nitro-1-nitrosoguanidine		+			
Pyridine	110-86-1	+		+/-	
Quinol	123-31-9	+	+*		
Sodium benzoyloxybenzene sulphonate		+	+		
Sodium 4-(2-ethylhexyloxycarboxy)benzene sulphonate		+	+*		
Sodium 4-sulphophenyl acetate		+	+*		
Sodium benzoyloxy-2-methoxy-5-benzene sulphonate		+	+*		
Sodium lauryl sulphate	151-21-3	+	-	-	-
Sodium norbornanacetoxy-4-benzene sulphonate		+	+*		
Streptomycin	57-92-1	+	+		
Tetrachlorosalicylanilide	7426-07-5	+	+	+	
Tetradecyl iodide	19218-94-1	+			

APPENDIX B (of Original Submission): Table 1. Chemicals Tested in Local Lymph Node Assay

Chemical	CAS number	LLNA	GPMT /BT <sup>#</sup>	HMT	MEST
Tetramethyl thiuram disulphide	137-26-8	+	+*	+	
1-Thioglycerol	96-27-5	+	+	+	
Toluene diamine bismaleimide		+	+		
2,4,5-Trichlorophenol	95-95-4	+			
2,4,6-Trichloro-1,3,5-triazine	87-90-1	+			
α-Trimethylammonium-4-tolyloxy-4-benzene sulphonate		+	+*		
3,5,5-Trimethylhexanoyl chloride	36727-29-4	+	+		
Vinyl pyridine	1337-81-1	+			
Xylene	1330-20-7	+		-	
Zinc sulphate	7733-02-0	+			
2-Acetamidofluorene	53-96-3	-			
4-Acetylphenylbenzoate	1523-18-8	-			
4-Aminobenzoic acid	150-13-0	-	-	-	+
Benzalkonium chloride	8001-54-5	-	-		+
3-(Benzenesulphonyloxymethyl)-5,5-dimethyldihydro-2(3H)-furanone		-			
Benzoic acid	65-85-0	-	-		-
Benzoyloxy-3,5 benzene dicarboxylic acid		-	+*		
1-Bromobutane	109-65-9	-			
Chlorobenzene	108-90-7	-	-		
3-(Chlorobenzenesulphonyloxymethyl)-5,5-dimethyl dihydro-2(3H)-furanone		-			
2-Chloroethanol	107-07-3	-			
Dextran	9004-54-0	-	-		
2,4-Dichloronitrobenzene	611-06-3	-	-		
Di-2-furanylethanedione	492-94-4	-			
5,5-Dimethyl-3-(mesyloxymethyl)dihydro-2(3H)-furanone		-	+*		
5,5-Dimethyl-3-(methoxybenzenesulphonyloxymethyl) dihydro-2(3H)-furanone		-	+*		
5,5-Dimethyl-3-(nitrobenzenesulphonyloxymethyl) dihydro-2(3H)-furanone		-	+*		
Dimethylisophthalate	1459-93-4	-	-		
5,5-Dimethyl-3-(tosyloxymethyl)dihydro-2(3H)-furanone		-	-*		
Disodium benzoyloxy-3,5-benzenedicarboxylate		-	-		
Ditallowdihydroxypropenetrिमethyl ammonium		-	-		
Ethylmethanesulphonate	62-50-0	-			
Geraniol	106-24-1	-	-	-	
Glycerol	56-81-5	-	-		-
Hexane	110-54-3	-		-	
Hydrocortisone	50-23-7	-		-	
4-Hydroxybenzoic acid	99-96-7	-	-		
2-Hydroxypropylmethacrylate	923-26-2	-	-		
Isopropanol	67-63-0	-	-		
Kanamycin	25389-94-0	-	-*	+	
Lactic acid	50-21-5	-	-		

APPENDIX B (of Original Submission): Table 1. Chemicals Tested in Local Lymph Node Assay

Chemical	CAS number	LLNA	GPMT /BT <sup>#</sup>	HMT	MEST
Lanolin	8006-54-0	-	-		
Lead acetate	15347-57-6	-			
6-Methylcoumarin	92-48-8	-	-	-	
Methyl salicylate	119-36-8	-	-	-	
N'-(4-Methylcyclohexyl)-N-(2-chloroethyl)-N-nitrosourea		-			
Nickel chloride	7718-54-9	-	+		
Nickel sulphate	10101-98-1	-	+	+	+
2-Nitrofluorene	607-57-8	-			
Octadecylmethane sulphonate	31081-59-1	-	+*		
Phenol	108-95-2	-		-	-
Phthalic acid diethyl ester		-			
Propylparaben	94-13-3	-	-	+/-	
Propylene glycol	57-55-6	-	-		-
Resorcinol	108-46-3	-	-	-	
Salicylic acid	69-72-7	-	-	-	-
Streptozotocin	18883-66-4	-			
Sulphanilamide	63-74-1	-	-	+	
Sulphanilic acid	121-57-3	-	+		+
Tartaric acid	87-69-4	-	-*		
Tixocortol pivalate	55560-96-8	-			
Toluene sulphonamide formaldehyde resin		-	-		
Trimethylammonium-3-tolyl-ε-caprolactimide chloride		-			
Tween 80	9005-65-6	-	-		-

# Positive results based on EC classification threshold

\* result obtained in a non-standard guinea pig test

\*\* ref Benzocaine paper

**APPENDIX B (of Original Submission): Table 2. Discordant Results Between the Local Lymph Node Assay and Guinea Pig or Human Test Methods**

Chemical	CAS number	LLNA	GPMT/ BT <sup>#</sup>	HMT
Ammonium thioglycollate <sup>1</sup>	5421-46-5	+	-	
Benzocaine <sup>2</sup>	94-09-7	+/-**	+/-**	+
Copper chloride <sup>3</sup>	7758-89-6	+	-	
5,5-Dimethyl-3-methylenedihydro-2(3H)-furanone <sup>4</sup>		+	-*	
Ethylene glycol dimethacrylate <sup>5</sup>	97-90-5	+	-	
Musk ambrette	83-66-9	+	-	
Neomycin sulphate <sup>6</sup>	1405-10-3	+/-	+	
Pyridine <sup>7</sup>	110-86-1	+		+/-
Sodium lauryl sulphate <sup>3</sup>	151-21-3	+	-	-
Xylene	1330-20-7	+		-
Benzoyloxy-3,5 benzene dicarboxylic acid <sup>8</sup>		-	+*	
5,5-Dimethyl-3-(mesyloxymethyl)dihydro-2(3H)-furanone <sup>9</sup>		-	+*	
5,5-Dimethyl-3-(methoxybenzenesulphonyloxymethyl)dihydro-2(3H)-furanone <sup>9</sup>		-	+*	
5,5-Dimethyl-3-(nitrobenzenesulphonyloxymethyl)dihydro-2(3H)-furanone <sup>9</sup>		-	+*	
Kanamycin <sup>6</sup>	25389-94-0	-	-*	+
Nickel chloride <sup>9</sup>	7718-54-9	-	+	
Nickel sulphate <sup>9</sup>	10101-98-1	-	+	+
Octadecylmethane sulphonate <sup>10</sup>	31081-59-1	-	+*	
Propylparaben <sup>11</sup>	94-13-3	-	-	+/-
Sulphanilamide <sup>12</sup>	63-74-1	-	-	+
Sulphanilic acid <sup>13</sup>	121-57-3	-	+	

# Positive results based on EC classification threshold

\* result obtained in a non-standard guinea pig test

\*\* ref Benzocaine paper

<sup>1</sup> Significant human contact allergen that should be positive in a predictive test.

<sup>2</sup> Very weak, difficult sensitiser in predictive tests that is only a human allergen under forcing exposure conditions.

<sup>3</sup> A false positive in the LLNA.

<sup>4</sup> Likely to be a true positive based on both the LLNA and structure activity considerations; the guinea pig data are from a non-standard version of the GPMT that omits the patch induction phase.

<sup>5</sup> Acrylate allergy is a complex subject, with many acrylate derivatives being suspected of giving rise at least to some degree of clinical disease.

<sup>6</sup> A well described contact allergen in medicaments, but which was much weaker than Kanamycin in a human predictive test.

<sup>7</sup> A very weak allergen in human predictive test (equivalent to paraben) and which is thus an unexpected positive in the LLNA.

<sup>8</sup> Whilst this substance was positive in the GPMT (which involves injection), its size and charge will result in extremely poor skin penetration, such that it is unlikely to cause allergic contact dermatitis. Thus, the LLNA result is likely to be the most meaningful.

<sup>9</sup> False negative in the LLNA.

<sup>10</sup> A false negative probably due to poor skin penetration engendered by the size of the compound, its very high log P and the presence of a charged group.

<sup>11</sup> This substance is a rare allergen except in specific disease states; it is not positive in predictive assays except the human maximization test.

<sup>12</sup> Unexpected negative in both the LLNA and guinea pig tests.

<sup>13</sup> Although a clear positive in the GPMT, this substance was negative in both the LLNA and on the basis of substantial human exposure experience, suggesting it is the LLNA result which is correct.

**APPENDIX B (of Original Submission): Table 3. Disintegrations Per Minute (DPM) Data and Stimulation Indices (SI) for Discordant Results**

<b>Chemical</b>	<b>Concentration<sup>1</sup> (%)</b>	<b>DPM</b>	<b>SI</b>
<b>Hexyl cinnamic aldehyde</b>	Vehicle (AOO)	495	1.0
<b>Example of positive LLNA response</b>	2.5	691	1.4
	5.0	1056	2.1
	10.0	1615	3.3
	25.0	4107	8.3
	50.0	6857	14.0
<b>para-Aminobenzoic acid</b>	Vehicle (AOO)	453	1.0
<b>Example of negative LLNA response</b>	0.5	399	0.9
	1.0	457	1.0
	2.5	626	1.4
	5.0	519	1.1
	10.0	452	1.0
<b>Ammonium thioglycollate</b>	Vehicle (DMSO)	807	1.0
	10.0	2389	3.0
	25.0	2490	3.1
	50.0	3250	4.0
<b>Benzocaine</b>	Vehicle (DMF)	325	1.0
	2.5	562	1.7
	5.0	574	1.8
	10.0	698	2.1
	25.0	794	2.4
<b>Copper chloride</b>	Vehicle (DMSO)	605	1.0
	1.0	4920	8.1
	2.5	8341	13.8
	5.0	8225	13.6
<b>5,5-Dimethyl-3-methylenedihydro -2(3H)-furanone</b>	Vehicle (AOO)	672	1.0
	1.77	2022	3.0
	3.53	5002	7.4
	7.06	6213	9.2
<b>Ethylene glycol dimethacrylate</b>	Vehicle (Acetone)	365	1.0
	10.0	675	1.8
	25.0	1312	3.6
	50.0	4046	11.1

<b>Neomycin sulphate</b>	Vehicle (DMSO)	355	1.0
	25.0	379	1.1

**APPENDIX B (of Original Submission): Table 3. Disintegrations Per Minute (DPM) Data and Stimulation Indices (SI) for Discordant Results**

<b>Chemical</b>	<b>Concentration<sup>1</sup> (%)</b>	<b>DPM</b>	<b>SI</b>
Pyridine	Vehicle (AOO)	250	1.0
	25.0	274	1.1
	50.0	578	2.3
	100.0	978	3.9
Sodium lauryl sulphate	Vehicle (DMF)	369	1.0
	1.0	747	2.0
	2.5	954	2.6
	5.0	1301	3.5
	10.0	1814	4.9
	20.0	1628	4.4
Xylene	Vehicle (AOO)	382	1.0
	25.0	487	1.3
	50.0	1138	3.0
	100.0	1182	3.1
Benzoyloxy-3,5 benzene dicarboxylic acid	Veh (Ace/Sal, 1:1)	382	1.0
	2.5	346	0.9
	5.0	315	0.8
	10.0	419	1.1
5,5-Dimethyl-3-(mesyloxymethyl)-dihydro-2(3H)-furanone	Vehicle (AOO)	526	1.0
	3.42	494	0.9
	6.83	791	1.5
	13.66	702	1.3
5,5-Dimethyl-3-(methoxybenzenesulpho-nyloxymethyl)dihydro-2(3H)-furanone	Vehicle (AOO)	672	1.0
	4.84	802	1.2
	9.67	612	0.9
	19.34	690	1.0
5,5-Dimethyl-3-(nitrobenzenesulphonyl-oxymethyl)dihydro-2(3H)-furanone	Vehicle (AOO)	657	1.0
	5.07	493	0.8
	10.13	490	0.7
	20.26	585	0.9

Hydrocortisone	Vehicle (AOO)	250	1.0
	2.5	74	0.3
	5.0	29	0.1
	10.0	16	0.06

**APPENDIX B (of Original Submission): Table 3. Disintegrations Per Minute (DPM) Data and Stimulation Indices (SI) for Discordant Results**

<b>Chemical</b>	<b>Concentration<sup>1</sup> (%)</b>	<b>DPM</b>	<b>SI</b>
Kanamycin	Vehicle (AOO)	382	1.0
	5.0	842	2.2
	10.0	301	0.8
	25.0	391	1.0
Nickel chloride	Vehicle (DMSO)	898	1.0
	1.0	1363	1.5
	2.5	1940	2.2
	5.0	2133	2.4
Nickel sulphate	Vehicle (DMSO)	898	1.0
	0.5	986	1.1
	1.0	1315	1.5
	2.5	1376	1.5
Octadecylmethane sulphonate	Vehicle (AOO)	510	1.0
	2.5	594	1.2
	5.0	374	0.7
	10.0	444	0.9
Propylparaben	Vehicle (AOO)	433	1.0
	10.0	595	1.4
	25.0	445	1.0
	50.0	575	1.3
Sulphanilamide	Vehicle (DMF)	416	1.0
	10.0	429	1.0
	25.0	415	1.0
	50.0	393	0.9
Sulphanilic acid	Vehicle (DMSO)	436	1.0
	2.5	667	1.5
	5.0	827	1.9
	10.0	967	2.2

<sup>1</sup> Abbreviations Used: DMSO = dimethylsulphoxide; DMF = dimethylformamide;  
AOO = acetone:olive oil (4:1); Ace/Sal = acetone:saline (1:1)



## Local Lymph Node Assay References Included in ICCVAM Submission

1. Basketter D.A. and Scholes E.W. (1992) Comparison of the Local Lymph Node Assay with the guinea-pig maximization test for the detection of a range of contact allergens. *Fd. Chem. Toxic.* **30**, 65-69.
2. Basketter D.A., Selbie E., Scholes E.W., Lees D., Kimber I. and Botham P.A. (1993) Results with OECD recommended positive control sensitizers in the maximization, Buehler and local lymph node assays. *Fd. Chem. Toxic.* **31**, 63-67.
3. Basketter D.A., Scholes E.W. and Kimber I. (1994) The performance of the local lymph node assay with chemicals identified as contact allergens in the human maximization test. *Fd. Chem. Toxic.* **32**, 543-547.
4. Basketter D.A., Gerberick G.F., Kimber I. and Loveless S.E. (1996) The local lymph node assay: a viable alternative to currently accepted skin sensitization tests. *Fd. Chem. Toxic.* **34**, 985-997.
5. Basketter D.A., Gerberick G.F. and Kimber I. (1998) Strategies for identifying false positive responses in predictive skin sensitization tests. *Fd. Chem. Toxic.* **36**(4): 327-333.
6. Chamberlain M. and Basketter D.A. (1996) The local Lymph node assay: status of validation. *Fd. Chem. Toxic.* **34**, 999-1002.
7. Gerberick G.F., House R.V., Fletcher, R.E. and Ryan, C.A. (1992) Examination of the local lymph node assay for use in contact sensitization risk assessment. *Fund. Appl. Toxicol.* **19**, 438-445.
8. Kimber I., Hilton J., Dearman R.J., Gerberick G.F., Ryan C.A., Basketter D.A., Scholes E.W., Ladics G.S., Loveless S.E., House R.V. and Guy A. (1995) An international evaluation of the murine local lymph node assay and comparison of modified procedures. *Toxicology* **103**, 63-73.
9. Kimber I., Hilton J., Dearman R.J., Gerberick G.F., Ryan C.A., Basketter D.A., Lea L., House R.V., Ladics G.S., Loveless S.E. and Hastings K.L. (1998) Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: an inter-laboratory exercise. *J Toxicol. Environ. Health.* **53**(7): 563-579.
10. Loveless S.E., Ladics G.S., Gerberick G.F., Ryan C.A., Basketter D.A., Scholes E.W., House R.V., Hilton J., Dearman R.J. and Kimber I. (1996) Further evaluation of the local lymph node assay in the final phase of an international collaborative trial. *Toxicology* **108**, 141-152.

**APPENDIX D**

**SAMPLE PROTOCOL**

**STANDARD OPERATING PROCEDURE**

**THE LOCAL LYMPH NODE ASSAY  
(LLNA)**

**STANDARD OPERATING PROCEDURE**  
**METHOD:**

**THE LOCAL LYMPH NODE ASSAY (LLNA)**

**1. PRE-TEST PREPARATION**

The Local Lymph Node Assay (LLNA) has been developed as an alternative method for the identification of skin sensitizing substances and measures the proliferation of lymphocytes isolated from lymph nodes draining the site of exposure in mice.

Each test is defined by a Protocol. The Protocol states the purpose of the test, test substance and concentrations to be assayed, and other details necessary to ensure that the test is conducted properly in compliance with the principles of Good Laboratory Practice (GLP).

Upon receipt of the protocol, the Test Operator plans the test, prepares test documents and requests test samples.

**2. THE LOCAL LYMPH NODE ASSAY - TEST METHOD**

**2.1 Introduction**

The LLNA determines the extent to which sensitization to a test substance has developed by measuring the proliferation of lymphocytes in the auricular lymph nodes draining the site of exposure (ears). Lymphocyte proliferation is measured by determining the incorporation of <sup>3</sup>H-methyl thymidine (<sup>3</sup>HTdR).

The LLNA involves treatment of laboratory mice which is performed by experienced, trained and qualified personnel. Such persons have been granted a Home Office License which permits them to carry out experiments on animals listed in this section.

This Standard Operating Procedure fully describes the LLNA. The completion of each treatment/task outlined must be recorded immediately on the appropriate sheet by signature and date (APPENDIX 1).

**2.2 Summary of experimental design**

LLNA PROTOCOL	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6
5 DAYS	T	T	T	-	-	3H	C

T - Topical application of test substance/vehicle.

<sup>3</sup>H - 0hrs - Administration of 20μCi <sup>3</sup>HTdR.  
+5hrs - Excision and processing of pooled lymph nodes. Incubation of pooled LNC with TCA overnight.

C - <sup>3</sup>HTdR incorporation into pooled LNC determined.

The method is based upon the assay developed some years ago at the Central Toxicology Laboratory, Zeneca (see References, section 2.15).

Mice, housed in groups of four, are treated by topical application of the test substance to the dorsum of each ear one time per day over three consecutive days to induce sensitization. Control mice are treated with the vehicle alone. Five days after the first topical application, the mice are injected with radiolabelled thymidine (<sup>3</sup>H-methyl thymidine). Approximately five hours after injection, the mice are sacrificed and the draining auricular lymph nodes excised and pooled per group. Single cell suspensions of lymph node cells (LNC) are prepared from pooled lymph nodes which are subsequently washed and incubated with trichloroacetic acid (TCA) overnight. The proliferative capacity of pooled LNC is then determined by the incorporation of <sup>3</sup>H-methyl thymidine measured on a β-scintillation counter. Each stage of the method is described below:

### 2.3 Animals

CBA/Ca strain mice, purchased from Harlan UK Ltd or Charles River UK Ltd, are housed in groups of four in cages lined with 'Lignocel' animal bedding RS Grade 3/4. Diets consists of SDS PCD 3/8" SQC pellets and water ad libitum. The mice are acclimated for at least six days before initiation of a study. At the start of a study, 4 young female adults (approximately 8-12 weeks) per test group are housed according to treatment.

All clinical signs, especially at the treatment sites (ie. skin reactions), should be recorded for the animals during a study. Details concerning the care and maintenance of mice can be found in the testing facility's SOPs. Cage and bottle washing procedures can be found in the testing facility's SOPs.

More information concerning animal maintenance (including diet batch numbers) are detailed on the 'Animal Log' sheet archived separately from the Study Report.

### 2.4 Test substance

Handling and characterisation of test substances must comply with the principles established in the testing facility's GLP policy documents and SOPs. Subsample archiving is conducted by the sample processing unit of the testing facility.

The amount of sample used is recorded on the Sample Accountability form (APPENDIX 1). Details of the subsample (including date received, appearance and the subsample identification) are filled in when the sample is received from the sample processing unit. The amount of sample actually weighed out and the weight of sample + container before and after removing a sample is recorded. Significant deviations of amount of sample used from the difference in weight of sample container before and after must be noted and commented upon on the back of the form. If a sample is sent for analysis, this should also be recorded on the form. At the end of the test, record the amount of material returned to the sample processing unit and the date returned. The Sample Accountability form must be signed by the test operator and archived with the final Study Report.

### 2.5 Solvent vehicle selection and preparation

When preparing solutions, a suitable solvent vehicle is selected from the following list or according to instructions from the Study Director:

4:1 v/v Acetone/Olive oil (AOO)  
Acetone  
Methyl ethyl ketone (MEK)  
4:1 v/v Methyl ethyl ketone/paraffin oil (MEKPO)  
Dimethyl sulfoxide (DMSO)  
N,N-Dimethylformamide (DMF)  
Propylene glycol (PG)  
Physiological saline (0.9%)  
50% v/v acetone saline

The vehicles AOO, MEKPO and acetone saline are prepared as follows:

AOO                    - add 160ml of acetone to 40ml of olive oil.

MEKPO - add 160ml of MEK to 40ml of paraffin oil.  
Acetone saline - add 100ml of acetone to 100ml of physiological saline (0.9%).

All vehicles are labelled with "Name" of contents, date of preparation, expiry date/condition, storage/handling and the name/initials of the operator who prepared it.

Where possible the following vehicles should be used (in order of preference): A00 > DMF > MEK > PG > DMSO.

## 2.6 Test solution preparation

Safety glasses and gloves must be worn during solution preparation and all procedures must be carried out in a fume cupboard where the test substance and/or vehicle is known to present an inhalation hazard.

The test substance is normally assayed at three to five consecutive concentrations from within the following range:

100%, 50%, 25%, 10%, 5%, 2.5%, 1.0%, 0.5%, 0.25%, 0.1%,

using a suitable vehicle. Test concentrations are primarily based upon previous experience in guinea pig tests, structure analysis and solubility factors. In the event of no such support data optimal test concentrations will be prepared based upon the solubility of the test substance in the vehicle.

Solids and liquids are weighed and solutions prepared on a weight upto (→) a volume basis (this must be specified in the record of solution preparation as w/v). 0.2ml graduated stoppered 10ml measuring cylinders, stoppered 5ml/10ml volumetric flasks and disposable 1.0ml syringes are used in the preparation of solutions. Such measuring cylinders/volumetric flasks are deemed sufficiently accurate for solution preparation. 1.0ml syringes are also sufficiently accurate for solution preparation. Details of solution preparation are recorded in the data sheets for the particular study and archived with the Study Report (APPENDIX 1).

Substances of low solubility can be mixed using a mechanical agitator or using a magnetic stirrer. Heat above 38°C is not used unless the substance is known to be heat stable.

## 2.7 Topical application

Gloves must be worn during this operation.

Each group of mice are treated by topical application to the dorsal surface of each ear with a different selected concentration of the test substance. A further group of mice is treated with the vehicle alone. The application volume, 25µl, is administered using a 0-50µl positive displacement pipette and is spread over the entire dorsal surface of the ear. For treatment, one mouse is removed from the home cage, treated and placed in an empty cage. When all mice from that group have been treated they are returned to the home cage. Topical application is performed once daily over three consecutive days. After the final topical application each group of mice are transferred into plastic disposable cages.

After treatments excess sample or the empty container is returned to the sample processing unit. Excess solutions, in small quantities, can normally be emptied down the drains using plenty of cold water. Hazardous solutions, however, must be returned to the sample processing unit for correct disposal.

## 2.8 Working with radiation

All work with radionuclides is conducted in a room which is a designated area approved by the test facility's Radiation Safety Office. The workstation has a 'Designated Workstation Log' in which details of the work undertaken and monitoring data is recorded.

Only suitably trained and approved staff will be allowed to work with unsealed radioactive sources.

Bench surfaces where radionuclides are handled are lined with absorbent plastic-lined paper, such as 'Benchkote' and plastic 'lipped' trays are used to confine contamination in the event of spills. Personal protection must be used when handling radionuclides, these include a labcoat, plastic gloves and safety glasses.

## 2.9 Preparation of $^3\text{H}$ -methyl thymidine

The radionuclide  $^3\text{H}$ -methyl thymidine ( $^3\text{HTdR}$ ) is used in the LLNA.  $^3\text{HTdR}$  is purchased from Amersham International, catalogue Code No. TRA.310 (specific activity, 2.0Ci/mMol; concentration 1.0mCi/ml). 'Radiochemical Batch Analysis' sheets received with each batch of  $^3\text{HTdR}$  are recorded separately from the Study Report.

The  $^3\text{HTdR}$  is diluted to a working concentration of 80 $\mu\text{Ci/ml}$  on a volume to volume basis using sterile phosphate buffered saline (PBS).  $^3\text{HTdR}$  is prepared in sterile 30ml disposable 'Universal' containers and is prepared fresh prior to the study. A disposable B-D plastipak 1ml syringe + 26G  $^3/8$ " hypodermic needle and disposable B-D plastipak 1ml/10ml/30ml syringes + 0.2mm micropore filter are used for the measurement of volumes of  $^3\text{HTdR}$  and PBS respectively.

The concentration of 80mCi/ml of  $^3\text{HTdR}$  is confirmed by removing a 80 $\mu\text{l}$  aliquot, diluting to 200ml with tap water and 'counting' two 1ml aliquots of this dilution in a  $\beta$ -Scintillation Counter after adding 10mls of 'Optiphase-mp' scintillant.

Details of  $^3\text{HTdR}$  preparation and confirmation of the concentration are recorded in the data sheets for the particular Study and archived with the Study Report (APPENDIX 1, Section 3). Further details concerning  $^3\text{HTdR}$  preparation and use are also detailed on 'Radioactive Log' sheets archived separately from the Study Report.

## 2.10 Incorporation of $^3\text{H}$ -methyl thymidine in vivo

Five days after the first topical application treatment, all mice are administered  $^3\text{H}$ -methyl thymidine ( $^3\text{HTdR}$ ). Several minutes prior to  $^3\text{HTdR}$  administration mouse tail veins are visualised by placing the mice in a warm air environment. This is achieved using a 'Thermacage' (Beta medical and Scientific; Datesand Ltd) which consists of four separate compartments each fitted with a lid, catch and vent control enabling temperature adjustment of each chamber. 20 $\mu\text{Ci}$   $^3\text{HTdR}$  is administered per mouse by injecting intravenously via tail vein with 250 $\mu\text{l}$  of 80 $\mu\text{Ci/ml}$   $^3\text{HTdR}$  using B-D Plastipak 1.0ml disposable syringes + 26G  $^3/8$ " hypodermic needles. 1.0ml disposable syringes are deemed sufficiently accurate for the measurement of volumes in the range 0.2-1.0ml.

## 2.11 Preparation of single cell suspensions

Approximately five hours after  $^3\text{HTdR}$  injection all mice are sacrificed by carbon dioxide asphyxiation, the draining auricular lymph nodes rapidly excised and pooled for each experimental group (8 nodes per group). Pooled lymph nodes are collected into 7ml disposable bijou bottles containing 1.0ml of phosphate buffered saline (PBS). A single cell suspension (SCS) of pooled lymph node cells (LNC) is prepared and collected into the base of a 90mm plastic Petri dish by gentle mechanical disaggregation of pooled lymph nodes through stainless steel gauze (200 mesh size) using the plunger of a B-D 'Discardit' 5.0ml disposable syringe (catalogue code no. 309050). The gauze is washed with 4-5mls of PBS into the base of the Petri dish, and the SCS transferred into a 10ml graduated plastic round-bottomed Sarstedt centrifuge tube. The SCS is finally made up to 10 mls with 4-5mls of PBS used to rinse the Petri dish. This procedure is repeated for each group of pooled lymph nodes.

Pooled LNC are pelleted with a relative centrifugal force (RCF) of 190 x g (RCF calculated to bottom of centrifuge tube) for 10 minutes in a centrifuge set at 4°C. After centrifugation each supernatant is removed by aspiration using disposable plastic pipettes leaving 1-2mls of supernatant above each pellet. Each pellet is gently agitated before making up to 10mls with PBS and resuspending the LNC. This washing procedure is repeated twice.

## 2.12 Determination of incorporated $^3\text{H}$ -methyl thymidine

Safety glasses and gloves must be worn when handling TCA and 'Optiphase mp' scintillation fluid.

After the final wash each supernatant is removed leaving just a small volume (<0.5ml) of supernatant above each pellet. Each pellet is gently agitated before resuspending the LNC in 3mls of 5% TCA for precipitation of macromolecules. After incubation with 5% TCA at +4°C overnight, each precipitate is recovered by centrifugation at 190 x g for 10 minutes, removing each supernatant and resuspending in 1ml of 5% TCA. Each precipitate is transferred to a 25ml glass scintillation vial with 10mls of 'Optiphase mp' scintillation liquid and thoroughly mixed. The vials are loaded into a  $\beta$ -scintillation counter, and after approximately 30 minutes  $^3\text{HTdR}$  incorporation is measured. The  $\beta$ -counter expresses  $^3\text{HTdR}$  incorporation as the number of radioactive disintegrations per minute (DPM), the results of which are produced on a printout. Similarly, background  $^3\text{HTdR}$  levels are also measured in two 1ml aliquots of 5% TCA.

### 2.13 Radioactive contamination monitoring

After completing an otherwise uneventful work routine the workplace must be thoroughly monitored. Such monitoring must be carried out regardless of the level of activity at which the work is done. Monitoring data is recorded in the 'Designated Workstation Log' and on 'Radioactive Monitoring Swabs' sheets which are archived separately from the Study Report. If necessary these will be made available to the Radiation Safety Officer. If contamination has been detected then the area contaminated must be decontaminated immediately using a suitable detergent such as 'Decon 90'.

In addition personal exposure to  $^3\text{HTdR}$  is monitored by monthly urine analysis.

Prompt whole body examination will be compulsory for staff who have been exposed to radionuclides as a result of accidents and major spillages.

Accidental contamination of personnel and equipment must be immediately reported to the local Radiation Safety Officer and medical department. Decontamination measures must be undertaken without delay. Contaminated protective clothing may be laundered in a 'Hot Lab' and personal contamination must be reduced by washing and scrubbing. Success of decontamination measures must be assessed by monitoring.

### 2.14 Disposal of radioactive waste

All contaminated solid waste from each experiment including animal carcasses is placed in biohazard plastic bags lined with plastic bin liners, sealed, labeled 'Radioactive material' and sent for incineration. If radioactive carcasses cannot be incinerated immediately then they must be placed in double plastic bags and frozen until it is convenient to do so.

Contaminated liquid waste is temporarily stored in a 2.5 litre impact resistant bottle and the contents sent for incineration when full.

Contaminated waste should not be allowed to accumulate and should be sent for incineration as soon as practically possible.

The quantity of radioactivity present within the waste is recorded on the 'Radioactive Log' sheet and archived separately from the Study Report. The quantity of radioactivity incinerated each week is submitted to the Radiation Safety Officer.

### 2.15 References

Kimber, I. and Weisenberger, C. 1989. A modified murine local lymph node assay for the identification of contact allergens. In "Current Topics in Contact Dermatitis". pp 592-595. Eds. Frosch, P.J. et al., Springer-Verlag Berlin Heidelberg.

Kimber, I. et al. 1989. The murine local lymph node assay for the identification of contact allergens: a preliminary evaluation of in situ measurement of lymphocyte proliferation. Contact Dermatitis, 21, 215-220.

Kimber, I. et al. 1991. The murine local lymph node assay: results of an inter-laboratory trial. *Toxicology Letters*, 55, 203-213.

Kimber, I. and Basketter, D.A. 1992. The murine local lymph node assay. A commentary on collaborative studies and new directions. *Fd. Chem. Toxic.*, 30, 165-169.

### **3. RESULTS**

#### **3.1 Interpretation/treatment of results**

The proliferative response of lymph node cells (LNC) is expressed as the number of radioactive disintegrations per minute per lymph node (DPM/NODE) and as the ratio of <sup>3</sup>HTdR incorporation into LNC of test lymph nodes relative to that recorded for control lymph nodes (TEST/CONTROL RATIO). Before DPM/NODE values are determined, background <sup>3</sup>HTdR is subtracted from test and control raw DPM data.

A substance is regarded as a sensitizer in the LLNA if at least one concentration of the test substance results in a 3-fold or greater increase in <sup>3</sup>HTdR incorporation into LNC of test lymph nodes relative to that recorded for control lymph nodes, as indicated by the TEST/CONTROL RATIO. The data should also not be incompatible with a biological dose response, although allowance must be made, especially at high topical application concentrations, for either local toxicity or immunological suppression.



### 3.2 Example

Raw data:	Background <sup>3</sup> HTdR in two 1ml TCA samples - 90 DPM	100 DPM
	<sup>3</sup> HTdR incorporation into LNC of 8 control lymph nodes - 3,000 DPM	
	<sup>3</sup> HTdR incorporation into LNC of 8 test lymph nodes - 21,000 DPM	
Derived data:	Mean background <sup>3</sup> HTdR	= $\frac{90 \text{ DPM} + 100 \text{ DPM}}{2}$
		= <b>95 DPM</b>
	Control DPM/NODE	= $\frac{3000 \text{ DPM} - 95 \text{ DPM}}{8 \text{ NODES}}$
		= <b>363 DPM/NODE</b>
	Test DPM/NODE	= $\frac{21,000 \text{ DPM} - 95 \text{ DPM}}{8 \text{ NODES}}$
		= <b>2613 DPM/NODE</b>
	TEST/CONTROL RATIO	= $\frac{2613 \text{ DPM/NODE}}{363 \text{ DPM/NODE}}$
		= <b>7.2</b>

Since the TEST/CONTROL RATIO is greater than 3, the test substance fulfils the criteria to be classified as a sensitizer in the LLNA. If the TEST/CONTROL RATIO is less than 3, the test substance fails to fulfil the criteria to be classified as a sensitizer in the LLNA.

## 4. EQUIPMENT DETAILS

Refer to the appropriate test facility SOPs; for instruction guides, calibration and maintenance care for the equipment. Calibration and Service records associated with the studies are archived independent to studies annually. Refer to the SOP for instruction guides, calibration and maintenance care for use of  $\beta$ -scintillation counters.

## 5. DATA HANDLING

The recording and handling of data must comply with the principles established in the GLP policy document of the testing facility and any applicable SOPs.

Data is transferred from the data sheets to produce a Study Report. All original data, Protocols and data sheets must be retained and archived with the Study Report as a Study Package.

Archiving procedures are described in the testing facility's SOPs. Study Packages should be archived within 6 months of completion of the Study. Other supporting data which is not included in the Study Package (calibration/maintenance and animal room day books, animal and radioactive logs) are archived annually.

APPENDIX 1

Local Lymph Node Assay Data Test Sheets

Sample Accountability

Solution Preparation

Reagent Preparation

Background and Control Raw Data

Test Raw Data

Expression and Interpretation of Results

Mouse Maintenance, Treatment and Task Record

THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER \_\_\_\_\_.

Sample Accountability

Test substance :  
Sub-sample ref. no. :  
Appearance of sub-sample :  
Active ingredient level :

Date sample received:

Procedure	Wt. Sample + Container		Amount Used	Operator	Date
	Before	After			
Initial Weight					
To Archive					
To Analytical					
Solvent Determination					
Topical Application					
Returned to Sample Processing					

Comments:

THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER \_\_\_\_\_.

Table

Test substance :  
Sample ref. no. :  
Active ingredient level :  
Storage :  
Handling :

1. Description of test solutions and preparation

Solvent vehicle:

Test Conc. (%)	Preparation	Description	Operator	Date

2. Method of test solution preparation

Test Conc. (%)	Method of Preparation	Storage Conditions	Other Comments

THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER \_\_\_\_\_

Reagent Preparation

- (i) Phosphate buffered saline (PBS) - 1 sachet of PBS powder -----> 1000ml distilled water. Stored at + 4°C. Prepared
- (ii) Trichloroacetic acid (TCA) - 7.5g TCA -----> 150ml tap water. Stored at + 4°C. Prepared
- (iii) <sup>3</sup>H-methyl thymidine (<sup>3</sup>HTdR), specific activity 2.0Ci/mMol (Concentration 1.0mCi/ml). Stored at + 4°C. '**Radiochemical Batch Analysis**' sheets received with each batch of <sup>3</sup>HTdR are recorded separately from this study. 80μCi/ml activity <sup>3</sup>HTdR was prepared as follows:

<sup>3</sup> HTdR Code No.	In-Use Activity	Preparation	Operator	Date
	80μCi/ml*	ml of 1mCi/ml <sup>3</sup> HTdR + ml of sterile PBS.		

\* Dilution activity of <sup>3</sup>HTdR confirmed by removing a 80μl aliquot, diluting to 200ml with tap water and removing two 1ml aliquots (0.032 μCi) and counting these on the β-scintillation counter:

β-Counter printout inserted here

Mean Count : DPM

Since 1.0μCi = 2220000 DPM (37000 Bq)  
then 0.032μCi = 71040 DPM.

Therefore 
$$\text{DPM} = \frac{\text{DPM}}{71040 \text{ DPM}} \times 80\mu\text{Ci/ml}$$

$$= \underline{\hspace{2cm}} \mu\text{Ci/ml}$$

More information concerning <sup>3</sup>HTdR preparation, use, disposal and monitoring during this study are detailed on the '**Radioactive Log**' and '**Radioactive Monitoring Swabs**' sheets recorded separately from this study.

Signed : Date:

THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER \_\_\_\_\_.

Table

Background and control raw data retrieved from the  $\beta$ -scintillation counter

Results:

(i) Background and Control results

Background  $^3\text{HTdR}$  in two 1ml TCA samples was determined and  $^3\text{HTdR}$  incorporation into Control LNC determined \_\_\_\_\_ days after the first vehicle topical application.

$\beta$ -Counter printout inserted here

Rack/Sample Position	Sample Description	No. Lymph Nodes	Sample DPM

Mean background count: \_\_\_\_\_ DPM

Signed : \_\_\_\_\_ Date : \_\_\_\_\_

THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER  
INDIVIDUAL ANIMAL LYMPH NODES

Table

Control raw data retrieved from the  $\beta$ -scintillation counter

Results:

(i) Control results

$^3\text{HTdR}$  incorporation into Control LNC determined    days after the first vehicle topical application.

$\beta$ -Counter printout inserted here

Rack/Sample Position	Sample Description	Control Group Animal No.	Sample DPM

Mean background count:    DPM

Signed :                      Date :

THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER \_\_\_\_\_

Table

Test Raw data retrieved from b-Scintillation Counter

Test substance :  
Sample ref. no. :

<sup>3</sup>HTdR incorporation into test LNC determined \_\_\_\_\_ days after the first test substance topical application.

Results

(ii) Test results

β-Counter printout inserted here

Rack/Sample Position	Sample Description	No. Lymph Nodes	Sample DPM

Signed :                      Date :



THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER \_\_\_\_\_

Table

Test Raw data retrieved from b-Scintillation Counter

Test substance :  
Sample ref. no. :

<sup>3</sup>HTdR incorporation into test LNC determined \_\_\_\_\_ days after the first test substance topical application.

Results

(ii) Test results

β-Counter printout inserted here

Rack/Sample Position	Sample Description	No. Lymph Nodes	Sample DPM

Signed :                      Date :

THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER \_\_\_\_\_

Table

Expression and Interpretation of results

Test Substance :  
Sample ref. no. :  
Exposure period (days) :

The proliferative response of lymph node cells (LNC) is expressed as the number of radioactive disintegrations per minute per lymph node (DPM/NODE) and as the ratio of <sup>3</sup>HTdR incorporation into LNC of test nodes relative to that recorded for control nodes (TEST/CONTROL RATIO). The test substance can be regarded as 'a sensitizer' if at least one test concentration produces a test/control ratio equal to or greater than 3.0. The data must also be compatible with a biological dose response, although allowance must be made, especially at high topical application concentrations, for local toxicity and/or immunological suppression. Where the data does not fulfill these criteria, the test substance can be regarded as 'unlikely to be a strong sensitizer'.

Background count : DPM

Sample Description	Sample DPM - B'grd DPM	No. Lymph Nodes	DPM/NODE	TEST/CONTROL RATIO	+/-

Biological dose response - Yes/No.

Comments:

Signed :

Date :



THE LOCAL LYMPH NODE ASSAY - STUDY NUMBER  
INDIVIDUAL ANIMAL LYMPH NODES

Table

Expression and Interpretation of results

Test Substance  
Sample ref. no.  
Exposure period (days)

The proliferative response of lymph node cells (LNC) is expressed as the number of radioactive disintegrations per minute per individual animal (DPM), the test or control group mean DPM and as the ratio of <sup>3</sup>HTdR incorporation into LNC of test nodes relative to that recorded for control nodes (TEST/CONTROL RATIO). The test substance can be regarded as 'a sensitizer' if at least one test concentration produces a test/control ratio equal to or greater than 3.0. The data must also be compatible with a biological dose response, although allowance must be made, especially at high topical application concentrations, for local toxicity and/or immunological suppression. Where the data does not fulfill these criteria, the test substance can be regarded as 'unlikely to be a strong sensitizer'.

Sample Description Test or control Group	Group Mean DPM	Group Mean Standard Error	TEST/CONTROL RATIO	+/-

Biological dose response - Yes/No.

Comments:

Signed :

Date :

## Evaluation Guidance to the Peer Review Panel

### A. Instructions for Peer Review Panel Members

The Peer Review Panel was charged with developing a consensus on the usefulness of the proposed LLNA test method (appendix D) as an alternative for the currently accepted guinea pig assay. In reaching this determination, the panel was asked to evaluate all of the available information in the submission in accordance with the published criteria for validation and acceptance of toxicological test methods (NIEHS, 1997). The Peer Review Panel was charged with preparing a written report that summarized the extent to which each of these criteria were addressed, and that addressed the acceptability of this method as a substitute for the guinea pig assay.

An outline of the major items addressed in the Peer Review Panel report is provided below in “B. Points for Evaluation.” Specific questions and considerations were added by the Interagency Immunotoxicity Working Group to ensure that the assessment provided adequate information to facilitate agency decisions on the regulatory acceptability of the method.

One primary and at least two secondary reviewers were designated for each section by the NIEHS Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) in consultation with the Peer Review Panel Chair. These individuals were requested to prepare draft written responses for their assigned sections. All reviewers were encouraged to familiarize themselves with the entire set of questions and to comment on any or all sections. All reviewers were asked to complete the summary conclusions section.

In conducting this review, the primary focus of the Peer Review Panel was to evaluate the information supporting the usefulness of the proposed LLNA Test Method Protocol (LLNA ICCVAM Submission). Based on the information provided in the Submission, the panel was asked to determine if the LLNA is an acceptable alternative to standard guinea pig assays for identifying human contact allergens. Two overall questions that they were asked to address were:

***Has the LLNA been evaluated sufficiently and is its performance satisfactory to support its adoption as a stand-alone alternative?***

***Does the LLNA offer advantages with respect to animal welfare considerations (refinement, reduction, and replacement)?***

The focus of the Peer Review Panel evaluation was on the utility of the LLNA, as described in the proposed Test Method Protocol, for detecting possible human contact allergens. The Panel was made aware that modifications to the proposed LLNA protocol have been made or were under development (*e.g.*, *ex-vivo* use of radiolabeled thymidine, use of nonradioactive methods) which were outside the scope of this evaluation. However, the Panel was asked to submit suggestions for future evaluations or workshops to review proposed test method revisions.

## **B. Points for Evaluation**

### **1. Summary Conclusions**

Based on the information provided:

- a. Compared with current methods [e.g., the guinea pig maximization test (GPMT)], could this method be used to provide equivalent or better prediction of human allergic contact dermatitis?
- b. Does the LLNA adequately identify the lack of potential of chemicals to induce human allergic contact dermatitis? If applicable, specify those circumstances (e.g., specific chemicals/chemical classes) where the LLNA, or test results from the LLNA, would be considered either (i) inadequate or (ii) equal to or better than current methods for concluding that the test article is not a contact sensitizer.
- c. Does the LLNA adequately identify the potential of chemicals to induce human allergic contact dermatitis? If applicable, specify those circumstances (e.g., specific chemicals/chemical classes) where the LLNA, or test results from the LLNA, would be considered either (i) inadequate or (ii) equal to or better than current methods for concluding that the test article is a contact sensitizer.
- d. Discuss conditions/limitations/restrictions that may affect the intended use of the LLNA, and that are justified based upon the presence or lack of scientific evidence.
- e. Discuss advantages of the proposed LLNA, as compared to the standard guinea pig methods.
- f. Has there been adequate consideration and appropriate incorporation of animal use refinement, reduction, and replacement alternatives? Will the LLNA reduce the number of animals required or refine the procedure to eliminate pain or distress compared with the reference tests?

### **2. Test Method Description (see Appendix D, LLNA Protocol)**

- a. Are the test method and protocol described in sufficient detail, including the scientific and mechanistic basis of the test, range of applications, endpoints, numbers of replicates, need for dose-response curves, and acceptable variations in the protocol?
  - 1) Is the protocol used to generate the supporting submission data in agreement with the proposed protocol (Section II. D.)? If not, discuss the adequacy of the rationale provided for changes incorporated in the proposed protocol.
  - 2) Evaluate the appropriateness of the dose selection procedure. Discuss the need for determination of dermal irritation (e.g., as done for the guinea pig test) or acute toxicity data prior to conducting the actual test.

- 3) Evaluate the appropriateness of the number of dose groups recommended as necessary for an adequate study.
- b. Comment on the adequacy and completeness of the test method protocol, including:
    - 1) Description of the material and equipment needed to conduct the test. Is the number of mice per dose group appropriate? Is the age range appropriate? Is the designated gender and strain appropriate?
    - 2) Description of what is measured and how it is used.
    - 3) Description of data analysis, evaluation, and decision criteria (*i.e.*, a >3-fold stimulation factor) used to identify substances as: 1) a positive skin sensitizer, and 2) a negative skin sensitizer.
  - c. Are there appropriate provisions for the use of positive, negative, and irritation control chemicals?
  - d. Discuss the role of a dose response relationship in interpreting the results of this assay.
  - e. What are the strengths and/or limitations of the LLNA and are they described adequately, including the usefulness for testing mixtures, extracts, and metals?
  - f. Are there editorial/technical corrections necessary for the proposed protocol?

### 3. Test Method Data Quality

Is there evidence of sufficient quality assurance/quality control [i.e., were experiments conducted and data collected and maintained in accordance with Good Laboratory Practice (GLP) standards and procedures; in the “spirit” of GLPs (e.g., GLP standards without audits)]? If not, is there clear indication from the technical data that there was adequate record-keeping or data collection.

- a. Is there an assurance provided that indicates there was adherence to the protocol during the validation studies? Are deviations from the standard protocol clearly described and justified?
- b. If changes were made to the test method protocol during the validation studies, is the rationale for the changes provided, are data clearly identified to indicate which protocol was used, and are the potential impact of these changes on evaluation of the test method presented?
- c. Was a data audit conducted by a Quality Assurance Unit? If so, is the data quality satisfactory based on the audit results (e.g., adequate adherence to protocols, record-keeping following GLPs)?

#### 4. Test Method Performance

- a. Are the data provided in sufficient detail for you to evaluate the results and conclusions obtained with the LLNA?
- b. Comment on the adequacy of the methods used to evaluate the performance of the test method. Are results of the LLNA and the reference test(s) compared and evaluated appropriately?
- c. Comment on the adequacy of the numbers of chemicals/products selected to evaluate the performance (end result) of the method for each chemical/product class. Are there limitations in application of this assay to specific chemical/product classes?
- d. Are sufficient data provided to adequately evaluate the performance of the method for its proposed use?
- e. Comment on the sensitivity, specificity, concordance, false positive rate, and false negative rates for the chemical/product classes that the method is proposed to be used for.
  - 1) To what extent does the method correctly predict negative effects for some or all chemicals/products?
  - 2) To what extent does the method correctly predict positive effects correctly for some or all classes? Does it consistently over or under predict toxicity compared with the current test method?
- f. Are the sensitivity, specificity, concordance, and false positive and negative rates acceptable for the chemical/product classes tested?
- g. Are the conclusions on the usefulness of this method scientifically sound?
  - 1) Are results of the LLNA clinically relevant and is the test predictive for human contact allergens?
  - 2) Is the utility of the method clearly established for regulatory use in hazard assessment of chemicals as potential contact sensitizers?

#### 5. Determination of Test Method Reliability (Repeatability/Reproducibility)

Are intra- and inter-laboratory reproducibility adequately evaluated?

- a. Comment on the adequacy of the evaluation of intralaboratory repeatability and reproducibility of the test method, and the data used to define and describe the level of intralaboratory variability.
- b. Comment on the adequacy of the evaluation of interlaboratory reproducibility of the test method, and the data used to define and describe the level of interlaboratory variation.
  - 1) Consider the range of vehicle control data within and across laboratories in the validation studies. Do these differences affect data quality



(reproducibility, sensitivity, etc)?

- c. Was the reproducibility of the test method evaluated on a series of appropriate reference chemicals or products, and do these adequately represent the types of substances for which the test method is proposed to be used?
- d. Are the results obtained with the LLNA sufficiently repeatable and reproducible?
- e. Comment on the reproducibility and reliability of the LLNA as compared to standard guinea pig assays.

## **6. Other Scientific Reviews**

Comment on and compare the conclusions published in independent peer-reviewed reports or other independent scientific reviews of the test method, compared to the conclusions reached in this report, and comment on any other ongoing evaluations of this method.

## **7. Other Considerations**

- a. Can the test method be readily transferred among properly equipped and staffed laboratories; that is:
  - 1) Is it relatively insensitive to minor changes in protocol (e.g., the acceptable temperature range for reagents and for the location where the test will be conducted)?
  - 2) Are the level of training and expertise required to conduct the test reasonable?
  - 3) Are the necessary equipment and supplies relatively easy to obtain?
- b. Is the method cost-effective, relative to the cost of conducting the currently accepted test methods for hypersensitivity?
- c. Is the time needed to conduct the test reasonable?
- d. Is there any other information that should be added to the report, published or unpublished?
- e. Has there been adequate consideration and appropriate incorporation of animal use refinement, reduction, and replacement alternatives? Will the LLNA reduce the number of animals required or refine the procedure to reduce or eliminate pain or distress compared with the reference tests?

## **C. Related Issues**

- 1. Although this evaluation is for a specific LLNA protocol proposed as an alternative for currently used guinea pig tests, what other endpoints or test methods would you like to see evaluated by ICCVAM in the future?
- 2. Are there ideas for potential workshops and validation efforts that you think that ICCVAM or others should support in this area of contact hypersensitivity?

**Reference:**

NIEHS (National Institute of Environmental Health Sciences). 1997. Validation and regulatory acceptance of toxicological test methods: A report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative Methods. NIH Publication No. 97-3981. NIEHS, Research Triangle Park, NC.

## ICCVAM Validation and Regulatory Acceptance Criteria

### Validation Criteria<sup>1</sup>

For a new or revised test method to be considered validated for regulatory risk assessment purposes, it should generally meet the following criteria (the extent to which these criteria are met will vary with the method and its proposed use). However, there needs to be flexibility in assessing a method given its purpose and the supporting database. Because tests can be designed and used for different purposes by different organizations and for different categories of substances, the determination of whether a specific test method is considered by an agency to be useful for a specific purpose must be made on a case-by-case basis. Validation of a test method is a prerequisite for it to be considered for regulatory acceptance.

- The scientific and regulatory rationale for the test method, including a clear statement of its proposed use, should be available.
- The relationship of the test method's endpoint(s) to the biologic effect of interest must be described. Although the relationship may be mechanistic or correlative, tests with biologic relevance to the toxic process being evaluated are preferred.
- A detailed protocol for the test method must be available and should include a description of the materials needed, a description of what is measured and how it is measured, acceptable test performance criteria (e.g., positive and negative control responses), a description of how data will be analyzed, a list of the species for which the test results are applicable, and a description of the known limitations of the test including a description of the classes of materials that the test can and cannot accurately assess.
- The extent of within-test variability, and the reproducibility of the test within and among laboratories must have been demonstrated. Data must be provided describing the level of intra- and interlaboratory reproducibility and how it varies over time. The degree to which biological variability affects this test reproducibility should be addressed.
- The test method's performance must have been demonstrated using reference chemicals or test agents representative of the types of substances to which the test method will be applied, and should include both known positive and known negative agents. Unless it is hazardous to do so, chemicals or test agents should be tested under code to exclude bias.
- Sufficient data should be provided to permit a comparison of the performance of a proposed substitute test with that of the test it is designed to replace. Performance should be evaluated in relation to existing relevant toxicity testing data, and relevant toxicity information from the species of concern. Reference data from the comparable traditional test method should be available and of acceptable quality.
- The limitations of the method must be described; for example, in vitro or other non-animal test methods may not replicate all of the metabolic processes relevant to chemical toxicity that occur in vivo.

<sup>1</sup>From: National Institute of Environmental Health Sciences (NIEHS). Validation and Regulatory Acceptance of Toxicological Test Methods: A report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). NIH Publication No. 97-3981, NIEHS, Research Triangle Park, NC, USA; 1997

- Ideally, all data supporting the validity of a test method should be obtained and reported in accordance with Good Laboratory Practices (GLPs). Aspects of data collection not performed according to GLPs must be fully described, along with their potential impact.
- All data supporting the assessment of the validity of the test method must be available for review.
- Detailed protocols should be readily available and in the public domain.
- The method(s) and results should be published or submitted for publication in an independent, peer-reviewed publication.
- The methodology and results should have been subjected to independent scientific review

### Regulatory Acceptance Criteria<sup>1</sup>

Validated methods are not automatically accepted by regulatory agencies; they need to fit into the regulatory structure. Flexibility is essential in determining the acceptability of methods to ensure that appropriate scientific information is considered in regulatory risk assessment. A test method proposed for regulatory acceptance generally should be supported by the following attributes:

- The method should have undergone independent scientific peer review by disinterested persons who are experts in the field, knowledgeable in the method, and financially unencumbered by the outcome of the evaluation.
- There should be a detailed protocol with standard operating procedures (SOPs), a list of operating characteristics, and criteria for judging test performance and results.
- Data generated by the method should adequately measure or predict the endpoint of interest and demonstrate a linkage between either the new test and an existing test, or the new test and effects in the target species.
- There should be adequate test data for chemicals and products representative of those administered by the regulatory program or agency and for which the test is proposed.
- The method should generate data useful for risk assessment purposes, i.e., for hazard identification, dose-response assessment, and/or exposure assessment. Such methods may be useful alone or as part of a battery or tiered approach.
- The specific strengths and limitations of the test must be clearly identified and described.
- The test method must be robust (relatively insensitive to minor changes in protocol) and transferable among properly equipped and staffed laboratories.
- The method should be time and cost effective.
- The method should be one that can be harmonized with similar testing requirements of other agencies and international groups.
- The method should be suitable for international acceptance.
- The method must provide adequate consideration for the reduction, refinement, and replacement of animal use.

<sup>1</sup>From: National Institute of Environmental Health Sciences (NIEHS). Validation and Regulatory Acceptance of Toxicological Test Methods: A report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). NIH Publication No. 97-3981, NIEHS, Research Triangle Park, NC, USA; 1997.

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Health Service

#### National Institute of Environmental Health Sciences (NIEHS); Notice of Meeting to Review the Murine Local Lymph Node Assay (LLNA) as an Alternative Test Method for Contact Hypersensitivity; Request for Comments

**SUMMARY:** Pursuant to Public Law 103-43, notice is hereby given of a public meeting sponsored by the NIEHS and the National Toxicology Program (NTP), and coordinated by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NTP Center). The agenda topic is the scientific peer review of the murine local lymph node assay (LLNA), which is proposed as an alternative toxicological test method for assessing contact hypersensitivity (allergic contact dermatitis) potential of chemicals and products. The meeting will be held on September 17, 1998, at the Gaithersburg Hilton, 620 Perry Parkway, Gaithersburg, Maryland. The meeting will take place from 8:30 a.m. to 4:30 p.m. and is open to the public.

#### Background

Public Law 103-43 directed the NIEHS to develop and validate alternative methods that can reduce or eliminate the use of animals in acute or chronic toxicity testing, establish criteria for the validation and regulatory acceptance of alternative testing methods, and recommend a process through which scientifically validated alternative methods can be accepted for regulatory use. Criteria and processes for validation and regulatory acceptance were developed in conjunction with 13 other Federal agencies and programs with broad input from the public. These are described in the document "Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the Ad Hoc Interagency Coordinating Committee on the Validation of Alternative Methods" NIH publication 97-3981, March 1997, which is available on the internet at <http://ntp-server.niehs.nih.gov/htdocs/ICCVAM/ICCVAM.htm>. An Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) was subsequently established in a collaborative effort by NIEHS and 13 other Federal regulatory and research

agencies and programs. The Committee's functions include the coordination of interagency reviews of toxicological test methods and communication with stakeholders throughout the process of test method development and validation. The following Federal regulatory and research agencies and organizations are participating in this effort:

Consumer Product Safety Commission  
Department of Defense  
Department of Energy  
Department of Health and Human Services  
Agency for Toxic Substances and Disease Registry  
Food and Drug Administration  
National Institute for Occupational Safety and Health/CDC  
National Institutes of Health  
National Cancer Institute  
National Institute of Environmental Health Sciences  
National Library of Medicine  
Department of the Interior  
Department of Labor  
Occupational Safety and Health Administration  
Department of Transportation  
Research and Special Programs Administration  
Environmental Protection Agency

The LLNA was proposed to the ICCVAM for consideration as a stand-alone test to identify chemicals that have a potential to cause contact hypersensitivity (allergic contact dermatitis). An ICCVAM Immunotoxicity Working Group composed of Federal employees determined that there was sufficient information available to merit an independent scientific peer review of the LLNA test method. Peer review has been determined to be an essential prerequisite for consideration of a method for regulatory acceptance. The peer review panel will be charged with developing a scientific consensus on the usefulness of the test method to generate information for various human health risk assessment purposes. Following evaluation at this peer review meeting, the proposed test method and results of the peer review will be forwarded by ICCVAM to Federal agencies for consideration. Federal agencies will determine the regulatory acceptability of a method according to their mandates.

#### Agenda

There will be a brief orientation on the ICCVAM and the ICCVAM review process, followed by peer review of the proposed LLNA test method and supporting information. The peer

review panel will discuss the usefulness of the LLNA as an alternative to test methods currently accepted by government regulatory authorities for the assessment of the contact hypersensitivity potential of chemicals and products. Copies of the proposed LLNA Test Method Protocol and supporting documentation may be obtained from the NTP Center for the Evaluation of Alternative Toxicological Methods, MD EC-17, P.O. Box 12233, Research Triangle Park, NC, 27709 (919-541-3398), FAX (919-541-0947), e-mail: [ICCVAM@niehs.nih.gov](mailto:ICCVAM@niehs.nih.gov). The LLNA test method documents and copies of written public comments can also be viewed at the Documents Management Branch, Food and Drug Administration, 5630 Fishers Lane, Room 1081, Rockville, MD, 20852 on Monday through Friday from 9:00 a.m. to 4:00 p.m.

#### Public Comment

The NTP Center invites the submission of written comments on the proposed LLNA test method, and other available information regarding the usefulness of the LLNA, including information about completed, ongoing, or planned studies. Written comments and additional information should be sent by mail, fax, or e-mail to the NTP Center at the address listed above by August 14th. Written comments will be made available to the peer review panel members, ICCVAM agency representatives and experts, and will be made available for attendees at the meeting. Members of the public who wish to present oral statements at the meeting should also contact the NTP Center as soon as possible, but not later than September 11, 1998. Speakers will be assigned on a first-come, first-serve basis and will be limited to a maximum of five minutes in presentation length. Written comments accompanying the oral statement should be submitted in advance so that copies can be made and distributed to the peer panel members.

The NTP Center will furnish an agenda and a roster of peer review panel members just prior to the meeting. Summary minutes and a final report of the LLNA peer review meeting will be available subsequent to the meeting upon request to the Center. Persons needing special assistance, such as sign language interpretation or other special accommodations should contact the NTP Center as described above.

Dated: June 30, 1998.

Kenneth Olden,

Director, National Toxicology Program.

[FR Doc. 98-18320 Filed 7-9-98; 8:45 am]

BILLING CODE 4140-01-M

---

## LLNA Peer Review Meeting Agenda

---

Interagency Coordinating Committee on the  
Validation of Alternative Methods (ICCVAM)  
and the  
National Toxicology Program Interagency Center for the  
Evaluation of Alternative Toxicological Methods (NICEATM)

*September 17, 1998, 8:30 a.m. to 5:30 p.m.*

Ballroom A  
Gaithersburg Hilton, 620 Perry Parkway  
Gaithersburg, Maryland

---

8:30 a.m.	Introductions	Dr. Jack Dean
	Welcome from the National Toxicology Program	Dr. George Lucier
	Introduction to ICCVAM and NICEATM	Dr. William Stokes
	Overview of the LLNA Peer Review Process	Ms. Denise Sailstad
	Summary of Current Agency Requirements	Dr. David Hattan
	Overview of the Proposed LLNA Test Method Protocol	Drs. G. Frank Gerberick, Ian Kimber, and David Basketter
	Questions Regarding the Test Method Protocol	
9:55 a.m.	<u>Peer Review Panel Discussion</u>	
	Test Method Description	Dr. Jean Meade, Coordinator Drs. Paul Bailey, Martinus Lovik, Howard Maibach, and Jean Regal
	Break	
10:50 a.m.	<u>Peer Review Panel Discussion</u> (continued)	
	Test Method Data Quality	Dr. Lorraine Twerdok, Coordinator Drs. Martinus Lovik, Ralph Smialowicz, and Stephen Ullrich
	Test Method Performance	Dr. Peter Thorne, Coordinator Drs. Klaus Andersen, Paul Bailey, Jean Meade, and Joe Haseman
12:30 p.m.	Public Comment	
1:00 p.m.	Lunch Break	



## LLNA Peer Review Meeting Summary Minutes

### Introduction

A public meeting of an independent peer review panel was convened on September 17, 1998, in Gaithersburg, Maryland to review the murine local lymph node assay (LLNA), which was proposed as an alternative toxicological test method for assessing contact hypersensitivity (allergic contact dermatitis) potential of chemicals and products. The meeting was coordinated by ICCVAM and the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and was sponsored by the National Institute of Environmental Health Sciences (NIEHS) and the National Toxicology Program (NTP).

The following expert scientists served on the peer review panel:

- Jack Dean, Ph.D., Sanofi Pharmaceuticals, Inc., Malvern, Pennsylvania (Panel Chair)
- Klaus Andersen, M.D., Ph.D., Odense University Hospital, Odense, Denmark
- Paul Bailey, Ph.D., Mobil Oil Corporation, Paulsboro, New Jersey
- Robert G. Hamilton, Ph.D., Johns Hopkins University, Baltimore, Maryland
- Joseph Haseman, Ph.D., National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina
- Masato Hatao, Ph.D., Shiseido Research Center, Yokohama, Japan
- Martinus Lovik, M.D., Ph.D., National Institute of Public Health, Oslo, Norway
- Howard Maibach, M.D., University of California/SF, San Francisco, California
- B. Jean Meade, D.V.M., Ph.D., National Institute of Occupational Safety and Health, Morgantown, West Virginia
- Jean Regal, Ph.D., University of Minnesota, Duluth, Minnesota
- Ralph Smialowicz, Ph.D., US Environmental Protection Agency, Research Triangle Park, North Carolina
- Peter Thorne, Ph.D., University of Iowa, Iowa City, Iowa
- Lorraine E. Twerdok, Ph.D., American Petroleum Institute, Washington, District of Columbia
- Stephen E. Ullrich, Ph.D., MD Anderson Cancer Center, Houston, Texas

### Introductions

Dr. Jack Dean, chair, called the meeting to order at 8:30 a.m., and asked each person in attendance to state their name and affiliation.

### Welcome from the National Toxicology Program

Dr. George Lucier, Director of the National Toxicology Program, thanked the ICCVAM participating agencies and stakeholders, the LLNA sponsors, and the peer review panel for their efforts. Dr. Lucier also provided a brief overview of the history of ICCVAM and NICEATM.

### Introduction to ICCVAM and NICEATM

Dr. William Stokes, ICCVAM Co-Chair and Director of NICEATM, explained the ICCVAM review process, and the steps that had been undertaken in the review of LLNA. He discussed the role of the ICCVAM committee, its expert subgroup



(Immunotoxicology Working Group) and the peer review panel, and the process by which test methods are reviewed and forwarded to agencies for action.

Public Law 103-43 directed the NIEHS to develop and validate alternative methods that can reduce or eliminate the use of animals in acute or chronic toxicity testing, to establish criteria for the validation and regulatory acceptance of alternative testing methods, and to recommend a process through which scientifically validated alternative methods can be accepted for regulatory use. Criteria and processes for validation and regulatory acceptance were developed in conjunction with 14 other Federal agencies and programs with broad input from the public. These are described in the document "Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the Ad Hoc Interagency Coordinating Committee on the Validation of Alternative Methods," NIH Publication 97-3981, March, 1997. This document is available via the internet at <http://ntp-server.niehs.nih.gov/htdocs/ICCVAM.htm>.

ICCVAM was subsequently established in a collaborative effort by NIEHS and 13 other Federal regulatory and research agencies and programs. The Committee's functions include the coordination of interagency reviews of toxicological test methods and communication with stakeholders throughout the process of test method development and validation. The following Federal regulatory and research agencies and organizations are participating in this effort:

- Consumer Product Safety Commission
- Department of Defense
- Department of Energy

- Department of Health and Human Services
  - Agency for Toxic Substances and Disease Registry
  - Food and Drug Administration
  - National Institutes of Health
    - Office of the Director
    - National Cancer Institute
    - National Institute of Environmental Health Sciences
      - National Library of Medicine
  - National Institute for Occupational Safety and Health/CDC
- Department of the Interior
- Department of Labor
  - Occupational Safety and Health Administration
- Department of Transportation
  - Research and Special Programs Administration
- Environmental Protection Agency

The LLNA was proposed to ICCVAM for consideration as a stand-alone test to identify chemicals that have the potential to cause contact hypersensitivity (allergic contact dermatitis). The test method submission was prepared by three co-sponsors: Drs. G. Frank Gerberick (Procter & Gamble, US); Ian Kimber (Zeneca, UK); and David A. Basketter (Unilever, UK). Independent peer review is an essential prerequisite for consideration of a method for regulatory acceptance (NIEHS, 1997). The peer review panel (PRP) was charged with developing a scientific consensus on the usefulness of the test method to generate information for human health risk assessment purposes. The proposed test method and results of the peer review will be forwarded by ICCVAM to Federal agencies for consideration. Federal agencies will determine the regulatory acceptability of the method according to their mandates.

## **Overview of the LLNA Peer Review Process**

Ms. Denise Sailstad, IWG Co-Chair, provided an overview of the role of the IWG in the review of the LLNA, outlining the specific accomplishments of the IWG. She reiterated the two main questions that the working group had drafted as the focus of the review. The questions were as follows:

1. Has the LLNA been evaluated sufficiently and is its performance satisfactory to support its adoption as a stand-alone alternative?
2. Does the LLNA offer advantages with respect to animal welfare considerations (refinement, reduction, and replacement)?

## **Summary of Current Agency Requirements**

Dr. David Hattan, IWG Co-Chair, summarized Federal agency and international regulations and recommendations for dermal contact hypersensitivity testing. Several test methods are currently accepted by the EPA. EPA OPPTS and the OECD (Guideline Number 405) both currently accept the LLNA as a screening test for dermal hypersensitivity. If the test results are positive, no further testing is required. However, if the LLNA test is negative, then one of the guinea pig tests must be conducted; FDA currently recommends the use of the Guinea Pig Maximization Test (GPMT) or the Buehler Assay (BA).

## **Overview of the Proposed LLNA Test Method Protocol**

Each of the test method sponsors (Drs. G. Frank Gerberick, David Basketter, and Ian Kimber) gave a brief introduction to the

LLNA. Allergic contact dermatitis results from two separate but related sequential immunological events caused by a chemical substance. First, an initial exposure(s) causes a primary immune response known as sensitization. If there is additional exposure following sensitization, then a secondary immune-mediated response occurs, which is characterized by skin erythema, swelling, and pruritis. The scientific basis for the proposed LLNA test is that lymphocytes in draining lymph nodes of ears of mice proliferate as the primary response to topical exposure with chemicals that cause dermal sensitization. This proliferation is detected by measuring the amount of  $^3\text{H}$ -methyl thymidine incorporated into dividing lymphocytes. Radioactive thymidine incorporation results from increased proliferation of resident or migratory lymphocytes in the lymph node in response to the chemical challenge. The resulting data are measured on an individual lymph node basis and presented as a stimulation index (SI) after comparing the level of radioactive incorporation in treated versus the control mice. The measured lymphocyte response is an essential element in the process of sensitization. In contrast, currently accepted guinea pig assays measure skin reactivity to a secondary challenge with the test substance. Their presentations were followed by assay-related questions from the PRP.

## **Review of the LLNA submission**

The PRP then proceeded to present and discuss the various sections that they were asked to evaluate. The conclusions for each of the sections are summarized below.

### **Test Method Description**

Dr. J. Meade, the section coordinator, presented the analysis and conclusions reached by the test method description section reviewers, which included Drs. P. Bailey, M. Lovik, H. Maibach, and J. Regal

The panel concluded that the proposed test method protocol (Local Lymph Node Assay ICCVAM Submission, April, 1998) was generally adequate, but recommended the following additions and/or changes:

1. Until a systematic comparison of data between (a) mouse strains, and (b) male and female mice are conducted, the protocol should specify the use of female CBA mice only.
2. Animals should be individually identified.
3. Body weight data should be collected at the start and end of the assay.
4. Lymphocyte proliferation data should be collected at the level of the individual animal.
5. Statistical analysis should be performed.
6. A single dose of a moderate sensitizer should be included as a concurrent positive control in each study.
7. <sup>3</sup>H-methyl thymidine or <sup>125</sup>I-iododeoxyuridine may be used in the LLNA.
8. The decision process to identify a positive response should include an SI  $\geq$  3, statistical significance, and dose response information.
9. An illustration should be added to the protocol, indicating the nodes draining the exposure site that are to be harvested.

### **Test Method Data Quality**

Dr. L. Twerdok, the section coordinator, presented the analysis and conclusions reached by the test method data quality

section reviewers, which included Drs. M. Lovik, R. Smialowicz, and S. Ullrich. The PRP recommended that retrospective data audits be conducted on at least three of the intra- and inter-laboratory LLNA validation studies conducted by the Sponsors.

### **Test Method Performance**

Dr. P. Thorne, the section coordinator, presented the analysis and conclusions reached by the test method performance section reviewers, which included Drs. K. Andersen, P. Bailey, J. Meade, and J. Haseman. The panel concluded that the LLNA performed at least as well as the currently accepted guinea pig methods (GPMT/BA) for the hazard identification of chemical sensitizing agents. The review involved the evaluation of LLNA data on 203 chemicals, of which both LLNA and guinea pig data were provided for 126 chemicals. Both LLNA and human (Human Maximization Test [HMT]/ Human Patch Test Allergen [HPTA]) data were provided for 74 of the 203 chemicals. From the analysis generated during the review process, the accuracy<sup>1</sup> of the LLNA when compared to the GPMT/BA was 89% (N = 97), and when compared to all guinea pig tests (GPT) was 86% (N = 126). The accuracy of the LLNA when compared to human tests was 72% (N = 74). The accuracy of the GPMT/BA when compared to human tests was 72% (N = 57), and the accuracy of the GPT when compared to human tests was 73% (N = 62).

Additionally, when the analysis was limited to only those compounds for which there was LLNA, guinea pig, and human data, the accuracy of the LLNA when compared to human tests and the accuracy of the GPMT/BA when compared to human tests was 72% (N = 57) in both comparisons. In terms of accuracy, sensitivity, specificity,

and positive and negative predictivity, the PRP found the performance of the LLNA to be similar to that of the GPMT/BA. Equally important, the performance of the LLNA and GPMT/BA were similar in regard to human data (HMT/HPMT)

### **Test Method Reliability**

Dr. R. Smialowicz, the section coordinator, presented the analysis and conclusions reached by the test method reliability section reviewers, which included Drs. R. Hamilton, M. Hatao, J. Haseman, and P. Thorne.

The panel concluded that the data submitted for review demonstrated that the LLNA has adequate repeatability and reproducibility, and that the qualitative data demonstrated good inter- and intra-laboratory reliability.

### **Other Literature and Scientific Reviews**

Dr. S. Ullrich, the section coordinator, presented the analysis and conclusions reached by the reviewers for the other literature and scientific reviews section, which included Drs. K. Andersen, H. Maibach, and J. Regal.

This section evaluated the published literature on the LLNA that was not generated by the test sponsors. The results presented in the literature support the use of the LLNA for testing the sensitization potential of chemicals. Future protocol modifications may allow for the assay to more accurately predict the sensitizing potential of metal salts and irritants; these groups of chemicals appear to have high false positive and false negative rates, respectively, when evaluated using the submitted protocol.

### **Other Considerations**

Dr. J. Regal, the section coordinator, presented the analysis and conclusions reached by the other considerations section reviewers, which included Drs. R. Hamilton and M. Hatao.

The panel discussed the transferability of the test method, and issues relating to cost and time effectiveness. It was concluded that the test method was transferable among labs and that there is potential for the method to be more cost effective than the guinea pig assays.

### **Related Issues**

Dr. M. Hatao, the section coordinator, presented the analysis and conclusions reached by the related issues section reviewers, which included Drs. H. Maibach, J. Meade, and S. Ullrich.

This section reviewed other potential endpoints and modifications that could be considered in the future. The following workshops were recommended:

1. A workshop on the ICCVAM evaluation process focusing on providing guidance for individuals planning on making future assay submissions as well as for individuals that may be involved in the evaluation process;
2. A workshop on the use of the LLNA for detecting the photosensitization potential in conjunction with UVA irradiation;
3. A workshop to identify the most predictive methods for detecting immediate-type hypersensitivity following oral exposure to chemicals and drugs;
4. A workshop to explore alternative endpoints of the LLNA; and
5. A workshop to consider the potential of the *ex vivo* LLNA as well as other

<sup>2</sup>One abstaining member of the panel expressed agreement with the PRP conclusion after the public meeting.

possible refinements. It was concluded by the PRP that more research is needed before such a workshop should be planned.

### **Public Comments**

Several individuals from Federal regulatory agencies made comments at the meeting with respect to issues that would be important from a regulatory standpoint. Dr. Ken Hastings, FDA/CDER, stated that their agency would want individual animal data collected in order to consider the data.

Dr. John Langone, FDA/CDRH, stated that the dataset definitely supports the use of the LLNA for detecting the sensitization potential of moderate and potent sensitizers, but that the data was not as conclusive for weak sensitizers. Because of this point, Dr. Langone recommended using statistics as part of the criteria for identifying sensitization hazard potential. He further stated that established reference statistical data would help in future refinements to the assay.

Dr. Al Munson, NIOSH, encouraged the PRP to accept the 3-fold index as the method for determining contact hypersensitivity potential. He added that this method of determination came about as a judgement factor, and that to this point, the use of this index has been adequate. Further, Dr. Munson felt that as further knowledge of the assay is collected, it may be appropriate to consider other factors, such as statistical analysis. He reiterated that the test was designed and validated using the 3-fold index, and that there was no data to support the use of a different measurement as the predictive endpoint.

Dr. Lynnda Reid, FDA/CDER, stated that her agency would like to see the use of

concurrent positive controls when testing using the LLNA. Dr. Reid stated that without such controls, it would be difficult for her agency to accept negative results.

Other public comments were also offered. A representative from the Institute for In Vitro Sciences requested caution in adding items to the existing validation model. He stated that to adequately address the use of statistics instead of the 3-fold index, the data would need to be entirely reevaluated.

A representative from Eli Lilly stated that for determining if a compound is immunotoxic, a review of incidences would be important. Thus, he stated that he would want the lymph nodes to be collected at the level of the individual animal, and statistics to be used in decisionmaking.

Dr. Martin Stephens, Humane Society of the United States (HSUS), stated that HSUS is pleased with the ICCVAM process since it allows for consideration of animal welfare in new assay development. Dr. Andrew Rowan, HSUS, further stated that the HSUS would like to see alternative tests approved when they are at least as good as current animal tests; he felt that it is unnecessary (and inappropriate from an animal welfare perspective) to wait until enough data is gathered to show that the alternative method is better than the animal test.

### **Peer Review Panel Conclusions**

The peer review panel conclusions were summarized by Drs. J. Dean and L. Twerdok.

The PRP unanimously<sup>1</sup> concluded to recommend the LLNA as a stand-alone alternative for contact sensitization hazard

---

<sup>1</sup> After the peer review meeting, one abstention was changed to approval

assessment, provided that the protocol modifications discussed under the test method description (above) were made.

The PRP also agreed that the LLNA had several advantages over guinea pig methods in that it provided quantitative data, allowed dose-response assessment, reduced animal distress, potentially reduced animal numbers, was potentially more cost effective, required much less time, involved the induction phase of sensitization, and will allow future refinement and mechanistic studies. Possible assay weaknesses (e.g., false negative results with some metals and weak sensitizing agents, false positive results with some strong irritants) were identified; it was concluded that these should be addressed in future workshops. Also, data to support the testing in the LLNA of mixtures was not provided and the evaluation of pharmaceuticals was limited.

### **Adjournment**

The meeting was adjourned by Dr. Jack Dean at 5:30 p.m.

<sup>2</sup>One abstaining member of the panel expressed agreement with the PRP conclusion after the public meeting.

## **SAMPLE PROTOCOL<sup>1</sup>:**

### **TESTING OF CHEMICALS FOR CONTACT SENSITIZING (ALLERGIC CONTACT DERMATITIS) POTENTIAL: LOCAL LYMPH NODE ASSAY (LLNA)**

#### **INTRODUCTION**

1. OECD Guidelines for Testing of Chemicals are reviewed periodically in light of scientific progress and animal welfare considerations. Guideline 406 (1992) describes methods for assessing skin sensitization potential of chemicals in animals (1). While this Guideline mentions certain alternative screening tests, it relies on guinea pigs tests, notably the Guinea Pig Maximization Test and the Buehler Assay, for the hazard identification of skin sensitizers and non-sensitizers.
2. The details that follow in this Guideline describe the Local Lymph Node Assay (LLNA), an alternative procedure using the mouse (2-4). The LLNA provides advantages with regard to animal welfare (both reduction and refinement) and scientific aspects (specifically, the objective and quantitative nature of the endpoint measured). This method was mentioned in Guideline 406 (1) as a screening test, but has now undergone sufficient validation that it should be considered as a stand-alone method. The details of this validation and a review of the associated work have been published (5-8). In addition, it should be noted that the mild/moderate sensitizers recommended as suitable positive control

substances for guinea pig test methods are also appropriate for use with the LLNA (6, 8, 9, 10).

3. Prior to modification of this protocol, changes should be adequately validated and determined to be acceptable (11).

#### **GENERAL PRINCIPLE OF DETECTION OF SKIN SENSITIZATION USING THE LOCAL LYMPH NODE ASSAY**

4. The basic principle underlying the LLNA is that sensitizers induce proliferation of lymphocytes in the lymph node draining the site of chemical application. Generally, under appropriate test conditions, this proliferation is proportional to the dose applied, and provides a means of obtaining an objective, quantitative measurement of sensitization. The test measures cellular proliferation as a function of *in vivo* radioisotope incorporation into the DNA of dividing lymphocytes. The LLNA assesses this proliferation in the draining lymph nodes proximal to the application site (see Appendix 1). This effect occurs as a dose-response in which the proliferation in test groups is compared to that in concurrent vehicle-treated controls. A positive control is added to each assay to provide an indication of appropriate assay performance.

---

<sup>1</sup> This protocol is a modification of the "Draft OECD Guideline for Testing of Chemicals. Skin Sensitisation: Local Lymph Node Assay," and was provided to ICCVAM by R. J. Fielder, Department of Health (UK), on August 6, 1998 as background information for the peer review. The protocol was modified by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) to reflect the conclusions and recommendations of the ICCVAM-coordinated LLNA peer review meeting that took place on September 17, 1998 in Gaithersburg, MD.

## DESCRIPTION OF THE LOCAL LYMPH NODE ASSAY

### Sex and strain of animals

5. Young adult female mice (nulliparous and non-pregnant) of the CBA/Ca or CBA/J strain should be used at age 8-12 weeks. All animals should be age-matched (preferably within a one-week time frame). Females are used because the existing database is predominantly based on this gender. Other strains and males should not be used until it is sufficiently demonstrated that significant strain-and/or gender-specific differences in the LLNA response do not exist.

### Preparation of animals

6. The temperature of the experimental animal room should be 21°C ( $\pm$  3°C) and the relative humidity 30-70%. When artificial lighting is used, the light cycle should be 12 hours light:12 hours dark. For feeding, standard laboratory mouse diets should be used with an unlimited supply of drinking water. The mice should be acclimatised for at least 5 days prior to the start of the test. Animals may be housed individually, or caged in small groups of the same sex. Healthy animals are randomly assigned to the control and treatment groups. The animals are uniquely identified prior to being placed on study. Although a variety of techniques exist to uniquely mark mice, any method that involves identification via ear marking (e.g., ear tags) should not be used.

### Preparation of doses

7. Solid test substances should be dissolved in appropriate solvents or vehicles and

diluted, if appropriate, prior to dosing of the animals. Liquid test substances may be dosed directly or diluted prior to dosing. Fresh preparations of the test substance should be prepared daily unless stability data demonstrate the acceptability of storage.

### Test conditions

#### Solvent/vehicle

8. The solvent/vehicle should be selected on the basis of maximizing the test concentrations while producing a solution/suspension suitable for application of the test substance. In order of preference, recommended solvents/vehicles are acetone/olive oil (4:1 v/v), *N,N*-dimethylformamide (DMF), methyl ethyl ketone (MEK), propylene glycol (PG), and dimethyl sulfoxide (DMSO), but others may be used (2). Particular care should be taken to ensure that hydrophilic materials are incorporated into a vehicle system that wets the skin and does not immediately run off. Thus, wholly aqueous vehicles are to be avoided. It may be necessary for regulatory purposes to test the chemical in the clinically relevant solvent or product formulation.

#### Controls

9. Concurrent negative (solvent/vehicle) and positive controls should be included in each test. In some circumstances, it may be useful to include a naïve control. Except for treatment with the test substance, animals in the control groups should be handled in an identical manner to animals of the treatment groups.



10. Positive controls are used to ensure the appropriate performance of the assay. The positive control should produce a positive LLNA response at an exposure level expected to give an increase in the stimulation index (SI)  $>3$  over the negative control group. The positive control dose should be chosen such that the induction is clear but not excessive. Preferred positive control substances are hexyl cinnamic aldehyde (HCA) and mercaptobenzothiazole. There may be circumstances where, given adequate justification, other positive control substances may be used.

Although the positive control substance should be tested in the vehicle that is known to elicit a consistent response (i.e., acetone:olive oil), there may be certain regulatory situations where a non-standard vehicle (clinically/chemically relevant formulation) is necessary to test the effect (interaction) of a positive control with this unconventional vehicle.

## Methodology

11. A minimum of five successfully treated animals are used per dose group, with a minimum of three consecutive concentrations of the test substance plus a solvent/vehicle control and a positive control group. Test substance treatment doses should be based on the recommendations given in Kimber and Basketter (1992) (2) and in the ICCVAM Peer Review Panel Report (8). Doses are selected from the concentration series 100%, 50%, 25%, 10%, 5%, 2.5%, 1%, 0.5%, etc. The maximum concentration tested should be the highest achievable level while avoiding overt systemic toxicity and excessive local irritation. To identify the appropriate maximum test substance dose, an initial toxicity test,

conducted under identical experimental conditions except for an assessment of lymph node proliferative activity, may be necessary. To support an ability to identify a dose-response relationship, data must be collected on at least three test substance treatment doses, in addition to the concurrent solvent/vehicle control group. For negative LLNA studies, the concurrent positive control must induce a SI  $>3$  relative to its vehicle-treated control (see Section 10.).

12. The LLNA experimental procedure is performed as follows:

*Day 1* – Individually identify and record the weight of each mouse prior to dermal applications. Apply 25  $\mu\text{L}$ /ear of the appropriate dilution of the test substance, or the positive control, or the vehicle alone to the dorsum of both ears.

*Days 2 and 3* – Repeat the application procedure as carried out on day 1.

*Days 4 and 5* - No treatment.

*Day 6* – Record the weight of each mouse. Inject 250  $\mu\text{L}$  of sterile phosphate-buffered saline (PBS) containing 20  $\mu\text{Ci}$  of  $^3\text{H}$ -methyl thymidine ( $^3\text{H}$  – TdR) or 250  $\mu\text{L}$  PBS containing 2  $\mu\text{Ci}$  of  $^{125}\text{I}$ -iododeoxyuridine ( $^{125}\text{IU}$ ) and  $10^{-5}$  M fluorodeoxyuride into each experimental mouse via the tail vein (12, 13). Five hours later, the draining (auricular) lymph node of each ear (8) is excised and pooled in PBS for each animal. Both bilateral draining lymph nodes must be collected (see diagram and description of dissection in Appendix 1). A single cell suspension of lymph node cells (LNC) is prepared for each mouse. The single cell suspension is

prepared in PBS by either gentle mechanical separation through 200-mesh stainless steel gauze or another acceptable technique for generating a single cell suspension. LNC are washed twice with an excess of PBS and the DNA precipitated with 5% trichloroacetic acid (TCA) at 4°C for approximately 18h.

For <sup>3</sup>H – TdR method, pellets are resuspended in 1 mL TCA and transferred to 10 mL of scintillation fluid. Incorporation of tritiated thymidine is measured by  $\beta$ -scintillation counting as disintegrations per minute (dpm) for each mouse and expressed as dpm/mouse. For the <sup>125</sup>IU method, the 1 mL TCA pellet is transferred directly into gamma counting tubes. Incorporation of <sup>125</sup>IU is determined by gamma counting and also expressed as dpm/mouse.

Observations: Mice should be carefully observed for any clinical signs, either of local irritation at the application site or of systemic toxicity. Weighing mice prior to treatment and at the time of necropsy will aid in assessing systemic toxicity. All observations are systematically recorded, with records being maintained for each individual mouse.

13. Results for each treatment group are expressed as the mean SI. The SI is the ratio of the mean dpm/mouse within each test substance treatment group and the positive control treated group against the mean dpm/mouse for the solvent/vehicle treated control group. However, the investigator should be alert to possible “outlier” responses for individual animals within a group that may necessitate the use of an alternative measure of response (e.g., median rather than mean) or elimination of the outlier. Each SI should include an appropriate measure of

variability that takes into account the inter-animal variability in both the dosed and control groups (8).

In addition to an assessment of the magnitude of the SI, a statistical analysis should be conducted which includes an assessment of the dose-response relationship as well as pairwise dosed group versus concurrent solvent/vehicle concurrent control comparisons (e.g., linear regression analysis to assess dose-response trends; Dunnett’s test to make pairwise comparisons). In choosing an appropriate method of statistical analysis, the investigator should be aware of possible inequality of variances and other related problems that may necessitate a data transformation or a nonparametric statistical analysis.

## DATA AND REPORTING

14. Individual mouse dpm data should be presented in tabular form, along with the group mean dpm/mouse, its associated error term, the SI (and associated error term) for each dose group compared against the concurrent solvent/vehicle control group.

### Evaluation and interpretation of results

15. In general, when the SI for any single treatment dose group is  $\geq 3$ , the test substance is regarded as a skin sensitizer (3, 6, 8). However, the magnitude of the SI should not be the sole factor used in determining the biological significance of a skin sensitization response. A quantitative assessment may be performed by statistical analysis of individual animal data and may provide a more complete evaluation of the test agents (see Section 13). Factors that should be considered

include the results of the SI, statistical analyses, the strength of the dose-response relationship, chemical toxicity, solubility, and the consistency of the vehicle and positive control responses. Equivocal results should be clarified by considering statistical analysis, structural relationships, available toxicity information, and dose selection.

16. A test substance not meeting the above criteria is considered a non-sensitizer in this test.

17. The test report must contain the following information:

Test substance, controls, and solvent/vehicles

- identification data and CAS no., if known;
- physical nature and purity;
- physiochemical properties relevant to the conduct of the study;
- stability of the test substance, if known; and
- lot number of the test substance.

Solvent/vehicle:

- use of the regulatory relevant vehicle;
- justification for choice of solvent/vehicle; and
- solubility and stability of the test substance in the solvent/vehicle.

Test animals:

- strain of mice used;
- number, age, and sex of mice;
- source, housing conditions, diet, etc.;
- individual weight of the animals at the start and end of the test, including

body weight range, mean and associated error term for each group; and

- microbiological status of the mouse

Test conditions:

- positive and negative (vehicle/solvent) control data;
- data from range-finding study, if conducted;
- rationale for dose level selection;
- details of test substance preparation;
- details of the administration of the test substance;
- details of food and water quality;
- detailed description of treatment and sampling schedules;
- methods for measurement of toxicity;
- criteria for considering studies as positive, negative, or equivocal.

Results:

- signs of toxicity;
- dpm/mouse values for each mouse within each treatment group;
- mean and associated error term for dpm/mouse for each treatment group;
- calculated SI and associated error term for each test substance treatment dose group and concurrent positive control group;
- dose-response relationship;
- statistical analyses and method applied;
- concurrent and historical negative control data as established in the testers laboratory;
- concurrent positive control data

Discussion of the results

Conclusion

## LITERATURE

1. OECD (Organization for Economic Cooperation and Development). (1992). OECD guideline for testing of chemicals 406: Skin Sensitisation. OECD, Paris.
2. Kimber, I., and Basketter, D.A. (1992). The murine local lymph node assay; collaborative studies and new directions: A commentary. *Food and Chemical Toxicology* 30, 165-169.
3. Kimber, I., Dearman, R.J., Scholes E.W., and Basketter, D.A. (1994). The local lymph node assay: developments and applications. *Toxicology* 93, 13-31.
5. Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E., and Hastings, K.L. (1998). Assessment of the skin sensitisation potential of topical medicaments using the local lymph node assay: An interlaboratory exercise. *Journal of Toxicology and Environmental Health* 53, 563-579 (1998).
6. Chamberlain, M., and Basketter, D.A. (1996). The local lymph node assay: status of validation. *Food and Chemical Toxicology* 34, 999-1002.
7. Basketter, D.A., Gerberick, G.F., Kimber, I., and Loveless, S.E. (1996). The local lymph node assay—A viable alternative to currently accepted skin sensitisation tests. *Food and Chemical Toxicology* 34, 985-997.
8. Basketter, D.A., Gerberick, G.F., and Kimber, I. (1998). Strategies for identifying false positive responses in predictive sensitisation tests. *Food and Chemical Toxicology*. (in press) 36, 327-33.
9. ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods). (1999). The murine local lymph node assay: A test method for assessing the allergic contact dermatitis potential of chemicals/compounds. NIH Publication No. 99-4494, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.
10. Basketter, D.A., Selbie, E., Scholes, E.W., Lees, D., Kimber, I., and Botham, P.A. (1993). Results with OECD recommended positive control sensitisers in the maximisation. Buehler and local lymph node assays. *Food and Chemical Toxicology* 31, 63-67.
11. OECD (Organization for Economic Cooperation and Development). (1996). Report of the OECD workshop on harmonization of validation and acceptance criteria for alternative toxicological test methods. OECD, Paris.
12. Dearman, R.J., Hilton, J., Evans, P., Harvey, P., Basketter, D.A., and Kimber, I. (1998). Temporal stability of local lymph node assay responses to hexyl cinnamic aldehyde. *Journal of Applied Toxicology* 18, 281-284.

13. Loveless, S. E., Ladics, G. S., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Scholes, E.W., House, R.V., Hilton, J., Dearman, R.J., and Kimber, I. (1996). Further evaluation of the local lymph node assay in the final phase of an international collaborative trial. *Toxicology* 108, 141-152.
14. Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Scholes, E.W., Ladics, G.S., Loveless, S.E., House, R.V., and Guy, A. (1995). An international evaluation of the murine local lymph node assay and comparison of modified procedures. *Toxicology* 103, 63-73.
15. Tilney, N.L. (1971). Patterns of lymphatic drainage in the adult laboratory rat. *Journal of Anatomy* 109, 369-383.

## APPENDIX 1: DISSECTION AND IDENTIFICATION OF THE DRAINING LYMPH NODES

### Background

Although minimal technical training of the LLNA is required, extreme care must be taken to obtain appropriate and consistent dissection of the lymph nodes. It is recommended that technical proficiency be achieved by the dissection and identification of the lymph nodes draining the ear by: a) practice dissection on mice that have been injected with a colored agent (dye); and/or b) practice dissection with mice sensitized with a strong positive sensitizer. Brief descriptions of these practice dissections are provided below. Recognizing that nodes from vehicle treated and naïve mice are smaller, laboratories performing the LLNA must also gain proficiency in the dissection of these nodes. It may be helpful for laboratories inexperienced in this procedure to request guidance from laboratories that have successfully performed the LLNA.

### Training and preparation for node identification

#### *Identification of the draining node – colored treatment:*

There are several methods that can be used to provide color identification of the draining nodes. These techniques may be helpful for initial identification and should be performed to ensure proper isolation of the appropriate node. Examples of such treatments are listed below. It should be noted, that other such protocols may be used effectively.

#### **A. *Evan's Blue Dye treatment:***

Inject approximately 0.1 ml of 2% Evan's Blue Dye (prepared in sterile saline) intradermally into the pinnae of an ear.

Euthanize the mouse after several minutes and continue with the dissection as noted below.

#### **B. *Colloidal carbon and other dye treatments:***

Colloidal carbon and India ink are examples of other dye treatments that may be used (14).

#### ***Identification of the draining node – application of strong sensitizers***

For the purpose of node identification and training, a strong sensitizer is recommended. This agent should be applied in the standard acetone:olive oil vehicle (4:1). Suggested sensitizers used for this training exercise include 0.1% oxazolone, 0.1% (w/v) 2,4-dinitrochlorobenzene, and 0.1% (v/v) dinitrofluorobenzene. After treating the ear with a strong sensitizer, the draining node will dramatically increase in size, thus aiding in the identification and location of the node.

Using a procedure similar to that listed in the protocol, the agent is applied to the dorsum of both ears (25  $\mu$ L/ear) for three consecutive days. On the fourth day, the mouse is euthanized. Identification and dissection (listed below) of the node should be performed in these animals prior to practice in non-sensitized or vehicle-treated mice, where the node is significantly smaller.


Please note: Due to the exacerbated response, the suggested sensitizers are not recommended as controls for the assay performance. They should only be used for training and node identification purposes.

## Dissection Approach

### *Lateral Dissection (Figure 1):*

Although lateral dissection is not the conventional approach used to obtain the nodes draining the ear, it may be helpful as a training procedure when used in combination with the ventral dissection. This approach is performed bilaterally (on both sides of the mouse). After the mouse is euthanized, it is placed in a lateral position. The facial and neck area is wetted with 70% ethanol. Using scissors and forceps, an initial cut is made from the neck area slightly below the ear. This incision is carefully extended toward the


mouth and nose. During this procedure, the tip of the scissors should be angled slightly upward to prevent the damage of deeper tissue. The glandular tissue in the area is gently retracted using the forceps. Using the masseter muscle, facial nerves, blood vessels, and the bifurcation of the jugular vein as landmarks, the draining node is isolated and removed (Figure 1). The draining node will be positioned adjacent to the masseter muscle and proximal to and slightly above the jugular bifurcation.



### Ventral Dissection (Figure 2):

The most commonly used dissection approach is from the ventral surface of the mouse. This approach allows both right and left draining nodes to be obtained without repositioning the mouse. With the mouse ventrally exposed, the neck and abdomen area is wetted with 70% ethanol. Using scissors and forceps, carefully make the first incision across the chest and between the arms. Make a second

incision up the mid-line, perpendicular to the initial cut, and then cut up to the chin area. Reflect the skin to expose the external jugular veins in the neck area. Care should be used to avoid salivary tissue at the midline and nodes associated with this tissue. The nodes draining the ear are located distal to the masseter muscle, away from the midline, and near the bifurcation of the jugular veins.



### Accuracy in identification:

The nodes can be distinguished from glandular and connective tissue in the area by the uniformity of the nodal surface and a shiny translucent appearance. The application of sensitizing agents (especially the strong

sensitizers used in training) will cause an enlargement of the node size. If a dye is injected for training purposes, the node will take on the tint of the dye.



---

**NICEATM Assessment of Intra/Inter-Laboratory  
Variability in the LLNA**  
(July 11, 1998)

This assessment of the extent of intra- and inter-laboratory variability was based on the data provided in Table 2, page 12, of the LLNA Submission (Tab B). These are the only data located which are amenable to the type of analysis described in ASTM E691-92 A Standard Practice for Conducting an Interlaboratory Study to Determine the Precision of a Test Method. Two data sets were analyzed. The first one consisted of EC<sub>3</sub> (dose calculated to induce a stimulation index of 3) data for DNCB tested twice in each of 5 laboratories. The second consisted of EC<sub>3</sub> data for HCA tested six times in each of two laboratories. This analysis calculates h, the within laboratory consistency statistic, where  $h = d$  (the difference between each laboratory mean value and the mean for all laboratories)/the standard deviation of test averages, and k, the between laboratory consistency statistic, where  $k = \frac{\text{standard deviation for individual laboratories/repeatability}}{\text{standard deviation}}$ . Once calculated, 95% confidence limits can be derived from a table provided in the ASTM Guideline. It should be appreciated that (i) the analysis is based on EC<sub>3</sub> data, the calculation of which is not a part of the submitted protocol, and (ii) a corresponding analysis of guinea pig test data may not be feasible given the nature of the assay.

1. DNCB Data.

The original data and calculations are provided in the attached table, the individual h and k values for each laboratory are presented graphically in the accompanying figures. The 95% confidence limits for h and k were 1.74 and 2.11, respectively. None of the h and k values for the individual laboratories exceeded these confidence limits, indicating the lack of significant within and between laboratory variability.

2. HCA Data.

The original data and calculations are provided in the attached table. The 95% confidence limits for h could not be calculated due to the fact that only two laboratories were involved; k was 1.52. The k values for the two laboratories did not exceed this confidence limit, indicating the lack of significant between laboratory variability.

**Interlaboratory Comparison for LLNA<sup>a</sup>**  
**Assessment of DNCB Data from Five Laboratories<sup>b</sup>**


Laboratory	Test Results		Average	Standard Deviation	d	h	k
	1	2					
1	0.05	0.03	0.0400	0.0141	-0.0130	-0.96	0.79
2	0.06	0.05	0.0550	0.0071	0.0020	0.15	0.40
3	0.04	0.06	0.0500	0.0141	-0.0030	-0.22	0.79
4	0.06	0.09	0.0750	0.0212	0.0220	1.63	1.19
5	0.03	0.06	0.0450	0.0212	-0.0080	-0.59	1.19
Average of test averages			0.0530	95% confidence limits		±1.74	2.11
Standard deviation of test averages			0.0135				
Repeatability standard deviation			0.0164				
Reproducibility standard deviation			0.0178				


<sup>a</sup> Analysis as described in ASTM E691-92 Standard Practice for Conducting an Interlaboratory Study to Determine the Precision of a Test Method.

<sup>b</sup> EC<sub>3</sub> (dose calculated to induce a stimulation index of 3) data from LLNA Submission, Tab B, page 12, Table 2  
 -Reproducibility of LLNA Quantitative Data.

Abbreviations: d = difference between individual laboratory mean and mean for all laboratories; h = within laboratory consistency statistic = d / standard deviation of test averages; k = between laboratory consistency statistic = standard deviation for individual laboratories / repeatability standard deviation.

**LLNA Between-Laboratory Consistency Statistic (h) for DNCB**





**Interlaboratory Comparison for LLNA<sup>a</sup>**  
**Preliminary Assessment of HCA Data from Two Laboratories<sup>b</sup>**

Laboratory	Test Results						Average	Standard deviation	d	h	k
	1	2	3	4	5	6					
1	7.9	6.9	9.6	8.7	4.0	9.2	7.7167	2.0605	-0.7250	-0.71	1.02
2	7.6	7.2	8.8	9.5	10.0	11.9	9.1667	1.7166	0.7250	0.71	0.85
	Average of test averages						8.4417	95% confidence limits		---	1.52
	Standard deviation of test averages						1.0253				
	Repeatability standard deviation						1.8964				
	Reproducibility standard deviation						2.0120				

<sup>a</sup> Analysis as described in ASTM E691-92 Standard Practice for Conducting an Interlaboratory Study to Determine the Precision of a Test Method.

<sup>b</sup> EC<sub>3</sub> (dose calculated to induce a stimulation index of 3) data from LLNA Submission, Tab B, page 12, Table 2  
 –Reproducibility of LLNA Quantitative Data.

Abbreviations: d = difference between individual laboratory mean and mean for all laboratories; h = within laboratory consistency statistic = d / standard deviation of test averages; k = between laboratory consistency statistic = standard deviation for individual laboratories / repeatability standard deviation.

**NICEATM Assessment of the Performance of Irritants in the LLNA**  
(July 11, 1998)

In Basketter et al. (1998), information is provided on the performance of human irritants in the LLNA. The irritants are classified as low, moderate, or high, while the LLNA data are classified as negative, equivocal, or positive. These data are summarized in the attached 3 by 3 table, showing that 2 of 14 known irritants tested positive in the LLNA.

Performance of a Range of Irritants in the LLNA

Chemical name	Irritancy potential		LLNA result		
	Human 4 hour patch test data <sup>1</sup>	Conclusion	Concentration (%)	Stimulation indices <sup>3</sup>	Conclusion <sup>4</sup>
Chlorbenzene	Not done	Low <sup>5</sup>	5.0/10/25	1.1/1.7/1.6	Negative
Hexane	Not done	Low <sup>5</sup>	25/50/100	0.8/0.8/2.2	Negative
Isopropanol	0% / 53%	Low	10/25/50	1.7/1.1/1.0	Negative
Propylene glycol	6% / 72%	Low	50/100	1.2/1.6	Negative
Resorcinol	Not done	Low <sup>5</sup>	5.0/10/25	2.2/2.2/2.7	Negative
Cetyltrimethyl ammonium chloride	25% / 75%	Moderate	3.5/8.8/17.5	3.0/3.0/1.1	Equivocal
C <sub>12-13</sub> β-branched primary alcohol sulphate	84% / 90%	Moderate	7.7/15.4/38.5	2.1/3.1/4.3	Positive
Methyl salicylate	Not done	Moderate <sup>5</sup>	25/50/100	0.9/1.0/2.6	Negative
Salicylic acid	Not done	Moderate <sup>5</sup>	5.0/10/25	0.8/1.5/2.5	Negative
Sodium lauryl sulphate	70% <sup>6</sup>	Moderate	2.5/5.0/10/25	2.3/3.8/4.1/5.3	Positive
Benzalkonium chloride	52% / 83%	High	1/2.5	2/5/2.4	Negative
Lactic acid	81% / 60%	High	5.0/10/25	1.0/1.4/2.2	Negative
Octanoic acid	68% / 58%	High	10/25/50	0.7/1.0/1.6	Negative
Phenol	Not done	High <sup>5</sup>	1/2.5/5.0	0.7/1.5/1.6	Negative

<sup>1</sup>Results taken from human 4 hour patch tests carried out according to the standard protocol (York et al, 1996); most of the data is reported elsewhere (Basketter et al, 1997). The first figure is the % of the panel responding to the test material, the second the % reacting to the 25% SLS positive control.

<sup>2</sup>Overall judgement on the irritation potential of the substance based on human 4 hour patch test data together with other information available in the general literature, including standard patch test concentrations used in diagnostic testing (de Groot, 1994).

<sup>3</sup>Proliferation in test animals was compared with that in sham treated controls.

<sup>4</sup>Overall judgement on sensitization potential from data generated in the standard LLNA and using the criteria previously described (Kimber and Basketter, 1992).

<sup>5</sup>As there is no data from a human 4 hour patch test, the judgement on irritation potential has been based on information available in the general clinical literature.

<sup>6</sup>Average derived from 18 experiments, representing 380 positives amongst the 544 individuals tested.

PERFORMANCE OF A RANGE OF IRRITANTS IN THE LLNA

		LLNA RESULTS			TOTAL # CHEMICALS
		Negative	Equivocal	Positive	
IRRITANCY	Low	5			5
	Moderate	2	1	2	5
	High	4			4
TOTAL # CHEMICALS		11	1	2	14

Data from Basketter et al. (Submitted key paper - Tab 5, Table 2).



## NICEATM Assessment of Cost and Time Differences Between the LLNA and the Guinea Pig Maximization Test (GPMT)

Table 1 provides a summary of information gathered regarding the number of animals used in the LLNA and the GPMT and the time involved in conducting the test. The revised protocol supplied by Gerberick et al. (1998) states that groups of four or five mice per dose group are used, depending on whether the lymph nodes will be pooled by treatment group or whether individual animal nodes will be scored. A control group and three to five testing groups are evaluated. Therefore, the total number of animals used in the LLNA for testing one chemical ranges from 16 to 30. The revised protocol indicates that the LLNA takes 7 days to conduct, as calculated from the

time of initial treatment to the time that <sup>3</sup>HTdR incorporation into lymph nodes is determined. Based on information provided in Klecak (1996) regarding procedures for conducting the GPMT, 20 test and 10 to 20 control guinea pigs are used. A pilot study using two to three animals is recommended to determine appropriate concentrations. Therefore, the total number of animals used in the GPMT ranges from 32 to 43. The time to conduct the GPMT is 25 days, as calculated from the time of the initial induction to the observation time 48 hours after removal of the challenge patch. Adding a one week period for the pilot study increases the length to a total of 32 days.

**Table 1**

Test Method	Total Number of Animals	Time to Conduct Test (days)	Reference
LLNA	16-30 mice	7	Gerberick et al. (1998)
GPMT *	32-43 guinea pigs	32	Klecak (1996)

\* Includes 7-day toxicity test

Table 2 presents a comparison of the animal cost associated with conducting the LLNA and GPMT. Costs per animal are presented based the 1998 price lists for the laboratories supplying the animals. For the LLNA, Jackson Laboratories, Bar Harbor, ME quoted the cost of a 6-week-old CBA/J mouse as \$10.05. Using the number of animals as specified in Table 1, the animal cost associated with conducting the LLNA ranges from \$160.80 to \$301.50.

For the GPMT, the cost of one 400 to 450 gram outbred Crl:(Ha)BR Hartley guinea pig, as quoted by Charles River Laboratories, MA, is \$57.25. When the number of animals necessary to conduct the test is factored in, the animal cost associated with conducting the GPMT ranges from \$1,832.00 to \$2,461.75.

**Table 2**

Test Method	Species, Strain, and Age or Weight	Cost per Animal	Total Animal Cost	Source of Animal
LLNA	Mice (CBA/J, 6 weeks old)	\$10.05	\$160.80- \$301.50	Jackson Laboratories, Bar Harbor, ME
GPMT	Guinea Pigs (Outbred Crl:(Ha)BR Hartley, 400-450 g)	\$57.25	\$1,832.00- \$2,461.75	Charles River Laboratories, MA

Table 3 outlines cost estimates for conducting the LLNA and the GPMT. Illinois Institute of Technology Research Institute, IL (IITRI, 1998) quoted the costs of conducting the LLNA as \$6,900 if one chemical is tested and \$4,950 each if two chemicals are tested. WIL Research Laboratories, Inc., Ashland, OH (1998) provided a written estimate of \$6,000 for conducting the LLNA regardless of the number of chemicals tested. IITRI stated that, in their particular situation, disposal costs were not increased due to the need to dispose of radioactive carcasses.

IITRI's estimate of the cost for conducting the GPMT was \$6,000 to \$7,000 regardless of the number of chemicals tested (IITRI, 1998). No other estimates were collected for the GPMT.

These cost estimates do not appear to reflect the actual cost to conduct each of the assays, however, judging by the differences in time to conduct each of the tests (Table 1) and the differences in animal costs (Table 2).

**Table 3**

Test Method	IITRI Estimate (single chemical)	IITRI Estimate (two chemicals)	WIL Research Labs Estimate
LLNA	\$6,900	\$4,950 each	\$6,000
GPMT	\$6,000-7,000	\$6,000-7,000	not provided

References

Charles River Laboratories, Inc. 1998. CRL Product Catalogue.

Gerberick, G. F., I. Kimber, and D. A. Basketter. 1998. Sample Protocol: Standard Operating Procedure, the Local Lymph Node Assay (LLNA). (Supplied as a replacement for the protocol provided in the Local Lymph Node Assay ICCVAM Submission).

IITRI. 1998. Phone conversation between Robert House, IITRI, and Bonnie Carson, ILS, Inc. (NICEATM), on June 1, 1998 regarding a comparison of prices between the LLNA and the GPMT.

Jackson Laboratories. 1998. Phone conversation between the customer service representative, Jackson Laboratories, and Karen Haneke, ILS, Inc. (NICEATM), on July 15, 1998 regarding the cost of CBA/J mice.

Klecak, G. 1996. Chapter 34: Test methods for allergic contact dermatitis in animals. In: F. N. Marzulli and H. I. Maibach (Eds.), *Dermatotoxicology*, 5th ed. Taylor and Francis, Washington, DC. pp. 437-459.

WIL Research Laboratories, Inc. 1998. Written cost proposal for conducting the LLNA prepared by Tom Kern. Received by Karen Haneke, ILS, Inc. (NICEATM) on July 13, 1998, by fax.

## NICEATM Assessment of the Effect of Different Stimulation Index (SI) Levels on Performance of the LLNA

Data on maximal dose tested and maximal SI response for each test substance included in Appendix A were obtained, when available, and used to generate a database capable of being analyzed for the effect of different SI criteria on sensitivity, specificity, positive predictivity, negative predictivity, and accuracy for the LLNA. The revised list, containing only chemicals where SI data were located, and for which guinea pig and/or human data were available, is attached. Multiple entries (highlighted in the list) for the same test substance were included where multiple tests had been conducted. Where the same data were present in multiple citations, only the earliest citation is provided. Arbitrary fold-increase SI criteria for a positive call (i.e., 4.0, 3.5, 2.4, 2.0) in addition to the standard increase SI criteria of 3.0 were used to distinguish a positive response from a negative one. The resulting calls were used to compare the sensitivity, specificity, positive predictivity, negative predictivity, and accuracy of the LLNA versus:

- The Guinea Pig Maximization Test (GPMT)/Buehler Assay (BA)
- Guinea Pig Tests (GPT) (i.e., GPMT/BA plus nonstandard guinea pig tests)

- Human Data, which included Human Maximization Test (HMT) results plus substances used as Human Patch Test Allergens.

The results of these analyses are presented in the accompanying table.

In making these comparisons and to be consistent with the previous evaluation, (1) discordant LLNA results (i.e., where multiple tests were conducted, with some positive and some negative calls) which could not be reconciled by inspection, were classified as negative; (2) equivocal HMT results were classified as positive; and (3) in cases where a negative result was recorded for the HMT but the substance was used as a HPTA, the chemical was classified as positive for human sensitization. In regard to item (1), one data set was omitted from each of 3 chemicals (cinnamic aldehyde, formaldehyde, sodium lauryl sulfate) as indicated in accompanying data list, because the low response was associated with a maximum dose considerable lower than that used in the other tests.

The resulting analyses indicates that an SI of 3.0 is a reasonable criteria for classifying an LLNA response as positive.

Effect of Different Stimulation Index (SI) Levels on Sensitivity, Specificity, Positive Predictivity, Negative Predictivity, and Accuracy of LLNA

Comparison	# of Comparisons	SI Level	Sensitivity		Specificity		Positive Predictivity		Negative Predictivity		Accuracy	
			%	Ratio	%	Ratio	%	Ratio	%	Ratio	%	Ratio
LLNA vs GPT	105	>4.0	77%	(59/77)	82%	(23/28)	92%	(61/64)	56%	(25/41)	78%	(82/105)
		>3.5	78%	(60/77)	79%	(22/28)	91%	(62/66)	56%	(24/39)	78%	(82/105)
		>3.0	79%	(61/77)	79%	(22/28)	91%	(63/67)	58%	(24/38)	79%	(83/105)
		>2.5	81%	(62/77)	68%	(19/28)	87%	(64/71)	56%	(20/34)	77%	(81/105)
		>2.0	83%	(64/77)	64%	(18/28)	86%	(66/74)	58%	(16/31)	78%	(82/105)
LLNA vs Human	60	>4.0	64%	(38/59)	80%	(4/5)	97%	(38/39)	16%	(4/25)	66%	(42/64)
		>3.5	68%	(40/59)	60%	(3/5)	95%	(40/42)	14%	(3/22)	67%	(43/64)
		>3.0	69%	(41/59)	60%	(3/5)	95%	(41/43)	14%	(3/21)	69%	(44/64)
		>2.5	76%	(45/59)	40%	(2/5)	94%	(45/48)	13%	(2/16)	73%	(47/64)
		>2.0	78%	(46/59)	20%	(1/5)	92%	(46/50)	7%	(1/14)	63%	(47/64)

LLNA = Local Lymph Node Assay; GPMT = Guinea Pig Maximization Test; BA = Buehler Assay; GPT includes GPMT/BT plus nonstandard Guinea pig tests; Human includes Human Maximization Test results and substances used as Human Patch Test Allergens.

Chemical Name	>4	>3.5	>3	>2.5	>2	Max Dose (%)	Max. Increase	GPMT/BT	HMT	HPTA	LLNA	References
Abietic acid// Sylvic acid	+	+	+	+	+	25	6.4	+		+		SBAS92-65
Abietic acid// Sylvic acid	+	+	+	+	+	25	5.9	+		+		SBAS91-30
Abietic acid// Sylvic acid	+	+	+	+	+	25	5.2	+		+		SASH95-177
Abietic acid// Sylvic acid	+	+	+	+	+	25	4.2	+		+		SBAS91-30
Abietic acid// Sylvic acid	-	-	-	+	+	25	2.9	+		+		SBAS91-30
3-Acetylphenyl benzoate	+	+	+	+	+	25	7.1	+				SASH95-177
4-Aminobenzoic acid// p-Aminobenzoic acid// PABA	-	-	-	-	-	10	1.6	-	-	+		SLOV96-141
4-Aminobenzoic acid// p-Aminobenzoic acid// PABA	-	-	-	-	-	10	1.6	-	-	+		SLOV96-141
4-Aminobenzoic acid// p-Aminobenzoic acid// PABA	-	-	-	-	-	10	1.4	-	-	+		SLOV96-141
4-Aminobenzoic acid// p-Aminobenzoic acid// PABA	-	-	-	-	-	10	1.2	-	-	+		SLOV96-141
4-Aminobenzoic acid// p-Aminobenzoic acid// PABA	-	-	-	-	-	10	1.1	-	-	+		SBAS94-543
4-Aminobenzoic acid// p-Aminobenzoic acid// PABA	-	-	-	-	-	10	1.1	-	-	+		SLOV96-141
3-Aminophenol// m-Aminophenol// 3-Hydroxyaniline	+	+	+	+	+	10	9.7	+ nonstd		+		SBAS91-30
3-Aminophenol// m-Aminophenol// 3-Hydroxyaniline	+	+	+	+	+	10	8.1	+ nonstd		+		SBAS91-30
2-Aminophenol// o-Aminophenol// 2-Hydroxyaniline	+	+	+	+	+	2.5	7.4	+ nonstd				SASH95-177
3-Aminophenol// m-Aminophenol// 3-Hydroxyaniline	+	+	+	+	+	10	7.1	+ nonstd		+		SBAS91-30
3-Aminophenol// m-Aminophenol// 3-Hydroxyaniline	+	+	+	+	+	10	5.7	+ nonstd		+		SBAS91-30
Ammonium tetrachloroplatinate// Ammonium platinous chloride	+	+	+	+	+	10	18.1	+		+		SBAS92-65
Ammonium thioglycolate// Ammonium mercaptoacetate	+	+	+	+	+	50	4.0	-			+	Appen B
Aniline// Benzenamine	-	-	-	+	+	50	2.9	+	+			SBAS92-65
Aniline// Benzenamine	-	-	-	+	+	50	2.6	+	+			SBAS91-30
Aniline// Benzenamine	-	-	-	+	+	50	2.5	+	+			SBAS91-30
Aniline// Benzenamine	-	-	-	-	-	50	1.0	+	+			SBAS91-30
Benzalkonium chloride	-	-	-	+	+	2.5	2.5	-		+		SGER97-97
Benzene-1,3,4-tricarboxylic anhydride// Trimellitic anhydride	+	+	+	+	+	10	50.5	+				SBAS92-65
1,2-Benzisothiazolin-3-one	+	+	+	+	+	50	4.9	+		+		SBOT91-172
Benzocaine	+	+	+	+	+	20	7.7	+	+	+		SKIM89-215
Benzocaine	-	-	-	+	+	25	2.9	+	+	+		SMON94-22
Benzocaine	-	-	-	-	+	25	2.4	+	+	+		Append B
Benzocaine	-	-	-	-	+	50	2.3	+	+	+		SKIM89-203
Benzocaine	-	-	-	-	-	50	1.8	+	+	+		SKIM91-203
Benzocaine	-	-	-	-	-	50	1.5	+	+	+		SKIM89-203
Benzocaine	-	-	-	-	-	50	1.4	+	+	+		SKIM91-203
Benzoquinone// p-Quinone// 1,4-Cyclohexadienedione	+	+	+	+	+	2.5	52.3	+				SBAS92-65
Benzoyl chloride	+	+	+	+	+	5	25.9	+		+		SASH95-177
Benzoyloxy-3,5-benzenedicarboxylic acid// 5-Benzoyloxyisophthalic acid	-	-	-	-	-	10	1.1	-nonstd				Append B
Benzoyl peroxide	+	+	+	+	+	10	26.5	+		+		SKIM98-563
Benzoyl peroxide	+	+	+	+	+	10	21.8	+		+		SKIM98-563
Benzoyl peroxide	+	+	+	+	+	10	18.6	+		+		SKIM98-563
Benzoyl peroxide	+	+	+	+	+	10	17.3	+		+		SKIM98-563
Benzoyl peroxide	+	+	+	+	+	10	16.1	+		+		SKIM98-563
Beryllium sulfate	+	+	+	+	+	10	9.4	+	+			SBAS94-543
1-Bromododecane// Lauryl bromide	+	+	+	+	+	25	17.6	+ nonstd				SASH95-177
1-Bromododecane// Lauryl bromide	+	+	+	+	+	25	4.5	+ nonstd				SBAS92-137
1-Bromohexadecane// n-Hexadecyl bromide// Palmityl bromide// Cetyl bromide	+	+	+	+	+	50	16.8	+				SBAS92-137
1-Bromohexadecane// n-Hexadecyl bromide// Palmityl bromide// Cetyl bromide	+	+	+	+	+	25	15.6	+				SBAS92-137
1-Bromohexane// n-Hexyl bromide	+	+	+	+	+	50	18.6	+ nonstd				Data supplied by sponsor
1-Bromohexane// n-Hexyl bromide	-	-	-	-	+	25	2.1	+ nonstd				SBAS92-137
1-Bromohexane// n-Hexyl bromide	-	-	-	-	-	25	1.4	+ nonstd				Data supplied by sponsor
Butyl glycidyl ether	+	+	+	+	+	50	5.6	+	+			SBAS94-542
Chloramine T	+	+	+	+	+	25	10.7	+		+		SBAS92-65

Chemical Name	>4	>3.5	>3	>2.5	>2	Max Dose (%)	Max. Increase	GPMT/BT	HMT	HPTA	LLNA	References
4-Chloroaniline	+	+	+	+	+	25	4.5	+				Data supplied by sponsor
4-Chloroaniline	-	-	+	+	+	10	3.3	+				SSCH92-217
4-Chloroaniline	-	-	-	+	+	10	2.5	+				SSCH92-217
4-Chloroaniline	-	-	-	-	-	10	1.8	+				SSCH92-217
4-Chloroaniline	-	-	-	-	-	10	1.8	+				SBAS92-65
4-Chloroaniline	-	-	-	-	-	25	1.4	+				Data supplied by sponsor
Chlorobenzene	-	-	-	-	-	25	1.7	-				\$ASH95-177
5-Chloro-2-methyl-4-isothiazolin-3-one [no locants & different CASRN in list]	+	+	+	+	+	0.1	27.7	+			+	BOT91-172
Chlorpromazine	+	+	+	+	+	50	8.9	+ nonstd	+			SBAS94-543
Cinnamic aldehyde// cinnamaldehyde	+	+	+	+	+	25	15.4	+	+	+	+	SBAS92-65
Cinnamic aldehyde// cinnamaldehyde	+	+	+	+	+	25	12.8	+	+	+	+	SMON94-22
Cinnamic aldehyde// cinnamaldehyde	+	+	+	+	+	5	9.8	+	+	+	+	SKIM89-215
Cinnamic aldehyde// cinnamaldehyde	-	-	+	+	+	2	3.3	+	+	+	+	SMAU91-209
Citral// 3,7-Dimethyl-2,6-octadienal// Geranial-Neral mixture	+	+	+	+	+	25	20.5	+	+			SBAS91-30
Citral// 3,7-Dimethyl-2,6-octadienal// Geranial-Neral mixture	+	+	+	+	+	25	9.3	+	+			SBAS91-30
Citral// 3,7-Dimethyl-2,6-octadienal// Geranial-Neral mixture	+	+	+	+	+	50	9.3	+	+			SBAS94-543
Citral// 3,7-Dimethyl-2,6-octadienal// Geranial-Neral mixture	+	+	+	+	+	25	6.2	+	+			SBAS91-30
Citral// 3,7-Dimethyl-2,6-octadienal// Geranial-Neral mixture	+	+	+	+	+	25	4.7	+	+			SBAS91-30
Cobalt chloride	+	+	+	+	+	5	13.6	+	+			Append B
Cobalt chloride	-	+	+	+	+	2.5	3.7	+	+			SBAS92-65
Cocoamidopropyl betaine//CAPB	+	+	+	+	+	25	11.3	+			+	\$ASH95-177
Copper chloride// Cuprous chloride	+	+	+	+	+	5	13.8	-				SBAS92-65
Dextran	-	-	-	-	-	10	1.5	-				SBAS92-65
2,4-Dichloronitrobenzene	-	-	-	-	+	1	2.2	-				SBAS96-55
Diethylenetriamine	+	+	+	+	+	10	12.1	+	+	+		SBAS94-543
Dimethyl isophthalate	-	-	-	-	-	25	1.8	-				SSCH92-217
Dimethyl isophthalate	-	-	-	-	-	50	1.6	-				SSCH92-217
Dimethyl isophthalate	-	-	-	-	-	25	1.5	-				SSCH92-217
Dimethyl isophthalate	-	-	-	-	-	25	1.0	-				SBAS92-65
5,5-Dimethyl-3-(mesyloxymethyl)dihydro-2(3H)-furanone	-	-	-	-	-	13.66	1.5	+ nonstd				Append B
5,5-Dimethyl-3-(mesyloxymethyl)dihydro-2(3H)-furanone	-	-	-	-	-	20	1.2	+ nonstd				\$ASH95-177
5,5-Dimethyl-3-(methoxybenzenesulfonyloxymethyl)dihydro-2(3H)-furanone	-	-	-	-	-	20	1.2	+ nonstd				Unpublished Unilever data
5,5-Dimethyl-3-methylenedihydro-2(3H)-furanone	+	+	+	+	+	8	9.2	- nonstd				\$ASH95-177
5,5-Dimethyl-3-(nitrobenzenesulfonyloxymethyl)dihydro-2(3H)-furanone	-	-	-	-	-	20	0.9	+ nonstd				\$ASH95-177
5,5-Dimethyl-3-(thiocyanatomethyl)dihydro-2(3H)-furanone	+	+	+	+	+	13	8.6	+ nonstd				\$ASH95-177
5,5-Dimethyl-3-(tosyloxymethyl)dihydro-2(3H)-furanone	-	-	-	-	-	18	1.4	- nonstd				\$ASH95-177
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	78.0	+				SLOV96-141
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	43.9	+				SKIM95-63
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	2	41.5	+				SKIM89-215
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	40.9	+				SKIM95-63
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	38.0	+				SLOV96-141
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	35.5	+				SKIM95-63
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	1	29.5	+				SHIL96-571
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	25.0	+				SLOV96-141
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	25.0	+				SLOV96-141
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.1	24.0	+				SBAS92-65
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.5	23.0	+				SMON94-22
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	22.5	+				SKIM95-63
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.1	21.1	+				\$GER92-438
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.1	15.0	+				\$ASH95-177
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	13.0	+				SLOV96-141
2,4-Dinitrochlorobenzene// DNCB	+	+	+	+	+	0.25	11.5	+				SKIM95-63
2,4-Dinitrothiocyanobenzene// 2,4-Dinitrophenyl thiocyanate// Nirit	+	+	+	+	+	2	10.3	+				SKIM89-274

Chemical Name	>4	>3.5	>3	>2.5	>2	Max Dose (%)	Max. Increase	GPMT/BT	HMT	HPTA	LLNA	References
Disodium benzoxyloxy-3,5-benzenedicarboxylate	-	-	-	-	+	25	2.1	-				SASH95-177
Disodium 1,2-diheptanoyloxy-3,5-benzenedisulfonate	+	+	+	+	+	25	15.4	+ nonstd				SASH95-177
Dodecyl methanesulfonate// Lauryl methanesulfonate	+	+	+	+	+	25	9.0	+ nonstd				SASH95-177
Ethylenediamine	-	-	-	-	-	2.5	1.7	+		+		SKIM98-563
Ethylenediamine	-	-	-	-	-	2.5	1.6	+		+		SKIM98-563
Ethylenediamine	-	-	-	-	-	2.5	1.5	+		+		SKIM98-563
Ethylenediamine	-	-	-	-	-	2.5	0.9	+		+		SKIM98-563
Ethylenediamine	-	-	-	-	-	2.5	0.7	+		+		SKIM98-563
Ethylene glycol dimethacrylate// EGDMA	+	+	+	+	+	50	9.2	-		+		Append. B
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	100	70.3	+		+		SKIM91-203
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	50	17.0	+		+		SLOV96-141
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	50	16.0	+		+		SLOV96-141
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	50	14.1	+		+		SKIM91-203
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	50	12.4	+		+		SLOV96-141
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	75	10.6	+		+		SGER92-438
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	100	10.2	+		+		SKIM91-203
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	50	9.6	+		+		SLOV96-141
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	100	9.3	+		+		SKIM91-203
Eugenol// Allylguaiacol// 4-Allyl-2-methoxyphenol	+	+	+	+	+	50	6.1	+		+		SLOV96-141
Formaldehyde	+	+	+	+	+	25	11.9	+	+			SKIM89-274
Formaldehyde	+	+	+	+	+	50	9.0	+	+	+		SHIL96-571
Formaldehyde	+	+	+	+	+	25	6.6	+	+	+		SKIM91-203
Formaldehyde	+	+	+	+	+	25	5.8	+	+	+		SKIM91-203
Formaldehyde	+	+	+	+	+	25	4.2	+	+	+		SKIM91-203
Formaldehyde	-	-	-	-	+	2	2.3	+	+	+		SMAU91-209
Geraniol	-	-	-	-	+	50	2.6	-	-	+		SBAS94-543
Glyoxal// Oxaldehyde// Ethanediol// Biformyl	+	+	+	+	+	25	18.1	+		+		SBAS94-543
Gold chloride	-	+	+	+	+		17.2			+		SBAS96-985
Hexane	-	-	-	-	+	100	2.2			-		SBAS96-985
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	+	+	+	+	+	50	20.0	+				SLOV96-141
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	+	+	+	+	+	50	17.0	+				SLOV96-141
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	+	+	+	+	+	50	17.0	+				SLOV96-141
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	+	+	+	+	+	50	16.0	+				SLOV96-141
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	+	+	+	+	+	50	14.0	+				SLOV96-141
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	+	+	+	+	+	50	10.0	+				SBAS93-63
Hexylcinnamic aldehyde// H.C.A.// .alpha.-Hexylcinnamaldehyde// 2-(Phenylmethylene)octanal	+	+	+	+	+	50	4.6	+				SBAS93-63
Hydrocortisone// Cortisol	-	-	-	-	-	10	0.3			-	+	SBAS96-985
Hydroquinone// Quinol [separate entry in submission]	+	+	+	+	+	2.5	33.4	+ nonstd			+	SKIM98-563
Hydroquinone// Quinol [separate entry in submission]	+	+	+	+	+	2.5	23.2	+ nonstd			+	SKIM98-563
Hydroquinone// Quinol [separate entry in submission]	+	+	+	+	+	2.5	16.4	+ nonstd			+	SBAS92-65
Hydroquinone// Quinol [separate entry in submission]	+	+	+	+	+	2.5	15.0	+ nonstd			+	SKIM98-563
Hydroquinone// Quinol [separate entry in submission]	+	+	+	+	+	2.5	13.1	+ nonstd			+	SKIM98-563
Hydroquinone// Quinol [separate entry in submission]	+	+	+	+	+	2.5	12.2	+ nonstd			+	SKIM98-563
4-Hydroxybenzoic acid	-	-	-	-	-	25	1.5	+				SBAS92-65
4-Hydroxybenzoic acid	-	-	-	-	-	25	1.5	+				SSCH92-217
4-Hydroxybenzoic acid	-	-	-	-	-	25	1.0	+				SSCH92-217
4-Hydroxybenzoic acid	-	-	-	-	-	10	0.8	+				SSCH92-217
Hydroxycitronellal	+	+	+	+	+	100	8.5	+		+	+	SBAS92-65
Hydroxycitronellal	+	+	+	+	+	50	6.7	+		+	+	SBAS94-543
Hydroxycitronellal	+	+	+	+	+	25	3.4	+		+	+	SMON94-22
2-Hydroxyethyl acrylate// HEA	+	+	+	+	+	25	18.1	+			+	SSCH92-217
2-Hydroxyethyl acrylate// HEA	+	+	+	+	+	50	11.7	+			+	SSCH92-217
2-Hydroxyethyl acrylate// HEA	+	+	+	+	+	50	9.9	+			+	SSCH92-217



Chemical Name	>4	>3.5	>3	>2.5	>2	Max Dose (%)	Max. Increase	GPMT/BT	HMT	HPTA	LLNA	References
2-Hydroxyethyl acrylate// HEA	+	+	+	+	+	25	8.2	+		+		SBAS92-65
2-Hydroxypropyl methacrylate// 2-HPMA	-	-	-	-	-	50	1.9	-			+	SSCH92-217
2-Hydroxypropyl methacrylate// 2-HPMA	-	-	-	-	-	50	1.4	-			+	SSCH92-217
2-Hydroxypropyl methacrylate// 2-HPMA	-	-	-	-	-	50	1.3	-			+	SBAS92-65
2-Hydroxypropyl methacrylate// 2-HPMA	-	-	-	-	-	50	1.0	-			+	SSCH92-217
Imidazolidinyl urea// Germall 115	+	+	+	+	+	50	5.5	+			+	SBAS92-65
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	29.5	+			+	SKIM91-203
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	25.3	+			+	SKIM91-203
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	21.3	+			+	SKIM91-203
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	14.6	+			+	SKIM91-203
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	12.9	+			+	SASH95-177
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	11.0	+			+	SLOV96-141
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	10.0	+			+	SLOV96-141
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	7.2	+			+	SLOV96-141
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	6.8	+			+	SLOV96-141
Isoeugenol// 2-Methoxy-4-propenylphenol// 4-Propenylguaiaicol	+	+	+	+	+	10	4.1	+			+	SLOV96-141
Isopropanol// Isopropyl alcohol// 2-Propanol	-	-	-	-	-	50	1.7	-				SBAS96-985
Kanamycin	-	-	-	-	+	25	2.2	- nonstd		+	+	SBAS96-985
Lactic acid// 2-Hydroxypropanoic acid	-	-	-	-	+	25	2.2	-				BAS98-327
2-Mercaptobenzothiazole	+	+	+	+	+	25	17.1	+		+	+	SMON94-22
2-Mercaptobenzothiazole	+	+	+	+	+	50	8.9	+		+	+	SSCH92-217
2-Mercaptobenzothiazole	+	+	+	+	+		8.6	+		+	+	SBAS93-63
2-Mercaptobenzothiazole	+	+	+	+	+	50	8.1	+		+	+	SSCH92-217
2-Mercaptobenzothiazole	+	+	+	+	+	50	5.5	+		+	+	SBAS92-65
2-Mercaptobenzothiazole	+	+	+	+	+		5.0	+		+	+	SBAS93-63
2-Mercaptobenzothiazole	+	+	+	+	+	50	4.8	+		+	+	SSCH92-217
Mercuric chloride// Corrosive sublimate	+	+	+	+	+	10	19.9	+		+	+	SBAS94-543
4-Methylaminophenol sulfate// Metol// p-Hydroxymethylaniline sulfate	+	+	+	+	+	2.5	6.7	+			+	SBAS92-65
6-Methylcoumarin// 6-MC	-	-	-	-	-	25	1.2	-		-	+	SSCH92-249
6-Methylcoumarin// 6-MC	-	-	-	-	-	25	1.1	-		-	+	SASH95-177
Methyl dodecanesulfonate	+	+	+	+	+	5	48.6	+				SBAS92-65
Methyl dodecanesulfonate	+	+	+	+	+	25	46.3	+				SASH95-177
Methyl hexadecanesulfonate	+	+	+	+	+	25	35.4	+ nonstd				SASH95-177
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	+	+	20	2.9	-		-		SKIM95-63
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	+	+	5	2.7	-		-		SKIM91-203
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	+	+	100	2.6	-		-		SBAS98-327
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	+	20	2.3	-		-		SKIM95-63
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	+	25	2.2	-		-		SASH95-177
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	+	20	2.1	-		-		SKIM95-63
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	+	20	2.0	-		-		SKIM98-563
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	+	20	2.0	-		-		SKIM98-563
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	20	1.9	-		-		SKIM95-63
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	20	1.9	-		-		SKIM98-563
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	20	1.6	-		-		SKIM98-563
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	20	1.4	-		-		SKIM98-563
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	5	1.3	-		-		SKIM91-203
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	5	1.2	-		-		SKIM91-203
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	5	1.1	-		-		SKIM91-203
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	20	1.1	-		-		SKIM95-63
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	5	0.8	-		-		SGER92-438
Methyl salicylate// Oil of wintergreen// 2-Hydroxybenzoic acid methyl ester	-	-	-	-	-	25	0.5	-		-		SKIM91-203
2-Methyl-4,5-trimethylene-4-isothiazolin-3-one	+	+	+	+	+	30	7.0	+				SASH95-177
Musk ambrette	+	+	+	+	+	25	8.2	-			+	SSCH92-249

Chemical Name	>4	>3.5	>3	>2.5	>2	Max Dose (%)	Max. Increase	GPMT/BT	HMT	HPTA	LLNA	References
Musk ambrette	+	+	+	+	+	25	6.5	-		+		SSCH92-249
Neomycin sulfate	-	-	-	-	-	25	1.1		+			Append B
Neomycin sulfate	-	-	-	-	-	25	1.0		+	+		SBAS94-543
Nickel chloride	-	-	-	-	+	5	2.4	+				SBAS92-65
Nickel sulfate	-	-	-	-	+	10	2.0	+	+	+		SSCH92-217
Nickel sulfate	-	-	-	-	-	2.5	1.5	+	+	+		SBAS92-65
Nickel sulfate	-	-	-	-	-	10	1.4	+	+	+		SSCH92-217
Nickel sulfate	-	-	-	-	-	25	0.8	+	+	+		SSCH92-217
Nickel sulfate	-	-	-	-	-	10	0.7	+	+	+		SSCH92-217
4-Nitrobenzyl chloride// 1-(Chloromethyl)-4-nitrobenzene	+	+	+	+	+	5	40.0	+ nonstd				\$ASH95-177
4-Nitroso-N,N-dimethylaniline// N,N-Dimethyl-4-nitrosobenzenamine	+	+	+	+	+	10	60.4	+				SKIM89-215
4-Nitroso-N,N-dimethylaniline// N,N-Dimethyl-4-nitrosobenzenamine	+	+	+	+	+	2	19.7	+				SMAU91-209
Octadecyl methanesulfonate// Stearyl methanesulfonate	-	-	-	-	-	10	1.2	+ nonstd				\$ASH95-177
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	2	93.0	+				SMAU91-209
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	1	63.0	+				SKIM89-215
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.05	59.0	+				SLOV96-141
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.05	55.2	+				\$GER92-438
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.5	44.6	+				\$ASH95-177
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.05	33.0	+				SLOV96-141
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.5	32.0	+				\$MON94-22
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.05	23.0	+				SLOV96-141
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.05	13.0	+				SLOV96-141
Oxazolone// 4-Ethoxymethylene-2-phenyloxazol-5-one	+	+	+	+	+	0.05	8.9	+				SLOV96-141
Penicillin G	+	+	+	+	+	50	17.0	+		+		SSCH92-217
Penicillin G	+	+	+	+	+	50	8.9	+		+		SBAS92-65
Penicillin G	+	+	+	+	+	25	8.9	+		+		SSCH92-217
Penicillin G	+	+	+	+	+	50	6.6	+		+		SKIM98-563
Penicillin G	+	+	+	+	+	50	6.5	+		+		SSCH92-217
Penicillin G	+	+	+	+	+	50	4.6	+		+		SKIM98-563
Penicillin G	-	+	+	+	+	50	3.6	+		+		SKIM98-563
Penicillin G	-	-	+	+	+	50	3.4	+		+		SKIM98-563
Penicillin G	-	-	+	+	+	50	3.4	+		+		SKIM98-563
Pentachlorophenol// Penta// PCP	+	+	+	+	+		5.4			+		SBAS96-985
Phenol// Carboic acid	-	-	-	-	-		1.6			-		SBAS96-985
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	10	75.3	+		+		SKIM91-203
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	10	37.4	+		+		SKIM91-203
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	10	26.5	+		+		SKIM89-215
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	5	23.7	+		+		SKIM91-203
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	10	23.3	+		+		SKIM91-203
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	10	20.4	+		+		\$ASH95-177
3-Phenylenediamine// m-Phenylenediamine	+	+	+	+	+	10	19.2	+ nonstd				\$ASH95-177
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	2	16.3	+		+		\$MON94-22
4-Phenylenediamine// p-PDA// p-Phenylenediamine	+	+	+	+	+	2	5.3	+		+		SMAU91-209
Phthalic anhydride	+	+	+	+	+	10	73.1	+				SKIM89-215
Phthalic anhydride	+	+	+	+	+	10	26.0	+				SBAS92-65
Picryl chloride// Trinitrochlorobenzene// TNCB	+	+	+	+	+	0.1	103.3	+				\$GER92-438
Picryl chloride// Trinitrochlorobenzene// TNCB	+	+	+	+	+	2	55.8	+				SMAU91-209
Potassium dichromate	+	+	+	+	+	0.5	33.6	+		+		SKIM91-203
Potassium dichromate	+	+	+	+	+	0.5	19.1	+		+		SKIM95-63
Potassium dichromate	+	+	+	+	+	0.5	16.1	+		+		SKIM95-63
Potassium dichromate	+	+	+	+	+	0.5	13.1	+		+		SKIM95-63
Potassium dichromate	+	+	+	+	+	0.5	13.0	+		+		SKIM95-63
Potassium dichromate	+	+	+	+	+	0.5	11.2	+		+		SKIM95-63

Chemical Name	>4	>3.5	>3	>2.5	>2	Max Dose (%)	Max. Increase	GPMT/BT	HMT	HPTA	LLNA	References
Potassium dichromate	+	+	+	+	+	0.5	10.4	+	+	+		SBAS92-65
Potassium dichromate	+	+	+	+	+	0.5	10.1	+	+	+		SKIM91-203
Potassium dichromate	+	+	+	+	+	0.5	6.9	+	+	+		SKIM91-203
Potassium dichromate	+	+	+	+	+	0.5	5.4	+	+	+		SKIM91-203
Propylene glycol// 1,2-Dihydroxypropane// 1,2-Propanediol	-	-	-	-	-	50	1.6	-		+		BAS98-327
Propyl gallate// Tenox PG// 3,4,5-Trihydroxybenzoic acid propyl ester	+	+	+	+	+	25	33.6	+		+		SBAS92-65
Propylparaben// Propyl 4-hydroxybenzoate	-	-	-	-	+	25	2.1	-	+/-	+		SBAS91-30
Propylparaben// Propyl 4-hydroxybenzoate	-	-	-	-	+	25	2.0	-	+/-	+		SBAS91-30
Propylparaben// Propyl 4-hydroxybenzoate	-	-	-	-	-	25	1.6	-	+/-	+		SBAS91-30
Propylparaben// Propyl 4-hydroxybenzoate	-	-	-	-	-	25	1.5	-	+/-	+		SBAS91-30
Pyridine	-	+	+	+	+		3.9			+		SBAS96-985
Resorcinol// 1,3-Dihydroxybenzene	-	-	-	+	+	25	2.7	-	-	+		SBAS94-543
Salicylic acid// 2-Hydroxybenzoic acid	-	-	-	+	+	25	2.5	-	-			SBAS94-543
Sodium benzoyloxy-2-methoxy-5-benzenesulfonate	+	+	+	+	+	25	7.2	+ nonstd				SASH95-177
Sodium 4-(2-ethylhexyloxy)carboxy)benzenesulfonate	+	+	+	+	+	25	24.0	+ nonstd				SASH95-177
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	+	+	+	+	+	20	8.6	-	-			SLOV96-141
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	+	+	+	+	+	20	8.0	-	-			SLOV96-141
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	+	+	+	+	+	25	7.6	-	-			SMON94-22
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	+	+	+	+	+	25	6.7	-	-			SMON94-22
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	+	+	+	+	+	20	5.3	-	-			SLOV96-141
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	+	+	+	+	+	25	4.2	-	-			SBAS94-543
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	-	+	+	+	+	20	3.6	-	-			SLOV96-141
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	-	+	+	+	+	20	3.5	-	-			SLOV96-141
Sodium lauryl sulfate// Sodium dodecyl sulfate// SLS// SDS// Irium	-	-	-	-	-	2	1.0	-	-			SMAU91-209
Sodium norbornanacetoxo-4-benzenesulfonate	+	+	+	+	+	25	13.6	+ nonstd				SASH95-177
Sodium 4-sulfophenyl acetate	+	+	+	+	+	25	10.1	+ nonstd				SASH95-177
Streptomycin sulfate	-	-	+	+	+	50	3.2	+				SKIM98-563
Streptomycin sulfate	-	-	-	-	-	50	1.9	+				SKIM98-563
Streptomycin sulfate	-	-	-	-	-	50	1.3	+				SKIM98-563
Streptomycin sulfate	-	-	-	-	-	50	1.3	+				SKIM98-563
Streptomycin sulfate	-	-	-	-	-	50	1.2	+				SKIM98-563
Sulfanilamide// 4-Aminobenzenesulfonamide// p-Anilinesulfonamide// p-Sulfamidoaniline	-	-	-	-	-	50	0.9	-	+	+		SBAS94-543
Sulfanilic acid// p-Aminobenzenesulfonic acid// p-Anilinesulfonic acid	-	-	-	-	-	25	2.2	+				SBAS92-209
Sulfanilic acid// p-Aminobenzenesulfonic acid// p-Anilinesulfonic acid	-	-	-	-	-	10	2.2	+				Append B
Sulfanilic acid// p-Aminobenzenesulfonic acid// p-Anilinesulfonic acid	-	-	-	-	-	25	1.8	+				SBAS92-209
Sulfanilic acid// p-Aminobenzenesulfonic acid// p-Anilinesulfonic acid	-	-	-	-	-	10	1.5	+				SBAS92-65
Sulfanilic acid// p-Aminobenzenesulfonic acid// p-Anilinesulfonic acid	-	-	-	-	-	25	1.3	+				SBAS92-209
Tetrachlorosalicylanilide// 3,5-Dichloro-N-(3,4-dichlorophenyl)-2-hydroxybenzamide// TCS	+	+	+	+	+	0.5	40.5	+	+	+		SSCH92-249
Tetrachlorosalicylanilide// 3,5-Dichloro-N-(3,4-dichlorophenyl)-2-hydroxybenzamide// TCS	+	+	+	+	+	1	18.0	+	+	+		SBAS94-543
Tetramethyl thiuram disulfide// Thiram// Bis(dimethylthiocarbamoyl) disulfide	+	+	+	+	+		5.1	+ nonstd	+	+		SBAS96-985
1-Thioglycerol// 3-Mercapto-1,2-propanediol	+	+	+	+	+	50	10.0	+	+			SBAS94-543
Toluenediamine bismaleimide	+	+	+	+	+	10	35.3	+			+	SSCH92-217
Toluenediamine bismaleimide	+	+	+	+	+	25	25.7	+			+	SSCH92-217
Toluenediamine bismaleimide	+	+	+	+	+	25	19.1	+			+	SSCH92-217
Toluenediamine bismaleimide	+	+	+	+	+	25	12.2	+			+	SBAS92-65
.alpha.-Trimethylammonium 4-tolyloxy-4-benzenesulfonate	-	-	-	-	+	25	2.2	+ nonstd				SASH95-177
3,5,5-Trimethylhexanoyl chloride	+	+	+	+	+	25	19.0	+				SASH95-177
Xylene// Dimethylbenzene (mixture of o-, m-, & p-isomers)	+	+	+	+	+		4.2			-		SBAS96-985

## NICEATM Assessment of LLNA vs. GPMT/BA Discordant Compounds

As requested, NICEATM has reviewed the LLNA data base in regard to compounds which have tested discordant in the LLNA vs GPMT/BA and for which there is human response information. Information on the six discordant and one potentially discordant

(benzalkonium chloride) compounds located are provided in the accompanying table. Notes attached to the table explain the information provided. The results can be summarized as follows:

Number of Compounds	LLNA Response	GPMT/BT Response	Human Response
4	Negative	Positive	Positive
0	Negative	Positive	Negative
2	Positive	Negative	Positive
1	Positive	Negative	Negative

Discordant Compounds for LLNA vs GPMT/BA Which Have Human Response Information

Compound	LLNA <sup>1</sup>	SI Values <sup>2</sup>	# of Tests	GPMT/BA	Max. Incidence <sup>3</sup>	HMT	HPTA
Aniline// Benzenamine	-	2.9,2.6,2.5,1.0	4	+	95%	+	
Benzocaine <sup>4</sup>	-	7.7,2.9,2.3,1.8,1.5,1.4	6	+	50%	+	+
Nickel sulfate <sup>5</sup>	-	2.0,1.5,1.4,0.8,0.7	5	+	33%	+	+
Sodium lauryl sulfate// Sodium dodecyl sulfate <sup>6</sup>	+	8.6,8.0,7.6,6.7,5.3,4.2,3.6,2.5	8	-		-	
Benzalkonium chloride <sup>7</sup>	+?	11.1,2.5	2	-			+
Ethylenediamine <sup>8</sup>	-	2.2,1.7,1.6,1.5,0.9,0.7	6	+			+
Musk ambrette <sup>9</sup>	+	8.2,6.5	2	-			+

Abbreviations: - = negative call; + = positive call; LLNA = Local Lymph Node Assay; GPMT/BA = Guinea Pig Maximization Test/ Buehler Assay; HMT = Human Maximization Test; HPTA = Human Patch Test Allergen

Notes:

1. LLNA: the call provided is based on the SI data presented for these compounds.
2. SI Values: these are the maximum SI values obtained (ranked from high to low) for the number of LLNA tests conducted.
3. The maximum incidence of responding animals in the GPMT/BA
4. Benzocaine: Sponsor states that GPMT/BA results are +/- . Some have classified as a moderate sensitizer.  
Nonirritant// 40/1135 dermatitis patients (Marzulli & Maibach, 1996), 2/1158 volunteers (Prystowsky et al., 1979)
5. Nickel Sulfate: 2.5% pet. in human patch test: 109/1123 sensitized// 8 showed irritation (Marzulli & Maibach, 1996).
6. SDS: Moderate irritant in 4-hour human patch test (70% of panel [380/544] responded) (Basketter et al., 1998)
7. Benzalkonium chloride was classified as negative for the LLNA submission but the SI for one test was 11.1 and for another 2.5.  
High human skin irritancy potential (52% of panel responded) (Basketter et al., 1998)
8. Ethylenediamine was classified as positive in the submission but the SI was not above 3.0.  
Human response: 66/1120 dermatitis patients (Marzulli & Maibach, 1996)// 5/1158 volunteers (Prystowsky et al., 1979)
9. Musk ambrette: causes photoallergy (Truitt, 1998)

## Comparison of LLNA versus GPMT/BA and Human Data, by Chemical and Product Class

The tabulated LLNA data provided in Appendix A was used to compare, by chemical and product class, the sensitivity, specificity, positive predictivity, negative predictivity, and accuracy of the:

- LLNA versus the Guinea Pig Maximization Test (GPMT)/Buehler Assay (BA);
- LLNA versus Guinea Pig Tests (GPT) (i.e., GPMT/BA plus nonstandard Guinea pig tests);
- LLNA versus human results, which includes Human Maximization Test (HMT) data and substances used as Human Patch Test Allergens (HPTA); and
- GPT versus the human results.

The results of these analysis are presented in the accompanying four tables. Tables 1 - 4 are based on a comparison by chemical class; Tables 5 - 8 by product class. The accuracy of each comparison are presented graphically in Figures 1 through 4.

Center staff member Bonnie Carson, M.S. Organic Chemistry, assigned the chemical classes based on substituent groups when a graphic molecular structure was readily available or could be drawn based on the chemical name. Some chemical class assignments, such as potential Michael-reactive

agent, were based on assignments by Ashby et al. (1995). Chemical classes selected for the Center's analysis were generally those that possessed electrophilic moieties. The sources for the product classes were Budavari (1996), Truett (1998) and Chemfinder (1997). A chemical or product may be present in more than one chemical or product class and not all chemicals listed could be placed in one of the classes used.

A number of these class/product comparisons are of very limited value considering the small number of chemicals tested in common among the various assays, and especially in terms of human sensitization results. To increase the number of possible comparisons to human data, all guinea pig test data were considered and human patch test allergens were included in the analyses. Their inclusion was based on an assumption that the substance would not be in use in a commercial test kit if it did not test positive in at least some individuals. In making these comparisons, unpublished data (as indicated in the Appendix) were included.

Although several chemical or product classes are clearly underrepresented in these analyses, the correlation between the LLNA and guinea pig tests appeared to be disparate, by chemical class, only for lactones and salts. However, when compared against human sensitization results, the LLNA and GPT appear to be equal in accuracy.

Table 1. Comparison of LLNA versus GPMT/BA by Chemical Class

Chemical Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Acylating Agents	9	7	100% (2/2)	100% (5/5)	100% (2/2)	100% (5/5)	100% (7/7)
Alcohols/Glycols	8	6	100% (2/2)	100% (4/4)	100% (2/2)	100% (4/4)	100% (6/6)
Alkyl Halides	25	3	100% (3/3)	(0/0)	100% (3/3)	(0/0)	100% (3/3)
Amides	11	6	100% (4/4)	100% (2/2)	100% (4/4)	100% (2/2)	100% (6/6)
Aromatic Amines	9	6	50% (2/4)	100% (2/2)	100% (2/2)	50% (2/4)	67% (4/6)
Aryl Halides	11	7	80% (4/5)	100% (2/2)	100% (4/4)	67% (2/3)	86% (6/7)
Epoxides (Actual/Potential)	15	8	100% (7/7)	0% (0/1)	88% (7/8)	(0/0)	88% (7/8)
Esters	26	14	100% (6/6)	88% (7/8)	86% (6/7)	100% (7/7)	93% (13/14)
Lactones	14	3	100% (1/1)	50% (1/2)	50% (1/2)	100% (1/1)	67% (2/3)
Michael-reactive Agents	17	13	100% (11/11)	100% (2/2)	100% (11/11)	100% (2/2)	100% (13/13)
Nitroso Compounds	8	1	100% (1/1)	(0/0)	100% (1/1)	(0/0)	100% (1/1)
Nitroaromatics	7	4	100% (3/3)	100% (1/1)	100% (3/3)	100% (1/1)	100% (4/4)
Phenolic Compounds	24	13	100% (8/8)	100% (5/5)	100% (8/8)	100% (5/5)	100% (13/13)
Salts	20	12	75% (6/8)	25% (1/4)	67% (6/9)	33% (1/3)	58% (7/12)

LLNA = Local Lymph Node Assay; GPMT = Guinea Pig Maximization Test; BA = Buehler Assay.

Number tested refers to the number of substances tested in the LLNA.

Number of comparisons refers to the number of substances tested in both LLNA and GPMT/BA.

Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.

Table 2. Comparison of LLNA versus Guinea Pig Test (GPT) by Chemical Class

Chemical Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Acylating Agents	9	8	100% (2/2)	100% (6/6)	100% (2/2)	100% (6/6)	100% (8/8)
Alcohols/Glycols	8	7	100% (2/2)	100% (5/5)	100% (2/2)	100% (5/5)	100% (7/7)
Alkyl Halides	25	7	100% (7/7)	(0/0)	100% (7/7)	(0/0)	100% (7/7)
Amides	25	6	100% (4/4)	100% (2/2)	100% (4/4)	100% (2/2)	100% (6/6)
Aromatic Amines	9	9	71% (5/7)	100% (2/2)	100% (5/5)	50% (2/4)	78% (7/9)
Aryl Halides	11	7	80% (4/5)	100% (2/2)	100% (4/4)	67% (2/3)	86% (6/7)
Epoxides (Actual/Potential)	15	11	100% (10/10)	0% (0/1)	91% (10/11)	(0/0)	91% (10/11)
Esters	26	22	93% (13/14)	88% (7/8)	93% (13/14)	88% (7/8)	91% (20/22)
Lactones	14	10	50% (3/6)	50% (2/4)	60% (3/5)	40% (2/5)	50% (5/10)
Michael-reactive Agents	17	14	100% (11/11)	67% (2/3)	92% (11/12)	100% (2/2)	93% (13/14)
Nitroso Compounds	8	1	100% (1/1)	(0/0)	100% (1/1)	(0/0)	100% (1/1)
Nitroaromatics	7	6	100% (5/5)	100% (1/1)	100% (5/5)	100% (1/1)	100% (6/6)
Phenolic Compounds	24	16	100% (11/11)	100% (5/5)	100% (11/11)	100% (5/5)	100% (16/16)
Salts	20	17	85% (11/13)	25% (1/4)	79% (11/14)	33% (1/3)	71% (12/17)

LLNA = Local Lymph Node Assay; GPT includes Guinea Pig Maximization Test, Buehler Assay, and nonstandard Guinea pig tests.

Number tested refers to the number of substances tested in the LLNA.

Number of comparisons refers to the number of substances tested in both LLNA and GPT.

Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.



Table 3. Comparison of LLNA versus Human Data by Chemical Class

Chemical Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Acylating Agents	11	0					
Alcohols/Glycols	8	5	40% (2/5)	(0/0)	100% (2/2)	0% (0/3)	40% (2/5)
Alkyl Halides	25	1	100% (1/1)	(0/0)	100% (1/1)	(0/0)	100% (1/1)
Amides	11	5	60% (3/5)	(0/0)	100% (3/3)	0% (0/2)	60% (3/5)
Aromatic Amines	7	7	57% (4/7)	(0/0)	100% (4/4)	0% (0/3)	57% (4/7)
Aryl Halides	11	4	100% (4/4)	(0/0)	100% (4/4)	(0/0)	100% (4/4)
Epoxides (Actual/Potential)	15	9	100% (9/9)	(0/0)	100% (9/9)	(0/0)	100% (9/9)
Esters	26	8	29% (2/7)	0% (0/1)	67% (2/3)	0% (0/5)	25% (2/8)
Lactones	14	2	50% (1/2)	(0/0)	100% (1/1)	0% (0/1)	50% (1/2)
Michael-reactive Agents	17	8	75% (6/8)	(0/0)	100% (6/6)	0% (0/2)	75% (6/8)
Nitroso Compounds	8	0					
Nitroaromatics	7	0					
Phenolic Compounds	24	14	80% (8/10)	100% (4/4)	100% (8/8)	67% (4/6)	86% (12/14)
Salts	20	7	83% (5/6)	0% (0/1)	83% (5/6)	0% (0/1)	71% (5/7)

LLNA = Local Lymph Node Assay; Human data includes results from Human Maximization Test and Human Patch Test Allergens.

Number tested refers to the number of substances tested in the LLNA.

Number of comparisons refers to the number of substances tested in both LLNA and GPT.

Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.

Table 4. Comparison of Guinea Pig Tests (GPT) versus Human Data by Chemical Class


Chemical Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Acylating Agents	7	0					
Alcohols/Glycols	7	5	40% (2/5)	(0/0)	100% (2/2)	0% (0/3)	40% (2/5)
Alkyl Halides	7	1	100% (1/1)	(0/0)	100% (1/1)	0% (0/0)	100% (1/1)
Amides	6	5	60% (3/5)	(0/0)	100% (3/3)	0% (0/2)	60% (3/5)
Aromatic Amines	10	7	57% (4/7)	(0/0)	100% (4/4)	0% (0/3)	57% (4/7)
Aryl Halides	7	2	100% (2/2)	(0/0)	100% (2/2)	0% (0/0)	100% (2/2)
Epoxides (Actual/Potential)	11	9	89% (8/9)	(0/0)	100% (8/8)	0% (0/1)	89% (8/9)
Esters	22	9	33% (2/6)	33% (1/3)	50% (2/4)	20% (1/5)	33% (3/9)
Lactones	10	2	0% (0/2)	(0/0)	0% (0/0)	0% (0/2)	0% (0/2)
Michael-reactive Agents	14	8	75% (6/8)	(0/0)	100% (6/6)	0% (0/2)	75% (6/8)
Nitroso Compounds	1	0					
Nitroaromatics	6	0					
Phenolic Compounds	16	11	75% (6/8)	100% (3/3)	100% (6/6)	60% (3/5)	82% (9/11)
Salts	17	8	86% (6/7)	100% (1/1)	100% (6/6)	50% (1/2)	88% (7/8)

GPT includes Guinea Pig Maximization Test, Buehler Assay, and nonstandard Guinea pig tests; Human data includes results from

Human Maximization Test and Human Patch Test Allergens.  
Number tested refers to the number of substances tested in the LLNA.

Number of comparisons refers to the number of substances tested in both LLNA and GPT.  
Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.

**Fig. 1 Comparative Accuracy of LLNA vs**



**Fig. 2 Comparative Accuracy of LLNA and**




Table 5. Comparison of LLNA versus GPMT/BA by Product Class

Product Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Antimicrobial	24	16	85% (11/13)	100% (3/3)	100% (11/11)	60% (3/5)	88% (14/16)
Chemical Intermediates	38	25	88% (15/17)	100% (8/8)	100% (15/15)	80% (8/10)	92% (23/25)
Cosmetics (including hair and fragrances)	38	32	100% (20/20)	92% (11/12)	95% (20/21)	100% (11/11)	97% (31/32)
Dyes (or Dye Intermediates)	16	11	63% (5/8)	100% (3/3)	100% (5/5)	50% (3/6)	73% (8/11)
Food Additives	14	12	100% (6/6)	100% (6/6)	100% (6/6)	100% (6/6)	100% (12/12)
Pesticides	6	2	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)
Pharmaceuticals	34	22	78% (7/9)	100% (13/13)	100% (7/7)	87% (13/15)	91% (20/22)
Photographic Chemicals	7	4	100% (4/4)	(0/0)	100% (4/4)	(0/0)	100% (4/4)
Polymers (including monomers, resins plastics, but not rubber)	16	12	100% (7/7)	80% (4/5)	88% (7/8)	100% (4/4)	92% (11/12)

LLNA = Local Lymph Node Assay; GPMT = Guinea Pig Maximization Test; BA = Buehler Assayt.  
 Number tested refers to the number of substances tested in the LLNA.  
 Number of comparisons refers to the number of substances tested in both LLNA and GPMT/BA.  
 Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.

Table 6. Comparison of LLNA versus Guinea Pig Test (GPT) by Product Class

Product Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Antimicrobial	24	19	80% (12/15)	100% (4/4)	100% (12/12)	57% (4/7)	84% (16/19)
Chemical Intermediates	38	28	95% (18/19)	100% (9/9)	100% (18/18)	90% (9/10)	96% (27/28)
Cosmetics (including hair and fragrances)	38	34	100% (22/22)	92% (11/12)	96% (22/23)	100% (11/11)	97% (33/34)
Dyes (or Dye Intermediates)	16	14	73% (8/11)	100% (3/3)	100% (8/8)	50% (3/6)	79% (11/14)
Food Additives	14	13	100% (6/6)	100% (7/7)	100% (6/6)	100% (7/7)	100% (13/13)
Pesticides	6	3	100% (2/2)	100% (1/1)	100% (2/2)	100% (1/1)	100% (3/3)
Pharmaceuticals	34	25	82% (9/11)	100% (14/14)	100% (9/9)	87% (14/16)	92% (23/25)
Photographic Chemicals	7	6	100% (5/5)	100% (1/1)	100% (5/5)	100% (1/1)	100% (6/6)
Polymers (including monomers, resins plastics, but not rubber)	16	14	100% (9/9)	80% (4/5)	90% (9/10)	100% (4/4)	93% (13/14)

LLNA = Local Lymph Node Assay; GPT includes Guinea Pig Maximization Test, Buehler Assay, and nonstandard Guinea pig tests.

Number tested refers to the number of substances tested in the LLNA.

Number of comparisons refers to the number of substances tested in both LLNA and GPT.

Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.

Table 7. Comparison of LLNA versus Human Data by Product Class

Product Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Antimicrobial	24	17	76% (13/17)	(0/0)	100% (13/13)	0% (0/4)	76% (13/17)
Chemical Intermediates	35	19	76% (13/17)	50% (1/2)	93% (13/14)	20% (1/5)	74% (14/19)
Cosmetics (including hair and fragrances)	38	28	63% (17/27)	100% (1/1)	100% (17/17)	9% (1/11)	64% (18/28)
Dyes (or Dye Intermediates)	16	8	100% (4/4)	(0/0)	100% (4/4)	0% (0/4)	50% (4/8)
Food Additives	14	8	57% (4/7)	0% (0/1)	80% (4/5)	0% (0/3)	50% (4/8)
Pesticides	6	4	75% (3/4)	(0/0)	100% (3/3)	0% (0/1)	75% (3/4)
Pharmaceuticals	34	26	50% (11/22)	100% (4/4)	100% (11/11)	27% (4/15)	58% (15/26)
Photographic Chemicals	7	6	100% (6/6)	(0/0)	100% (6/6)	(0/0)	100% (6/6)
Polymers (including monomers, resins plastics, but not rubber)	16	11	100% (7/7)	100% (4/4)	100% (7/7)	100% (4/4)	100% (11/11)

LLNA = Local Lymph Node Assay; Human data includes results from Human Maximization Test and Human Patch Test Allergens.  
 Number tested refers to the number of substances tested in the LLNA.  
 Number of comparisons refers to the number of substances tested in both LLNA and GPT.  
 Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.

Table 8. Comparison of Guinea Pig Tests (GPT) versus Human Data by Product Class

Product Class	# Tested	# of Comparisons	Sensitivity	Specificity	Positive Predictivity	Negative Predictivity	Accuracy
Antimicrobial	19	17	81% (13/17)	(0/0)	100% (13/13)	0% (0/3)	81% (13/17)
Chemical Intermediates	28	16	80% (12/15)	100% (1/1)	100% (12/12)	25% (1/4)	81% (13/16)
Cosmetics (including hair and fragrances)	34	26	64% (16/25)	100% (1/1)	100% (16/16)	10% (1/10)	65% (17/26)
Dyes (or Dye Intermediates)	14	9	67% (6/9)	(0/0)	100% (6/6)	0% (0/3)	67% (6/9)
Food Additives	13	8	57% (4/7)	0% (0/1)	80% (4/5)	0% (0/3)	50% (4/8)
Pesticides	3	3	67% (2/3)	(0/0)	100% (2/2)	0% (0/1)	67% (2/3)
Pharmaceuticals	25	20	50% (9/18)	100% (2/2)	100% (9/9)	18% (2/11)	55% (11/20)
Photographic Chemicals	6	5	100% (5/5)	(0/0)	100% (5/5)	(0/0)	100% (5/5)
Polymers (including monomers, resins plastics, but not rubber)	14	12	100% (7/7)	100% (5/5)	100% (7/7)	100% (5/5)	100% (12/12)

GPT includes Guinea Pig Maximization Test, Buehler Assay, and nonstandard Guinea pig tests; Human data includes results from


Human Maximization Test and Human Patch Test Allergens.  
Number tested refers to the number of substances tested in the LLNA.

Number of comparisons refers to the number of substances tested in both LLNA and GPT.


Numbers in parenthesis indicate actual number of resulting comparisons for each analysis.



**Fig. 3 Comparative Accuracy of LLNA vs**



**Fig. 4 Comparative Accuracy of LLNA and**



## NICEATM Quality Assurance Audit Summary

As recommended by the LLNA Peer Review Panel, a retrospective data audit was conducted by a National Toxicology Program (NTP) independent quality assurance contractor on the intra- and inter-laboratory LLNA validation studies submitted by the Sponsors. The purpose of the audit was to provide an independent assessment of published test data provided in the submission for accuracy, consistency, and completeness as compared to the original study records.

The published results on individual chemicals were compared against the original laboratory records from the following participating laboratories:

- Zeneca Central Toxicology Laboratory, Cheshire, UK;
- Unilever Safety and Environmental Assurance Center, Bedfordshire, UK;
- Procter & Gamble Company, Cincinnati, OH;
- ITT Research Institute (IITRI), Chicago, IL<sup>1</sup>; and
- E. I. du Pont de Nemours, Inc., Newark, DE.

The pertinent data from each laboratory for one chemical from each of the three published papers provided below were reviewed for completeness and accuracy. The chemical evaluated is provided in parentheses.

- Kimber, I., J. Hilton, R. J. Dearman, G. F. Gerberick, C. A. Ryan, D. A. Basketter, E. W. Scholes, G. S. Ladics, S. E. Loveless, R. V. House, and A. Guy. 1995. An international evaluation of the murine local lymph node assay and comparison of

modified procedures. *Toxicology* 103:63-73. (2,4-dinitrochlorobenzene [DNCB])

- Kimber, I., J. Hilton, R. J. Dearman, G. F. Gerberick, C. A. Ryan, D. A. Basketter, L. Lea, R. V. House, G. S. Ladics, S. E. Loveless, and K. L. Hastings. 1998. Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: An interlaboratory evaluation. *J. Toxicol. Environ. Health* 53:563-579. (penicillin-G)
- Loveless, S. E., G. S. Ladics, G. F. Gerberick, C. A. Ryan, D. A. Basketter, E. W. Scholes, R. V. House, J. Hilton, R. J. Dearman, and I. Kimber. 1996. Further evaluation of the local lymph node assay in the final phase of an international collaborative trial. *Toxicology* 108:141-152. (sodium lauryl sulfate [SLS])

Minimal findings were identified in the audit report. Audit procedures and findings are presented in the quality assurance report on file at the National Institute of Environmental Health Sciences (NIEHS). The audit supports the conclusion that the transcribed test data in the submission were accurate, consistent, and complete as compared to the original study records.

<sup>1</sup> Records from IITRI were not received prior to the publication of this report, thus the findings discussed here do not include audit findings from IITRI.